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ABSTRACT
Acute rejection remains an important cause of early renal allograft loss and a risk
factor for long term graft survival despite the substantial improvement in graft
survival over the past 3 decades. Immunological monitoring of alloreactivity
following organ transplantation has been the longstanding aim of transplant
clinicians. Most studies monitoring cytokine gene expression were single time point
"snap-shots" and hence conflicting findings abound in the literature with no
consensus about which cytokines are markers or mediators of acute rejection.
Sequential monitoring of peripheral T lymphocyte gene expression was performed in
renal transplant recipients in the first 6 weeks following transplantation. The level of
gene expression was correlated with clinical events, with emphasis on changes
occurring during acute rejection. Forty-three renal transplant patients were
monitored. Twenty-eight did not reject while 15 did. Peripheral T cells were isolated
at fixed time points within the first 6 weeks following transplantation, with additional
samples taken at the time of acute rejection and following anti-rejection therapy. A
robustly tested RT-PCR technique combined with a highly sensitive ELISA method
of detecting digoxigenin-labelled PCR products was used to semi-quantitatively
detect the sequential changes in interleukins (IL) 2, 4, 5, 10, 13, interferon (IFN)-y,
and the gene expression of 2 cytotoxic T lymphocyte (CTL) activation markers,
granzyme B (GrB) and fas ligand (fasL).
Overall, T helper (Th)-2 cytokines (IL-4, IL-5, IL-10 and IL-13) showed the most
interesting and varied changes in gene expression profiles following transplantation,
while Th-1 cytokines (IL-2 and IFN-y) showed unexpected changes and the CTL
activation markers (GrB and FasL) showed the most random changes.
The most significant finding was that peripheral T cell IL-4, IL-5 and IL-13 gene
expression increased at the time of acute rejection and decreased following
successful anti-rejection therapy. While clear differences in the gene expression
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profiles between non-rejectors and rejectors were seen for IL-5 and IL-13, there were
more similarities in the profiles between the two groups for IL-4. The increase in
IL-5 and IL-13 expression in the rejectors prior to, and during acute rejection, and the
subsequent return of both cytokines to their respective patterns for the non-rejectors,
suggest that these 2 cytokines may be important markers of acute rejection. The
similar decrease in IL-4 gene expression below its pre-transplant baseline in the first
week following transplantation in both non-rejectors and rejectors before returning to
the baseline, and a similar reduction in expression below the baseline following
anti-rejection therapy before returning again to the pre-transplant level suggest that
IL-4 was more likely a sensitive marker of the changing level of immunosuppression
rather than of the changes in alloreactivity. IL-4, IL-5 and IL-13 also had different
gene expression profiles in the non-rejectors. Both IL-5 and IL-13 had a flat
post-transplant gene expression profile, with IL-5 consistently below its
pre-transplant baseline at all post-transplant time points while IL-13 remained at its
baseline level throughout. IL-4 on the other hand had a variable profile, being below
its baseline during the first week post-transplant before returning to its baseline
subsequently.
In contrast, IL-10 gene expression profile was totally opposite to that for IL-4, IL-5
and IL-13 in both non-rejectors and rejectors. In the non-rejectors, IL-10 gene
expression was consistently above its pre-transplant baseline at all post-transplant
time points. At the time of acute rejection and even by 2 weeks post-transplant, IL-10
gene expression had decreased relatively by returning to its pre-transplant baseline,
and with successful anti-rejection therapy, IL-10 expression increased above its
baseline. The consistently high level of IL-10 expression in non-rejectors and the
relative fall in IL-10 prior to, and during acute rejection, suggest that a high IL-10
level may be important for graft acceptance.
As for the Th-1 cytokines (IL-2 and IFN-y), both showed similar flat profiles in
non-rejectors with their gene expression levels remaining at their respective
pre-transplant baselines at all post-transplant time points. In the rejectors, both
cytokines showed significant and paradoxical reduction in the level of their
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expression during the first week following transplantation and immediately following
anti-rejection therapy, but returned to their pre-transplant baselines at all other time
points. The unexpected fall in IL-2 and IFN-y gene expression at several
post-transplant time points in the rejectors only may represent a preferential
sequestration of these Th-1 cells within the renal allograft prior to acute rejection.
The 2 CTL activation markers (GrB and FasL) showed variable levels of gene
expression in both non-rejectors and rejectors, with no apparent correlation with the
clinical course following transplantation.
In conclusion, changes in some peripheral T cell cytokine gene expression correlated
closely with clinical events. The use of sequential monitoring of peripheral T cell
cytokine gene expression has the potential to provide a deeper understanding of the
complex interactions of cytokines following transplantation, during acute rejection
and the response to anti-rejection therapy.
- xii -
Chapter 1: INTRODUCTION
This chapter sets out the basis for the research project on which this thesis is based
and discusses the various contribution from the extensive but often conflicting
literature on the role of cytokines and cytotoxic T lymphocyte activation markers on
acute allograft rejection. In addition, the rationale for the development of a
technically robust but relatively simple, reliable and sensitive semi-quantitative
polymerase chain reaction-based method of monitoring changes in the levels of
cytokine and cytotoxic T lymphocyte activation marker gene expression in peripheral
blood T cells is outlined. In this study, this methodology was developed and applied
as a means of employing peripheral blood in monitoring the changes in alloreactivity
following adult clinical renal transplantation.
1.1 Background
Since the pioneering days over 30 years ago, kidney transplantation has progressed
rapidly from what was an essentially unsuccessful experimental procedure to the
successful and routine surgical procedure it is today, transforming the lives of an
estimated 35,000 patients with chronic renal failure worldwide each year [Allen and
Chapman, 1994],
Short and long term kidney graft survival rates have progressively improved over the
past decade [Cecka, 1997], However, up to 15% of grafts are lost within the first year
and the persistent annual attrition rate of approximately 5% leads to unsatisfactory
long-term survival with up to 60% of first cadaveric renal allografts failing 5 years
following transplantation, and there is a further increased risk of failure with
subsequent grafts [Morris, 1994b; Cecka, 1997],
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While graft failures are not always the consequence of immunological insults, it is
well established that the occurrence of early rejection episodes is a strong predictor of
late kidney failure [Cuturi et al, 1994], In terms of graft survival rates, the most
recent UNOS Scientific Renal Transplant Registry's ten-year results of kidney
transplantation [Cecka, 1997] has shown that transplant recipients who were
rejection-free at discharge from the hospital had a statistically significant 13% higher
one-year graft survival rate compared with those who experienced one or more
rejection episodes during their transplant hospitalization. Acute rejection is also
considered to be the single most important risk factor for the development of chronic
rejection, the commonest cause of long-term allograft failure [Almond et al, 1993].
Although the estimated half-life of kidney grafts (time taken for 50% of functioning
grafts at 1 year to fail) has improved in the past 10 years, the difference between
patients experiencing early rejection and those without has nevertheless increased by
over 70% (0.7 to 1.2 years) as demonstrated by the most recent estimated half-life of
grafts (1994-1996) for patients without rejection being 10.3 years, and 9.1 years for
those with one or more rejection episodes, compared with 8.3 years and 7.6 years
respectively for 1988-1990 [Cecka, 1997].
Clinical immunosuppression, likewise, has undergone a gradual parallel
transformation, both in terms of an increasing spectrum of immunosuppressive
agents available for clinical use, as well as a better understanding in the mode of
action of these agents [reviewed in Wilkinson et al, 1994]. Since the introduction of
cyclosporin A into renal transplantation by Calne and colleagues in Cambridge in
1978, its major beneficial impact on the improved graft survival in clinical
transplantation throughout the 1980s has led to its being the cornerstone of modern
immunosuppression [reviewed in Morris, 1994a],
In recent years, the emphasis in the development of immunosuppressive agents has
shifted from the older, established drugs like steroids and azathioprine which are
essentially non-specific in their mode of action, and even the relatively more specific
cyclosporin A, to the newer, more powerful agents like mycophenolate mofetil
(which targets specific metabolic pathways of lymphocytes by inhibiting the enzyme
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inosine monophosphate dehydrogenase required for purine synthesis) and rapamycin
(which blocks the common pathway of intracellular growth factor signaling by
interfering with the postreceptor signal transduction pathways for the IL-2 receptor
on the cell surface).
These developments are principally geared towards the prevention of acute rejection
since a reduction in the frequency and severity of acute rejection episodes has the
potential in improving the long-term survival of the transplanted allografts (although
there is no data yet to prove that these agents have improved long term survival).
Nevertheless, acute rejection of the allografts remains a principal cause of graft loss
in kidney transplantation. With up to 15 % of allograft kidneys lost to rejection in the
first year following transplantation, acute rejection, leading to early or delayed graft
loss, has become one of the leading causes of end-stage renal disease in developed
countries [Schmouder and Kunkel, 1995],
The continuing shortage of organs available for transplantation is well known, this
being principally due to the continued reliance on cadaveric donations which has
declined in recent years. The pressure on the transplant community will become even
more acute with increasing numbers of patients requiring organ transplantation. The
UKTSSA report for 1996 showed that the number of patients on the waiting list for a
kidney transplant in the UK was over three times greater than the number of
transplants performed [UKTSSA Transplant Activity 1996]. This trend is likely to
continue and indeed worsen as the steady increase in the number of patients joining
the waiting list is not matched by a comparable increase in cadaveric donation, or
even worse, a decrease in organ donation as in recent years. Until the introduction of
clinically successful xenotransplantation of tissue engineered kidneys, even with the
increase in the number of living-related kidney transplantation, cadaveric donors will
continue to be the principal source of kidneys for transplantation in the Western
world. Therefore, prolonging the duration of useful function for each renal transplant
remains the single most effective way of reducing the burden of renal replacement
therapy.
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To this end therefore, a better understanding of the immunological phenomenon of
acute allograft rejection remains an important imperative in the search for
improvements in the long-term results of not only renal allograft transplantation, but
also other solid organ transplants, in order that such a precious and scarce resource
may be maximally utilised.
1.2 Rejection of the allograft following transplantation
Three principal patterns of rejection of the transplanted allografts have been
recognised based on clinical presentation and histological criteria. These are, in the
order of the time scale of its occurrence, hyperacute rejection, acute rejection and
chronic rejection [reviewed in Dallman and Morris, 1994],
Hyperacute rejection, now a rarity, occurs in presensitised recipients within the first
few minutes to hours after organ engraftment, often even before the operation has
been completed. It is mediated by preformed circulating cytotoxic antibodies directed
specifically to the major histocompatibility complex (MHC) antigens expressed by
the donor organ resulting from previous exposure to MHC-incompatible tissues (eg.
following blood transfusions, pregnancies or previous organ transplantations).
Rejection is accompanied by the deposition of antibodies with complement activation
within the graft causing endothelial disruption, platelet margination and infiltration
by polymorphonuclear leucocytes [Kissmeyer-Nielson et al, 1966; Williams et al,
1968], The ensuing disseminated thrombosis within the graft results in immediate
loss of the graft. However, hyperacute rejection is no longer a problem in renal
transplantation, and indeed has become a rare phenomenon nowadays with the
routine practice of serological and/or flow cytometric cytotoxic crossmatch prior to
transplantation and the increasing practice of antibody characterisation in sensitised
patients.
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In contrast to hyperacute rejection, acute rejection occurs in naive recipients, and
commonly occurs within the first 14 days after transplantation. Acute rejection can
also take place at any time after transplantation if the recipients' immune system was
inadequately suppressed by a reduction in immunosuppressive therapy or stimulated
by an unrelated event such as a viral infection. As the study of acute allograft
rejection is the mainstay of this thesis, this subject will be dealt with in greater detail
in the next section.
Chronic rejection is the least characterised and understood form of the allograft
rejections. It usually develops over a much longer time scale than acute rejection,
probably has a multifactorial aetiology and the histological hallmark is obliterative
arterial changes and interstitial fibrosis caused by progressive microvascular
endothelial damage resulting possibly from both antibody-mediated and
cell-mediated processes. Although non-immunological factors like age of donor and
previous cytomegalovirus infection may influence the development of chronic
rejection, the frequency of acute rejection episodes in the early months after
transplantation is often a good predictor of the subsequent development of chronic
rejection [Dallman and Morris, 1994], The changes of chronic rejection are often
slow and insidious, it is nevertheless relentless and the final outcome is invariably
graft failure. There is no therapeutic manipulation currently available that has been
shown to be effective in altering the course of chronic rejection [Gibbs, 1997],
1.3 Acute allograft rejection
Acute rejection of a kidney allograft is a complex immunological process. It involves
both functional types of the body's immune system, namely, non-specific (or innate)
immunity and specific (or acquired) immunity, with considerable interdependence
between the different cell subpopulations [Hall, 1991; Schmouder and Kunkel,
1995]. The initial trigger for this complex immunological process commences with
the recognition of allogeneic MHC antigens on the allograft tissues by the recipient's
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immune system [Hutchinson, 1991], The principal components of the recipient's
immune system mediating this recognition process during acute allograft rejection
are the T cells .
1.3.1 Role of the cell surface molecules
The MHC antigens are glycoproteins present on cell membranes that determine the
response to tissue allografts between different members of the same species. The
MHC in each species is genetically determined, with considerable similarity between
the MHC in different species with respect to both the immunogenetics and
biochemistry of the different systems [Dallman and Morris, 1994], In man, the MHC
contains the human leucocyte antigen (HLA) system which is subdivided into class I
and class II antigens, based on their structure, tissue distribution and function. The
'classical' class I antigens (encoded by the HLA-A, -B and -C loci) each consist of a
polymorphic heavy chain (45kd) in association with a non-variable light chain (12kd)
- [32 microglobulin - are expressed on virtually all nucleated cells and platelets, and
are responsible for activating T cells of the CD8 (largely cytotoxic) phenotype by
presentation of peptides derived from antigens mostly of endogenous origin. The
class II antigens (of HLA-DP, -DQ and -DR subclasses) are each comprised of two
polymorphic chains of similar molecular weight (a chain 35kd and P chain 28kd) and
stimulate T cells of the CD4 (mainly helper) phenotype via presentation of peptides
derived from antigens largely of exogenous origin. Class II antigens have a more
restricted tissue distribution, being constitutively expressed by only B cells, dendritic
cells and some endothelial cells. The importance of HLA in renal transplantation has
been shown by the better short-term and long-term graft survival data from large
collaborative studies like UNOS and CTS registries based on improved
HLA-matching for HLA-A, -B and -DR [Morris, 1994],
T cells recognise the antigenic determinants presented by foreign MHC antigens via
the interaction of their surface-bound T cell receptors (TCR) and the MHC molecules
on the surface of antigen presenting cells (APCs). This cognate interaction between
TCR and MHC confers the first of two signals necessary for T cell activation and
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takes place in association with CD4 (for MHC class II antigens) and CD8 (for MHC
class I antigens) molecules on the surface of T cells. The second, or co-stimulatory
signals, which is essential for T cell activation, can be mediated by the interactions
between the other cell surface ligands on the T cells and APCs (like the interactions
between CD2 and CD58, CD5 and CD72, CDlla/CD18 and ICAM-1, -2, -3, and
CD28/CTLA-4 and CD80/B7-1) [Cuturi et al, 1994],
The interaction between TCR and MHC has been shown to take place by two
different pathways. In the so-called "direct" pathway (figure 1.3.1), T cells recognize
intact allo-MHC molecules, with or without bound peptides, expressed on the surface
of donor-APCs, while in the so-called "indirect" pathway (figure 1.3.2), T cells
recognize processed peptides of alloantigens presented in the context of the
recipient's self-APCs [reviewed in Sayegh et al, 1994). The indirect pathway is
therefore equivalent to that which operate in the normal immune response. These
pathways need not be mutually exclusive during the rejection process because each is
mediated by different sets of T cell clones. The direct pathway accounts for most of
the cytotoxic T cell function, whereas the indirect pathway resulting from processed
determinants presented on recipient class II MHC molecules may account for much
of the T helper cell function [Sayegh et al, 1994], The T cell response that will
ultimately result in early acute allograft rejection seems to be primarily via the direct
recognition of donor MHC molecules. The frequency of T cells that are engaged in
the indirect pathway of allorecognition has been estimated at about 100-fold lower
than that of T cells participating in direct allorecognition [Liu et al, 1993],
A complex series of events follows allorecognition resulting in the generation of
cell-mediated and humoral-mediated effector mechanisms. The cell-mediated
immune mechanisms include T cell-mediated processes with high degrees of
specificity, as well as more poorly restricted responses by natural killer (NK) cells,
lymphokine-activated killer (LAK) cells, and activated macrophages. The
humoral-mediated responses can be less-specific natural antibodies or highly specific
antibodies of a variety of isotypes that can mediate different functions, including
opsonisation, complement activation, antibody-dependent cell-mediated cytolysis,
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and neutrophil, eosinophil, or basophil activation [Hall, 1991], These effector
mechanisms, if left unchecked, will ultimately lead to graft destruction.
Figure 1.3.1 - Direct T cell recognition of allo-MHC (reproduced with permission
from Sayegh et al, 1994) - recipient's T cells can recognize empty MHC molecules
(top) or allo-MHC + peptide complex (bottom). These peptides could be derived













Figure 1.3.2 - Indirect self-restricted T cell recognition of alloantigen (reproduced
with permission from Sayegh et al, 1994) - recipient's T cells recognise allopeptides
bound to self-MHC. These peptides are predominantly processed donor MHC
molecules, although some may be derived from tissue-specific peptides.
1.3.2 Role of cytokines
The complexity and unpredictability of acute renal allograft rejection points to the
involvement of multiple signals which initiate, modulate and effect this process.
These important signals of intercellular communications [Dallman et al, 1991] are
now recognised as soluble endogenous biological products of cells, called cytokines,
a general term which refers to many different immune signal peptides like
lymphokines, chemokines, interleukins and colony stimulating factors. Indeed, it is
now clear that the ability of a T cell to respond to a given alloantigen is determined
not only by the TCR and other ligands expressed on their cell surface, but by their
capacity to produce these cytokines to promote their growth and function.
In contradistinction to hormones which acts systemically, cytokines are only active in
the local cellular microenvironment, serving as the medium of intercellular







source via both paracrine and autocrine means. Both immune and non-immune cells
are capable of secreting these different cytokines under various stimulatory
conditions.
Upon their release, cytokines can activate their target cells by binding to their specific
surface-bound cytokine receptors on the target cells. The end result of the cytokine
action can be the secretion of other cytokines; differentiation, upregulation or
downregulation of the target cells; or feed back upon the cell of origin inducing
further secretion of that particular cytokine. Consequently, a cascade of inflammatory
signals is created via these regulatory networks of positive and negative interactions
to produce the histological lesions characteristic of acute allograft rejection. These
characteristic lesions include the vascular abnormalities of vasodilatation, of
increased vascular permeability with augmented adherence of blood cells to vascular
endothelium leading to the infiltration of the rejecting allograft by inflammatory and
immune cells; and an increased pro-coagulant state resulting in thrombosis,
haemorrhage and eventually destruction of vessels [Chatenoud, 1992],
Current knowledge of the role of cytokines in acute allograft rejection is still rather
limited with most of the laboratory observations from in vitro and animal
experiments. Since cytokines are released locally into the cellular microenvironment
and their activities are transient in nature, the relevance of systemic measurement of
cytokine protein products in order to predict graft rejection is therefore rather limited.
Moreover, elevated cytokine product levels are non-specific indicators of the
presence of an acute inflammatory response since they have been found both during
rejection and infection [Vossen and Savelkoul, 1994], Studies into the role of
cytokines in acute allograft rejection have therefore moved from the analysis of the
cytokine products themselves to the detection of their gene expression within the
transplanted allografts.
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1.3.3 Cytokine gene expression in acute rejection
In the last few years, several studies looking at cytokine gene expression have linked
the expression of many different cytokines with acute rejection in different human
organ transplants. Most of these were single time-point studies in that cytokine gene
transcripts were only studied at the time of rejection and were not correlated with the
events in the grafts prior to the acute rejection episode or following anti-rejection
therapy. It is therefore not surprising that despite these numerous studies, there has
been no overall concensus as to which cytokines are truly indicative or predictive of
acute cellular rejection, or its corollary, tolerance. An overview of the literature
concerning the relevance of some of these key cytokines in acute allograft rejection is
detailed in section 1.5.
1.4 The T-helper (Th) 1/Th2 Paradigm
The discovery that T-helper lymphocytes in murine T-cell clones can be classified
into two groups based on their phenotypically distinct cytokine profiles with different
functional properties [Mosman et al, 1986, Mosmann and Coffman, 1989] has
resulted in the evolution of a unifying concept to explain the observed cytokine
profiles in studies elucidating the cytokine programs associated with T cell
activation, allograft rejection and tolerance induction, the so-called Thl and Th2
paradigm [Nickerson et al, 1994],
CD4! cells of the Thl subset are strongly associated with cell-mediated immunity,
producing interleukin (IL)-2, interferon-gamma (IFN-y) and lymphotoxin (also called
tumour necrosis factor-beta, TNF-P) on activation, while CD4+ cells of the Th2
subset are often associated with humoral immunity, producing IL-4, IL-5, IL-6, IT-10
and IL-13 [Nickerson et al, 1994; Mosman and Sad, 1996].
Both Thl and Th2 cells developed from a common precursor, the ThO cells
(producing IL-2, IL-4, IFN-y and TNF-P), and the commitment towards the
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development of either Thl or Th2 subsets depends on the presence of exogenous
IL-12 or IL-4 respectively [Nickerson et al, 1994]. ThO cells differentiate from
activated naive T cells in the presence of IL-2 following the complex event of
allorecognition described in the previous section. The two Th subsets cross-regulate
Thl/Th2 function by the release of their individual cytokines into the cellular
microenvironment, the central theme to this paradigm [Fiorentino et al, 1989; Fitch et
al, 1993], For example, IFN-y, a Thl product, inhibits expression of the Th2 program
while IL-4 and IL-10, both Th2 products, can act to block the Thl program. Hence,
activation of the Thl phenotype is often accompanied by silencing of the Th2
program and vice versa [Nickerson et al, 1994]. Figure 1.4.1 summarizes the
interaction between the various T helper cells.
It is widely believed that Thl cells play an important role in the allograft rejection
process since Thl-type immune activation is usually manifested during allograft
rejection [Strom et al, 1996], Since Th2 cells are antagonistic to Thl development
and function, a popular hypothesis states that preferential induction of
allograft-specific Th2 cells would down-regulate Thl-driven rejection responses,
thereby promoting allograft acceptance or tolerance [Lowry and Takeuchi, 1996;
Piccotti et al, 1997]. While this hypothesis is supported by a number of studies
demonstrating the preferential activation of cells producing Th2 cytokines (IL-4) in
conjunction with the absence/reduction of cells producing Thl cytokines (IL-2) in
allograft hosts receiving tolerizing therapies [Mohler and Streilein, 1989; Powell and
Streilein, 1990], the picture is not entirely clear with several preclinical models
showing the presence of Th2 response to accompany rejection [Strom et al, 1996],
The question of whether Th2 cells are beneficial, deleterious, or irrelevant in
promoting allograft survival was recently reviewed by Piccotti and colleagues [1997],
and their conclusion was that in the context of transplantation, Th2 cells may indeed
be beneficial, deleterious, and/or irrelevant! The confusing messages emanating from
the cytokine literature regarding the role of Thl and Th2 cytokines in the allograft
response are reviewed in the following section.
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Figure 1.4.1 - T cell activation and cross-regulation (reproduced with permission





Therefore, the Thl/Th2 paradigm while useful in explaining the observed cytokine
profiles in animal models, has not been as clear in human studies, even though the
Thl and Th2 patterns of cytokine production have also been described among human
T cells [Del Prete et al, 1991], Moreover, recent studies highlighting the redundancy
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of the immune system (both in term of the variety of cytokines able to act as T cell
growth factors, and in the use of common cytokine receptor subunits for signal
transduction by groups of cytokines) and the pleiotropic nature of the cytokine
network (in term of the numerous functions that any one cytokine can perform)
indicate that the Thl/Th2 paradigm in itselfmay not be sufficient to explain fully the
mechanisms underlying rejection and tolerance in transplantation [Nickerson et al,
1994],
Hence, it has become apparent that the Thl/Th2 paradigm, while providing a
valuable framework for probing various models, has undoubtedly oversimplified the
complexity of cytokine responses by individual T cells in vivo. Indeed, because
cytokines are pleiotropic, the microenvironment in which they are released may be
the determining factor whether the effects of a cytokine are immunoregulatory or
proinflammatory [Nickerson et al, 1997], It has also been suggested that Thl and Th2
cells may not, after all, be discrete cellular compartments in the immune systems but
rather two extreme endpoints in a continuous spectrum, and the two patterns of
cytokine expression may simply represent extremes of many possible outcomes
[Kelso, 1995; Mosmann and Sad 1996],
1.5 Review of the literature on cytokines and cytotoxic T lymphocyte
(CTL) markers studied in the project
The Thl cytokines studied in the project were IL-2 and IFN-y, and the Th2 cytokines
studied were IL-4, IL-5, IL-10 and IL-13. The reason why more Th2 cytokines were
studied than Thl cytokines was because following the first batch of gene expression
experiments looking at IL-2, IFN-y, IL-4 and IL-10, we have found much more
interesting and significant changes in the level of the two Th2 cytokines as compared
with Thl cytokines in the project's series of patients. Therefore, additional Th2
cytokines were studied in the latter part of the project.
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As the detection of other early activation markers of the immune system (apart from
cytokine profiles) had been published in the recent literature [Suthanthiran, 1997;
Strehlau et al, 1997], we chose to examine two of these cytotoxic T lymphocyte
(CTL) activation markers, namely granzyme B (GrB) and fas ligand (FasL), at the
same time points as for the cytokines and correlate their expression with the clinical
events.
Despite extensive literature into the roles cytokine play in the underlying
immunobiology of acute rejection in solid organ transplantation, there is still much
confusion about the exact role and relative importance of individual Thl and Th2
cytokines. The complex nature of the cytokine response to the presence of the
allograft during an acute rejection process, coupled to the confounding effect of the
different methods of measuring the cytokine response, have undoubtedly contributed
to many of the conflicting findings that have been published in cytokine research
literature [Baan and Weimar, 1998],
The following sub-sections review the literature on the evidence, or otherwise, for the
role in acute allograft rejection of the individual cytokines and CTL activation
markers studied in the project.
1.5.1 IL-2
IL-2 was discovered through its activity as a T cell growth factor (TCGF) [Gillis et
al, 1978] and is secreted and synthesized by activated T cells [reviewed in O'Garra,
1989a], It interacts with the binding site residues of its IL-2 receptor complex
(IL-2R), an a[3y heterotrimer of distinct polypeptide chains [Takeshita et al, 1992],
resulting in a high-affinity binding. By its principal activity as a TCGF, IL-2
stimulates the proliferation of CD4+ T cells (by clonal expansion of
alloantigen-activated T cells via autocrine stimulation) as well as activating CD8+
CTLs and LAK cells [O'Garra, 1989a; Nickerson et al, 1994], It also stimulates NK
cell proliferation and activation [O'Garra, 1989a; Chatenoud, 1992; Schmouder and
Kunkel, 1995]. It induces the production of other proinflammatory cytokines by
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activated NK cells (IFN-y and TNF-a) [Anegon et al, 1988] and macrophages
(TNF-a) [Economou et al, 1989], thus amplifying the acute inflammatory response.
Under some conditions, B cells may also be induced by IL-2 to proliferate and
differentiate into antibody-secreting cells [Mingari et al, 1984; Muraguchi et al,
1985], and this effect may be enhanced by IFN-y [Nakagawa et al, 1985],
As one of the main proinflammatory cytokine products of Thl cells, IL-2 has always
been seen as a central player in the allograft rejection process. It has been shown that
the administration of IL-2, as an adjunct to tolerizing therapies, precludes
engraftment [Dallman et al, 1991c], IL-2 protein products (detected directly or
following stimulation of peripheral lymphocytes) in plasma or urine have been found
to be elevated in patients experiencing acute rejection following renal transplantation
[Vie et al, 1985; Simpson et al, 1989; Colvin et al, 1990]. Some authors have found
that elevated plasma IL-2 predicts impending rejection [Kutukculer et al, 1995],
while others have found that although plasma IL-2 was significantly higher in
patients who experienced acute rejection, it was not sufficiently reliable for diagnosis
or exclusion of rejection [Johnson et al, 1990].
This association of IL-2 with allograft rejection is also seen in several animal studies
of cytokine gene expression [Dallman et al, 1991a; Papp et al, 1992; Takeuchi et al,
1992; Wu et al, 1992; O'Connell et al, 1993] and immunocytochemistry [Mottram et
al, 1995; Sayegh et al, 1995], In the clinical situation, similar associations were often
reported in renal transplants [Xu et al, 1995; Kirk et al, 1995; Suthanthiran et al,
1997], liver transplants [Gaweco et al, 1995] and heart transplants [Baan et al, 1994],
In a sequential analysis of intragraft IL-2 gene transcription in a small group of renal
transplant patients, Dallman et al [1992] found that IL-2 gene expression appeared at
a very early stage of the immune response to the graft, before acute rejection was
detectable by clinical or biochemical changes. The presence of IL-2R in renal
allografts was also found to be a significant correlate of acute cellular rejection
[Noronha et al, 1992].
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Indirect evidence for the importance of IL-2 in allograft rejection is seen by a
decrease in peripheral IL-2 products with anti-rejection treatment [Daniel et al, 1995]
and in experimental models of peripheral tolerance showing a lower level of
intragraft IL-2 gene expression in tolerant animals than in rejecting ones [Bugeon et
al, 1992; Takeuchi et al, 1992], Further indirect evidence supporting the role of IL-2
in the rejection process is also seen from the success of using monoclonal antibody to
IL-2 or IL-2R in prolonging allograft survival by preventing and/or reversing
rejection in experimental [Kirkman et al, 1985; Kupiec-Weglinski et al, 1986;
Sakagami et al, 1987] and clinical transplantation [Soulillou et al, 1990; Kirkman et
al, 1991],
However, while the association of IL-2 with allograft rejection may be important and
compelling, the presence of IL-2 is nevertheless non-specific as the Oxford group had
reported that proinflammatory cytokines like IL-2 and IFN-y may be "necessary but
not sufficient for the development of acute cellular rejection". Indeed, they found that
in non-rejectors, the patterns of these cytokines in the allografts were indistinguisable
from the rejectors [McLean et al, 1997], Experiments using IL-2 knock-out mice
(mice whose IL-2 gene has been functionally silenced by targeted gene disruption)
have shown that allograft rejection readily occurs in the absence of IL-2 [reviewed by
Nickerson et al, 1994],
At the same time, there have been many studies which failed to detect and/or
associate the presence of intragraft IL-2 gene expression with rejection episodes in
human cardiac transplants [Wu et al, 1994], liver transplants [Martinez et al, 1992;
Martinez et al, 1993b] and renal transplants [Krams et al, 1992; Jeyarajah et al, 1995;
Strehlau et al, 1996; Strehlau et al, 1997]. The reasons cited for the lack of
expression of IL-2 in these studies are that this cytokine gene is only expressed
transiently upon activation [Kronke et al, 1984; Wiskocil et al, 1985; Shaw et al,
1988], or it is expressed early in the rejection process and therefore not observed in
biopsies during overt rejection episodes [Martinez et al, 1992; Dallman, 1993], or the
failure to detect IL-2 gene expression is the result of inhibition by cyclosporin
[Kronke et al, 1984; Wiskocil et al, 1985; Wu et al, 1994], It is also well documented
- 17-
that the IL-2 message rapidly disappears with the removal of the stimulus [Shaw et
al, 1988; Swoboda et al, 1991].
The value of peripheral cytokine protein product measurement has always been
controversial. Since cytokines only act locally within the cellular microenvironment
by autocrine or paracrine action, and together with their short half-life, the
interpretation of their peripheral levels is difficult, thus making its value questionable
[McKenna et al, 1988], One group evaluating cytokines and cytokine-induced
secondary messages in sera of patients following liver transplantation has come to the
same conclusion that the clinical usefulness ofmeasuring cytokines is limited [Tilg et
al, 1990], They also found that acute rejection was not accompanied by the
preferential enhancement of IL-2 or IFN-y, indeed IL-2 was not detectable at all in
peripheral blood.
1.5.2 IFN-y
This cytokine, also called macrophage activating factor (MAF), is produced by
antigen-specific T cells during an immune response, by NK cells recruited by IL-2
[reviewed in O'Garra, 1989b], and by eosinophils [Lamkhioued B et al, 1996]. It
recruits and activates macrophages (by enhancing phagocytosis and tumour killing
capability) and enhances growth and activation ofCTLs and NK cells [Trinchieri and
Perussia, 1985], One of its most important activities is the upregulation of MHC
class I (widely distributed on all nucleated cells except foetal cytotrophoblast tissue
[Colvin, 1990]) and class II (normally expressed at high density by APCs like
dendritic/Langerhans cells, macrophages and B cells, human capillary endothelium,
and activated T cells [Colvin, 1990]). These activities of IFN-y, together with its
induction of the de novo synthesis of MHC class II antigens on cells which do not
constitutively express them and the expression of high-affinity Fc receptor for
monomeric IgG on myelo-monocytic cells [Trinchieri and Perussia, 1985; Gerrard et
al, 1988], have the effect of making the tissues more immunogenic. IFN-y regulates
humoral immune responses by inducing immunoglobulin secretion by activated B
cells stimulated by IL-2 [Nakagawa et al, 1985; Le thi Bich-Thuy et al, 1986] and
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potentiates IL-4-induced proliferation of B cells [Defrance et al, 1987]. It selectively
induces high levels of complement-fixing cytotoxic IgG2a antibody [Snapper et al,
1988a] and inhibits many of the activity of IL-4 [Rabin et al, 1986], which could
influence the proliferation of Th2 cells. Hence IFN-y and IL-4 reciprocally regulate
the immunoglobulin isotype production by B cells in T cell-dependent immune
responses [Coffman and Carty, 1986; Snapper et al, 1988a]. IFN-y also upregulates
the expression of ICAM-1 on many cell types, including endothelial cells and
fibroblasts [Dustin et al, 1986; Rothlein et al, 1988], thus indirectly mediating T cell
antigen-specific responses and their migration to sites of inflammation.
Like IL-2, IFN-y is a prominent member of the proinflammatory Thl family of
cytokines and consequently it has also been seen by many as another key player in the
allograft rejection process. Not surprisingly, therefore, several studies in
experimental and clinical transplantation which associated IL-2 with rejection also
implicated IFN-y [Wu et al, 1992; O'Connell et al, 1993; Mottram et al, 1995; Kirk et
al, 1995; Sayegh et al, 1995; Thai et al, 1995]. In addition, a number of other studies
looking at stimulated cytokine products [Benvenuto et al, 1991; Merville et al, 1993;
Kaminski et al, 1995], in situ cytokine expression [Noronha et al, 1992] and cytokine
gene expression [Nast et al, 1994; Zuo et al, 1995] also associate IFN-y with allograft
rejection.
Indirect evidence suggesting a role for IFN-y in the mechanisms underlying allograft
rejection is seen in experimental models of peripheral tolerance where intragraft
IFN-y expression was reduced by more than 90% in grafts from tolerant recipients
[Takeuchi et al, 1992] and a lower level of IFN-y gene transcripts accumulated within
the grafts with delayed kinetics (i.e. a slower rate of rise in intragraft IFN-y) is seen in
tolerant grafts compared with rejected ones, and that treatment of the animals with
IFN-y abrogates the induction of tolerance in the recipients receiving the tolerizing
regime of pretransplant donor blood transfusion [Bugeon et al, 1992], In a more
recent study, the co-injection of IFN-y at the time of alloimmunization to induce
neonatal tolerance in mice restored the ability of the neonatal primed mice to reject
donor-bearing skin grafts, leading to the conclusion that the prevention of Thl
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responses that lead to rejection is critical for experimental tolerance induction [Chen
et al, 1996],
As mentioned in the previous section on IL-2, McLean et al [1997] have concluded
that IFN-y, like IL-2, may be "necessary but not sufficient for the development of
acute cellular rejection" as the sequential patterns of IFN-y gene expression in
rejectors were indistinguisable from that found in non-rejectors in the first 10 days
following kidney transplantation. As for IL-2, workers have found that IFN-y
knockout hosts reject heterotopic heart transplants with a time course and histologic
pattern similar to those of the wild-type host, and expression of other
proinflammatory cytokines noted during the allograft response in IFN-y knockout
mice is unchanged [Konieczny et al, 1996], Similarly, islet allograft rejection in
IFN-y receptor knockout hosts is brisk and T cell dependent [Steiger et al, 1996],
Several other studies examining the level of cytokine products following liver [Tilg
et al, 1990] and renal [Kutukculer et al, 1995] transplantation, and gene expression
studies following renal transplantation [Vandenbroecke et al, 1991; Krams et al,
1992; Xu et al, 1995] also failed to associate the presence of IFN-y with allograft
rejection. Failure to detect IFN-y in some of the studies was blamed on early or
transient expression or suppression by cyclosporin A, as for IL-2 as described
previously.
1.5.3 IL-4
IL-4, previously called B-cell stimulatory factor-1, was originally discovered as a
costimulator of B cell proliferation [Howard et al, 1982], but it has since been shown
to act on a wide variety of cell types including T cells, macrophages, mast cells and
several haematopoietic lineage cells [Paul and Ohara, 1987], It is produced by the
Th2 subset of activated T cells [O'Garra, 1989b] and eosinophils [Lamkhioued B et
al, 1996], It stimulates resting T cells to proliferate [Hu-Li et al, 1987] and is
considered to be the central autocrine growth factor that drives the development of
Th2 cells [Swain et al, 1990]. Its principal activity, however, is as B cell growth
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factor, causing clonal expansion of antigen-specific B cells [reviewed in O'Garra,
1989b]. It is also very important in the regulation of immunoglobulin isotype
switching in uncommitted B cells, inducing the production of IgGi isotype and high
levels of IgE [Bergstedt-Lindqvist et al, 1988; Snapper et al, 1988b], thus modulating
the humoral responses to different antigenic stimuli.
The other proinflammatory activities of IL-4 include its ability to: (a) selectively
induce resting B cells to increase their expression ofMHC class II antigens [Noelle et
al, 1986] and B7 costimulatory ligands [Stack et al, 1994], thus enhancing the ability
of B cells to present antigens and making the immune system more sensitive to
smaller amounts of antigens; (b) increase chemoattraction ofmacrophages [Hiester et
al, 1992]; (c) increase expression of adhesion molecules VCAM-1 on vascular
endothelium [Masinovsky et al, 1990; Thornhill et al, 1991] and ICAM-1 on
interstitial fibroblasts [Piela-Smith et al, 1992] either on its own or synergistically
with other cytokines, thus facilitating transmigration of immune cells; (d) induce both
proliferation and cytolytic activity ofCTL [Widmer and Grabstein, 1987],
On the other hand, some of the other effects of IL-4 can be classified as being
immunosuppressive. For example, it antagonises many activities mediated by IFN-y
[Mossman and Sad, 1996], and together with its downregulatory effect on IL-2R and
blocking of IL-2-dependent proliferation of T cells [Martinez et al, 1990], IL-4
indirectly inhibits the development and function of Thl cells. It downregulates IFN-y
production by human peripheral blood mononuclear cells [Peleman et al, 1989],
inhibits the IFN-y-induced production of IgG2a [Rabin et al, 1986] and inhibits
IL-2-induced proliferation of B cells [Defrance et al, 1988; Jelinek and Lipsky, 1988;
Karray et al, 1988] and LAK cells [Spits et al, 1988], IL-4 is also a potent inhibitor of
macrophage functions mediated by IFN-y, reducing their production of TNF-a, IL-1,
prostaglandin E2 [Essner et al, 1989; Hart et al, 1989], and reactive oxygen
intermediates [Lehn et al, 1989].
As one of the principal Th2 cytokines, IL-4 has in general been associated with the
induction and/or maintenance of tolerance following experimental allograft
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transplantation [Mohler and Streilein, 1989; Powell and Streilein, 1990; Takeuchi et
al, 1992; Donckier et al, 1995; Mottram et al, 1995; Sayegh et al, 1995] and tolerance
fails in the absence of IL-4 [Schurmans et al, 1990], However, in a recent review of
tolerance induction in experimental transplantations, Nickerson et al [1997]
concluded that IL-4 on its own does not lead to tolerance nor does the absence of
IL-4 preclude permanent engraftment.
Indeed, IL-4 gene expression had been associated with allograft rejection in different
clinical organ transplantations [Krams et al, 1992; Whitehead et al, 1993; Gaweco et
al, 1995; Lang et al, 1995; Lang et al, 1996], and in several other experimental
models of rejection/tolerance where expression of both IL-4 and IFN-y occurred with
rejection [Dallman et al, 1991a; Papp et al, 1992; Chan et al, 1995; Chen et al, 1996].
Enhanced intragraft IL-4 expression was found during acute xenograft rejection and
it was selectively enhanced in induced rejection of long-term functioning xenograft in
mice [Morris et al, 1995], Nevertheless, in other animal [O'Connell et al, 1993] and
clinical studies [Xu et al, 1995; Strehlau et al, 1996; Strehlau et al, 1997], IL-4 was
found not to be associated with allograft rejection. Likewise, the presence of IL-4
cytokine products by direct assay [Kutukculer et al, 1995] or following stimulation of
isolated peripheral mononuclear cells [Kaminski et al, 1995] have reached opposite
conclusions with regard to the role of IL-4 in acute rejection.
1.5.4 IL-10
IL-10 was initially described as a murine Th2 cell product which inhibited cytokine
synthesis by Thl cells and was originally called cytokine synthesis inhibitory factor
because of its inhibitory in vitro effects on a number of immune assays [Fiorentino et
al, 1989], However, IL-10 is not a typical Th2 cytokine as it is synthesized by other T
cells (including CD4+ ThO and Thl cells, and CD8+ T cells) [Yssel et al, 1992], B
cells [O'Garra et al, 1990; Vieira et al, 1991; O'Garra et al, 1992], antigen-presenting
cells (monocytes/macrophages) [de Waal Malefyt et al, 1991b; Fiorentino et al,
1991a], eosinophils [Lamkhioued B et al, 1996], various tumour cell lines, including
melanomas and ovarian and other carcinomas [Yssel and de Waal Malefyt, 1995] and
-22-
keratinocytes [Enk and Katz, 1992], Indeed, it has been reported recently that CD14+
monocytes/macrophages are the dominant source of human IL-10 [Hagiwara et al,
1995], serving an autoregulatory role [de Waal Malefyt et al, 1991b; de Waal Malefyt
et al, 1995] and very recently, it has also been shown that human NK cells produced
IL-10 following stimulation with IL-2 [Mehrotra et al, 1998].
IL-10 is a pleiotropic cytokine and modulates the function of T cells, B cells, NK
cells, monocytes/macrophages, mast cells and neutrophils [Moore et al, 1993; Yssel
and de Waal Malefyt, 1995; de Waal Malefyt et al, 1995]. Although the effect of
IL-10 on the expression of other cytokines has suggested that it promotes Th2 cells
and inhibits Thl cells, cytokines and related immune phenomena, these effects are by
no means strictly compartmentalised, as human Thl and Th2 clones can both
produce and be inhibited by IL-10 [Del Prete et al, 1993], This is especially true in
the context of transplantation, where IL-10 has been seen as an immunosuppressive
cytokine although conflicting evidence prevailed [Bromberg, 1995].
Most of the activities of IL-10 can be classed as being immunosuppressive. IL-10
indirectly prevents antigen-specific T cell activation and proliferation by its action on
APC, via the inhibition of antigen presentation and accessory cell functions of APC
[Fiorentino et al, 1991b; Enk et al, 1993; Moore et al, 1993; de Waal Malefyt et al,
1995] such as the production of IL-12 and TNF-a [D'Andrea et al, 1993; Trip et al,
1993], costimulatory B7 ligand expression [Ding et al, 1993], ICAM-1 expression
[Chang et al, 1994], and the downregulation of MHC class II molecules [de Waal
Malefyt et al, 1991a]. IL-10 also inhibits T cell activation and proliferation directly
via its inhibitory effects on the production of IL-2 and IFN-y by the responding
T cells [Del Prete et al, 1993; de Waal Malefyt et al, 1993a]. The other
monocyte-derived cytokines that IL-10 suppresses are IL-1, IL-6, IL-8,
granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte
colony stimulating factor (G-CSF) [de Waal Malefyt et al, 1991b; Fiorcntino et al,
1991a], IL-10 also prevents macrophage cytotoxic activity by suppressing the release
of reactive oxygen intermediates [Bogdan et al, 1991] and nitric oxide production
[de Waal Malefyt et al, 1995]. A further immunosuppressive property of IL-10 is
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seen via the blockade of the proinflammatory activities of IL-1 by IL-1 receptor
antagonist (IL-lra) released from monocytes and polymorphonuclear leucocytes
[Cassatella et al, 1994; Jenkins et al, 1994] which is upregulated by IL-10. Recent
evidence suggests that IL-10 may also have a role in suppressing Th2-mediated
allergic inflammatory processes both directly by its effects on eosinophils and
indirectly by its inhibition of IL-5 synthesis by resting CD4+ T cells and by
differentiated ThO or Th2 clones [reviewed in Pretolani and Goldman, 1997].
Conversely, some actions of IL-10 are immunostimulatory in nature, such as its
support for the growth and differentiation of mast cells in the presence of IL-3 or
IL-4 [Thompson-Snipes et al, 1991], and enhancing B cell growth, immunoglobulin
production [Rousset et al, 1992] and MHC class II expression [Go et al, 1990]. IL-10
stimulated or potentiated the cytolytic activity of LAK cells [Schwarz et al, 1994] and
serves as a growth cofactor for immature and mature T cells in the presence of IL-2
and IL-4 [MacNeil et al, 1990]. It is also a specific chemoattractant for human CD8+
T cells, since it lacks chemotactic activity towards CD4+ T cells, monocytes or
neutrophils [Jinquan et al, 1993], IL-10 has been reported to promote the survival of
IL-2-dependent T cells otherwise destined to die by apoptosis [Taga et al, 1993], thus
prolonging proinflammatory influence of these alloreactive T cells.
The evidence pointing to the important role that IL-10 plays in inducing long-term
alloantigen-specific T cell unresponsiveness in vitro, and its possible contribution to
the induction and maintenance of transplantation tolerance are accumulating
[Roncarolo, 1995; Roncarolo et al, 1996], As for IL-4, some models of experimental
tolerance have also associated IL-10 in the induction and maintenance of tolerance
[Takeuchi et al, 1992; Mottram et al, 1995; Sayegh et al, 1995]. Other supportive
evidence that IL-10 is directly involved in the process of inducing tolerance and
maintaining the tolerant state, and that its presence is not merely an epiphenomenon,
come from experimental transplantation models where IL-10 function was
deliberately introduced, by adoptive transfer of a Th2-like cell line into mice
receiving MHC class II disparate skin grafts, resulting in improved skin allograft
survival [Maeda et al, 1994], or blocked with monoclonal antibodies to IL-10,
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resulting in accelerated allogeneic skin graft rejection [Gorczynski and Wojcik,
1994],
On the other hand, while some investigators have found that the presence of a high
frequency of IL-10-secreting T cells in the graft did not inhibit allograft rejection
[Merville et al, 1993; Merville et al, 1995], other workers have found that the
systemic administration of IL-10 in a murine cardiac transplantation model resulted
in accelerated rejection [Lowry et al 1995; Qian et al, 1996] and that ex-vivo
perfusion of donor hearts with IL-10 did not affect subsequent graft survival [Qian et
al, 1996], Other cytokine gene expression studies in clinical liver [Bishop et al, 1993]
and renal [Xu et al, 1995; Strehlau et al, 1997; Suthanthiran, 1997] transplantation
have associated the presence of IL-10 with acute allograft rejection. One group
studying cytokine mRNA profile during acute rejection in renal transplantation found
that while IL-10 was not detectable in the biopsies, there was a decrease in the level
of IL-10 in the peripheral blood lymphocytes following successful anti-rejection
treatment [Jeyarajah et al, 1995].
Conflicting findings are also seen in the ELISA measurement of IL-10 itself in
different clinical organ transplantation situations, with one group finding a significant
elevation of IL-10 in bile during rejection [Lang et al, 1995; Lang et al, 1996] while
another group found that successful treatment of rejection in renal transplant patients
appears to induce IL-10 secretion [Daniel et al, 1995],
1.5.5 IL-5
IL-5 is another product of activated Th2 cells [Mosmann and Coffman, 1989] and
eosinophils [Lamkhioued B et al, 1996], Originally called T cell replacement factor
and initially described as a factor that induces terminal differentiation of
late-developing B cells to Ig-secreting cells [Takatsu et al, 1988], the IL-5 cDNA has
been cloned in both mouse and human [Kinashi et al, 1986; Azuma et al, 1986]. IL-5
is a growth and differentiation factor for murine B cells [Harada et al, 1985; Swain,
1985; Takatsu et al, 1988], but its effect on human B cells is more controversial
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[Sanderson et al, 1988]. IL-5 may promote the generation of CTL [Takatsu et al,
1987] and IL-2-mediated LAK cell activity [Aoki et al, 1989], IgA and IL-4-induced
IgE synthesis by B cells are enhanced by IL-5 [Yokota et al, 1988]. Finally, IL-5 has
profound effects on human eosinophil activation and function [Sanderson et al, 1985;
Lopez et al, 1988; Sanderson et al, 1988; Fujisawa et al, 1990], maintaining
eosinophil viability, inducing superoxide anion production by eosinophils, and
possessing eosinophil chemotactic properties [Yamaguchi et al, 1988],
The principal function of IL-5 that is of interest in transplantation is through its effect
on eosinophil activation and function. The role of eosinophils as effector cells in
allograft rejection has not been clearly established. Although blood eosinophilia
following renal transplantation had been reported to be invariably associated with
acute cellular episodes of rejection [Lautenschlager et al, 1985], it had no diagnostic
or predictive value for rejection or rejection outcome [Frenken et al, 1987], Intragraft
eosinophilia has also been linked with an adverse outcome following acute renal
allograft rejection [Weir et al, 1986; Kormendi and Amend, 1988], but tissue
eosinophil count did not differentiate the rejectors from the non-rejectors [Kormendi
and Amend, 1988]. Eosinophils have also been shown as one of the principal
components in the rejection infiltrate following pig proislet xenograft rejection in
mice [Morris et al, 1995], In clinical liver transplantation, graft eosinophilia has been
shown to predict rejection with high sensitivity and specificity [Foster et al, 1989],
Similarly, peripheral eosinophilia has been associated with rejection episodes in renal
[Kormendi and Amend, 1988] and liver [Foster et al, 1989] transplantation, and the
products of eosinophil degranulation have been detected in renal allograft rejection
[Ten et al, 1989],
The association of intragraft expression of IL-5 with allograft rejection has been
shown principally by one group of workers in clinical liver [Martinez et al, 1992;
Martinez et al, 1993a; Martinez et al, 1993b] and renal transplantation [Krams et al,
1992]. The same group has also found that the level of IL-5 product is specifically
elevated in the bile and serum of rejecting liver allograft recipients [Lang et al, 1995].
The link between IL-5 and intragraft eosinophilia with acute allograft rejection has
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raised the possibility of a non-classical pathway for allograft rejection mediated by
eosinophils [Martinez et al, 1993a], Only two other group of workers have reported
an association of IL-5 with acute allograft rejection, one found a modest increase in
IL-5 expression with acute rejection following human lung transplantation
[Whitehead et al, 1993], while in another group, IL-5 was readily detectable in
rejecting murine cardiac allografts which was accompanied by an influx of
eosinophils [Chan et al, 1995],
Most other groups of workers studying cytokine gene expression in different organ
transplantation, both experimental and clinical [Dallman et al, 1991a; Wu et al, 1994;
Gaweco et al, 1995; Kirk et al, 1995; Jeyarajah et al, 1995], have not found an
association of IL-5 with allograft rejection.
1.5.6 IL-13
IL-13 is a cytokine produced by activated Th2 cells, which was first described in
mice [Brown et al, 1989], and more recently in humans [McKenzie et al, 1993; Minty
et al, 1993], Activated mast cells produce IL-13 too [Burd et al, 1995], Like the other
Th2 cytokines described previously, IL-13 has both proinflammatory as well as
immunosuppressive properties. Indeed, IL-13 has a lot in common with IL-4, not
only because of a 20 to 25% amino acid sequence homology, but more importantly in
its spectrum of biological activities [McKenzie et al, 1993; Minty et al, 1993], and
there is evidence to suggest that they also share a common receptor or receptor
component, with the IL-13 receptor appearing to be a functional receptor for IL-4
[Callard et al, 1996],
The proinflammatory actions of IL-13 include the induction of phenotypic changes in
human monocytes by the upregulation of adhesion molecules and MHC class II
antigen expression thus enhancing its antigen presenting function, and by inhibiting
its production of IL-10 [de Waal Malefyt et al, 1993b], a Th2 cytokine widely
regarded as an immunosuppressive cytokine. IL-13 has important proinflammatory
activities on human B cells by directly modulating their surface phenotype, including
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the upregulation of MHC class II antigen expression, besides inducing B cell
proliferation, differentiation and immunoglobulin production [McKenzie et al, 1993;
Minty et al, 1993; Punnonen et al, 1993]. Moreover, IL-13 acts as an isotype switch
factor for IgG4 and IgE synthesis for both naive human B cells and immature human
B cells derived from fetal bone marrow [Punnonen et al, 1993; Punnonen et al,
1994], although its IgE-inducing activity is independent of IL-4 [Punnonen et al,
1993], Like IL-4, IL-13 induces VCAM-1 expression in vitro [Bochner et al, 1995],
and thus might play an important role in VCAM-1 mediated accumulation of
eosinophils, basophils, lymphocytes and monocytes at sites of allergic inflammation.
IL-13 also has a small, direct effect on IFN-y synthesis by large granular
lymphocytes, and this effect is enhanced in the presence of IL-2 [Minty et al, 1993],
The immunosuppressive role of IL-13 is demonstrated by its action in decreasing the
cytotoxic potential of monocytes/macrophages through the inhibition of
antibody-dependent cellular cytotoxicity of human monocytes [de Waal Malefyt et al,
1993b] and decreasing the production of nitric oxide by activated macrophages
[Doherty et al, 1993], although this immunosuppression appears to be selective in
mice since the phagocytic function of the activated murine macrophages is not
affected by IL-13 [Doherty et al, 1993], Another important immunosuppressive effect
of IL-13 is its inhibition of the production of proinflammatory cytokines like IL-1,
IL-6 and TNF-a, chemokines like migratory inhibitory factor-la (MIF-la) and IL-8,
and haematopoietic growth factors like GM-CSF and granulocyte-colony stimulating
factor (G-CSF). Moreover by its downregulation of IL-12 and IFN-y, IL-13 may
suppress Thl cell development and favour the generation of Th2 cells [de Waal
Malefyt et al, 1993b].
IL-13 also enhances the production of IL-lra, which by its blockade of the
proinflammatory activities of IL-1, results in further immunosuppression [de Waal
Malefyt et al, 1993b], These immunosuppressive effects of IL-13 are direct and not
mediated via endogenous production of IL-10.
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Being a relatively recently described cytokine, the role of IL-13 in transplantation
immunology remains unknown and has not been systematically investigated in any
study published to date.
1.5.7 Granzyme B
Granzyme B (GrB) is a member of a family of serine proteases produced by CTL and
NK/LAK cells [Haddad et al, 1990] that in humans includes at least four members
[Hameed et al, 1988; Meier et al, 1990], The mechanisms by which these enzymes
exert their toxic effect are not fully understood, although they are clearly involved in
CTL-mediated cell lysis since selective serine protease inhibitors can abrogate such
activities in vitro [Chang et al, 1980; Redelman and Hudig, 1980; Pasternack et al,
1983; Rodgers et al, 1988]. GrB together with other cytotoxic molecules like
perforin, are contained within cytoplasmic granules of CTL [Peters et al, 1989],
which supposedly undergo directed exocytosis towards the target cell upon contact
with the CTL [Jenne and Tschopp, 1988].
Early studies on clinical renal transplantation [Strom et al, 1975] and experimental
cardiac transplantation [Strom et al, 1977] has conclusively demonstrated the
presence of functionally active CTLs accumulating within rejecting allografts. More
recently, studies from two groups of workers in clinical renal transplantation have
found that intragraft [Lipman et al, 1992; Lipman et al, 1994; Sharma et al, 1996;
Strehlau et al, 1996; Strehlau et al, 1997; Suthanthiran, 1997] and peripheral blood
leucocyte [Vasconcellos et al, 1998] expression of GrB gene transcripts were
associated with acute allograft rejection.
1.5.8 Fas ligand (FasL)
The human Fas antigen is a cell surface protein belonging to the tumour necrosis
factor/nerve growth factor receptor family mediating apoptosis [Itoh et al, 1991]. Fas
ligand is also a membrane protein belonging to the tumour necrosis factor family
which is expressed in activated T lymphocytes [Takahashi et al, 1994], By binding to
-29-
its receptor, Fas, FasL induces apoptosis in cells expressing Fas and it is therefore
involved in CTL-mediated cytotoxicity [Takahashi et al, 1994],
This CTL activation marker has not been studied extensively in the context of organ
transplantation, although there has been a recent upsurge in interest in it. The two
groups of workers in clinical renal transplantation who had correlated intragraft
[Sharma et al, 1996; Strehlau et al, 1996; Strehlau et al, 1997] and peripheral blood
leucocyte [Vasconcellos et al, 1998] GrB gene expression with acute allograft
rejection had also found that FasL gene expression was associated with acute
allograft rejection. However, while recent studies in clinical liver transplants
[Tannapfel et al, 1999], and experimental renal [Wang et al, 1997] and cardiac [Seino
et al, 1996; Josien et al, 1998] transplantation have supported the significant
contribution of FasL to acute allograft rejection, another study using a murine
non-vascularized heterotopic cardiac allograft model has shown that
Fas/FasL-mediated cytotoxicity is not required for murine cardiac allograft rejection
[Djamali and Odorico, 1998]. Indeed, Tannapfel et al [1999] had found that increased
apoptosis, Fas, and FasL expression were, taken by themselves, not useful as
indicators of acute rejection and Borson et al [1999] had concluded that while FasL
gene expression correlated closely with the rejection of murine skin allografts, FasL
was not required for allograft rejection.
1.6 Methods of evaluating the cytokine response following organ
transplantation
As was mentioned in the previous section, the monitoring of cytokines in an attempt
to shed light on the role they play in acute allograft rejection has progressed from the
actual measurement of cytokine protein products to the determination of cytokine
gene expression within the allografts or immune cells. This section briefly reviews
some of the methods used in monitoring the cytokine response.
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Cytokine protein products may be detected in the plasma directly [Johnson et al,
1990; Kutukculer et al, 1995a; Daniel et al, 1995], following stimulation of the
isolated peripheral lymphocytes [Vie et al, 1985; McKenna et al, 1988; Kaminski et
al, 1995] or graft infiltrating cells [Merville et al, 1993; Yard et al, 1994], or from
other body fluids like urine [Simpson et al, 1989; van Oers et al, 1988] and bile [Tilg
et al, 1990; Lang et al, 1996], The advantages of direct measurement of cytokine
protein products are the ease of obtaining samples like plasma and other body fluids
for measurement, and the assays used to detect the cytokines are familiar techniques
of standard ELISA methodology, which have been simplified further by the
widespread availability of pre-packed cytokine ELISA kits. However, as cytokines
produced within the transplanted allograft are secreted locally into the cellular
microenvironment and not directly into the bloodstream, the cytokines detected in
plasma or body fluids are therefore considerably diluted out and consequently the
failure to detect a particular cytokine in plasma or body fluids may not imply an
absence of expression of that cytokine but that the assay has failed to detect it due to
the dilutional effect. The detection of stimulated cytokine protein products from
isolated peripheral lymphocytes or graft infiltrating cells gets over the problem of the
dilutional effect but one needs to be cautious in interpreting results from in vitro
stimulation of these cells since the pattern of cytokine release from the cells have
been artificially created and may therefore not reflect their in vivo cytokine release
patterns.
Cytokine gene expression within the tissues obtained from the allografts may be
detected by in situ hybridisation techniques [Vandenbroecke et al, 1991; Grimm et al,
1995], or the level of gene expression may be detected indirectly by the
reverse-transcriptase polymerase chain reaction (RT-PCR) technique, as the majority
of the studies into acute allograft rejection quoted in the previous section were based
on. The techniques for detecting cytokine gene expression gets over the problem of
dilutional effect seen in direct measurements of cytokine protein products since the
technique is highly sensitive and detects the transcripts present within cells.
However, these techniques are technically more demanding, especially the in situ
-31 -
hybridisation technique. The RT-PCR was the technique used in the present project
and will be described in greater detail in the remainder of this section.
The RT-PCR technique is a powerful molecular biological method that can be used
to measure cytokine gene transcription in a small number of cells [reviewed in
O'Garra and Vieira, 1992], Basically, the technique is a two-stage process, the first
requiring the reverse transcription of the cytokine gene transcripts or messenger
ribonucleic acids (mRNAs) into complementary deoxyribonucleic acids (cDNAs),
followed by the standard polymerase chain reaction (PCR) to amplify these cytokine
cDNAs using two specific oligonucleotide primers that flank each cDNA sequence to
be amplified. Repeated cycles of thermal denaturation of the cDNA, annealing of the
primers to their complementary sequences, and primer extension give an exponential
accumulation of the target fragments. The use of a thermostable DNA polymerase
from Thermus aquaticus (Taq) has substantially improved the specificity, yield,
sensitivity and length of targets that could be amplified, as well as simplifying the
method and making it amenable to automation. The RT-PCR technique may be used
to obtain either qualitative or quantitative determinations of cytokine gene
expression.
In a qualitative RT-PCR determination of cytokine gene expression, it is only
possible to indicate the presence or absence of the particular cytokine gene transcripts
in the tissue sample by the detection of the RT-PCR products using the methods
described in the next section. Qualitative RT-PCR is a commonly used technique in
cytokine research to study acute allograft rejection in the different organ transplants
cited in the previous section [Martinez et al, 1992; Krams et al, 1992; Whitehead et
al, 1993],
The main drawback of qualitative RT-PCR is the inability to distinguish the
difference in the level of cytokine gene expression. Moreover, the determination of
positivity or negativity in a qualitative RT-PCR is dependent on the sensitivity of the
detection technique used. Some form of quantitation of the cytokine gene expression
signals is therefore desirable if changes in the level of expression of the cytokine
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gene transcripts are to be demonstrated. Semi-quantitative RT-PCR where the level
of gene expression of each cytokine is compared with the level of expression of a
constitutionally expressed "housekeeping" gene like (3-globin or actin as an internal
standard, allows for the differential losses that occur during RNA recovery as well as
standardising to some extent the subsequent reverse transcription and PCR. The
popularity of the semi-quantitative RT-PCR technique is demonstrated by its
widespread use in the study of acute allograft rejection [Dallman et al, 1991a;
Lipman et al, 1992; Gaweco et al, 1995; Kirk et al, 1995; McLean et al, 1997],
The ultimate in quantitative RT-PCR is the use of competitive PCR, where a known
amount of a synthetic mRNA (requiring simultaneous reverse transcription first) or
cDNA construct is used as an internal standard and co-amplified in the same reaction
tube with the cytokine gene transcripts to be quantitated using the same primers
[Wang et al, 1989; Gilliland et al, 1990]. The competitor DNA fragment usually
differs from the cDNA of interest by having either a small intron or a mutated
restriction enzyme site, and the two PCR products can then be easily separated by gel
electrophoresis after amplification. As the same PCR conditions are applied to both
the competitor DNA fragment and the cDNA of interest, by titrating an unknown
amount of the cDNA of interest against a dilution series containing known amounts
of the competitor DNA fragment, the amount of the cDNA of interest can then be
reliably quantitated. Theoretically, this technique provides a strategy for absolute and
reproducible quantitation of cDNA by PCR. However, as the competitor is a DNA
standard, there is no standardisation of the reverse transcription of the sample RNA
into cDNA. Therefore, the use of a synthetic RNA construct as the competitor
internal standard instead has been advocated to overcome this potential problem of
differential efficiency in reverse transcription [Kanangat et al, 1992; Alms et al,
1996]. As quantitative RT-PCR is clearly a much more technically demanding
technique, it is not surprising that there are only a few studies in transplantation
cytokine literature that uses this technique [Strehlau et al, 1996; Strehlau el al, 1997].
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1.7 Detection of RT-PCR products
It is obvious that just as the different RT-PCR methodologies described in the
previous section have significant bearings on the type and quality of results obtained,
it must be emphasized too that the method chosen for detecting and quantitating the
amount of the resultant PCR products is equally important no matter which method
of RT-PCR is chosen to amplify the gene transcripts of interest.
Several commonly used methods in the detection of RT-PCR products have been
described in the current cytokine research literature. These methods are reviewed in
the following paragraphs, not as an exhaustive treatise on the subject, but in order
that the method chosen for the project may be put in its context. Although these
methods are in common use in molecular biology laboratories, no reviews of the
methods are available in the literature and so the references quoted in this section are
only examples of the methods described.
The simplest method of detecting PCR products is the visual assessment of the
"brightness" of bands on the image (captured on a Polaroid film, or more recently,
captured digitally by a computer and subjected to manipulations before printing)
produced after ultra-violet trans-illumination following electrophoresis of PCR
products loaded in agarose or polyacrylamide gel with ethidium bromide staining of
the PCR products [Martinez et al, 1992], The presence of the appropriately sized
PCR products can be predicted by the position of the primers on the cDNA sequence.
The detection of small amounts of PCR products using this method is poor, and
being a non-quantitative method, the differentiation of quantitative differences
between the bands is crude. To enable a quantitative assessment of the "brightness"
of the bands, the photographic image of the gel on a special film can be scanned by
laser densitometry [Strehlau et al, 1997],
A more sensitive and specific method of detecting PCR products, which can also be
used to quantify the amount of PCR products, involves the detection of radioactivity
which had been incorporated into the PCR products. The PCR products are first
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resolved by gel electrophoresis and the incorporated radioactivity may then be
quantitated directly from the excised gel bands using a scintillation counter
[Kanangat et al, 1992], or the gel can be dried on a special paper and the radioactivity
analysed using a gel scanner [Kirk et al, 1995].
An alternative to the previous method is to transfer the PCR products onto a nylon
membrane first by Southern blotting [Alms et al, 1996] or dot blotting [Dallman et al,
1991a], followed by radioactive-labelled oligonucleotide probing of the PCR
products. The subsequent detection of the hybridised product/probe complex can be
accomplished either by exposure on a radiographic film for qualitative analysis
[Whitehead et al, 1993], or the radioactive signal can be quantitated directly by image
scanning of the nylon membrane [O'Garra and Vieira, 1992], An alternative to direct
quantitation of the radioactive signal on the nylon membrane is the assessment of the
intensity of the band on the autoradiograph using scanning densitometric analysis
[Lipman et al, 1992],
A similar concept to the radioactive-based method described previously is using
non-radioactive-labelled immunochemical oligonucleotide probes following the
transfer of the PCR products onto a nylon membrane, with the exposure of the
membrane-bound signal onto a radiographic film resulting from an enzyme-activated
chemiluminescence. The signal detected on the radiographic film can be assessed
qualitatively [Martinez et al, 1993], or the signal on the film can be quantitated using
a laser densitometer [Wagner et al, 1997],
The latest method available at the commencement of this study was again a
non-radioactive-based method called PCR ELISA. As the name suggest, it uses an
enzyme-linked immuno-sorbent assay to detect the PCR products [Janezic et al,
1995], This is a relatively novel method to detect PCR products with no published
study in clinical transplantation demonstrating its use. This method was chosen for
the project because it is highly sensitive in detecting PCR products (much more so
than the gel electrophoresis method) and is relatively easy to use. Moreover, the
spectrophotometric readings generated by the PCR ELISA provide a numerical
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expression of the amounts of PCR products present which will allow
semiquantitative comparison of level of gene expression at the different time points
for each cytokine/CTL activation marker for the same patient. The details of this
method will be described further in section 2.5 of chapter 2.
1.8 Outline of the project
This project aims to establish whether sequential monitoring of peripheral T cell
cytokine gene expression can correlate and reflect the clinical immunological status
of renal transplant patients.
In addition, the sequential changes in peripheral T cell cytokine gene expression may
also shed light on their role in graft acceptance and acute rejection.
We set out to monitor the changes in the immunological status of patients following
renal transplantation by studying the changes in peripheral T cell alloreactivity based
on its cytokine and CTL activation marker gene expression profiles during the first
six weeks following renal transplantation. There are several differences and unique
features in our approach from the many studies reported in the literature and these are
set out in the following paragraphs.
As many single time-point studies so prevalent in the cytokine literature can only
provide a "snap-shot" of what is happening immunologically at the time of sampling,
it is not surprising that conflicting findings about the association of certain cytokines
with acute allograft rejection have been reported by these studies as discussed in the
literature review set out in section 1.5. We have chosen to do a sequential study
instead, so that the gene expression of the immune cells from each patient can be
monitored longitudinally and the level of gene expression at the different sampling
time points can be compared with one another.
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Instead ofmonitoring the level of cytokine gene expression within the allografts as in
most of the intragraft studies quoted in section 1.5, we chose to study the changes in
the alloreactivity of peripheral blood T cells for several reasons. We have chosen to
study T cells because they are the central player of the body's immune system
orchestrating the complex allograft response seen during acute rejection. We accept
that the population of T cells activated by the allograft would inevitably be diluted in
the peripheral blood during its recirculation from the allograft back to the rest of the
body, and therefore their contained immune activation signals would be faint in
comparison to that obtained from within the graft itself. Nevertheless, as it is
relatively easy to separate out the different cellular components of the circulating
immune system, it would be possible to concentrate our study on the changes in
alloreactivity of a single subset of immune cells, in this case the peripheral blood T
cells. One could then attempt to correlate the gene expression profiles of peripheral T
cells as a result of their exposure to the transplanted allograft over a period of time
with the clinical course following renal transplantation, without the confounding
problem of having multiple immune activation signals produced by the numerous cell
populations contained in an intragraft sample. This problem is inevitable in intragraft
studies since it is not possible to separate out the different immune and non-immune
cell populations from needle core biopsies or fine needle aspirations obtained directly
from the allografts, and this problem could also contribute to the many conflicting
findings from such studies mentioned previously.
The validity of using peripheral T cells in our study to monitor intragraft
alloreactivity has been supported by phenotypic studies which have shown that
changes in the peripheral mononuclear cell subpopulations do reflect closely changes
in these subpopulations within the allografts [Takahara et el, 1989; Tashiro et al,
1989], Moreover, if immunological monitoring is to become a clinical reality in the
future, then peripheral blood sampling as a means to achieve this would be a much
more acceptable investigative modality to patients and clinicians alike than either
needle core biopsy or fine needle aspirations.
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The aim of our study was to investigate the changes in the alloreactivity of peripheral
blood T cells following renal transplantation by monitoring the sequential changes in
gene expression levels of Thl and Th2 cytokines (i.e., to elucidate the nature of the
Thl/Th2 paradigm in the periphery), as well as CTL activation markers, in peripheral
blood samples during the early post renal transplant period, which we have limited to
the first 6 weeks following renal transplantation. We were interested in establishing
the cytokine/CTL activation marker gene expression profiles in the following groups
of patients: namely, patients with no acute rejection episode (i.e. tolerant to the graft),
patients with episode(s) of acute rejection responsive to anti-rejection therapies, and
patients with acute rejection unresponsive to anti-rejection therapies.
A total of 6 cytokines and 2 CTL activation markers were studied in the project, and
they were studied in two phases. In the first phase of the project, two Thl cytokines
(IL-2 and IFN-y) and two Th2 cytokines (IL-4 and IL-10) were studied. Based on
these preliminary results, we decided to study two other Th2 cytokines (IL-5 and
IL-13) and two CTL activation markers (GrB and FasL).
Following full approval from the hospital's ethical committee for the project, patients
were recruited from the renal transplant programme of the Wessex Renal and
Transplant Unit based at St Mary's Hospital, Portsmouth. Peripheral blood samples
were taken from recruited patients prior to transplantation and then at 4 time intervals
following transplantation (day 2 to 3, day 5 to 7, day 10 tol4 and around day 30) to
cover the critical period when acute rejection commonly occurs. In addition, with
each documented rejection episode, blood would be taken prior to the
commencement of anti-rejection therapy, at the end of the anti-rejection therapy, and
then at approximately 1 week and 1 month following anti-rejection therapy, so that
the changes in peripheral T cell alloreactivity at the time of acute rejection and the
effect of the treatment for the acute rejection episode could be monitored.
The cytokine/CTL activation marker gene expression of peripheral T cells were
assayed indirectly using genetic engineering technology described in the previous
section. In summary, the polymerase chain reaction technique was used to amplify
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the cDNA derived from reverse transcription of the cytokine/CTL activation marker
gene transcripts isolated from the peripheral blood T cells, and the resulting amount
of specific amplified product was assayed using spectrophotometric quantitation
following an enzyme-linked immunosorbent assay.
The T cell gene expression profile of each cytokine or CTL activation marker for
each patient was obtained by measuring the gene expression of all the samples from
each patient at the same time to enable suitable sequential semi-quantitative
comparison in the level of gene expression between the different sampling time
points. The details of the technique involved in isolating the T cells, the extraction,
quantitation and standardisation of total RNA extracted from the T cells, the reverse
transcription of the total RNA to cDNA, followed by the polymerase chain reaction
and semi-quantitative detection of the amplified products are set out in the next
chapter.
There are several potential benefits in monitoring changes in the immunological
status of patients following renal transplantation which are clinically relevant. The
most obvious benefit is that it may result in the earlier detection of acute rejection,
thus facilitating an earlier and more effective treatment of the rejection episode,
thereby reducing the degree of graft damage and consequently improving the
long-term function of the allograft. The corollary of this benefit is the confident
exclusion of the diagnosis of acute rejection as the cause of early graft dysfunction
and allowing the diagnosis of cyclosporin A toxicity to be considered earlier and
tested by a confident dose reduction.
Another potential benefit of immunological monitoring may be the achievement of
one of the long term objectives in transplantation, that is, the maintenance of the
allografts free of acute rejection episodes using the minimal amount of
immunosuppressive drugs, both in terms of the dosages of the individual drug and
the number of drugs used in the immunosuppressive regimens. This objective may be
achievable if immunological monitoring can reliably detect a state of acquired graft
tolerance thus allowing a safe and earlier reduction in immunosuppression in the post
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transplant period, with the accompanying benefit of a reduction in the number and
severity of opportunistic infections both in the short and medium term, and possibly
ofmalignancies in the long term.
Finally, immunological monitoring may aid in the clinical decisions about
continuing, changing or stopping the powerful immunosuppressive agents used to
treat acute rejections. If immunological monitoring could predict the success or
failure of an anti-rejection regime during the course of the treatment, it could enable
an earlier switch to a different anti-rejection regimen, or even spare patients of the
unavoidable associated morbidity of persisting with further immunosuppression, if
immunological monitoring suggests a likely failure of the anti-rejection regimen
used.
We hope that this project would contribute towards achieving some of these potential
benefits of immunological monitoring of patients following their renal
transplantation.
In summary, the specific issues addressed in this thesis are as follows:
1. the development of an efficient method of isolating T cells from peripheral blood.
2. the validation and further development of a semi-quantitative molecular assay of
cytokine/CTL activation marker gene expression that is both reliable and
reproducible.
3. the establishment of the sequential cytokine/CTL activation marker gene
expression profiles in patients experiencing acute allograft rejection and those
who do not.
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Chapter 2: MATERIALS & METHODS
This chapter details all the materials and methods of all the experimental protocols
used for the project and the statistical methods applied to the data collected. The first
section deals with the cell separation protocol while the next 4 sections record all the
molecular protocols, beginning with the main work with RNA (extraction of total
RNA, its quantitation and standardisation), followed by reverse transcription, through
the main polymerase chain reaction (PCR) protocols and finishing with the PCR
ELISA (enzyme-linked immunosorbent assay) detection methodology. The
penultimate section describes the verification of the integrity of the stored cDNAs by
PCR of the house-keeping (3-globin gene, and the final section gives a brief
description of the statistical methodology used in the analysis of the data from the
preliminary cell separation experiments and from the patients recruited in the project.
2.1 Cell separation
The first stage in the laboratory work-up for each peripheral blood sample taken from
the patients was the separation of the peripheral blood lymphocytes from the rest of
the blood components. The cell separation methodology evolved from detailed
preliminary experiments on blood samples taken from healthy individuals as well as
from post-transplant patients prior to the recruitment of patients for the study (see
chapter 3 for details). The method finally chosen was selected to ensure the highest
possible purity of lymphocytes obtainable while avoiding prolonged and excessive in
vitro manipulation of the cells which has the potential of influencing the gene
expression signal by causing not only the induction of a particular cytokine mRNA,





The mononuclear cells from the peripheral blood were first isolated by density
gradient centrifugation using Lymphoprep. Following the centrifugation, the
peripheral blood sample would be separated into four layers based on the density of
the various blood components relative to the Lymphoprep, namely (from the bottom
of the tube): (1) the red blood cells clumped together with the granulocytes; (2) a
clear Lymphoprep layer; (3) a narrow and variable-sized band of "buffy coat"
containing the mononuclear component of the white blood cells; (4) the straw-
coloured plasma finally as the top layer. The "buffy coat" layer of mononuclear cells
was carefully retrieved and subjected to the next step of cell purification.
Cell purification
The aim of this step is to produce a highly enriched preparation of T lymphocytes.
This consisted of a sequential combination of non-specific and specific methods to
remove monocytes, B cells and NK cells. The non-specific physical method of
adherence onto plastics by monocytes was based on their phagocytic properties
[Koller et al, 1973], Platelets were also removed during this step because of their
inherent adherent properties upon activation. The specific method, termed panning,
involved using mouse anti-human monoclonal antibodies to remove the remaining
monocytes, B lymphocytes and NK cells by negative selection onto plates coated
with rabbit anti-mouse antibodies [Wysocki and Sato, 1978], At the end of the
panning step, the remaining mononuclear cells consist essentially of enriched T
lymphocytes.
Consumables:
1. Lymphoprep, specific gravity 1.077 g/1 [Nycomed, UK]
2. Phosphate buffered saline (PBS) without calcium or magnesium (10X) [Life
Technologies, UK]
3. Dulbecco's PBS (with calcium and magnesium) (10X) [Life Technologies, UK]
4. RPM1 1640 (with 25 mM HEPES & L-glutamine) [Life Technologies, UK]
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5. Sodium pyruvate (100 mM) [Life Technologies, UK], 1 ml added per 100 ml
RPMI 1640
6. L-glutamine (200 mM) [Life Technologies, UK], 1 ml added per 100 ml RPMI
1640
7. Fetal calf serum (FCS) [Life Technologies, UK], heat inactivation of
complements at 56 °C for 30 mins and filtered prior to use
8. Rabbit anti-mouse antibodies (1.6 g/1) [Dako, UK]
9. Monoclonal mouse anti-human antibodies to CD lib (MCA551X), CD 14
(MCA596XZ), CD 16 (MCA1193XZ) & CD 19 (MCA662X) - all at 1 mg/ml
[Serotec, UK]
10. Sigma Trizma Base (Sigma, UK) - 0.05 M Tris (hydroxymethyl)aminomethane,
pFI 9.5 prepared by dissolving 3.03 g of Trizma base in 500 ml of sterile distilled
water, adjusting the pH to 9.5 with 2.5 M hydrochloric acid
11. Sterile 50 ml skirted conical-based polypropylene tubes [Greiner Labortechnik,
UK]
12. Sterile 15 ml conical-based polypropylene tubes [Greiner Labortechnik, UK]
13. Tissue culture grade petri dishes [Greiner Labortechnik, UK]
14. Sterile 3.5 ml Pasteur pipettes [Greiner Labortechnik, UK]
15. Sterile petri dishes [Bibby Sterilin, UK]
16. 10 ml Becton Dickinson Vacutainers tubes with sodium citrate [liospital
Management & Supplies, UK]
17. 0.22 p. filters [Life Sciences, UK]
Equipment:
1. MSE Mistral 3000i centrifuge [Sanyo, UK]
2. Stuart Scientific tilting tube roller with 5 rollers providing rocking and rolling
shaking [Philip Flarris Scientific, UK]
3. Water-jacket incubator, Model 3157 [Forma Scientific, USA]
4. Techne MWB-10L microcarrier water bath [Techne (Cambridge), UK]
5. Micro flow pathfinder laminar flow cabinet [MDF1, UK]
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Method:
For each sampling, up to 20 ml of peripheral blood was collected into two 10 ml
vacutainer tubes, each tube containing 1 ml of sodium citrate as anti-coagulant. The
volume of blood collected was variable because of the nature of the tubes used
(variability in the amount of vacuum within the tubes) and dependent on the duration
that each tube was connected to the vacutainer collection system during venesection.
The volume of blood for cell separation was first diluted 1 in 1 with PBS/2% FCS in
a sterile 50 ml polypropylene tube. About 10 ml of the diluted blood was then
carefully layered onto 4 ml of Lymphoprep in a sterile 15 ml conical-based
polypropylene tube. Usually three or four of these tubes were used for each patient's
blood sample. The tubes were spun at 2500 rpm (llOOg) for 20 mins in an MSE
Mistral 3000i centrifuge at room temperature (set at 20 °C) and without any
acceleration or brake settings.
Following centrifugation, the "buffy coat" containing the mononuclear cells was
carefully removed onto a sterile 50 ml polypropylene tube using a Pasteur pipette.
The mononuclear cells were then washed once with PBS/2% FCS and the cells
pelleted by centrifuging at 1500 rpm (400g) for 10 mins with maximum acceleration
and brake applied.
The pelleted cells were resuspended in 8 ml of warm tissue culture medium (RPMI
1640 with HEPES, L-glutamine, sodium pyruvate and 10% FCS). The cell
suspension was then incubated on 2 tissue culture grade petri dishes in an incubator
at 37 °C for 30 mins. The non-adherent cells were removed onto a sterile 50 ml
polypropylene tube by gently washing the petri dishes with warm tissue culture
medium using the Pasteur pipette. The cells were again pelleted by centrifuging at
1500 rpm (400g) for 10 mins with maximum acceleration and brake applied.
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Table 2.1.1 - Monoclonal antibodies used for panning and the cells they identify
mAb Mononuclear cells identified bv the monoclonal antibodies
CDllb Monocytes B cells NK cells
CD14 Monocytes - -
CD16 Monocytes - NK cells
CD19 - B cells -
The pelleted cells were resuspended in 400 pi of Dulbecco's PBS/5% FCS and 10 pi
of each of the 4 monoclonal antibodies (to CD lib, 14, 16 & 19) were added to the
cell suspension. The different mononuclear cells which these monoclonal antibodies
identify is listed in table 2.1.1. The cell suspension was then incubated at 4 °C (by
placing the 50 ml polypropylene tube containing the cell suspension in a bottle filled
with ice) on a Stuart roller for 30 mins to ensure thorough mixing.
The excess antibodies were then washed off with Dulbecco's PBS/5% FCS and
centrifuging at 1500 rpm (400g) for 10 mins with maximum acceleration and brake
applied. The pelleted cells were resuspended in 8 ml of Dulbecco's PBS/5% FCS and
incubated on a Sterilin petri dish coated with rabbit anti-mouse antibodies for 45
mins at 4 °C (by placing the plate in the fridge). Each Sterilin petri dish was prepared
by incubating 50 pi of rabbit anti-mouse antibodies (at 1.6 g/1) in 8 ml of 0.05 M Tris
(at least overnight incubation at 4 °C) and then blocked against non-specific
adherence with Dulbecco's PBS/2% FCS for at least 1 hour prior to use.
The non-adherent cells were recovered onto a sterile 50 ml polypropylene tube by
gentle washing of the Sterilin petri dish with Dulbecco's PBS/5% FCS using a
Pasteur pipette, reconstituting the volume to 15 ml final volume. 2 ml of the cell
suspension was removed for cell counting, while the remaining cells were pelleted by
centrifuging at 1500 rpm (400g) for 10 mins with maximum acceleration and brake
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applied. The cell count was performed using a Coulter counter by the Haematology
department at St Mary's Hospital.
2.2 Extraction of total RNA , RNA quantitation & standardisation
Extraction of total RNA from the cell pellet was commenced by homogenising the
cell pellet in 1 ml of RNAzol B, a commercial preparation for undegraded RNA of
high purity. The homogenate was transferred to a sterile 1.5 ml eppendorf for
temporary storage in a minus 20 °C freezer.
The extraction of total RNA from the cell pellet was based on the single-step method
of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
[Chomczynski and Sacchi, 1987]. This method provided a high yield of undegraded
RNA preparations with high purity.
Consumables: all the reagents and pipette tips were strictly allocated for RNA use
only to prevent inadvertent contamination with ribonucleases.
1. RNAzol B [Biogenesis, UK], a commercial preparation containing guanidinium
thiocyanate, phenol and P-mercaptoethanol. Guanidinium thiocyanate, a potent
denaturing agent [Cox, 1968], together with the reducing agent P-mercaptoethanol
[Sela et al, 1957], are both potent inactivators of ribonucleases.
2. 0.1% diethyl pyrocarbonate (DEPC) [Sigma, UK] in distilled water (DEPC-water)
- this is a strong, but not absolute, inhibitor of ribonucleases [Fedorcsak and
Ehrenberg, 1966] and is prepared by adding 100 pi of DEPC to 100 ml of
double-distilled water, leaving the solution overnight in a fume cupboard and then
autoclaving the solution.
3. Chloroform [Merck, UK]
4. Isopropanol [Merck, UK]
5. 75% ethanol - prepared by dilution of absolute ethanol [James Burroughs, UK]
with DEPC-water
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6. Sterile pipette tips of various sizes [Greiner Labortechnik, UK]
7. Sterile 1.5 ml eppendorfs [Greiner Labortechnik, UK]
Equipment:
1. Heraeus Sepatec Contifuge 17RS centrifuge [Heraeus, UK]
2. Windsor Incubator, set at 45 °C [Sandrest, UK]
3. Whirlimixer (vortex) [Jencons Scientific, UK]
4. Water bath, set at 55 °C [Grant Instruments, UK]
5. GeneQuant RNA/DNA Calculator [Pharmacia, UK]
6. Ultramicrovolume cell (5 pi) [Pharmacia, UK]
7. Pipettes of various volume ranges (Gilson, Eppendorf, Biohit) [Anachem, UK;
Merck, UK; Alpha Laboratories, UK]
Method: RNA extraction
The RNAzol B homogenates were completely thawed out during their transport from
Portsmouth to the Molecular Biology Laboratory in Southampton. On arrival, they
were placed on ice to reduce the risk ofRNA degradation.
The centrifuge was first cooled down to 4 °C prior to use. 100 pi of chloroform was
added to each eppendorf of RNAzol B homogenate. The eppendorf was shaken
(rather than vortexed) vigorously for at least 15 sec and then left to stand on ice for
5 mins. The mixture was then centrifuged at 12000 rpm (12000g) for 15 mins at 4 °C.
Following centrifugation, the homogenate separated into two phases, a lower bluish
phenol-chloroform phase and a colourless upper aqueous phase containing the RNA,
with a whitish interphase containing DNA and proteins. The upper aqueous phase
(usually 500 to 600 pi) was transferred into a sterile 1.5 ml capped eppendorf,
carefully avoiding the interphase.
The RNA was precipitated in isopropanol. 600 pi of isopropanol was added to the
aqueous phase, the two solutions were thoroughly mixed by the vortexing. The
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mixture was left to stand on ice for about 45 mins to allow the RNA to precipitate.
The precipitated RNA was then pelletted by centrifuging at 12000 rpm (12000g) for
15 mins at 4 °C. The supernatant was discarded, carefully avoiding the RNA pellet
which appeared as a whitish streak at the bottom of the eppendorf.
The RNA pellet was washed by vortexing in 500 pi of cold 75% ethanol (stored at
minus 20 °C) before being pelleted again by centrifuging at 7500 rpm (7500g) for
8 mins at 4 °C. The ethanol was removed to dryness, again carefully avoiding the
RNA pellet, and the RNA pellet was then dried by leaving the eppendorf open in a
sterile petri dish placed in an incubator (set at 45 °C) for about 10 to 15 mins. It was
important to avoid over-drying the RNA pellet as it would make its solubilization
difficult.
Depending on the size of the RNA pellet, between 15 and 50 pi of DEPC-water was
added to solubilize the RNA pellet. To aid solubilization, the eppendorf containing
the RNA solution was placed in a 55 °C water bath for 5 mins prior to quantitation.
The eppendorf containing the RNA solutions were placed on ice upon removal from
the 55 °C water bath.
Method: RNA quantitation
The setup of the GeneQuant RNA/DNA calculator was first set for RNA quantitation
by the following criteria:
- path length = 5
- use 320 nm? = Yes
- RNA factor = 40.0
- bases number (A, C, G, T, U) = 0
- oligo length = 1
- mw calc = 0.0
- ratio expected = 2.000
- conc. expected = 0.000
- protein coeff. 1 = 1.550; protein coeff. 2 = 0.760
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Prior to using the ultramicrovolume cell for each reading, the cell was cleaned by
sequentially flushing the cell chamber with 0.1 M sodium hydroxide, 0.1M
hydrochloric acid, ultra-high quality water and DEPC-water, flicking the fluid off
each time. The cell was wiped dry with tissue paper and the cell chamber aspirated to
dryness using a Cristal-tip on a 10 pi pipette.
The GeneQuant was zeroed by using DEPC-water as the reference. For each
quantitation, 5 pi of the neat RNA solution or its appropriate dilution was placed in
the cleaned cell chamber. The absorbance at 260 nm and 280 nm, its ratio and the
RNA concentration in pg/ml was read from the GeneQuant. A 260/280 ratio of
greater than 1.9 was expected from the RNA extraction technique used.
When the absorbance at 260 nm was high (eg. nearly or greater than 3.000) resulting
in a 260/280 ratio of less than 1.9, a dilution of the RNA solution was quantitated and
the original RNA concentration calculated from the readings made of the dilution.
Method: RNA standardisation
Once the diluted RNA solutions were quantitated, the concentrations of the undiluted
RNA solutions were calculated by multiplying the concentrations of the RNA
solutions by the dilution factor of the RNA solutions used in the quantitation.
The RNA solutions were standardised into 1 pg of total RNA in 8 pi volumes prior to
reverse transcription by diluting the calculated amount of RNA solution with the
corresponding volume of DEPC-water.
Following some preliminary experiments, it was found that 1 pg of total RNA would
be an appropriate quantity of RNA for reverse transcription both in terms of the
corresponding quantity of first-strand cDNA necessary for successful cytokine PCR
and the available quantity of total RNA extractabie from the often lymphopaenic
post-transplant patients.
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Four 1 pg aliquots of RNA solutions (8 pi each) for each patient sample were
prepared whenever possible. To simplify the reverse transcription procedure, all the
1 pg aliquots of RNA were combined into a single 0.75 ml eppendorf tube for the
denaturation step before aliquoting the 1 pg of RNA solution into the cDNA
synthesis reaction tubes. To compensate for evaporative loss during the denaturation
step, about 1 to 2 pi of extra DEPC-water were added to the combined aliquots of
RNA solutions (depending on the amount of cDNA to be synthesized) during the
standardisation procedure.
2.3 First-strand cDNA synthesis (reverse transcription)
The reverse transcription of total RNA extracted was catalyzed by Moloney Murine
Leukaemia Virus (M-MuLV) reverse transcriptase. The First-Strand cDNA Synthesis
Kit from Pharmacia Biotech provide all the reagents necessary to generate full-length
first-strand cDNAs from RNA templates 7 kilobases or more in length using primers
provided.
Consumables: Kit components used for the reverse transcription
1. Bulk first-strand cDNA reaction mixes - cloned, FLP Cpure® Murine Reverse
Transcriptase, RNAguard, RNase/DNase-Free BSA, dATP, dCTP, dGTP and
dTTP in aqueous buffer.
2. DTT solution - 200 mM aqueous solution of dithiothreitol (a reducing agent).
3. Not I-d(T)i8 Afunctional primer - an aqueous solution at 5 pg/pl of RNA (primer
sequence: 5'-d[AACTGGAAGAATTCGCGGCCGCAGGAAT,8]-3'), diluted 1
in 25 prior to use.
4. RNase-free water - treated with diethyl pyrocarbonate (DEPC).
Equipment:
1. Amplirad UV cabinet [Gene Research Instrumentation, UK] - previously sterilised
0.75 ml eppendorf tubes were UV-irradiated for at least 10 minutes before use.
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2. Laminar airflow cabinet [MDH, UK]
3. Pipettes of various volume ranges (Gilson, Eppendorf) [Anachem, UK; Merck,
UK]
4. Hybaid thermal reactor [Hybaid, UK]
5. Whirlimixer (vortex) [Jencons Scientific, UK]
6. Water bath, set at 37 °C [Grant Instruments, UK]
Method:
Following standardisation of the total RNA into 1 pg (in 8 pi volume) aliquots, the
standardised RNA solutions were heated to 65 °C for 10 minutes using a Hybaid
thermal reactor to denature the RNA before being chilled in ice for 5 to 10 mins.
While the RNA solutions were being heated, cDNA reaction tubes were set up by
adding 5 pi of bulk first-strand reaction mix, 1 pi of DTT and 1 pi of Not I-d(T)is
primer into labelled 0.75 ml sterile eppendorf tubes (UV-irradiated).
Next, 8 pi of the denatured RNA solutions were transferred to each cDNA reaction
tube (making a total volume of 15 pi each) and the resulting reaction mixture was
mixed thoroughly by pipetting it in and out. The cDNA reaction tubes were incubated
in a 37 °C water bath for one hour before being stored at minus 70 °C for subsequent
molecular analysis.
2.4 Polymerase chain reaction (PCR) for cytokine and cytotoxic
T-lymphocyte (CTL) activation marker gene expression
The PCR protocols used in the project were modified from the protocols developed
by the Molecular Immunology Laboratory of the Department of Medicine, University
of Southampton. The cytokine primer sequences and their biotinylated capture probe
sequences used in the PCR ELISA detection system were also kindly provided by the
Department of Medicine.
As for the CTL activation markers, the primer sequences for granzyme B and fas
ligand were obtained from a recent paper by Strom's group [Strehlau et al, 1997],
The capture probe sequences for use in the PCR ELISA system for both PCR
products were kindly designed for us by John Holloway (Molecular Genetics Group,
University of Southampton), using the OLIGO 5 programme.
The preliminary experimental work on all the molecular protocols used in the project
is detailed in chapter 4.
Consumables:
1. Ultra-violet light irradiated double-distilled water (ddLLO)
2. Magnesium chloride (MgCf) at 25 mM concentration [Boehringer Mannheim,
UK]
3. PCR reaction buffer without magnesium chloride, 10X concentration, containing
100 mM Tris-HCl, 500 mM KC1, pH 8.3 [Boehringer Mannheim, UK]
4. PCR digoxigenin (DIG)-labelling mix, containing 2 mM dATP, dCTP, dGTP
each, 1.9 mM dTTP, 0.1 mM digoxigenin-11-dUTP, pH 7.0 [Boehringer
Mannheim, UK]
5. Cytokine and CTL activation marker primers, diluted from stock solutions to
10 pM concentrations [R&D Systems, UK & Eurogentec, UK]
6. Thermus aquaticus (Taq) polymerase at 5 U/pl [Boehringer Mannheim, UK]
7. 1.5 ml eppendorfs [Greiner Labortechnik, UK]
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8. 0.2 ml thin-walled PCR tubes/caps (strip of 8 tubes/caps each) [Advanced
Biotechnologies, UK]
9. Sterile pipette tips of various sizes [Greiner Labortechnik, UK]
Oligonucleotide primer sequences (5' to 3'):
1) Interleukin-2 (IL-2): product size 255 base pairs (as amplified from cDNA)
Sense primer - GCC ACA GAA CTG AAA CAT CT
Anti-sense primer - AGT CAG TGT TGA GAT GAT GC
2) IL-4: product size 449 base pairs (as amplified from cDNA)
Sense primer - CTG CAA ATC GAC ACC TAT TA
Anti-sense primer - GAT CGT CTT TAG CCT TCC
3) Interferon gamma (IFN-y): product size 270 base pairs (as amplified from cDNA)
Sense primer - GGT CAT TCA GAT GTA GCG GA
Anti-sense primer - GCG TTG GAC ATT CAA GTC AG
4) IL-10: product size 231 base pairs (as amplified from cDNA)
Sense primer - CTT GTC TGA GAT GAT CCA G
Anti-sense primer - CTC ATG GCT TTG TAG ATG CC
5) IL-5: product size 257 base pairs (as amplified from cDNA)
Sense primer - CTG AGG ATT CCT GTT CCT GT
Anti-sense primer - CAA CTT TCT ATT ATC CAC TC
6) IL-13: product size 500 base pairs (as amplified from cDNA)
Sense primer - CGG TCA TTG CTC TCA CTT GCC TT
Anti-sense primer - TTA CCC CTC CCT AAC CCT CCT T
7) Granzyme B (GrB): product size 431 base pairs (as amplified from cDNA)
Sense primer - GGG GAA GCT CCA TAA ATG TCA CCT
Anti-sense primer - TAC ACA CAA GAG GGC CTC CAG AGT
8) Fas ligand (FasL): product size 301 base pairs (as amplified from cDNA)
Sense primer - GCC TGT GTC TCC TTG TGA
Anti-sense primer - GCC ACC CTT CTT ATA CTT
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Equipment:
1. Elgastat Option 4 water purifier (for double-distilled water) [Elgaserve, UK]
2. Amplirad ultra-violet light cabinet [Genetic Research Instrumentation, UK]
3. Laminar airflow cabinet [MDH, UK]
4. Whirlimixer (vortex) [Jencons Scientific, UK]
t
5. Pipettes of various volume ranges (Gilson, Eppendorf, Biohit) [Anachem UK;
Merck, UK; Alpha Laboratory, UK]
6. Perkin-Elmer GeneAmp System 9600 thermal cycler [Perkin-Elmer, UK]
Method:
Prior to the start of PCR experiments, sterile 1.5 ml eppendorfs and double-distilled
water were first irradiated with UV light for 10 to 15 mins to destroy any inadvertent
contamination of the experiments with foreign DNA. The cDNA from each patient
series and the reagents for PCR were thawed out in ice.
A master reagent mix was made for each PCR by using the volumes (in pi) of each
reagent as set out in table 2.4.1 for IL-2, IL-13 and IFN-y, table 2.4.2 for IL-4 and
IL-10 and table 2.4.3 for IL-5, GrB and FasL, depending upon the number of samples
in each patient series to be analysed per PCR run.
The total volume of master reagent mix for each patient sample series set out in the
tables include an extra aliquot for the negative control (using UV-irradiated
double-distilled water) for each PCR. Moreover, to overcome the inherent
inaccuracies (small but nevertheless unavoidable) arising from multi-aliquot
pipetting, and to ensure that the sufficient master reagent mix was available for each
sample, an excess aliquot of each PCR master reagent mix was prepared. Each
reagent was vortexed immediately prior to aliquoting into the master reagent mix.
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Table 2.4.1 - Master reagent mix for IL-2, IL-13 and IFN-y PCR
Number of samples in patient series 5 6 7 8
ddH20 - 12.5 pi* 87.5 100.0 112.5 125.0
MgCl2 (25 mM) - 2.0 pi* 14.0 16.0 18.0 20.0
Boehringer 10X reaction buffer
(without MgCI2) - 2.5 pi*
17.5 20.0 22.5 25.0
DIG-labelling mix - 2.5 pi* 17.5 20.0 22.5 25.0
Sense primer (10 pM) - 1.5 pi* 10.5 12.0 13.5 15.0
Anti-sense primer (10 pM) -1.5 pi* 10.5 12.0 13.5 15.0
Taq polymerase (Boehringer) - 0.2 pi* 1.4 1.6 1.8 2.0
Notes: * volume of reagent per sample; all the volumes are in pi
Table 2.4.2 - Master reagent mix for IL-4 and IL-10 PCR
Number of samples in patient series 5 6 7 8
ddH20 - 12.0 pi* 84.0 96.0 108.0 120.0
MgCl2 (25 mM) - 2.5 pi* 17.5 20.0 22.5 25.0
Boehringer 10X reaction buffer
(without MgCl2) - 2.5 pi*
17.5 20.0 22.5 25.0
DIG-labelling mix - 2.5 pi* 17.5 20.0 22.5 25.0
Sense primer (10 pM) - 1.5 pi* 10.5 12.0 13.5 15.0
Anti-sense primer (10 pM) - 1.5 pi* 10.5 12.0 13.5 15.0
Taq polymerase (Boehringer) - 0.2 pi* 1.4 1.6 1.8 2.0
Notes: * volume of reagent per sample; all the volumes are in pi
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Table 2.4.3 - Master reagent mix for IL-5, GrB & FasL PCR
Number of samples in patient series 5 6 7 8
ddH20 - 13.5 pi* 94.5 108.0 121.5 135.0
MgCl2 (25 mM) - 1.0 pi* 7.0 8.0 9.0 10.0
Boehringer 10X reaction buffer
(without MgCh) - 2.5 pi*
17.5 20.0 22.5 25.0
DIG-labelling mix - 2.5 pi* 17.5 20.0 22.5 25.0
Sense primer (10 pM) - 1.5 pi* 10.5 12.0 13.5 15.0
Anti-sense primer (10 pM) - 1.5 pi* 10.5 12.0 13.5 15.0
Taq polymerase (Boehringer) - 0.2 pi* 1.4 1.6 1.8 2.0
Notes: * volume of reagent per sample; all the volumes are in pi
2.5 pi of ddHhO (serving as negative control) and 2.5 pi of each cDNA in the patient
sample series (thoroughly mixed first by pipetting in and out several times) were
aliquoted into previously labelled 0.2 ml PCR tubes, the number of tubes per strip
being adjusted according to the number of samples in each patient sample series. The
Taq polymerase (kept at minus 20 °C) was added to the master reagent mix
immediately before it was aliquoted into the PCR reaction tubes containing the
cDNA or ddfFO. 22.5 pi of each PCR reagent mix (thoroughly mixed by vortexing
prior to use) was added to each PCR tube containing ddFfO or cDNA, making a total
PCR reaction volume of 25 pi.
The PCRs were performed in the Perkin-Elmer 9600 thermal cycler using the
program set out in table 2.4.4 and their corresponding optimal annealing temperature
(Ta) in table 2.4.5. The annealing temperature for each primer pairs was deduced
experimentally by the Molecular Immunology Laboratory of the Department of
Medicine, University of Southampton, for all the cytokine primers while the
annealing temperature for the two CTL activation markers were obtained from a
published source [Strehlau et al, 1997], Although a single annealing temperature and
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PCR condition was used for all 15 different PCRs in that paper, my preliminary
experiments have pointed to a higher optimal annealing temperature of 60 °C for
granzyme B while the published optimal annealing temperature stated for fas ligand
was found to be satisfactory.
Table 2.4.4 - Cytokine PCR program
• Denaturation: 95 °C for 1 minute
• 3 temperature PCR cycle with the following profile for 35 cycles:
94 °C for 20 seconds, ramp over 45 seconds, optimum Ta for 30 seconds,
ramp over 45 seconds, 72 °C for 1 minute
• Final extension: 72 °C for 10 minutes
• Hold at 10 °C until the PCR products were stored at 4 °C
Table 2.4.5 - Optimal annealing temperatures (Ta)
Cytokine/CTL activation markers Ta (°C)
IL-2 and IFN-y 54
IL-4 and IL-5 50
IL-10 52
IL-13 and GrB 60
FasL 55
The PCRs were conducted in two batches. IL-2, IL-4, IL-10 and IFN-y PCRs were
performed in the first batch and IL-5, IL-13, GrB and FasL were performed in the
second. To save time, the PCR in each batch with the same annealing temperature
were performed together. Hence, in the first batch, IL-2 and IFN-y PCRs were
performed together while IL-4 and IL-10 PCRs were performed separately. For the
second batch, IL-13 and GrB PCRs were performed at the same time, while IL-5 and
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FasL PCRs were performed separately. Each PCR run took approximately two and a
half hours to complete. For each batch, all the four PCRs in the batch for each patient
sample series were performed on the same day. The PCR products were stored at
4 °C for the ELISA detection of the PCR products as soon as possible (all within 4
days).
2.5 Detection of cytokine and CTL activation marker PCR products
Principle of PCR ELISA
This is an extremely sensitive method to detect PCR products, being about a
thousand-fold more sensitive than the resolution obtainable using gel electrophoresis
(Janezic et al, 1995). The basic principle of the method is illustrated in figure 2.5.1.
The first stage involves the generation of PCR products containing digoxigenin
which was described in the previous section on cytokine PCR. The
digoxigenin-labelled PCR products are then detected by cytokine-specific
biotinylated capture probes which hybridise with an internal sequence of the
digoxigenin-labelled PCR products. The digoxigenin-labelled PCR product/
cytokine-specific biotinylated capture probe "dimers" are firmly immobilised onto
streptavidin coated wells by the interaction between the biotin on the capture probes
and the streptavidin coated at the bottom/side of each well. Repeated washing of the
wells following a period of incubation result in only the specific cytokine PCR
product/capture probe dimers being retained in the wells. The digoxigenin moieties
in the PCR products are then detected using an anti-digoxigenin (anti-DIG) antibody
conjugated to a peroxidase (POD) enzyme. The peroxidase enzyme reacts with a
substrate to give a colour change which is quantitated spectrophotometrically
(figure 2.5.2).
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Figure 2.5.1 - Principle of PCR ELISA
1. PCR - using DIG-labelling mix for the PCR (DIG-11-dUTP 0.0ImM, 0.19 mM dTTP and
0.2 mM of dATP, dCTP & dGTP)




2. Capture probe (20 bp) - hybridises with internal part of PCR product (3 hours incubation





V V = Biotin








4. DIG-detection using an antibody-enzyme peroxidase system - peroxidase-conjugated anti-
digoxigenin antibody (anti-DIG-POD)
POD POD POD POD anti-
U U U U = DIG-





5. PCR product visualised by colour change (green) with addition of enzyme substrate (ABTS).
6. Spectrophotometry quantitation by colour absorbance at 405 nm by ELISA plate reader.
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Figure 2.5.2 - An ELISA plate ready for reading - the intensity of the colour change
in each pair of duplicate wells is dependent on the amount of PCR products present.
As the ELISA detection of PCR products from the batch of PCR runs for each patient
sample series were performed on the same ELISA plate (i.e. PCR products from the
same time point for each cytokine/CTL marker in each batch of PCRs were analysed
on the same plate), the quantitative differences in the amount of PCR product levels
detectable using the PCR ELISA allows the differences in the level of gene
expression between the different samples of each patient sample series to be
compared in a semi-quantitative way for each cytokine or CTL activation marker.
Consumables:
1. Sterile 1.5 ml and 0.75 ml eppendorfs [Greiner Labortechnik, UK]
2. Sterile pipette tips of various sizes [Greiner Labortechnik, UK]
3. Eppendorf Combitips 0.5 ml & 5 ml [Merck, UK]
4. 20 ml universal containers [Bibby Sterilin, UK]
-60-
5. 50 ml polypropylene tubes [Greiner Labortechnik, UK]
6. Cytokine biotinylated capture probes, diluted to 5 ng/pl [R&D Systems, UK]
7. PCR ELISA kit as detailed below [Boehringer Mannheim, UK]
8. Double-distilled water (ddtBO)
9. Aluminium foils [Merck, UK]
PCR ELISA kit components:
1. Washing solution - this was prepared by dissolving one washing tablet (provided
in the kit) in 2 1 of double-distilled water. The solution was stable for 6 weeks at
4 °C.
2. Anti-digoxigenin-peroxidase conjugate (anti-DIG-POD) - 250 mU as stabilized
lyophilisate, resuspended in 250 pi of double-distilled water, mixing carefully
for 15 mins to ensure full reconstitution. Reconstituted conjugate was stable for
about 2 months at 4 °C
3. Denaturation solution containing sodium hydroxide (NaOH)
4. Conjugate dilution buffer
5. Hybridisation buffer
6. Substrate buffer
7. Substrate tablets - 5 mg ABTS® (2,2-Azinodi-3-ethylbenzthiazoline sulphonate
[6]) per tablet
8. Microtitre plate (MTP) modules (8 wells per module) - the wells were precoated
with streptavidin and postcoated with blocking agent
9. Strip frame for 8-well MTP modules (maximum of 12 strips per frame)
10. Cover foils for MTP
Biotinylated capture probe sequences (5' to 3'): biotin at 5' end
1) IL-2 - CTG AAC AGA TGG ATT ACC TT
2) IL-4 - CCG TAA CAG ACA TCT TTG CT
3) IL-10- TGA GAA CCA AGA CCC AGA CA
4) IFN-y - CAC TCT TTT GGA TGC TCT GG
5) IL-5 - GGG AAT AGG CAC ACT GGA GA
6) IL-13 - CGA GAA GAC CCA GAG GAT GC
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7) GB - AGG AAC AGG AGC CGA CCC AG
8) FasL - TAG GCC ACC CCA GTC CAC CC
Equipments:
1. Pipettes of various sizes (Gilsons, Eppendorfs) [Anachem, UK; Merck, UK]
2. Eppendorf Multipette 4780 [Merck, UK]
3. Biohit Proline 500 electronic pipette [Alpha Laboratories, UK]
4. Finnepipette 8-channel electronic multiple-pipette [Life Sciences, UK]
5. Jencons Mixamatic (Vortex) [Jencons Scientific, UK]
6. DPC Micromix 5 microtitre plate shaker [Diagnostic Product Corporation, UK]
7. Dynatech MR5000 microtitre plate reader [Dynatech Laboratories, UK]
Method:
Preparations for PCR ELISA:
• On the day prior to each PCR ELISA experiment, the tubes for the experiment
were labelled and the various buffers were aliquoted as set out in tables 2.5.1 to
2.5.4.
• At the start of the experiment, the working concentration of the anti-DIG-POD
conjugate was prepared by diluting 1 volume of anti-DIG-POD conjugate in 99
volumes of its conjugate dilution buffer as set out in table 2.5.1. Care was taken
to avoid foaming the mixture by gentle mixing and the solution was kept away
from light by wrapping the universal container (or polypropylene tube) in
aluminium foil. It was then left to stand at room temperature until required.
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Table 2.5.1: Anti-DIG-POD working concentration





Table 2.5.2: Calculation of number of tubes and wells
No. of samples No. of tubes No. of wells No. of strips (plates)
5 45 92 12(1)
6 53 110 14 (lV6)
7 61 126 16 (lV3)
8 69 142 18 (l'/2)
No. of tubes = [No. of samples X 4 (PCR) x 2 (dilutions)] + 4 {controls) + 1 {blank)
No. of wells = [No. of tubes x 2] + 2 {ABTS only) [+ 2 (blanks on second plate)]
Each strip = 8 wells & each plate = 12 strips (96 wells)
Table 2.5.3 (a): IL-2, IL-10 & IFN-y capture probe in hybridisation solution
(100 ng/ml):






Table 2.5.3 (b): IL-4 capture probe in hybridisation solution (100 ng/ml):





Table 2.5.4: Substrate solution (1 ABTS tablet per 5 ml substrate buffer)





Dilution of PCR products:
• Next, 1 in 10 (1/10) and 1 in 40 (1/40) dilutions of the digoxigenin-labelled
cytokine PCR products were prepared by diluting 5 pi of the digoxigenin-labelled
cytokine PCR products in 45 pi of ddTEO and 5 pi of 1/10 dilution in 15 pi of
ddfTO respectively. Each time the solutions were thoroughly mixed before use
by vortexing. Preliminary PCR ELISA experiments using PCR products at
various other dilutions (including neat concentration, 1 in 2, 1 in 4, 1 in 20
dilutions) have shown that the above dilutions were the appropriate dilution to
ensure satisfactory readings by the MTP reader.
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• However, with further experience of the PCR ELISA system used on the project
samples and following the analysis of the data for the first 13 patients, we found
that it was perfectly adequate to do only a single dilution for each
digoxigenin-labelled cytokine PCR products and the 1 in 10 dilution was chosen
for the remaining project samples since the spectrophotometric readings at this
dilution were considerably higher than at the 1 in 40 dilution, thus aiding the
comparison between the readings for each sample time point.
Denaturation of PCR products and capture probe hybridisation:
• 10 pi of the diluted digoxigenin-labelled cytokine PCR products and their
negative controls were transferred to sterile 1.5 ml eppendorfs, serving as reaction
tubes. 10 pi of sodium hydroxide (the denaturation solution provided in the kit)
was used as the blanks for the MTP. 40 pi of sodium hydroxide was added to
each reaction tube using the multipette with its combitips for rapid pipetting. The
tubes' contents were mixed thoroughly by vortexing and then left to stand at
room temperature for at least 10 minutes to denature the cytokine PCR products.
• During the denaturation step, the working solution of each cytokine biotinylated
capture probe was prepared to a final concentration of 100 ng per ml of
hybridisation buffer as set out in table 2.5.3. The MTP was prepared by mounting
the correct number of streptavidin-coated MTP modules (8 wells per module)
onto its frame.
• Following the period of denaturation, 450 pi of each cytokine biotinylated
capture probe/hybridisation buffer was added to each corresponding cytokine
PCR product reaction tube. Each reaction tube content was thoroughly mixed by
vortexing and 200 pi of the reaction tube content per well was transferred to
duplicate wells on the MTP. The position of the duplicate wells in the MTP
corresponding to their reaction tubes on the plate was recorded. The MTP was
then covered with self-adhesive cover foil (provided in the kit to prevent
evaporation) and then incubated on a MTP shaker at 37 °C (the plate shaker was
in the warm room) for 3 hours.
-65 -
Detection of captured PCR products:
• At the end of the 3-hour incubation period, the solutions in the MTP were
discarded by flicking the solutions in the wells off the plate and each well was
washed 5 times with 250 pi of washing solution. The washing step was facilitated
by using an 8-channel electronic pipette. At the last washing step, the washing
solution was discarded and the MTP tapped dry on lint-free tissue paper. 200 pi
of the working solution of the anti-DIG-POD conjugate was added to each well,
the MTP again covered with the self-adhesive cover foil and then incubated on a
microtitre plate shaker at 37 °C for 30 mins.
• During the incubation period for the anti-DIG-POD conjugate, the substrate was
prepared by adding the ABTS tablets to the substrate buffer according to table
2.5.4. This was done 15 mins prior to use and the substrate was kept away from
light by covering the universal container (or polypropylene tube) to minimise the
natural extinction of the substrate with time and exposure to light. Following the
incubation period, the solutions in the MTP was again discarded, the wells
washed 5 times and tapped dry at the last washing step. 200 pi of the substrate
was added to each well, the MTP was covered with the self-adhesive cover foil
and aluminium foil to keep the MTP in the dark during the colour development
phase. The MTP was again incubated on a MTP shaker at 37 °C.
• From 5 mins to 30 mins after the addition of the ABTS substrate, the MTP was
removed at 5 mins intervals and read in a Dynatech MR5000 MTP reader set at
dual wavelength mode, with the test filter set at 405 nm and reference filter set at
490 nm. The result was printed out for analysis.
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2.6 Checking the integrity of the stored cDNA samples by PCR of
the house-keeping (3-globin gene
The integrity of the cDNA samples from each patient sample series in the project was
verified by checking for the presence of the ubiquitous constitutionally expressed
(3-globin gene in each cDNA sample. This was done using a simple PCR for p-globin
gene expression and resolving the PCR product band by agarose gel electrophoresis.
As this check was performed after all the main experimental work was completed,
both the integrity of the reverse transcription process as well as the intactness of the
cDNAs following a variable period of storage at minus 80 °C were assessed.
The methodology for P-globin PCR was adapted from the standard operating
procedure of the Molecular Laboratory, Wessex Immunology Service [Harris and
Jones, 1997],
Consumables:
1. Ultra-violet light irradiated double-distilled water (ddH20)
2. Magnesium chloride (MgCb) at 25 mM concentration [Boehringer Mannheim,
UK]
3. PCR reaction buffer without magnesium chloride, 10X concentration, containing
100 mM Tris-HCl, 500 mM KC1, pH 8.3 [Boehringer Mannheim, UK]
4. dNTP (deoxynucleotide triphosphate) mix, prepared by adding 12.5 pi of each
stock Ultrapure dNTP [Pharmacia, UK] to 950 pi of ddH20, giving a
concentration of 1.25 mM of each dNTP. This was used instead of the PCR
DIG-labelling mix.
5. p-globin primers (300 ng) [R&D Systems, UK]:
Sense sequence: 5'-CTG TGG GGC AAG GTG AAC G-3'
Anti-sense sequence: 5'-CAA AGG ACT CAA AGA ACC TC-3'
6. Thermus aquaticus (Taq) polymerase at 5 U/pl [Boehringer Mannheim, UK]
7. autoclaved 1.5 ml eppendorfs [Greiner Labortechnik, UK]
8. autoclaved 0.75 ml PCR tubes [Greiner Labortechnik, UK]
9. Sterile pipette tips of various sizes [Greiner Labortechnik, UK]
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10. Mineral oil [Sigma, UK]
11. HGT agarose [Sigma, UK] - 2% gel prepared by dissolving 4 g of agarose in
200 ml of IX TAE (in a microwave), stained with 10 pi of ethidium bromide, and
set in a gel tray with 22-well combs.
12. 50X TAE (Tris-Acetate-EDTA) - prepared with 121 g Tris [Sigma, UK],
28.55 ml glacial acetic acid [Merck, UK] and 50 ml 0.5 M EDTA pEl 8.0, made
up to 500 ml with ddH20 and autoclaved. The IX TAE was prepared by diluting
the 5OX TAE with ddH20.
13. 0.5 M EDTA pH 8.0 - 186 g/1 EDTA [Merck, UK] with 20 g sodium hydroxide
pellets [Merck, UK] to aid dissolution, the pH adjusted with 10 M sodium
hydroxide [Merck, UK] and the solution autoclaved.
14. Ethidium bromide 10 mg/ml [Sigma, UK]
15. 6X stop mix - a mixture of 4 g sucrose [BRL, UK], 0.025 g bromophenol blue
[Sigma, UK], 1.25 ml 50X TAE buffer diluted to 10 ml with ddH20. Working
aliquots stored at 4 °C, stocks stored at minus 20 °C.
16. Molecular weight ladders VIII (19-1114 base pairs) and IX (72-1353 base pairs)
[Boehringer Mannheim, UK]
17. Gel-loading pipette tips [Alpha laboratory, UK]
Equipment:
1. Elgastat Option 4 water purifier (for double-distilled water) [Elgaserve, UK]
2. Amplirad ultra-violet light cabinet [Genetic Research Instrumentation, UK]
3. Laminar airflow cabinet [MDH, UK]
4. Whirlimixer (vortex) [Jencons Scientific, UK]
5. Pipettes of various volume ranges (Gilson, Eppendorf, Biohit) [Anachem UK;
Merck, UK; Alpha Laboratory, UK]
6. Perkin-Elmer thermal cycler [Perkin-Elmer, UK]
7. Gel tray, electrophoresis tank and power pack [Pharmacia, UK]
8. Ultra-violet light transitluminator [Genetic Research Instrumentation, UK]
9. DS 34 Polaroid direct screen instant camera and Polaroid ISO 3000 films
[Genetic Research Instrumentation, UK]
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Method:
Prior to the start of PCR experiments, sterile 1.5 ml eppendorfs, 0.75 ml PCR tubes
and double distilled water were first irradiated with UV light for 10 to 15 mins to
destroy any inadvertent contamination of the experiments with foreign DNA. The
cDNA from each patient series and the reagents for PCR were thawed out in ice.
A master reagent mix was made for the p-globin PCR using the volumes of each
reagent as set out in table 2.6.1. An extra aliquot for the negative control (using
UV-irradiated double-distilled water) and an excess aliquot (to overcome the small
but nevertheless unavoidable inherent inaccuracies arising from multi-aliquot
pipetting), was included in the master reagent mix to ensure that the sufficient master
reagent mix was available for each sample. Each reagent was vortexed immediately
prior to aliquoting into the master reagent mix.
Each cDNA sample (thoroughly mixed first by pipetting in and out several times)
was diluted down 1 in 10 (1 pi cDNA to 9 pi ddH20) first before aliquoting 10 pi of
the diluted cDNA into a previously labelled 0.75 ml PCR tube. A negative control
(10 pi ddH20 instead of the diluted cDNA) was used for each run of the P-globin
PCR. The Taq polymerase (kept at minus 20 °C) was added to the master reagent mix
immediately before it was aliquoted into the PCR reaction tubes containing the
diluted cDNA or ddH20. 90 pi of the PCR reagent mix (thoroughly mixed by
vortexing prior to use) was added to each PCR tube containing ddH20 or cDNA,
making a total PCR reaction volume of 100 pi. Each PCR reaction was overlayed
with 100 pi of mineral oil to prevent evaporation.
The PCRs were performed in the Perkin-Elmer thermal cycler using the program set
out in table 2.6.2. A drop ofmineral oil was also added to each slot (holding the PCR
tube) in the metal block of the Perkin-Elmer thermal cycler before adding the PCR
tubes to aid heat conduction. The PCR products were resolved in a 2% agarose gel.
10 pi of each PCR product was mixed with 2 pi of 6X stop mix and loaded into a
well in the gel. The gel electrophoresis was run at 150 volts for about 1.5 hours with
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a molecular weight ladder. A polaroid image of the UV-transilluminated agarose gel
was performed to enable a visual assessment of the PCR product bands.
Table 2.6.1 - Master reagent mix for (3-globin PCR
PCR reagents Volume per reaction ( p.1)
UV-irradiated double distilled water 55.6
MgCl2 (25 mM) 6.0




Taq polymerase (Boehringer) 0.4
Table 2.6.2 - P-globin PCR program
• Denaturation: 94 °C for 5 minute
• 3 temperature PCR cycle with the following profile for 40 cycles:
94 °C for 2 minutes, 55 °C for 2 minutes, 72 °C for 3 minutes
• Final extension: 72 °C for 5 minutes
• Hold at 10 °C until the PCR products were stored at 4 °C
-70-
2.7 Statistical analyses of the data applied in this thesis
The statistical software "SPSS for Windows Release 7.5" [SPSS Inc, USA] was used
to analyse the data from the preliminary cell separation experiments set out in chapter
3, all the clinical and laboratory data set out in chapter 5, and the RT-PCR ELISA
data set out in chapter 6, generating the box plots and p values (when statistical tests
were applied) in these chapters. The theoretical aspects of the statistical tests used in
these analyses are briefly described in this section and a more comprehensive
discourse on the subject can be obtained from "Practical Statistics For Medical
Research" by Douglas G. Altman [Chapman & Hall, 1991]. The statistical tests used
in the analyses of the data were chosen following consultation with a medical
statistician of the University of Southampton.
When comparing groups of continuous data (numerical data which can take any
value based on some form of measurement), both parametric tests (tests which make
distributional assumptions on the population from which the sample is taken) and
non-parametric tests (tests which do not make any distributional assumptions on the
population from which a sample is taken) were used. The parametric tests used were
the paired t test for comparison of means and the two sample t test for equality of
means, and the non-parametric tests used were the Wilcoxon signed rank sum test for
matched pairs and the Mann-Whitney U test. When comparing groups of categorical
data (data based on the categories which an individual can be classified into), the Chi
squared (x ) analysis of contingency tables or cross-tabulation was applied, with the
Fisher's exact test being used as well when sample sizes were small (resulting in the
expected frequencies within a contingency table being less than 5).
For each statistical test, the null hypothesis is that there is no difference between two
sample means (or groups) and a p value of 0.05 or less is usually accepted as a
reasonable probability for rejecting the null hypothesis, i.e. that the difference
between the two sample means is statistically significant. The use of a statistical
software program like "SPSS for Windows Release 7.5" gives much more precise p
values than that obtainable from statistical tables described in the following sections.
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In the results of every statistical tests used, a two-sided or two-tailed p value is
always quoted.
Paired t test for comparison of means and two sample t test for equality of
means
Both of these tests are based on the t distribution, described by W. S. Gossett, writing
under the name of 'Student' in the early part of this century, hence it was sometimes
also known as the Student's t distribution. He found that the mean of a sample from a
Normal distribution with unknown variance has a distribution that is similar to, but
not quite the same as, a Normal distribution. As the sample size increases the
sampling distribution of the mean becomes closer to the Normal distribution. The t
distribution has one parameter, a quantity called the degrees of freedom (df), which is
the sample number minus one.
In both tests, the test statistic t is first calculated, which is the difference in the
sample means divided by the standard error of the the sample means. For paired
samples, the standard error of the sample means is calculated from the standard
deviation of the differences between the paired observations divided by the square
root of the sample number. For two independent samples, the standard error of the
difference in sample means is the square root of the sum of the separate variances.
The individual variance of each independent sample is calculated from the square of
the standard deviation of the sample divided by its sample number. The p value is
then read off from the t distribution table corresponding to the test statistic t and the
degrees of freedom.
Wilcoxon signed rank sum test for matched pairs
This is a non-parametric equivalent of the paired t test. The Wilcoxon signed rank
sum test, unlike the sign test, not only considers whether each observation in one
sample is above or below the matched observation of the other sample, but also the
magnitude of the differences. Ignoring the signs of the differences of the matched
observations, each difference is first ranked in the order of its magnitude, and the
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sums of the positive and negative ranks are then calculated. The sum of positive (or
negative) ranks is then looked up against the corresponding sample size of matched
observations in the Wilcoxon one sample (or matched pairs) test table and the
corresponding p value read off.
Mann-Whitney U test
This is a non-parametric alternative to the t test for comparing data from two
independent groups. This test requires all the observations to be ranked in the order
of their magnitude as if they were from a single sample. Then the sum of the ranks in
one group is calculated and the p value corresponding that sum and the respective
sample sizes of the two groups are read off the Mann-Whitney test table. Note that
the Mann-Whitney test is based on the assumption that there are no tied ranks. If tied
ranks are present, statistical software like "SPSS for Windows Release 7.5" would
automatically adjust for them.
The test statistic U is calculated from the equation: U= nin2 + !/2ni(ni+l) - T, where
ni and n2 are the respective sample sizes and T is the sum of ranks in the smaller
group. This test statistic U is the number of all possible pairs of observations
comprising one from each sample for which one observation from one sample is less
than the observation from the other sample. The estimated probability that a new
observation from the first population will be less than a new observation sampled
from the second population is U divided by the product of the sample sizes ni and n2.
Chi squared (y2) test
This test is applied to the analysis of a contingency table or cross-tabulations of two
categorical variables, so that possible associations between the variables can be
evaluated. The test is based on the fact that when the null hypothesis is true (i.e., the
two variables in the contingency table are unrelated), then the calculated test statistic
% (described below) has a probability distribution called Chi squared distribution.
The Chi squared distribution is the distribution of the square of a variable which has
a standard Normal distribution on its own. The test involve the calculation of the
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expected frequencies in each cell (the combination of each row and column
categories) in the contingency table, which is the product of the relevant row and
column totals divided by the sum of all the observed frequencies in the table (i.e. the
sample size). The test statistic is then calculated, which is the sum of the square of
the difference between the observed and expected frequencies divided by the
expected frequency in each cell in the contingency table. As the expected frequencies
are calculated from the observed row and column totals, so the Chi squared test is
'conditional' on these totals. The test statistic £ thus follows the Chi squared
distribution with (r-l)(c-l) degrees of freedom under the null hypothesis, where r and
c are the number of rows and columns respectively in the contingency table. By using
this X test statistic and the appropriate degrees of freedom, the corresponding p value
can be read off the x distribution table.
When sample sizes are small (i.e., when the expected frequencies in over 20% of the
cells of the contingency tables are less than 5), the use of continuous Chi squared
distribution to approximate frequencies introduces some bias into the calculation, so
that the value of tends to be a little too large. A continuity correction, consisting of
moving the difference between observed and expected frequencies in each cell nearer
to zero by half, is used to remove this bias, and in the context of 2 X 2 tables, the
correction is known as Yates' correction.
For 2X2 tables with very small expected frequencies (less than 5), the Fisher's exact
test was applied. This method is also based on the observed row and column totals
and consists of evaluating the probability associated with all possible 2X2 tables
which have the same row and column totals as the observed data, making the
assumption that the null hyposthesis is true that the row and column variables are
unrelated. The details of this test is given in chapter 10 of the book by Altman
[1991],
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Chapter 3: OPTIMISATION OF CELL SEPARATION
METHODOLOGY
The cell separation method used for the project (as described in detail in section 2.1
of chapter 2) was chosen following preliminary experiments to evaluate the
suitability of the various known methods described for separating lymphocytes from
peripheral blood samples. The details of these preliminary experiments are described
in this chapter.
3.1 Comparison of three combinations of cell separation techniques
This experiment was set up to compare the different cell separation techniques that
could be used to separate lymphocytes from the buffy coat of mononuclear cells
obtained following density gradient centrifugation ofwhole blood using Lymphoprep
[Boyum et al, 1991], The three cell separation techniques of nylon wool column,
monocyte adherence to plastics and panning were used in three different
combinations to determine the best combination of cell separation techniques that
would give the highest yield and purity of lymphocytes. A shortened version of the
combined monocyte adherence/panning method was used [Stanciu et al, 1996],
Cell separation techniques
1. Nylon wool column: this is a non-specific physical method of cell separation
based on the ability of phagocytic cells and cells with detectable surface
membrane immunoglobulins to adhere onto a nylon wool column, while
non-adherent cells would be eluted from the column [Eisen et al, 1972; Greaves
and Brown, 1974], This technique mainly removes the monocytes and B cells
from the buffy coat of mononuclear cells.
2. Monocyte adherence to plastics: this is another non-specific physical method of
cell separation based on the ability of monocytes to adhere onto the microscopic
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irregularities in tissue culture grade petri dishes because of their phagocytic
properties [Cline and Lehrer, 1968; Koller et al, 1973]. This method also removes
platelets because of their inherent adherent properties upon activation.
3. Panning: this is a specific method of cell separation using mouse anti-human
monoclonal antibodies to remove the monocytes, B lymphocytes and NK cells by
negative selection onto plates coated with rabbit anti-mouse antibodies [Wysocki
and Sato, 1978], At the end of the panning step, the remaining mononuclear cells
consist essentially of enriched T lymphocytes.
Materials and methods
The equipment and consumables used for this experiment were similar to those listed
in section 2.1 (chapter 2) of the same subheading. Peripheral blood samples were
taken from five healthy volunteers to test out the cell separation techniques. A total
of 30 ml of blood was collected from each volunteer in three 10 ml vacutainer tubes
containing lithium heparin as anticoagulants. An extra 2 to 3 ml of blood per
volunteer was collected in a vacutainer tube (containing EDTA as anticoagulants) for
cell counts and FACS. One 10 ml vacutainer tube of peripheral blood from each
volunteer was used for each combination of cell separation experiment protocols (see
below). All three combinations of cell separation protocols were performed in
parallel on the same day. It was only possible to perform all three combinations of
cell separation experiments on one volunteer at a time because of the length of time
involved.
Cell counts of the whole blood and separated cells were performed using a Coulter
Counter [Coulter, UK], The purity of the separated cells was assessed in two ways.
The first was using a flow cytometer to count the different mononuclear cell
components in the separated cells. The second method was the visual assessment of
the lymphocyte count in a cytospin preparation of the separated cells stained with
haematoxylin and eosin dye. This visual assessment was performed by one of my
supervisors (Dr J L Smith, Consultant Immunologist at Wessex Immunology
Service, Southampton General Hospital).
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The three combinations of cell separation techniques are detailed in the next three
sections. For the description about Lymphoprep density gradient centrifugation, look
under "principle" in section 2.1 of chapter 2.
Combination A - Lymphoprep density gradient centrifugation + nylon wool
column
• Lymphoprep density gradient centrifugation: 10 ml of whole blood was carefully
layered onto 10 ml of Lymphoprep in a 20 ml universal container. The tube was
spun at 2500 rpm (llOOg) for 20 mins in an MSE Mistral 3000i centrifuge at
room temperature (set at 20 °C) and without any acceleration or brake settings.
• Nylon wool column: Following centrifugation, the buffy coat of mononuclear
cells were carefully removed directly onto a nylon wool column (this was
prepared by filling a sterile 20 ml syringe without its plunger loosely with nylon
wool) using a Pasteur pipette. The column was then incubated at 37 °C for
30 mins.
The non-adherent cells were then eluted from the nylon wool column with warm
tissue culture medium (RPMI 1640 with HEPES, L-glutamine, sodium pyruvate
and 10% FCS) and pelleted by centrifuging at 1500 rpm (400g) for 10 mins with
maximum acceleration and brake applied. The supernatant was discarded and the
cell pellet resuspended in 10 ml of warm tissue culture medium for cell count,
FACS and cytospins.
Combination B - Lymphoprep density gradient centrifugation + nylon wool
column + panning
• Lymphoprep density gradient centrifugation: 10 ml of whole blood was first
diluted 1 in 1 with PBS /2% FCS in a sterile 50 ml polypropylene tube and then
carefully layered into 3 sterile 15 ml conical-based polypropylene tubes
containing 4 ml of Lymphoprep each. The tubes were spun at 2500 rpm (llOOg)
for 20 mins in an MSE Mistral 3000i centrifuge at room temperature (set at
20 °C) and without any acceleration or brake settings.
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Following centrifugation, the buffy coat of mononuclear cells was carefully
removed into a sterile 50 ml polypropylene tube using a Pasteur pipette. The
mononuclear cells were then washed twice with PBS/2% FCS, the cells being
pelleted by centrifuging at 1500 rpm (400g) for 10 mins (with maximum
acceleration and brake applied), discarding the supernatant each time.
• Nylon wool column: The cell pellet was then resuspended in 5 ml of warm tissue
culture medium and incubated in a nylon wool column at 37 °C for 30 mins. The
non-adherent cells were then eluted from the nylon wool column with warm
tissue culture medium and pelleted by centrifuging at 1500 rpm (400g) for
10 mins with maximum acceleration and brake applied. The supernatant was
discarded and the cell pellet resuspended in 10 ml of warm tissue culture
medium.
2 ml of the cell suspension was removed at this stage for cell count, FACS and
cytospins. The remaining cell suspension was by spun at 1500 rpm (400g) for
10 mins (with maximum acceleration and brake applied), discarding the
supernatant.
• Panning: 500 pL of Dulbecco's PBS /5% FCS was first added to resuspend the
cell pellet and 5 pL of each of the 4 mouse anti-human monoclonal antibodies (to
CD lib, 14, 16 & 19) [Becton Dickinson, UK; Serotec, UK] were added to the
resuspended cells (table 2.1.1 in chapter 2 lists the different mononuclear cells
which these monoclonal antibodies identify). The cell suspension was then
incubated at 4 °C (by placing the 50 ml polypropylene tube containing the cell
suspension in a bottle filled with ice) on a Denley Spiramix 5 rocker/roller
[Denley Instruments, UK] for 30 mins to ensure thorough mixing.
The excess antibodies were washed off twice with Dulbecco's PBS/5% FCS,
centrifuging at 1500 rpm (400g) for 10 mins (with maximum acceleration and
brake applied), discarding the supernatant each time. The pelleted cells were
resuspended in 8 ml of Dulbecco's PBS/5% FCS and incubated on a Sterilin petri
dish coated with rabbit anti-mouse antibodies for 1.5 hours at 4 °C (by placing
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the plate in the fridge). The preparation of the rabbit anti-mouse antibodies
coated Sterilin petri dish is described under "method" in section 2.1 of chapter 2.
At the end of the incubation period, the non-adherent cells were recovered onto a
sterile 50 ml polypropylene tube by gentle washing of the Sterilin petri dish with
Dulbecco's PBS/5% FCS using a Pasteur pipette and then pelleted by
centrifuging at 1500 rpm (400g) for 10 mins (with maximum acceleration and
brake applied), discarding the supernatant. The pelleted cells were finally
resuspended in 5 ml of warm tissue culture medium for cell count, FACS and
cytospins.
Combination C - Lymphoprep density gradient centrifugation + monocyte
adherence + panning
• Lymphoprep density gradient centrifugation: This was performed as described in
the density gradient centrifugation step of combination B.
• Monocyte adherence to plastics: Following the two washes of the buffy coat of
mononuclear cells with PBS/2% FCS, the pelleted cells were resuspended in 8 ml
of warm tissue culture medium. The cell suspension was then incubated on 2
tissue culture grade petri dishes in an incubator at 37 °C for 1 hour. The
non-adherent cells were then removed onto a sterile 50 ml polypropylene tube by
gently washing the petri dishes with warm tissue culture medium using the
Pasteur pipette. The cells were again pelleted by centrifuging at 1500 rpm (400g)
for 10 mins with maximum acceleration and brake applied. The supernatant was
discarded and the cell pellet resuspended in 10 ml of warm tissue culture
medium.
2 ml of the cell suspension was removed at this stage for cell count, FACS and
cytospins. The remaining cell suspension was by spun at 1500 rpm (400g) for 10
mins (with maximum acceleration and brake applied), discarding the supernatant.
• Panning: This was performed as described in the panning step of combination B.
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Flow Cytometry
This section gives a brief and simplified description of flow cytometry. A thorough
introduction to flow cytometry is described by Carter and Meyer [1994], from which
most of the information in this section are based.
Flow cytometry is a technique for making rapid measurements on cells (or particles)
as they flow in a fluid stream one by one through a sensing point. The measurements
are made separately on each cell within the suspension in turn and not just as average
values of the whole population. The addition of fluorescence analysis to the
measurement of cellular parameters based on light scatter by the flow cytometer
enables it to identify functional subpopulations of cells based on their cell surface
and cytoplasmic determinants and receptors. These phenotypic markers are detected
by monoclonal or polyclonal antibodies conjugated to a fluorochrome, a fluorescent
dye which emits light of a certain wavelength when excited by light energy from a
laser (acronym for Tight amplification by stimulated emisson of radiation') beam in
the flow cytometer. The two common fluorochromes in general use are
phycoerythrin (PE) and fluorescein isothiocyanate (FITC).
Basically, flow cytometry involves the passage of a laser beam at right angle onto a
moving stream of cells carried by a sheath of fluid in order to identify the different
cell populations present within any given suspension of cells. The cells are
specifically labelled by being incubated with fluorochrome conjugated antibodies.
The effect of the laser beam on the individual cells passing through it is two fold. It
is scattered in different directions by each cell in the stream and it causes the
fluorochromes bound onto the cell surface via their conjugated antibodies to
fluoresce. The scattered and fluorescent light generated by the cells passing through
the laser beam are collected by photodetectors which convert the photon pulses into
electronic signals which are analysed by a computer program to give the proportion
of the different cell subpopulations in a given cell suspension.
The two main photodetectors in the flow cytometer are for the forward and side
scatters. Through the use of a beam splitter, a dichroic mirror placed at 45° to the
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incident beam, which reflects wavelengths shorter than 500 nm towards the side
scatter detector while the longer wavelengths pass onto a second dichroic mirror.
This separates the different wavelengths of the fluorescent light to pass through two
separate sets of light filters onto two fluorescence detectors. A schematic diagram
detailing the various components of a flow cytometer is shown in figure 3.1.1 .
The forward scatter detector "looks" at the scattered light gathered by the forward
collection lens from approximately 1 to 20 degrees off the laser beam axis. It
measures the angle of scatter of the laser beam when it strikes each cell. The size of
the angle of scatter gives a relative measure of the size of the cells, i.e. the larger the
angle, the larger the cell. The side scatter detector, on the other hand, "looks" at the
part of the laser beam that had been reflected at right angle to the incident beam and
it measures the degree of granularity of the cells. By combining the information
about the size and granularity of the cells, the computer program is able to separate
out the different cell types and give their proportion in a scatter diagram. Figure 3.1.2
gives an example of a computer-generated image of the distribution of the various
cellular components of lysed whole blood based on light scatter only.
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Figure 3.1.1 - Schematic diagram of flow cytometer
















Figure 3.1.2 - Illustration of forward angle light scatter (X-axis) versus orthagonal
(side) scatter (Y-axis) of lysed whole blood. The diagram shows the identification of
3 distinct cell populations based on light scatter only: R1 = Lymphocytes, R2 =
Monocytes, R3 = Granulocytes. RBCs represent the area where unlysed red cells and
debris will be found.
The resolution of the flow cytometer is related to the rate of aspiration of the sample
by the machine. At low flow rate of about 12 pl/min, a very high resolution is
possible and this is mainly used for cell sorting, while at high flow rate of about
60 pl/min, the resolution is lower and this is mainly used for phenotyping cells.
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Method
Seven FACS tubes [Becton Dickinson, UK] were used for each sample of separated
cell suspension. The control antibodies [Becton Dickinson, UK] used were
unconjugated. The mouse anti-human monoclonal antibodies (mAb) to leucocyte cell
markers [Becton Dickinson, UK; Serotec, UK] used for assessing the purity of the
separated cells, and the combinations in which they were used and their respective
conjugated fluorochromes, are shown in table 3.1.1. Table 3.1.2 sets out the principal
cell type corresponding to its cell marker cluster of differentiation (CD) numbers.
Each mAb was diluted 1 in 40 from its stock solution prior to use. 20 pi of each
diluted mAb was added to a 100 pi sample of separated cell suspension in each tube
in accordance with the combinations set out in table 3.1.1. The antibodies were
incubated with the separated cell suspensions for 30 mins at 4 °C before washing off
the excess antibodies with 2 ml of PBS, centrifuging the tubes at 1500 rpm (400g)
for 10 mins and discarding the supernatants. The cell pellets were then resuspended
in the remaining volume in each tube by flicking the bottom of the tubes repeatedly.
Due to insufficient time to complete both the cell separation experiments and FACS
data acquisition on the same day, the labelled cells in the FACS tubes were fixed in
1% paraformaldehyde in PBS to ensure that the labelled cells remained intact
(though obviously no longer viable) for FACS data acquisition the following day. A
Becton Dickinson FACSort [Becton Dickinson, UK] using the LYSIS II software
was used. Whenever possible, 10000 cells were acquired from every sample for
analysis. The data were stored in an optical disk for subsequent analysis.
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Table 3.1.1 - Conjugated monoclonal antibody combinations used in the
FACS tubes
Tube FITC PE
1 Control IgG Control IgG
2 CD 16 -
3 CD 19 -
4 - CD 14
5 - CD 3
6 CD 4 CD 3
7 CD 8 CD 3
Table 3.1.2 - Cluster of differentiation (CD) and cell phenotype
CD Principal cell type
3 All mature T lymphocytes
4 Helper T lymphocytes
8 Suppressor T lymphocytes
14 Monocytes




For each separated cell suspensions, cytospin slides were prepared by putting 2 to 3
drops of each separated cell suspension from a Pasteur pipette into the cytospin well
with the Surgipath microscope slide and Shannon filter card [Life Sciences, UK]
clamped to it. The loaded cytospin wells were then spun at 450 rpm for 10 mins in a
Shannon Cytospin 2 [Life Sciences, UK]. The cytospin slides were air-dried before
being stained with haematoxylin and eosin dye. A differential cell counts of each
stained cytospin slides were made by one of my supervisors (Dr J L Smith,
Consultant Immunologist, Southampton General Hospital).
Results
The cell counts and percentage mononuclear cell (MNC) loss following each cell
separation technique are shown in Tables 3.1.3a and b. Note that the percentage cell
loss in the tables takes into account the volume of separated cell suspension that were
removed for cell counts, FACS and cytospins. A reading error in the cell count was
obviously made by the Coulter counter for one of the samples from one volunteer
(subject 2) because the total cell count at the end of panning was higher than before
panning. Hence, this subject's cell counts was excluded from the analysis of cell loss.
Table 3.1.4 shows the statistical analysis using the student's t-test for paired samples
to compare the differences between the percentage of cell loss in the different
combinations of cell separation techniques.
Tables 3.1.5a to f detail the percentages of the natural killer cells (CD 16),
B lymphocytes (CD 19), monocytes (CD 14), T lymphocytes (CD 3), T-helper subset
(CD 4) and T-suppressor subset (CD 8) in the separated cell suspensions. No FACS
data were available for analysis for one volunteer (subject 1) because of technical
errors made during acquisition of his FACS data.
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1 25.0 10.0 60.0 12.0 52.0 6.0 75.4
3 20.0 7.0 65.0 3.5 82.5 1.25 93.5
4 28.0 13.0 53.6 6.0 78.6 2.0 92.5
5 33.0 19.0 42.4 10.0 69.7 2.5 91.9
Average 26.5 12.3 55.2 7.9 70.7 2.9 88.4



















1 25.0 12.5 50.0 9.2 62.4
3 20.0 12.5 37.5 7.5 57.1
4 28.0 15.0 46.4 7.5 70.0
5 33.0 17.0 48.5 10.5 64.5
Average 26.5 14.3 45.6 8.7 63.5
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Table 3.1.4 - Differences in percentage cell loss (t-test for paired samples)
Paired differences ofmean p-value
Nylon wool (A) and Nylon wool (B) NS
Nylon wool (A) and Monocyte adherence (C) NS
Nylon wool (B) and Monocyte adherence (C) NS
Nylon wool (A) and Panning (C) NS
Nylon wool (B) and Panning (B) 0.01
Monocyte adherence (C) and Panning (C) 0.005
Panning (B) and Panning (C) 0.015
note: NS = not significant at p<0.05


















2 2.76 1.95 8.65 1.15 1.22
3 2.77 1.27 0.81 1.01 0.23
4 10.86 2.80 0.84 0.51 0.62
5 5.64 0.68 0.29 0.64 0.16
Average 5.51 1.68 2.65 0.83 0.56
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2 29.86 29.74 30.45 2.40 0.60
3 12.64 16.93 15.48 3.44 0.99
4 35.64 30.92 22.37 1.90 1.66
5 17.94 21.59 17.95 0.77 0.31
Average 24.02 24.80 21.56 2.13 0.89


















2 7.39 1.84 6.29 0.21 0.73
3 5.98 2.89 7.03 1.99 1.98
4 11.54 2.01 9.20 0.41 1.11
5 6.45 2.74 3.42 0.65 0.44
Average 7.84 2.37 6.49 0.82 1.07


















2 56.81 60.68 54.89 79.32 81.64
3 60.28 73.16 73.69 89.54 94.21
4 37.64 50.91 59.57 84.14 65.37
5 63.7 68.95 73.30 91.33 95.92
Average 54.61 63.43 65.36 86.08 84.29
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2 32.96 34.18 32.86 48.55 54.54
3 29.08 36.46 35.17 47.46 47.86
4 29.26 34.04 41.00 57.88 46.25
5 42.01 40.93 49.12 58.88 64.98
Average 33.33 36.40 39.54 53.19 53.41


















2 24.58 19.85 16.49 32.17 28.72
3 23.22 30.84 28.81 35.83 42.80
4 14.50 12.29 20.11 24.95 28.80
5 19.17 21.85 21.45 25.89 25.50
Average 20.37 21.21 21.72 29.71 31.46
The student's t-test for paired samples was also applied to compare the differences
between the percentages of the different populations of mononuclear cells based on
their phenotypic cell markers obtained following the three combinations of cell
separation techniques (see Table 3.1.6).
Table 3.1.7 shows the percentage of lymphocytes as assessed by a visual differential
count of the cytospin slides of the separated cell suspensions from the different
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combinations of cell separation techniques. This serves as a comparison with the CD
3 count as obtained by FACS.
Using the student's t-test for paired samples, there were no significant differences
between the mean percentages of lymphocytes in the cytospins except that between
the cytospins for the separated cell suspensions at the end of the nylon wool and
panning stages in combination B (p=0.03).
Table 3.1.6 - Paired differences of mean percentages of mononuclear cell
components
Paired differences D-value (t-test for paired samples)
ofmean
CD 16 CD 19 CD 14 CD 3 CD 4 CD 8
Nylon wool (A) and
Nylon wool (B)
NS 0.033 NS 0.038 NS NS
Nylon wool (A) and
Monocyte adherence (C)
NS NS NS NS NS NS
Nylon wool (A) and
Panning (C)
0.021 0.015 NS 0.001 0.001 NS
Nylon wool (B) and
Panning (B)
0.008 0.008 NS 0.009 0.009 0.035
Monocyte adherence (C)
and Panning (C)
0.008 0.014 NS 0.026 0.027 0.021
note: NS = not significant at p<0.05
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1 94.3 92.9 98.6 97.4 99.5
2 96.8 89.4 88.8 95.6 94.7
3 82.8 95.4 95.6 98.8 96.8
4 89.9 88.3 92.5 90.9 93.0
5 98.8 98.9 99.3 99.0 97.1
Average 92.5 93.0 94.9 96.3 96.2
Discussion
In terms of percentage cell loss at the end of each cell separation technique, there
were no significant differences between the two non-specific physical techniques
which removes mainly monocytes. However, the addition of a second specific
technique to the cell separation combinations B and C resulted as expected in a
further significant cell loss (an extra 18%) by the negative selection of the panning
technique. The mean total percentage cell loss at the end of combination B was
significantly higher than for combination C. Interestingly, despite the significant
further cell loss by adding the panning step to monocyte adherence in combination C,
the mean total percentage cell loss for combination C was not significantly different
from that for combination A, which only uses a single physical step of cell separation
to improve the lymphocyte yield (tables 3.1.3a and b, 3.1.4).
There were no significant differences in the efficiency of removing monocytes
between the nylon wool column and monocyte adherence to plastics methods.
Although the addition of panning to the other two techniques further reduced the
percentage of CD 14 cells further, this was not significant statistically (table 3.1.5a).
However, panning significantly reduced the percentages ofNK cells (CD 16) and B
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cells (CD 19) in the separated cell suspensions (tables 3.1.5b and c), thus improving
the overall yield of T lymphocytes and its subsets (tables 3.1,5d to f, 3.1.6).
Overall, the visual assessment of the cytospins of the separated cell suspensions
suggested that a high lymphocyte yield (in excess of 90%) was obtainable from all
the cell separation techniques used (table 3.1.7), although it is obviously impossible
to separate out the NK cells and B cells visually in a haematoxylin and eosin slide
without resorting to immunohistochemical techniques.
In conclusion, combination C of cell separation techniques (combining monocyte
adherence to plastics with panning) gives the best yield of T lymphocytes as well as
the best purity in terms of low percentages of the other "contaminating" mononuclear
cell (CD 14, 16 and 19). This was therefore the cell separation method chosen for the
project.
3.2 Comparing full-time with half-time cell separation
This set of experiments was set up to see if the total time taken to perform the
combined monocyte adherence/panning cell separation method could be reduced
further without affecting the percentage of cell loss or the yield and purity of the T
lymphocytes obtained. The principal reason for trying to shorten the total time taken
to perform the combined monocyte adherence/panning cell separation method is to
decrease the time of in vitro manipulations of the T lymphocytes and thus minimise
the risk of activating these cells.
Method
The experiments were conducted in two separate batches. In the first batch, 14 stable
renal transplant patients visiting the outpatient department for routine follow-up
assessment were recruited. They were randomly assigned to two equal groups
(full-time and half-time cell separation). 15 to 20 ml of peripheral blood in lithium
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heparin vacutainer tubes and 2 to 3 ml of blood in an EDTA vacutainer tube were
collected from each patient.
In the second batch, parallel experiments to compare full-time and half-time cell
separations were performed on 2 healthy volunteers. Two 10 ml lithium heparin
vacutainer tubes of peripheral blood (one each for the full-time and half-time
experiments) and 2 to 3 ml of blood in an EDTA vacutainer tube were collected from
each volunteer. In all subjects, the EDTA blood was used for cell count only.
The cell separation methodology was as described for combination C in section 3.1
with modifications made in the duration of the incubation period for monocyte
adherence and panning steps. The incubation period for monocyte adherence was 1
hour for the full-time experiment and 30 mins for the half-time experiment, while the
incubation period for panning was 1.5 hours for the full-time experiment and 45 mins
for the half-time experiment. Both batches of experiments were performed in the
transplant laboratory in Portsmouth.
From each separated cell suspension, cell counts by Coulter counter in the
Haematology department of St Mary's Hospital, Portsmouth, were performed. The
samples for FACS data acquisition were sent to Wessex Immunology Service,
Southampton General Hospital but because of logistical reasons, the FACS data
acquisition were usually performed (by Wessex Immunology Service staff) the
following day.
Results
The cell counts and percentage mononuclear cell (MNC) loss for the first batch of
experiments are shown in table 3.2.1 and the flow cytometry data giving the yield
and purity of T lymphocytes are detailed in table 3.2.2.
No data are available for the percentage of B cells (CD 19) in the separated cell
suspensions as there were problems with the quality of the conjugated monoclonal
antibodies for phenotyping CD 19 making it impossible to gate the B cell population
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for analysis. For the full-time separation group, no FACS data were available for one
of the patients (no. 4).
The results for the second batch of experiments are shown in table 3.2.3 (cell counts
and percentage mononuclear cell loss) and table 3.2.4 (FACS data on T lymphocytes
yield and purity).
No statistical test was applied on any of these results.




& 1.5 hr panning Patient Whole blood
After 30 mins
monocyte adherence













1 13.3 4.0 69.9 8 47.5 22.0 53.7
2 45.6 12.0 73.7 9 28.5 4.0 86.0
3 45.6 14.0 69.3 10 43.5 30.0 31.0
4 28.5 12.0 57.9 11 66.5 36.0 45.9
5 41.8 14.0 66.5 12 26.6 10.0 62.4
6 23.8 8.0 66.4 13 30.4 18.0 40.8
7 26.0 16.0 38.5 14 34.2 18.0 47.4
Av 32.1 11.4 63.2 Av 39.6 19.7 52.4
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Table 3.2.2 - FACS data in full-time and half-time cell separation
VI
a




adherence & 1.5 hr panning -in«
Ph
adherence & 45 mins panning
CD 14 CD16 CD 3 CD 14 CD 16 CD 3
(%) (%} (%) m (%) £%)
1 13.01 0.82 74.68 8 17.40 0.23 79.12
2 4.66 1.56 94.20 9 1.35 1.42 97.68
3 3.06 0.62 89.55 10 1.66 0.17 89.03
4 - - - 11 2.79 0.71 95.75
5 9.33 1.72 87.42 12 4.23 0.95 78.60
6 5.41 0.41 51.02 13 15.98 0.72 72.89
7 6.39 0.41 95.11 14 2.66 0.27 79.23
Av 6.98 0.92 82.00 Av 6.58 0.64 84.61
Table 3.2.3 - Cell counts and % cell loss in full-time and half-time cell separation
Healthy subjects Whole blood
After 1 hr
monocyte adherence
& 1.5 hr panning Healthy subjects Whole blood
After 30 mins
monocyte adherence
& 45 mins panning
MNC MNC % Cell MNC MNC % Cell
(10") (10 s) Loss (10 *) (10') Loss
1 22.0 10.0 54.5 1 22 10.0 54.5
2 18.0 10.0 44.4 2 18 10.0 44.4
Av 20.0 10.0 49.5 Av 20.0 10.0 49.5
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Table 3.2.4 - FACS data in full-time and half-time cell separation (healthy subjects)

















1 2.02 0.14 2.64 84.57 1.93 0.28 2.27 87.05
2 3.62 0.16 2.98 86.01 2.69 0.14 1.37 81.86
Av 2.82 0.15 2.81 85.29 2.31 0.21 1.82 84.46
Discussion
The average percentage mononuclear cell loss in the first batch of cell separation
experiments on peripheral blood from stable renal transplant patients was less for the
half-time cell separation than for the full-time cell separation, but the T lymphocyte
yield and purity in the two groups were almost the same. While the reduced
incubation time for the two cell separation techniques may result in a decreased cell
loss, this was not at the cost of a poorer T lymphocyte yield or purity.
Similarly, results from the second batch of cell separation experiments almost mirror
the results of the first batch, with the average percentage of mononuclear cell loss
being the same for the full-time and half-time cell separation groups, and the T
lymphocyte yield and purity in the two groups being very close.
Based on these results, the half-time incubation period for monocyte adherence and
panning was adopted as the project protocol. This much shortened cell separation
method reduced the time of in vitro manipulations of the T lymphocytes and
consequently the risk of activating the cells.
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Chapter 4: OPTIMISATION AND VALIDATION OF
RT-PCR ELISA PROTOCOLS
This chapter reports on a series of experiments which were conducted to test and
validate the molecular protocols used in the project. The first section describes an
investigation into the optimum magnesium chloride concentration for use in the
polymerase chain reaction protocols. The next two sections look at the use of the
project's RT-PCR ELISA protocol to assay the gene expression levels of cDNA
samples from patients recruited for the project, firstly to check for reproducibility of
the results, and secondly to assess the relationship between the level of gene
expression of the cDNA samples and the resultant quantity of PCR products. The
final section details a comparison of the results of the RT-PCR ELISA protocol when
applied to neat and diluted cDNA samples in order to determine whether similar
patterns of sequential cytokine gene expression are demonstrable independent of the
absolute amount of starting cDNA.
4.1 Optimising the magnesium chloride concentration for
polymerase chain reaction (PCR)
The PCR protocols used in the project were modified from the original protocols
developed by the Molecular Immunology Laboratory of the Department of Medicine,
University of Southampton. These original PCR protocols had been extensively
tested and used by the research staff of the Department ofMedicine.
The first modification in the PCR protocols is the use of a different Taq DNA
polymerase. The Department of Medicine used Taq DNA polymerase manufactured
by Promega in their protocols while the Taq DNA polymerase used for this project
was purchased from Boehringer Mannheim (chosen because this Taq DNA
polymerase is routinely used in the Molecular Biology Laboratory of Wessex
Immunology Service, where this project was undertaken). The second modification
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is in the amount of magnesium chloride (MgC^) used in the PCR protocols. The
amount of MgCh in a PCR is important since the activity of the Taq DNA
polymerase requires free magnesium on top of that bound by template DNA,
primers, and dNTPs [Innis and Gelfand, 1990], Moreover, it may also affect any of
the following: primer annealing, strand dissociation temperatures of both template
and PCR product, product specificity, formation of primer-dimer artifacts, and
enzyme activity and fidelity. It was therefore prudent to check that the same MgCh
concentration used in the original PCR protocols with Promega Taq DNA
polymerase would remain optimal when used with Boehringer Taq DNA polymerase
instead, before the PCR protocols were applied to the project samples.
For granzyme B (GrB) and fas ligand (FasL) PCR amplification, it was necessary to
determine the optimal MgCb concentrations since these were not given in the paper
by Strehlau et al [1997] and PCR for these gene products had not been validated in
Southampton prior to this project.
Consumables and equipments:
Most of the consumables and equipments listed in section 2.6 (chapter 2) were used
for the optimisation experiment (and the other experiments described in this chapter),
with some changes listed below:
1. IL-2, IFN-y, IL-4 and IL-10 cytokine primers (see section 2.4, chapter 2)
2. 0.2 ml thin-walled PCR tubes/caps (strip of 8 tubes/caps each) [Advanced
Biotechnologies, UK]
3. Perkin-Elmer GeneAmp System 9600 thermal cycler [Perkin-Elmer, UK]
Method:
The PCR methodology used in this experiment is set out fully in section 2.4 (chapter
2). The cDNA samples used for this experiment were obtained by reverse
transcription of total RNA extracted from the purified peripheral T lymphocytes of
stable renal transplant patients (from the experiments described in section 3.2 of the
previous chapter) or renal failure patients. Three different cDNA samples were used
for each set of magnesium optimisation experiments. The magnesium chloride
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optimisation experiments were carried out for all the cytokines and cytotoxic T-cell
markers studied in the project.
The master reagent mix used for the magnesium chloride (MgCL) optimisation PCR
experiment is summarised in table 4.1.1. Five aliquots of master reagent mix were
prepared for each magnesium chloride concentration, this includes an extra aliquot
for the negative control (using UV-irradiated double-distilled water) and another
aliquot as the excess, to take into account the inherent inaccuracies (small but
nevertheless unavoidable) resulting from multi-aliquot pipetting, so that sufficient
volume of master reagent mix was available for each sample. The magnesium
chloride concentrations were varied between 1.0 mM and 2.5 mM for IL-2, IFN-y,
IL-4 and IL-10, and between 1.0 mM and 3.0 mM for IL-13, GrB and FasL, both sets
at 0.5 mM increments. It was only possible to do a limited magnesium chloride
optimisation experiment for IL-5 because preliminary experiments showed that it
was completely undetectable in any of the patient's or healthy volunteer's cDNA, but
was only detectable in one cDNA sample from stimulated peripheral lymphocytes
kindly supplied by the Department of Medicine. Due to this lack of cDNA, only
1.0 mM and 2.0 mM concentrations were used to assess the preferable magnesium
chloride concentration for IL-5 PCR.
The PCRs were performed in a Perkin-Elmer 9600 thermal cycler using the program
and corresponding optimal annealing temperatures set out in tables 2.4.4 and 2.4.5
(section 2.4, chapter 2). The PCR products were resolved in a 2% agarose gel. 10 pi
of each PCR product was mixed with 2 pi of 6X stop mix and loaded into a well in
the gel. The gel electrophoresis was run at 150 volts for about 1.5 hours with a
molecular weight ladder. A polaroid image of the UV-transilluminated agarose gel
was performed to enable a visual assessment of the PCR product bands.
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Table 4.1.1 - Master reagent mix for magnesium chloride optimisation RT-PCR
MgCh Concentration (mM): 1.0 1.5 2.0 2.5 3.0
ddH20 (pi) 60.0 57.5 55.0 52.5 50.0
25 mM MgCl2 (pi) 5.0 7.5 10.0 12.5 15.0
Boehringer 10X reaction buffer
(without MgCh) - 2.5 pi*
12.5 12.5 12.5 12.5 12.5
dNTP mix (1.25mM) - 4.0 pi* 20.0 20.0 20.0 20.0 20.0
Sense primer (10 pM) -1.5 pi* 7.5 7.5 7.5 7.5 7.5
Anti-sense primer (10 pM) -1.5 pi* 7.5 7.5 7.5 7.5 7.5
Taq polymerase (Boehringer) - 0.2 pi* 1.0 1.0 1.0 1.0 1.0
Notes: * this is the volume per aliquot; all volumes are in pi (a total of 5 aliquots of
master reagent mix were prepared)
Results
The result from the magnesium chloride optimisation experiment is summarised in
table 4.1.2, which compares the magnesium chloride concentrations from the original
RT-PCR protocols and what was considered optimum for the Boehringer Taq DNA
polymerase from the assessment of the gel image.
The criteria for the optimum magnesium chloride concentration is that concentration
which gives the brightest specific PCR product band on the agarose gel image and/or
having the least amount of non-specific bandings. All the agarose gel images from
the optimisation experiment are shown in figures 4.1.1 to 4.1.8. As a comparison, the
agarose gel image of p-globin RT-PCR for a selection of patients is shown in figure
4.1.9 (the details of the RT-PCR protocol is described in section 2.6).
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Table 4.1.2 - Optimum MgCf> concentrations - comparison of original
protocol concentrations with experimental findings







GrB not available 1.0
FasL not available 1.0
Discussion
The results of these experiments have demonstrated similar optimum MgCL
concentrations to the original PCR protocols for some cytokines (IL-5 and IL-13) but
different optimum MgCL concentrations in others (IL-2, IFN-y, IL-4 and IL-10). As
explained previously, no comparison was possible for GrB and FasL. These
experimentally derived optimum MgCL concentrations were used for all
experimental PCR protocols in this project.
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In both gel images: MW = molecular weight marker V (22 fragments, pBR322 DNA
cleaved with Hae III); each group consist of a negative control and 3 different cDNA
samples; 1 = 1.0 mM, 2=1.5 mM, 3 = 2.0 mM, 4 = 2.5 mM.
Arrow "a" marks the PCR product bands and arrow "b" marks the primer bands
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In both gel images: MW = molecular weight marker V (22 fragments, pBR322 DNA
cleaved with Hae III); each group consist of a negative control and 3 different cDNA
samples; 1-= 1.0 mM, 2=1.5 mM, 3 = 2.0 mM, 4 = 2.5 mM.
Arrow "a" marks the PCR product bands and arrow "b" marks the primer bands
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In both gel images: MW = molecular weight marker VIII (17 fragments, mixture of
pUCBM21 DNA, cleaved with Hpa II and pUCBM21 DNA, cleaved with Dr<x I and
Hind III); each group consist of a negative control and 3 different cDNA samples;
1 = 1.0 mM, 2 = 1.5 mM, 3 = 2.0 mM, 4 = 2.5 mM, 5 = 3.0 mM, 6 = 2.0mM and
double amount of primers.
Arrow "a" marks the PCR product bands and arrow "b" marks the primer bands
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In both gel images: MW = molecular weight marker VIII (17 fragments, mixture of
pUCBM21 DNA, cleaved with Hpa II and pUCBM21 DNA, cleaved with Dra I and
Hind III); each group consist of a negative control and 3 different cDNA samples;
1 = 1.0 mM, 2=1.5 mM, 3 = 2.0 mM, 4 = 2.5 mM, 5 = 3.0 raM.
Arrow "a" marks the PCR product bands and arrow "b" marks the primer bands
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Figure 4.1.9 - (3-globin (PCR product size 97 base pairs)
In this gel image: MW = molecular weight marker VIII (17 fragments, mixture of
pUCBM21 DNA, cleaved with Hpa II and pUCBM21 DNA, cleaved with Dra I and
Hind III); a single negative control and (3-globin bands for 31 samples from 7
different patients are shown here.
Arrow "a" marks the PCR product bands. The primer bands lies outside the gel
image.
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4.2 Testing the reproducibility of the RT-PCR ELISA protocol
This experiment was conducted to investigate the reproducibility of the project's
entire molecular protocol (combining RT-PCR with PCR ELISA detection of the
PCR products) for detecting IL-2, IFN-y, IL-4 and IL-10 cytokine gene expression
(4 out of the 8 gene products investigated in the project).
Method
The cDNA samples of all the sampling time points from one of the patients
(a non-rejector) recruited for the project were used in this experiment. The combined
RT-PCR ELISA protocol (sections 2.4 and 2.5) was repeated on the same time series
of cDNA samples from the same patient on 3 separate occasions. There was a 2
weeks' gap between the first and second runs of the RT-PCR ELISA protocol, and a
3 weeks' gap between the second and third runs.
Results
Figures 4.2.1 to 4.2.4 expressed the three runs of the reproducibility experiments
graphically for IL-2, IFN-y, IL-4 and IL-10 series respectively. In each graph, the
amount of PCR products (reflected by the level of absorbance units of the products
detected spectrophotometrically by the PCR ELISA technique) is set out along the
y-axis, while the different sampling time points (/PT - pre-transplant, /2 = early
post-transplant, /3 = 1 week post-transplant, /4 = 2 weeks post-transplant,
/5 = 4 weeks post-transplant) are shown along the x-axis. Rl, R2 and R3 denotes the
results from first, second and third runs respectively obtained from applying the




























/PT a /3 /4 /5
Sampling time points
Figures 4.2.1 and 4.2.2 show the RT-PCR ELISA profiles for IL-2 and IFN-y






















Figures 4.2.3 and 4.2.4 show the RT-PCR ELISA profiles for IL-4 and IL-10
respectively on 3 separate runs (Rl, R2 and R3) for the same patient.
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Discussion
The results of these experiments indicate that within the limits of biological
variability, the project's RT-PCR ELISA protocol is able to produce highly,
reproducible results when applied repeatedly to a patient series of samples. This is
true both for high level of cytokine gene expression (IFN-y, IL-10 and most of IL-4
series) as well as low level of cytokine gene expression (IL-2 series and time points 2
and 3 of IL-4 series).
4.3 Dilution experiment to assess the relationship between the level
of gene expression of the cDNA samples and the resultant
quantity of PCR products
Dilution experiments were set up to investigate the relationship between the starting
amounts of cytokine cDNA and the resultant quantity of IL-2, IFN-y, IL-4 and IL-10
PCR products, as measured in absorbance units spectrophotometrically by PCR
ELISA, reflecting the levels of cytokine gene expression in the peripheral T
lymphocyte samples of the patients recruited in the project. It is important for the
quantity of PCR products to be directly related to the level of cytokine gene
expression (i.e. an increase in PCR products implies an increase in cytokine gene
expression, and vice versa) so that the PCR ELISA data obtained in the project
patients can be interpreted in a semi-quantitative manner.
Method
For these experiments, 15 cDNA samples taken from 9 patients in the project (some
patients contributing samples from different sampling time points) were selected on
the single criterion of high levels of PCR products from using neat concentrations
(i.e. undiluted) of cDNA for the PCR. This was to ensure that a reasonable level of
PCR products would be obtained when the neat concentrations of cDNA were
diluted down for the experiments. For each cytokine studied, 6 cDNA samples were
used for the dilution experiments.
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The RT-PCR ELISA protocol (sections 2.4 and 2.5) was applied to the cDNA
samples chosen for the experiments. The cDNA samples were used neat, and at two
other dilutions (diluting the cDNA with UV-irradiated double-distilled water). For
IFN-y, IL-4 and IL-10 PCRs, the two dilutions of cDNA prepared were 1 in 5 and 1
in 20, but for IL-2 PCR, 1 in 2 and 1 in 8 dilutions were made instead. These lower
dilutions were used for IL-2 because of the generally low levels of IL-2 PCR
products generated from RT-PCR of neat cDNA samples (see appendices 8 and 9).
Results
The results of the dilution experiments for IL-2, IFN-y, IL-4 and IL-10 are expressed
graphically in figures 4.3.1 to 4.3.4 respectively. The amount of PCR products is set
out along the y-axis in absorbance units while the three different dilutions of cDNA
are shown along the x-axis. The 15 cDNA samples were labelled A to O. It can be
seen that some cDNA samples were used for more than one dilution experiment.
For IL-2, all diluted cDNA samples (both 1 in 2 and 1 in 8 dilutions) have lower
amount of PCR products compared with that from their corresponding neat cDNA,
except for one sample where the 1 in 2 dilution have a slightly higher amount of PCR
products than its corresponding neat cDNA sample (sample L, figure 4.3.1). For the
other 3 cytokines with known high levels of PCR products from neat cDNA, in 14
(77.8%) out of 18 samples (5 for IFN-y, 6 for IL-4 and 3 for IL-10), the amount of
PCR products were higher from 1 in 5 dilution of cDNA than from neat cDNA. With
further dilution of the cDNA down to 1 in 20, the resultant amount of PCR products
in 15 (83.3%) of 18 samples (5 for IFN-y, 4 for IL-4 and 6 for IL-10) were lower
than that from neat cDNA.
The unusually low amount of IL-4 PCR products from neat cDNA seen in sample F
(figure 4.3.3) clearly suggests an inefficient PCR (for whatever reasons), since the




The generally low level of IL-2 expression was seen in the rapid fall in the amount of
PCR products with a small dilution of the starting cDNA down to 1 in 8 compared
with the other 3 cytokines which were a lot more highly expressed than IL-2.
For the highly expressed cytokines (IFN-y, IL-4 and IL-10), it is interesting to note
that with the initial 1 in 5 dilution of cDNA, the resultant amount of PCR products
actually rose above that from neat cDNA in 77.8% of samples, and only fell to below
the PCR product levels from neat cDNA at the greater dilution of 1 in 20 (in 83.3%
of samples). As the cDNA samples chosen for the dilution experiments were all
known to result in a large amount of PCR products for these cytokines, reflecting a
lot of gene transcripts present in the starting cDNA samples, this interesting anomaly
may be explained by an inhibition of the PCR caused by a reduced efficiency of
cDNA template annealing with its primers when excessively large amounts of gene
transcripts were present in the starting cDNA samples [Wang et al, 1989].
The reason for this is that for an exponential increase in PCR products to be possible,
the amount of primers for each cytokine must be in a vast excess over that for its
template, so that primer-template annealing is greatly in excess of template-template
annealing. At high concentrations of cDNAs, this will become progressively less
true. With a little dilution of these highly concentrated cDNA samples, the efficiency
of cDNA template binding by its primers improved, resulting in a larger amount of
PCR products. With a higher dilution of the starting cDNA, the confounding factor
of template-template annealing is no longer a problem, so the amount of PCR
products then start to fall as one would expect.
These results also demonstrate the highly sensitive nature of PCR as a technique in
detecting the presence of cytokine cDNA gene transcripts. The disproportionately
much greater change in cDNA concentration compared to its corresponding PCR
product levels suggests that the relationship between the amount of PCR products is
























































Figures 4.3.1 and 4.3.2 show the dilution series for IL-2 and IFN-y respectively. Each


















































Figures 4.3.3 and 4.3.4 show the dilution series for IL-4 and IL-10 respectively. Each
graph (labelled by a capital letter) represents the dilution series for one sample of
cDNA.
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therefore only reasonable to compare the results of the PCR ELISA data at the
different time points for each patient in a semi-quantitative manner.
4.4 Would a diluted cDNA series of samples gives the same trend of
changes as the same but undiluted cDNA series of samples?
In view of the results of the previous dilution experiments showing a slight increase
in the amount of PCR products with the initial dilution of cDNA (those with high
levels of cytokine gene transcripts) before the expected fall in amounts of PCR
products with further dilution of the starting cDNA, the obvious question is whether
this finding would pose any problems in term of the trend of changes in a series of
samples from the same patient if neat cDNAs were used for the PCR instead of
diluted ones (i.e. is the trend independent of the absolute amount of starting cDNA
for any given time point)? This experiment was therefore conducted to answer this
very question.
Method
The complete series of cDNA samples from two patients (both non-rejectors) were
used in this experiment. The project's RT-PCR ELISA protocols for IL-2, IFN-y,
IL-4 and IL-10 were applied to each patient's cDNA samples used neat and at 1 in 10
dilution. Each experiment (either with neat or 1 in 10 dilution of cDNA) were
performed at different times.
Results
The results of the experiments are expressed graphically in figures 4.4.1 to 4.4.4 for
IL-2, IFN-y, IL-4 and IL-10 series respectively.
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Figure 4.4.1a - IL-2 series (patient 1)
/PT /2 /3 /4 15
Sampling time points
Figure 4.4.1b - IL-2 series (patient 2)
/PT /2 /3 /4 /5
Sampling time points
Figures 4.4.1a and 4.4.1b show the RT-PCR ELISA profile for IL-2 in two patients
using neat and 1 in 10 dilution of cDNA (as labelled within each figure).
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Figure 4.4.2a - IL-4 series (patient 1)
Figure 4.4.2b - IL-4 series (patient 2)
Figures 4.4.2a and 4.4.2b show the RT-PCR ELISA profile for IL-4 in two patients
using neat and 1 in 10 dilution of cDNA (as labelled within each figure).
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Figure 4.4.3a - IFN-y series (patient 1)
Figure 4.4.3b - IFN-y series (patient 2)
/PT 12 13 /4 15
Sampling time points
Figures 4.4.3a and 4.4.3b show the RT-PCR ELISA profile for IFN-y in two patients
using neat and 1 in 10 dilution of cDNA (as labelled within each figure).
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Figure 4.4.4a - IL-10 series (patient 1)
Figure 4.4.4b - IL-10 series (patient 2)
Figures 4.4.4a and 4.4.4b show the RT-PCR ELISA profile for IL-10 in two patients
using neat and 1 in 10 dilution of cDNA (as labelled within each figure).
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Discussion
Overall, the patterns of changes for all four cytokines in each patient series when
neat concentrations of cDNAs were used were quite similar to the patterns seen for
the same patient series when 1 in 10 dilutions of cDNAs were used instead.
The similarity in the patterns of changes was particularly true for IL-4 and IL-10, but
more variability was seen for IL-2 and IFN-y. Nevertheless, this variability is
acceptable for biological data of this kind since the two experiments using different
concentrations of cDNAs were not performed at the same, and therefore the PCR
conditions for each experiment although the same in term of the protocol used, but
would not be exactly the same in the practical sense.
It is therefore acceptable to use the cDNAs in neat concentrations or in diluted
concentrations for assaying the gene expression levels in the project samples.
Wherever possible, neat concentrations will be used (so that reasonable readings
would be obtained for the lowly expressed cytokines like IL-2 and IL-5) but when
there is a shortage of samples (usually in the post-anti-rejection samples), it was
decided that a 1 in 5 dilution of cDNAs would be used instead. Obviously, for
meaningful comparison of the levels of gene expression for each cytokine or CTL
activation marker at the different time points for any given patient to be possible, all
the samples for that patient would be assayed by RT-PCR ELISA using either neat or
diluted cDNA.
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Chapter 5: CLINICAL AND LABORATORY
CHARACTERISATION OF PATIENT STUDY
GROUP
This is a general results chapter summarizing the findings from different aspects of
patients' data that were recorded in their project proformas (appendix 1). The first
two sections describe the overall characteristics of the study patients and the apparent
differences in these characteristics between the patients with and without early acute
rejection episodes. The timing of the peripheral blood sampling from the patients
recruited is set out in the next section, with a summary of the cell separation and
RNA extraction data following this. The final two sections detail the biochemical
renal function and cyclosporin profiles of the study patients and their subsequent
clinical follow-up.
5.1 General patient details
With the full approval of the hospital's ethics committee (appendix 2), recruitment of
patients for the study was conducted in two stages: between May 1996 and July 1996,
and between October 1996 and May 1997. No pre-transplant selection criteria were
imposed, with all patients being recruited whenever possible. Informed consent was
obtained from each patient participating in the study (the consent form and patient
information leaflet in appendices 3 and 4 respectively). The reason for the gap in the
recruitment phase was to allow for optimisation of the laboratory protocols for
subsequent molecular analyses and to obtain preliminary results, allowing the
efficacy of the system to be evaluated before proceeding further.
A total of 58 patients were recruited from the transplant programme of the Wessex
Renal and Transplant Unit at St Mary's Hospital, Portsmouth. Fifteen (25.9%) of the
patients recruited were dropped from the study for the following reasons: 7 patients
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(46.7%) had primary non-function of their renal allografts (as defined by the need for
dialysis within the first week following transplantation, for reasons other than an
elevated serum potassium), and 8 patients (53.3%) failed to have their transplants (6
patients because of positive patient-donor cytotoxic antibody cross-matches detected
by complement-dependent cytotoxicity and/or flow cytometry and 2 patients who
were deemed to be unfit for surgery by the anaesthetists). Hence the overall primary
non-function rate for the study cohort was 14% (7 out of 50 transplants).
Of the 43 patients who were successfully recruited for the study, 26 (60.5%) were
male. The median age of the patients was 43 years (range 22 to 70 years).
Twenty-two (51.2%) of the patients were established on haemodialysis while 10
(23.3%) were on peritoneal dialysis. Eleven (25.6%) of the patients were pre-dialysis.
The causes of end-stage renal failure of the study cohort are listed in table 5.1.1.
The majority of the recipients and donors were blood group A (table 5.1.2) in our
study cohort, which is different from the national picture where group O is the
commonest blood group [UKTSSA Transplant Activity 1996], The CMV status of
recipients and donors is summarised in table 5.1.3. The proportion of CMV positive
recipients is in keeping with that in the general population of about 50%
seroconversion by adulthood, although the number of CMV positive donors were
slightly lower than would be expected. Overall, the majority of recipients (86%)
received matched CMV status or CMV negative kidneys (table 5.1.4).
Twenty-nine (67.4%) patients received cadaveric kidneys while 14 (32.6%) had
living-related renal transplants. Thirty-seven (86.0%) of the transplants were primary
grafts, 5 (11.6%) were second grafts and only one (2.3%) was a fourth transplant.
Twenty-five (58.1%) of the transplants were placed in the left iliac fossa.
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Table 5.1.1 - Causes of end-stage renal failure
Causes of end-staee renal failure No. of patients
Analgesic nephropathy 1
Chemotherapy for malignant testicular teratoma 1
Chronic pyelonephritis 3
Crescentic GN/Wegener's granulomatosis 1
Diabetes mellitus (insulin/non-insulin dependent) 3















Note: GN = glomerulonephritis
Table 5.1.2 - ABO blood groups of recipients and donors




















Table 5.1.3 - CMV status of recipients and donors
CMV Positive CMV Negative
Recipients 21 (48.8%) 22 (51.2%)
Donors 19(44.2%) 24 (55.8%)
Table 5.1.4 - CMV matching between recipients and donors
No. of transplants
Matched recipient/donor CMV status 29 (67.4%)
Recipient positive and donor negative 8(18.6%)
Recipient negative and donor positive 6 (14.0%)
The HLA matching status of the transplants is detailed in tables 5.1.5 and 5.1.6. The
importance of HLA matching for the HLA-DR locus was reflected by 97.7% of
patients transplanted having at least one HLA-DR antigen matched with the donor,
compared with only 81.4% and 67.4% of patients respectively with at least one
HLA-A and HLA-B antigen match (table 5.1.5). The overall average total mis-match
(i.e. the sum of mis-match at HLA-A, -B and -DR loci) per patient was 2.9 and 31
patients (72.1%) had 3 or less total HLA mis-matches.
As expected, the commonest pattern of HLA mis-match in our study cohort (16
patients, 37.2%) was a 1-A: 1-B: 1-DR mis-match and only 6 patients (14.0%) had a
"full house" HLA match with their donors. Seven patients (16.3 %) received
beneficially matched kidneys (where a beneficial match is defined as a 0:0:0, 1:0:0 or
0:1:0 pattern of HLA-A:-B:-DR mis-match). Based on the new UKTSSA favourable
matching group formed by including the 1:1:0 pattern of HLA-A:-B:-DR mis-match
with the beneficial match criteria [UKTSSA Transplant Activity, 1996], 9 patients
(20.9%) in the study cohort received kidneys in this new group.
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Table 5.1.5 - Tissue typing mis-match for each HLA antigen group
No. of mis-match HLA-A HLA-B HLA-DR
Zero 8 (18.6%) 9 (20.9%) 11 (25.6%)
One 27 (62.8%) 20 (46.5%) 31 (72.1%)
Two 8(18.6%) 14(32.6%) 1 (2.3%)
Table 5.1.6 - Patterns ofHLA mis-match
Pattern of A : B : DR mis-match (MM) No. of transplants
0:0:0 (MM=0) 6(14.0%)
1 : 0 : 0 (MM=1) 1 (2.3%)
1:1:0 (MM=2) 2 (4.7%)
1:0:1 (MM-2) 1 (2.3%)
1:2:0 (MM=3) 2 (4.7%)
0:2:1 (MM=3) 2 (4.7%)
1:1:1 (MM=3) 16(37.2%)
2:0:1 (MM=3) 1 (2.3%)
1:2:1 (MM=4) 5 (11.6%)
2:1:1 (MM=4) 2 (4.7%)
2:2:1 (MM=5) 4 (9.3%)
2:2:2 (MM=6) 1 (2.3%)
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5.2 Patients with early acute rejection
Of the 43 patients in the study, 15 patients (34.9%) had experienced early acute
rejection (defined as acute cellular and/or vascular rejection occurring within the first
6 weeks following transplantation), with 14 (93.3%) of these patients experiencing
their rejection episode within 3 weeks of their transplantation (of whom 10 (66.7%)
occurred in the first 2 weeks). All diagnoses of acute allograft rejection were made by
a combination of clinical and laboratory criteria of graft dysfunction, and confirmed
histologically by graft biopsy.
The demographic characteristics of the two groups of patients within the study cohort
were statistically comparable. The details of these demographic characteristics (age,
sex distribution, type of transplant, transplant number, mode of pre-transplant renal
replacement therapy, recipient and donor blood groups, recipient and donor CMV
status and matching, and pattern and number of HLA mis-match) in patients
experiencing early rejection and those who did not are shown in tables 5.2.1 to 5.2.6
respectively. No significant differences between the two groups (table 5.2.7) were
found for any of these factors at the 5% level.
Table 5.2.1 - Age, sex distribution, proportion of cadaveric and primary transplants
in patients with/without early acute rejections
Early acute rejections? Yes (n=15) No (n=28)
Median age of recipients (range) 49 years (26 - 59) 36 years (22-70)
Male recipients 7 (46.7%) 19(67.9%)
Cadaveric transplants 12(80.0%) 17(60.7%)
Primary transplants 14(93.3%) 23 (82.1%)
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Table 5.2.2 - Methods of renal replacement therapy in patients with/without early
acute rejections
Early acute rejections? Yes (n=15) No (n=28)
Haemodialysis 6 (40.0%) 16(57.1%)
Peritoneal dialysis 5 (33.3%) 5 (17.9%)
None (i.e. pre-dialysis) 4 (26.7%) 7 (25.0%)
Table 5.2.3 - Donors and recipients blood groups in patients with/without early acute
rejections
Early acute rejections?
Yes (n=15) No (n=28)
Blood
groups
Donor Recipients Donor Recipients
O 7 (46.7%) 7 (46.7%) 10(35.7%) 7 (25.0%)
A 7 (46.7%) 7 (46.7%) 17(60.7%) 19(67.9%)
B 1 (6.7%) 1 (6.7%) 1 (3.6%) 0
AB 0 0 0 2(7.1%)
Table 5.2.4 - CMV matching in patients with/without early acute rejections
Early acute rejections? Yes (n=15) No (n=28)
Matched recipient/donor CMV status 12(80.0%) 17(60.7%)
Recipient positive and donor negative 2(13.3%) 6(21.4%)
Recipient negative and donor positive 1 (6.7%) 5 (17.9%)
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Table 5.2.5 - Pattern ofHLA mis-match in patients with/without early acute
rejections
Pattern of A : B : DR mis-match (MM)
Early acute rejections?
Yes (n=15) No (n=28)
0:0:0 (MM=0) 0 6(21.4%)
1:0:0 (MM=1) 0 1 (3.6%)
1:1:0 (MM=2) 0 2(7.1%)
1:0:1 (MM=2) 0 1 (3.6%)
1:2:0 (MM=3) 1 (6.7%) 1 (3.6%) |
0:2:1 (MM=3) 0 2(7.1%)
1:1:1 (MM=3) 8 (53.3%) 8 (28.6%)
2:0:1 (MM=3) 0 1 (3.6%)
1:2:1 (MM=4) 2(13.3%) 3 (10.7%)
2:1:1 (MM=4) 2(13.3%) 0
2:2:1 (MM=5) 1 (6.7%) 3 (10.7%)
2:2:2 (MM=6) 1 (6.7%) 0
Although the total HLA mis-match was greater in patients experiencing early acute
rejection with an average total mis-match per patient of 3.7 (2.5 for patients not
experiencing early acute rejections), this difference was not statistically significant
(table 5.2.7). Nonetheless, it is interesting to observe that patients experiencing early
acute rejections have less zero mis-match at all the three HLA loci (table 5.2.6) and
only 60.0 % had 3 or less total HLA mis-match per patient (compared to the 78.6%
of patients without early acute rejection episodes who had 3 or less total HLA
mis-match).
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Table 5.2.6 - HLA mis-match (MM) in patients with/without early acute rejections
Early acute rejections?
Yes (n=15) No (n=28)
No. of
mis-match



































Of the 15 patients who experienced early acute rejection, 9 had histological evidence
of acute cellular rejection only, while the other 6 patients had acute vascular rejection
in addition to acute cellular rejection. All rejection episodes were treated in the first
instance with a three-day course of methylprednisolone pulses (half a gram per day),
although 3 patients received an extra dose and 2 patients had a second course of
methylprednisolone to successfully treat their rejection episode.
Of the 6 patients with histological evidence of acute vascular rejection as well as
acute cellular rejection, biological anti-rejection agents were used in 5 patients (4
with polyclonal antibodies and 1 with monoclonal antibodies). The remaining patient
with vascular and cellular rejection had concomitant sepsis from transplant urinary
leak and was therefore unable to tolerate further immunosuppression with biological
agents to rescue his rejecting renal allograft. One other patient with acute cellular
rejection only who failed to respond to methylprednisolone pulses was also given
biological therapy with a polyclonal agent. Between 3 and 5 doses of each biological
agent were given over a 10-day period depending on the degree of additional
immunosuppression achieved with that agent as assessed by the daily FACS CD3
counts (the agent was given when the total CD3 count was greater than
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50,000 per ml). The polyclonal antibodies used were anti-lymphocyte globulin,
Lymphoglobuline® [Pasteur Merieux, France] or anti-thymocyte globulin,
Thymoglobuline® [Pasteur Merieux, France] and the monoclonal antibodies used
was Orthoclone OKT3® [Janssen-Cilag, Switzerland].








Age distribution t test - - 0.125
Sex distribution x2 test 1.835 1 0.176 (0.206)
Cadaveric/living-related X2 test 1.654 1 0.198 (0.308)
Previous transplants X2 test 1.165 2 0.558
Renal replacement therapy X2 test 1.578 2 0.454
Recipient blood group X2 test 5.072 3 0.167
Donor blood group X2 test 0.843 2 0.656
CMV matching X2 test 1.759 2 0.415
Total HLA mis-match X2 test 9.510 6 0.147
Notes: df = degrees of freedom; i = Chi squared
* 2-tailed p-value; Fisher's exact test applicable in 2X2 tables only
5.3 Timing of peripheral blood sampling
A total of 237 peripheral blood samples were taken from the 43 patients in the study.
For the patients who did not experience any early acute rejection episode, 5 samples
of peripheral blood per patient were taken within six weeks of their transplantation,
while for those who experienced early acute rejections, a median of 6 samples (range
5 to 8) of peripheral blood per patient were taken.
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The details of the timing of peripheral blood sampling from all patients without early
acute rejection are summarised in table 5.3.1. For the patients with early acute
rejection episodes, the same blood sampling schedule as for the patients without early
acute rejection episodes was followed up to the time when acute allograft rejection
was diagnosed and confirmed (table 5.3.2a). The time schedule for additional
peripheral blood sampling prior to commencing anti-rejection therapy and following
anti-rejection therapy in order to study the effect of acute allograft rejection and
anti-rejection therapy on changes in gene expression levels is shown in table 5.3.2b.
The medians and ranges in all the tables in this section refer to the number of days
pre-transplant or post-transplant as indicated by the sampling time points. The day of
transplantation was taken as day zero.
Table 5.3.1 - Protocol blood sampling time points (non-rejectors)






Pre-transplant 28 0 0-14*
Early post-transplant 28 2 2-4
1 week post-transplant 28 6 5 - 8
2 weeks post-transplant 28 12 10- 14
4 weeks post-transplant 28 29 27-43
*days before transplantation
Most of the patients had their pre-transplant bloods sampled within 24 hours prior to
their kidney transplantation. The 6 patients who had their pre-transplant bloods
sampled between 2 and 14 days prior to their transplants were all living related
transplants and their bloods were sampled earlier than the rest either because their
transplants were postponed for medical reasons, or because it was convenient to take
their pre-transplant blood at the time when they came into the unit for their T and B
cell serological and FACS crossmatch.
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Table 5.3.2a - Protocol blood sampling time points (early rejectors)






Pre-transplant 15 0 0-2
Early post-transplant 15* 2 2-4
1 week post-transplant 13 6 5-7
2 weeks post-transplant 8 12 10- 14
4 weeks post-transplant 0 - -
* see text for explanation
Table 5.3.2b - Additional blood sampling time points (early rejectors)






Pre-anti-rejection therapy 14* 1 0-5
Early post-anti-rejection therapy 15 2 1-5
1 week post-anti-rejection therapy 13* 7 6-10
4 weeks post-anti-rejection therapy 9* 28 18-36
* see text for explanation
For patients experiencing early acute rejection episodes, the early post-transplant
samples were the same as the pre-anti-rejection therapy samples in two patients (table
5.3.2a).
Missing samples
There was no opportunity to take a sample prior to commencing anti-rejection
therapy for one patient with early rejection as she was admitted from the outpatient
clinic and given anti-rejection therapy before I could see her (table 5.3.2b).
Unfortunately the same patient did not have the sample taken one week following the
completion of her anti-rejection therapy due to logistical reasons. Another patient
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also did not have the one week post-anti-rejection therapy sample taken because he
had graft nephrectomy by then.
The 4 weeks post-anti-rejection therapy samples were only done on the last 9 patients
who experienced early acute rejections because this time point was not in our original
additional blood sampling schedule, it was only added to the protocol after
preliminary data from the first 6 patients who had experienced early acute rejection
suggested that it would be useful to obtain a further sample from these patients so
that the immunological status when the rejection process has been fully overcome
may be determined.
5.4 Cell separation and RNA extraction
The median volume of blood taken at each sampling time point (excluding the
volume of citrate in the vacutainers) was 15.5 ml (range 8.1 - 19.0). The details of the
cell separation results for the study cohort are set out in the appendix 6 and a
summary of the results is shown in table 5.4.1.
The median interval between the addition ofRNAzol B to the cell pellet at the end of
the cell separation step and the extraction of the total RNA from the RNAzol B
homogenates was 2 days (range 1 to 17 days). The details of the RNA extraction
results are set out in appendix 7. A summary of the results is shown in table 5.4.2.
The lower total mononuclear cells (MNC) available for total RNA extraction was
discounted by the small volume of MNC suspension removed for cell count by the
Coulter counter. Overall, the total RNA extracted by the chosen method yielded a
reasonable quantity of total RNA with high purity (free ofDNA and proteins) and has
a 260/280 absorbance ratio higher than 1.9 (according to the maker of RNAzol B).
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Table 5.4.1 - Summary of cell separation results
Cell counts Median 5th Percentile 95th Percentile
Before cell
separation
LY (xl06/ml) 1.3 0.3 2.9
MO (xl06/ml) 0.6 0.2 1.3
% Monocytes 32.8 12.5 60.0
MNC (x 106) 28.8 10.8 57.7
After cell
separation
MNC (x 106) 12.0 3.0 29.7
% cell loss 58.2 37.5 79.7
Note: LY= lymphocyte count; MO=monocyte count; MNC=mononuclear cell count
Table 5.4.2 - Summary of the RNA extraction results
Median 5th Percentile 95th Percentile
MNC (x 106) 11.6 2.9 28.7
Purity (260/280 ratio) 2.0 1.9 2.1
Total RNA (pg) 11.8 2.9 37.3 !
Total RNA/106 cells (pg) 1.2 0.4 2.4
Note: MNC=mononuclear ce Is
5.5 Biochemical renal function profiles & cyclosporin levels
For clarity, table 5.5.1 lists the blood sampling time points numerically as used in
annotating the x-axes of all the graphs in this section.
In all the graphs, the open circles (o) denote outliers (defined as cases with values
between 1.5 and 3 box lengths from the upper or lower edge of each box plot), while
the asterisks (*) denote the extremes (defined as cases with values more than 3 box
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lengths from the upper or lower edge of each box plot). The box length represents the
interquartile range. Both the outliers and extremes data are labelled with the case
numbers of the patients as they were entered into the SPSS database. N refers to the
number of results available.




3 1 week post-transplant
4 2 weeks post-transplant
5 4 weeks post-transplant
6 Pre-anti-rejection therapy
7 Early post-anti-rejection therapy
8 1 week post-anti-rejection therapy
9 4 Weeks post-anti-rejection therapy
10 3 months post-transplant
n 6 months post-transplant
12 12 months post-transplant
The overall biochemical renal function profiles of the patients with and without early
acute rejection episodes are shown in figures 5.5.1 to 5.5.4. No formal statistical test
was applied to any of these data as the trends of changes are obvious and do not
require statistical tests to demonstrate them.
Notice that the majority of the acute rejection episodes had been successfully treated
as seen by the sizeable fall in the mean serum urea and creatinine of the patients by
the end of the first week following anti-rejection therapy (time point 8) in figures
5.5.2 and 5.5.4 respectively. The mean fall in serum urea and creatinine between
pre-anti-rejection therapy (time point 6) and 1 week following anti-rejection therapy
(time point 8) were 18.9% and 21.6% respectively, with nearly 70% of patients (9 out
of 13 available comparisons) recording a fall ofmore than 10%.
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Within the subgroup of patients who did not experience early acute rejections, the
evidently superior quality of living-related kidneys as compared to cadaveric kidneys
is demonstrated by an earlier and greater fall in serum urea and creatinine from the
pre-transplant level following renal transplantation in this subgroup of patients
(figures 5.5.5 to 5.5.8). This subgroup analysis comparing the performance of
cadaveric with living-related kidneys was not applied to the patients who experienced
early acute rejections because the numbers in the two groups would be too small for
the comparison to be meaningful.
The cyclosporin A profiles of the patients without and with early acute rejections are
set out in figures 5.5.9 to 5.5.10 respectively. The steady rise in plasma cyclosporin A
levels in the first two weeks following transplantation in both groups of patients
corresponded with the initial loading up of cyclosporin A during that period.
Interestingly, although the cyclosporin A level in the early post-transplant period was
similar in the two groups of patients, it was clearly higher in patients who had early
acute rejections at 2 and 4 weeks post-transplant, suggesting that at least in this group
of patients most of the early acute rejections episodes were not due to inadequate
immunosuppression.
In the medium term follow-up (3 to 12 months post-transplant), the mean plasma
cyclosporin A level in both groups of patients were similar, the mean level settling
down to the target level of between 100 and 200 ng/ml from 3 months post-transplant
onwards.
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5.6 Follow-up clinical data
5.6.1 Medium term follow-up data
The clinical follow-up data detailed in this section have been included for
completeness. These data are intended to give a more complete clinical picture of
what happened to the study cohort following transplantation, by detailing the
subsequent clinical events experienced by the study patients.
Having excluded the 2 patients who had graft nephrectomies and therefore had no
meaningful follow-up data, all the remaining study patients were followed up to 12
months following their renal transplantation whenever possible. All the medium term
follow-up data were recorded at fixed time points of 3, 6 and 12 months
post-transplant to allow a reasonable time-frame comparison of the follow-up data.
Of the 41 patients left to follow-up, there were 3 (7.3%) patients with missing data at
3-month follow-up, two of whom were discharged early to their health authority
outside the district and another patient had returned to the USA following her
living-related transplant. By the 6-month follow-up, the number of missing data had
increased to 5 (12.2%) patients, caused again by patients being discharged to health
authorities outside the district. For the 12-month mark, there were 14 (34.1%)
patients with missing data, but this further increase in the number of missing
follow-ups were due mainly to these patients being recruited in the last two months
of the recruitment phase and thus their 12-month follow-up had not come up by the
time I left my research post in March 1998.
5.6.2 Outcome of anti-rejection therapy, further rejection episodes and
mortality
Of the 15 patients who experienced early acute rejections, 2 lost their grafts. The
graft nephrectomies were performed at 3 and 11 weeks post-transplant, and the
histology of both grafts did confirm acute cellular and vascular rejection, with the
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presence of acute pyelonephritis being seen also in the graft from a patient who had
urinary leak.
The other 13 patients responded well to the anti-rejection therapy. One patient who
had an acute cellular and vascular rejection 2 days following his living-related
transplant which was successfully rescued with a combination of pulse
methylprednisolone and anti-thymocyte globulin therapy, had a late rejection episode
suggested by a deterioration in renal function and a biopsy showing borderline
cellular rejection with some degree of vascular rejection as well as evidence of
chronic rejection 8 months post-transplant. He was given a further pulse of
methylprednisolone therapy and was converted from azathioprine to mycophenolate
mofetil as a second line rescue therapy.
Of the 28 patients who did not experience early acute rejection, 2 had a suspected
acute rejection episode 3 months post-transplant. Both were treated with pulse
methylprednisolone therapy even though their biopsies showed non-specific changes
only. One patient with a borderline cellular rejection confirmed on biopsy at over 4
months post-transplant was treated with pulse methylprednisolone and another
episode of biopsy-proven cellular rejection occurred a month later requiring rescue
with tacrolimus. This patient was already commenced on mycophenolate mofetil
immunosuppression for this second living-related transplant, having lost his first
cadaveric kidney to acute rejection. Another patient with a progressive deterioration
in graft function from about 6 months post-transplant was found to have evidence of
chronic tubular damage on biopsy together with an element of cellular rejection, but
this did not respond to pulse methylprednisolone therapy.
Overall, one patient died 9 months post-transplant. He was an insulin-dependent
diabetic who suffered a stroke about 3 weeks following a cadaveric renal transplant.
Although he recovered well from his stroke, he subsequently succumbed to the
diabetic complications affecting his feet despite intensive surgical interventions,
including amputations, and marked reductions in the level of his immunosuppression.
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5.6.3 Changes in immunosuppressive therapy
The immunosuppressive regimens used by the patients are shown in table 5.6.1. The
majority of patients remained on triple immunosuppressive regimens, with the
standard triple regime of cyclosporin A, prednisolone and azathioprine being the
commonest immunosuppressive regimen. The patient who was on cyclosporin A,
prednisolone and mycophenolate mofetil (marked with * in table 5.6.1) was
commenced on this regime from the outset as he had received a living-related second
transplant, having lost his first cadaveric transplant to acute rejection. He was
converted from cyclosporin A to tacrolimus by his 6-month follow-up following a
late acute rejection episode. One patient was converted from cyclosporin A to
tacrolimus following the successful rescue of her early acute rejection with a
combination of pulse methylprednisolone and anti-thymocyte globulin (marked with
** in table 5.6.1). Another patient mentioned in the previous section was converted
from azathioprine to mycophenolate mofetil as a second line rescue therapy
following a further episode of acute rejection and so showed up as a change in
immunosuppression at 12 month follow-up (marked with f in table 5.6.1).
The 3 patients who were only on cyclosporin A and prednisolone at their 3 month
follow-up had their azathioprine stopped temporarily because of a low leucocyte
count, two of them having been on intravenous ganciclovir for acute CMV disease
shortly prior to their 3 month follow-up appointment. The two patients who were on
dual therapy only at their 12 month follow-up had the third immunosuppressive
stopped deliberately by their nephrologists, the prednisolone was stopped as part of
their long term immunosuppressive policy while the azathioprine was stopped
because of leucopaenia.
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Table 5.6.1 - Immunosuppressive regimens
Months post-transplant
follow-up
Immunosuppressive regimens used 3 6 12
Cyclosporin A, Prednisolone, Azathioprine 33 34 22
Cyclosporin A, Prednisolone, Mycophenolate mofetil 1* 0 If
Tacrolimus, Prednisolone, Azathioprine 1 ** 1 ** j **
Tacrolimus, Prednisolone, Mycophenolate mofetil 0 1* 1*
Cyclosporin A, Prednisolone 3 0 1
Cyclosporin A, Azathioprine 0 0 1
5.6.4 Infective complications in the post-transplant period
The early infective complications (those occurring during the patients' first inpatient
stay following their renal transplant) whether confirmed by laboratory investigation
or suspected clinically, are detailed in table 5.6.2. Although the numbers in each
category are set against each post-transplant time point, they refer to the infective
complications that were present either at or during the time period immediately
preceding that stated post-transplant time point. The category "Chest" refers to the
presence of clinical and radiological evidence of chest infection but not necessarily
with positive sputum culture, while the category "Urine" refers to the presence of
urinary tract infection confirmed with positive culture of pathogenic organisms from
mid-stream specimens or catheter specimens of urine. The category "Others" lists the
individual infective complications other than chest or urinary tract infections and
"PUO" refers to patients having a temperature greater than 37.5 °C with no obvious
cause. "N" denotes the total number of patients with available post-transplant data for
analysis.
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Table 5.6.2 - Early infective complications




Early post-transplant 43 2 0 0 6
1 week post-transplant 41 1 4 0 3
2 weeks post-transplant 37 1 1 1 Cold 2
4 weeks post-transplant 29 0 1 1 Dental abscess 0
The prospective evaluation of the number of early infective complications detailed in
table 5.6.2 refers only to the infective complications recorded in the proforma during
each protocol blood sampling time point. Since most of the blood sampling time
points prior to and following anti-rejection therapy for the patients who experienced
early acute rejections usually fall outside these protocol blood sampling time points,
no data on infective complications were recorded in the proforma for these patients.
However, a detailed retrospective review of the transplant flow charts of these
patients did not reveal any additional early infective complications.
At the 3-month, 6-month and 12-month follow-ups, none of the patients had
experienced any chest, urinary tract or other infections during these follow-up
periods. The only infective complication during the late follow-up period was acute
CMV disease occurring in 4 patients, presenting at between 6 and 11 weeks
post-transplant and all were treated with intravenous ganciclovir for three weeks.
Three of the patients had primary CMV disease, having been CMV negative prior to
their transplantation and had received CMV positive kidneys, while the fourth
patient's acute CMV disease was a reactivation of her previous CMV infection, as
she was CMV positive prior to her transplant and had received a CMV negative
kidney. Interestingly, all the 3 patients who had primary CMV disease did not
experience any rejection episodes while the patient who had reactivated CMV disease
had experienced severe acute cellular and vascular rejection requiring two courses of
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pulse methylprednisolone therapy as well and biological anti-rejection agent to rescue
her kidney.
5.7 Discussion
The study group characterisation, sampling strategy and transplant outcome data
presented in this chapter establish the background for the main body of this thesis,
namely, the molecular analyses of cytokines and CTL activation markers gene
expression of peripheral T lymphocytes in patients following renal transplantation,
which is described in the following chapter. More specifically, this analysis showed
no significant differences between those patients who did experience early acute
rejection and those who did not experience early acute rejection of their renal
allografts.
The proportion of living-related transplants in the study cohorts was considerably
higher than the Wessex Renal and Transplant Unit's living-related transplant rate of
around 15%. This skew towards living-related transplants in the study cohorts was
inevitable because logistically it was much easier to recruit these patients than those
receiving cadaveric kidneys since living-related transplants were elective operations,
whereas cadaveric transplantations may take place outside of normal working hours
and therefore the patients may be brought in for their transplants at times unsuitable
for the laboratory work that accompanied the recruitment process. Apart from this,
none of the other characteristics of the study patients were particularly unusual for
renal transplant patients.
The statistical analysis of the patients' characteristics between those who had
experienced early acute rejection and those who had not has clearly demonstrated that
these two groups of patients were comparable. The medians and ranges of the timing
of all the protocol peripheral blood sampling following transplantation were also very
similar between the two groups. Therefore, any differences in the subsequent
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molecular analyses between them cannot be accounted by any apparent differences
between their patients' characteristics or the timings of their peripheral blood
sampling.
The pattern of changes in the plasma levels of cyclosporin A in the post-transplant
period is as one would expect from a policy of regular optimisation of the dose of
cyclosporin A based on a twice weekly plasma cyclosporin A assay. The relative ease
of achievement of the target range of plasma cyclosporin A in the patients is a
reflection of the much improved absorption kinetics of the new microemulsion
formulation of cyclosporin A, Neoral, resulting in a better correlation of plasma level
of the drug with the oral dose.
The biochemical renal function profiles of the patients in the study have provided the
documentary evidence of the dramatic impact of renal transplantation, as well as the
impact of the acute rejection process and its treatment on these parameters. The
marked superiority in the quality of living-related kidneys over cadaveric kidneys has
been clearly demonstrated with the biochemical renal function profiles in the two
groups.
The medium term follow-up data has completed the clinical picture of the study
cohorts. Overall, graft loss in the study cohort was small, with 2 lost to acute
rejections and one from patient death. The number of immunological events
occurring after the study period was also small, with 3 patients overall with
histological evidence of further acute cellular/vascular rejection or chronic rejection,
although there were 2 other patients with suspected but unconfirmed acute rejection
episodes.
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Chapter 6: SEQUENTIAL GENE EXPRESSION
PROFILES OF PERIPHERAL T CELLS
BASED ON RT-PCR ELISA MONITORING
This chapter sets out the analyses of the molecular results of the project, namely the
semi-quantitative RT-PCR ELISA data relating to the sequential changes in the level
of cytokine and CTL activation marker gene expression in the early post renal
transplant period. The RT-PCR ELISA data have been analysed in three ways, and
each is set out in separate sections.
The first section looks at the profile of changes for each cytokine/CTL activation
marker studied in the project in the two groups of patients, those who did not
experience early acute rejection episodes (henceforth described as "non-rejectors")
and those who did (henceforth described as "rejectors"). For the non-rejectors, data
from all 5 protocol sampling time points were included in the analysis, while for the
rejectors, the additional sampling time points around the acute rejection episode (i.e.
the time point prior to commencing anti-rejection therapy and the time points
following completion of the anti-rejection therapy) were analysed together with the
first 2 protocol sampling time points for comparison. The next section looks at the
cytokine and CTL activation marker gene expression profiles over the protocol
sampling time points prior to the acute rejection episode in the rejectors and
compares them with the profiles over the same protocol sampling time points in the
non-rejectors. The final section compares the data at each protocol sampling time
prior to the acute rejection episode in the rejectors with the data at the same time
points in the non-rejectors.
Statistical analyses applied in the graphs
The RT-PCR ELISA data at all sampling time points (protocol sampling time points
and the additional sampling time points) were compared using the non-parametric
Wilcoxon signed rank sum test for matched pairs in the following analyses:
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(i) Sequential analysis: the data (percentage change or ratio) at one time point was
compared with the data at the time point immediately preceding it.
(ii) Pre-transplant baseline analysis: the data at all post-transplant time points were
compared with the baseline pre-transplant time point.
(iii) Pre-rejection baseline analysis: for the rejectors, in addition to the first two
analyses, the data in all the time points following anti-rejection therapy were
compared with a second baseline, the pre-anti-rejection therapy time point.
Annotation of the graphs
The results of all the RT-PCR ELISA data are expressed in the standard box and
whiskers plots. In all the graphs shown in this chapter, the outliers and extremes data
are not shown for the sake of clarity, although it is emphasized that all data were
included in the statistical analyses. The different sampling time points together with
the number of samples at each time point are shown along the x-axis, while the
y-axis gives the percentage change from the pre-transplant sample, which was taken
as the baseline. All the raw data from the RT-PCR ELISA molecular analyses are
shown in the appendices 8 to 11. A 2-tailed p value is quoted for all statistical
analyses, and in all the graphs, only the p values obtained from the sequential
analysis were quoted. The p values from the other two analyses are stated in the
individual sections commenting on the profile of changes in the level of each
cytokine/CTL activation marker in the study patient groups. Note also that both in
the text and in the figures, only significant p values are quoted, otherwise the
abbreviation "NS" for not significant will be used to denote all p values greater than
0.05.
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6.1 Analysis of cytokine and CTL activation marker gene expression
profiles in patients with and without early acute rejections
In the following sub-sections, sequential changes in cytokine (IL-2, IFN-y, IL-4,
IL-10, IL-5 and IL-13) and CTL activation marker (GrB and FasL) gene expression
are considered in turn, and expressed in terms of the percentage change in the
amount of their corresponding PCR products (expressed numerically by the ELISA
plate readings) for each gene transcript at each post-transplant time point compared
with the pre-transplant baseline (set at 100%). The validity of using the changes in
the ELISA plate readings as a measure of the changes in the level of gene expression
of a given cytokine has been shown by the various preliminary experiments
validating the molecular techniques used in the project as detailed in chapter 4. These
changes are plotted in figures 6.1.1 to 6.1.8, with the graphs for the non-rejectors and
the rejectors set out next to each other in graphs (a) and (b) respectively within each
figure. In the rejectors, the only pre-rejection time points included in the analysis
here were the pre-transplant baseline and the early post-transplant time points.
All 15 patients experiencing early acute rejection were analysed for all cytokines and
CTL activation markers listed above. All 28 non-rejectors were analysed for IL-2,
IFN-y, IL-4 and IL-10. Twenty-seven out of 28 non-rejectors were analysed for IL-5,
IL-13, GrB and fasL, the second phase of molecular analyses, because the early
post-transplant sample from one patient was not available for analysis, it was decided
that analysing the remaining samples from this patient with the missing early
post-transplant sample would not be appropriate as data analysis would be difficult
because of the missing sample.
Overall from the ELISA plate readings, IL-2 and IL-5 have a general tendency
towards a lower level of expression compared to the other cytokines or CTL
activation marker at any time points and in both non-rejectors and rejectors (see the
appendices 8 and 9 respectively for the raw ELISA plate readings).
- 152-
6.1.1 IL-2 (figure 6.1.1)
In the non-rejectors, there were no significant differences in the levels of IL-2 gene
expression not only sequentially from one time point to another, but also when all
post-transplant time points were compared with the pre-transplant baseline.
In the rejectors, however, there was a significant fall in the level of IL-2 gene
expression in the early post-transplant period (p=0.023). There were no further
significant sequential changes in any of the subsequent time points. Nevertheless,
this low level of IL-2 gene expression remained significantly lower than the
pre-transplant baseline at the pre-anti-rejection therapy (p=0.035) and early
post-anti-rejection therapy time points (p=0.001), returning to the pre-transplant
baseline 1 week and 4 weeks following anti-rejection therapy (p=NS when these time
points were compared with the pre-transplant baseline).
There were no significant differences in the level of IL-2 between all 3 time points
following anti-rejection therapy and the pre-anti-rejection therapy time point.
6.1.2 LFN-y (figure 6.1.2)
Like IL-2, no significant differences in the levels of IFN-y gene expression were
found in the non-rejectors both sequentially between all the time points and between
all post-transplant time points and the pre-transplant baseline.
In the rejectors, as for IL-2, there was a significant fall in IFN-y gene expression in
the early post-transplant period (p=0.003), with no further significant sequential
changes in the level of IFN-y at all time points following this. However, unlike IL-2,
the level of IFN-y at the time of rejection (pre-anti-rejection therapy time point) was
not significantly different from the pre-transplant baseline, but at the early
post-anti-rejection therapy time point, IFN-y level was again significantly below the
pre-transplant baseline (p=0.027). IFN-y level was not significantly different from
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Figure 6.1.2 - Percentage change in IFN-y gene expression in non-rejectors and
rejectors
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As for IL-2, there were no significant differences between the pre-anti-rejection
therapy level of IFN-y and all the post-anti-rejection therapy time points.
6.1.3 IL-4 (figure 6.1.3)
IL-4 gene expression in peripheral T cells showed the most sequential changes of all
the cytokines and CTL activation markers studied. In the non-rejectors, IL-4 fell
significantly in the early post-transplant period (p=0.001) before rising significantly
at the 1 week post-transplant time point, p=0.029 (although this level was still
significantly below the pre-transplant baseline, p=0.006), and continuing to rise
further at the 2 weeks post-transplant time point, p=0.003 (the level of IL-4 returning
back to the pre-transplant baseline level at this time point, p=NS). This level of IL-4
gene expression was maintained at 4 weeks post-transplant (p=NS when comparing
with the previous time point and with pre-transplant baseline).
In the rejectors, there was a similar significant fall in IL-4 gene expression at the
early post-transplant time point (p=0.002). However, at the time of acute rejection
(pre-anti-rejection therapy time point), there was a significant rise in IL-4 gene
expression (p=0.023) above the early post-transplant time point level, although this
level was not significantly different from the pre-transplant baseline.
The potent effect of anti-rejection therapy on peripheral IL-4 gene expression can be
seen by its dramatic fall at the early post-anti-rejection therapy time point to a level
not only significantly below the pre-anti-rejection therapy level (p=0.022), but also
significantly below the pre-transplant baseline (p=0.015). This suppression of IL-4
following anti-rejection therapy was then followed by a significant rise back to the
pre-transplant baseline 1 week after anti-rejection therapy (p=0.019), which remained
unchanged by the 4 weeks post-anti-rejection therapy time point (p=NS for both time
points when compared with the pre-transplant baseline). In addition, the levels of
IL-4 gene expression at both these time points were not significantly different from
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Figure 6.1.3 - Percentage change in IL-4 gene expression in non-rejectors and
rejectors
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6.1.4 IL-10 (figure 6.1.4)
The changes in peripheral T cell IL-10 gene expression appeared to be in the
opposite direction to the changes seen in IL-4. In both non-rejectors and rejectors,
there was a significant increase in IL-10 gene expression at the early post-transplant
time point (p=0.002 and 0.004 respectively). In the non-rejectors, IL-10 remained
elevated above the pre-transplant baseline at all subsequent post-transplant time
points (p=0.008, 0.041 and 0.001 respectively for 1 week, 2 weeks & 4 weeks
post-transplant time points compared with pre-transplant baseline). Interestingly,
there was a further significant increase in IL-10 gene expression at the 4 weeks
post-transplant time point from the 2 weeks post-transplant level in the non-rejectors
(p=0.045).
In the rejectors, although there was no significant difference in the level of IL-10
gene expression between the pre-anti-rejection therapy and the early post-transplant
time points (which was significantly higher than the pre-transplant baseline as
mentioned in the previous paragraph), it is interesting that the level of IL-10 at the
time of rejection was nevertheless not significantly different from the pre-transplant
baseline. Although there were no further significant sequential changes in the level of
IL-10 gene expression following anti-rejection therapy, the early post-anti-rejection
therapy level was nevertheless significantly higher than the pre-transplant baseline
(p=0.005). However, peripheral IL-10 gene expression at 1 week and 4 weeks
post-anti-rejection therapy time points were not significantly different from the
pre-transplant baseline.
Finally, there were no significant differences between the level of IL-10 at all the
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Figure 6.1.4 - Percentage change in IL-10 gene expression in non-rejectors and
rejectors
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6.1.5 IL-5 (figure 6.1.5)
In the sequential analysis, there was a significant fall in IL-5 gene expression from
the pre-transplant baseline at the early post-transplant time point in both
non-rejectors (p=0.012) and rejectors (p=0.028), but there were no further significant
sequential changes in IL-5 gene expression at all subsequent post-transplant time
points in both groups of patients.
In the non-rejectors, IL-5 remained significantly suppressed below the pre-transplant
baseline at all the other post-transplant time points (p=0.001, 0.001 and 0.009 for 1
week, 2 weeks and 4 weeks post-transplant respectively). In the rejectors, although
no significant increase in IL-5 expression was detectable at the pre-anti-rejection
therapy time point compared with the early post-transplant time point (which was
suppressed from the pre-transplant baseline), IL-5 expression at the pre-anti-rejection
therapy time point was nevertheless not significantly different from the
pre-transplant baseline.
However, following the completion of anti-rejection therapy, IL-5 gene expression
had dropped significantly below the pre-transplant baseline at the early
post-anti-rejection therapy time point (p=0.008), and remained significantly below
the pre-transplant baseline at all the subsequent post-anti-rejection therapy time
points (p=0.046 and 0.038 respectively at 1 and 4 weeks post-anti-rejection therapy
time points), which was the same pattern as the IL-5 gene expression profile for
non-rejectors described in the previous paragraph.
Although the fall in IL-5 gene expression at the early post-anti-rejection therapy time
point from the pre-anti-rejection therapy time point was just outside statistical
significance (p=0.056), the levels of IL-5 at 1 and 4 weeks post-anti-rejection therapy
time points were nevertheless significantly below the level at the pre-anti-rejection
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Figure 6.1.5 - Percentage change in IL-5 gene expression in non-rejectors and
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6.1.6 IL-13 (figure 6.1.6)
In the non-rejectors, there were no significant changes in the level of IL-13 gene
expression either sequentially from one time point to another or when all
post-transplant time points were compared with the pre-transplant baseline.
However, in the rejectors, although IL-13 expression at the early post-transplant time
point was not significantly different from the pre-transplant baseline (as in the
non-rejectors), there was a significant rise in the level of IL-13 at the time of
rejection (the pre-anti-rejection therapy time point) both above the pre-transplant
baseline (p=0.013) and the early post-transplant time point (p=0.003). At the early
post-anti-rejection therapy time point, IL-13 gene expression had fallen significantly
below the pre-anti-rejection therapy level (p=0.048) to the pre-transplant baseline
(p=NS), and it remained at the pre-transplant level at both 1 and 4 weeks
post-anti-rejection therapy time points (p=NS for both time points when compared
sequentially, with the pre-transplant baseline, or with the pre-anti-rejection therapy
time point).
6.1.7 GrB (figure 6.1.7)
In the non-rejectors, there were no significant differences in the level of GrB gene
expression at all sequential time points from pre-transplant to 2 weeks
post-transplant. However, the level of GrB at 1 and 2 weeks post-transplant time
points were both significantly lower than the pre-transplant baseline (p=0.003 and
0.011 respectively). Interestingly, at 4 weeks post-transplant, GrB level rose
significantly from 2 week post-transplant (p=0.039) back to the pre-transplant level
(p=NS).
In the rejectors, unlike in the non-rejectors, there was a significant fall in GrB gene
expression at the early post-transplant time point (p=0.002), but there were no
significant differences at all subsequent time points when compared with each other
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Figure 6.1.7 - Percentage change in GrB gene expression in non-rejectors and
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6.1.8 FasL (figure 6.1.8)
The sequential pattern of changes in FasL gene expression in non-rejectors has
similarities with the pattern of changes seen for GrB. There were no significant
changes sequentially from pre-transplant to 2 weeks post-transplant. At the 4 weeks
post-transplant time point, a significant rise in FasL gene expression above the level
at 2 weeks post-transplant was evident (p=0.008), but this level was not significantly
different from the pre-transplant baseline. However, unlike GrB, only the FasL level
at 1 week post-transplant was significantly below the pre-transplant baseline
(p=0.032).
In the rejectors, there were no significant differences in the level of FasL between all
the post-transplant time points when compared with each other sequentially, with the
pre-transplant baseline, or with the pre-anti-rejection therapy time point.
6.2 Analysis of cytokine gene expression ratio profiles in patients
with and without early acute rejections
From the previous section, it was demonstrated that IL-4 and IL-10 gene expression
profiles appeared to be opposing in pattern. Hence, the ratio of IL-10 to IL-4 was
examined to assess the balance between these two Th2 cytokines by taking the ratios
of the raw RT-PCR ELISA data of these two Th2 cytokines, and this is shown in
figure 6.2.1. As in the previous section, the graphs for non-rejectors, (a), and
rejectors, (b), are set next to each other within each figure in this section. We also
analysed the balance between Thl and Th2 cytokines by taking similar ratios
between Th2 (IL-4 and IL-10) to Thl cytokines (IL-2 and IFN-y). The profile of
changes in these ratios are shown in figures 6.2.2 to 6.2.5. Finally, for completeness,
the ratio of IFN-y to IL-2 was also taken, and this is shown in figure 6.2.6. It was
appropriate for these ratios to be taken as all the 4 cytokines were analysed on the
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6.2.1 IL-10/1L-4 Ratio (figure 6.2.1)
The sequential changes in IL-10/IL-4 ratios in both non-rejectors and rejectors were
the most prominent of all the cytokine ratios taken. In the non-rejectors, there was a
highly significant rise in the ratio at the early post-transplant time point (p<0.001).
Although IL-10/IL-4 ratio fell significantly and sequentially at 1 and 2 weeks
post-transplant (p=0.003 and 0.043 respectively) before settling down at 4 weeks
post-transplant (p=NS between 2 and 4 weeks post-transplant ratios), all the
IL-10/IL-4 ratios at 1, 2 and 4 weeks post-transplant time points remained
significantly higher than the pre-transplant baseline (p<0.001, p=0.038 and 0.003
respectively).
In the rejectors, there was a similar significant rise in IL-10/IL-4 ratio at the early
post-transplant time point (p=0.002). This ratio fell significantly at the time of
rejection (pre-anti-rejection therapy time point, p=0.003) to a level not significantly
different from the pre-transplant baseline, a distinct deviation from the consistently
elevated IL-10/IL-4 ratios seen in the non-rejectors' profile.
At the early post-anti-rejection therapy time point, IL-10/IL-4 ratio rose significantly
above both the pre-anti-rejection therapy (p=0.003) and pre-transplant (p=0.001)
levels, before falling back significantly at the 1 week post-anti-rejection therapy
(p=0.006) and plateauing out at the 4 weeks post-anti-rejection therapy time point to
the pre-transplant baseline level (p=NS when the ratios at 1 and 4 weeks
post-anti-rejection time points were compared with each other and with the
pre-transplant baseline).
As IL-10/IL-4 ratio at the pre-anti-rejection therapy time point was not significantly
different from the pre-transplant baseline, it was not surprising therefore that both the
ratios at 1 and 4 weeks post-anti-rejection therapy time points were not significantly
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Figure 6.2.1 - IL-10/IL-4 ratios in non-rejectors and rejectors
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6.2.2 IL-4/IL-2 Ratio (figure 6.2.2)
In the non-rejectors, the IL-4/IL-2 ratio fell significantly below the pre-transplant
baseline in the early post-transplant time point (p=0.011) and this ratio rose
significantly at 1 week post-transplant (p=0.036) back to the pre-transplant baseline
(p=NS). There were no further significant changes in the remaining post-transplant
time points when compared sequentially with each other or with the pre-transplant
baseline.
However, in the rejectors, no significant change in IL-4/IL-2 ratio was found at the
early post-transplant time point. At the time of rejection (pre-anti-rejection therapy
time point), this ratio rose significantly both above the early post-transplant time
point (p=0.034) and the pre-transplant baseline (p=0.016). There were no further
sequential changes in the IL-4/IL-2 ratio in all the subsequent post-anti-rejection
therapy time points. Although the ratio at the early post-anti-rejection therapy time
point was not significantly different from the pre-transplant baseline, the ratio at 1
and 4 weeks post-anti-rejection therapy time points were significantly higher than the
pre-transplant baseline (p=0.011 and 0.028 respectively). There were no significant
differences between the IL-4/IL-2 ratios of any of the post-anti-rejection therapy time
points and the pre-anti-rejection therapy time point.
6.2.3 IL-4/IFN-y Ratio (figure 6.2,31
The pattern of changes in IL-4/IFN-y ratios was similar to that seen for IL-4 in the
non-rejectors, with a highly significant initial fall in the ratio at the early
post-transplant time point (p<0.001) and then a steady rise in the ratio at 1 week
(p=0.026) and 2 weeks (p=0.05) post-transplant back to the pre-transplant level (the
IL-4/IFN-y ratio was not significantly different to the pre-transplant ratio at both time
points). The IL-4/IFN-y ratio at the 4 weeks post-transplant time point was
maintained at the pre-transplant baseline level (p=NS compared with previous time
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Figure 6.2.3 - IL-4/IFN-y ratios in non-rejectors and rejectors
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In the rejectors, there was a similar significant fall in IL-4/IFN-y ratio at the early
post-transplant time point (p=0.007). At the pre-anti-rejection therapy time point,
there was a significant rise in the ratio from the early post-transplant time point
(p=0.003) back to the pre-transplant baseline ratio (p=NS when the pre-anti-rejection
therapy time point was compared with the pre-transplant baseline). There were no
significant differences in IL-4/IFN-y ratios at all the post-anti-rejection therapy time
points when compared sequentially with each other or with either the pre-transplant
or pre-anti-rejection therapy baselines.
6.2.4 IL-10/IL-2 Ratio (figure 6.2.4)
In the non-rejectors, a significant rise in IL-10/IL-2 ratio was seen at the early
post-transplant time point (p=0.001) but there were no further significant sequential
changes in the ratios at all subsequent post-transplant time points. The IL-10/IL-2
ratio remained significantly above the pre-transplant baseline ratio at 1 week
(p<0.001) and 4 weeks (p=0.006) post-transplant time points but was not
significantly different from the pre-transplant baseline at 2 weeks post-transplant.
IL-10/IL-2 ratios rose significantly at the early post-transplant time point (p=0.001)
in the rejectors, but there was no significant difference in the ratio at the time of
rejection (pre-anti-rejection therapy time point) compared with the early
post-transplant time point, although this ratio was still significantly higher than the
pre-transplant baseline (p=0.002). There were no significant changes in IL-10/IL-2
ratios in all the post-anti-rejection therapy time points when compared sequentially
with each other or with the pre-anti-rejection therapy time point as the second
baseline. However, the IL-10/IL-2 ratios at the early and 1 week post-anti-rejection
therapy time points were significantly higher than the pre-transplant baseline
(p=0.001 and 0.019 respectively), but there was no significant difference in
IL-10/IL-2 ratio at the 4 weeks post-anti-rejection time point when compared with
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Figure 6.2.4 - IL-10/IL-2 ratios in non-rejectors and rejectors
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6.2.5 IL-10/IFN-y Ratio (figure 6.2.5)
The overall non-rejectors' IL-10/IFN-y ratio profile was similar to their IL-10/IL-2
ratio profile, with a significant rise in IL-10/IFN-y ratio at the early post-transplant
time point (p=0.001) and no further significant sequential changes in the ratio at all
subsequent post-transplant time points. IL-10/IFN-y ratios, like IL-10/IL-2 ratios,
remained significantly above the pre-transplant baseline ratio at 1 week and 4 weeks
post-transplant (p=0.006 for both time points) but was not significantly different
from the pre-transplant baseline at the 2 weeks post-transplant time point.
The rejectors' IL-10/IFN-y ratio profile on the other hand was quite different to the
profile for IL-10/IL-2 ratio. The IL-10/IFN-y ratio rose significantly at the early
post-transplant time point (p=0.004) in the rejectors, but there was no significant
difference in the ratio at the time of rejection (pre-anti-rejection therapy time point)
compared with the early post-transplant time point, although this ratio was still
significantly higher than the pre-transplant baseline (p=0.026).
Although there was no significant change in IL-10/IFN-y ratio at the early
post-anti-rejection therapy time point from the pre-anti-rejection therapy time point
(this ratio was also significantly higher than the pre-transplant baseline, p=0.001),
there was a significant sequential fall in the ratio at the 1 week (p=0.039) and 4
weeks (p=0.015) post-anti-rejection therapy time points back to the pre-transplant
baseline ratio (p=NS when at both time points were compared with the pre-transplant
baseline). Flowever, there were no significant differences in the IL-10/IFN-y ratio at
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Figure 6.2.5 - IL-10/IFN-y ratios in non-rejectors and rejectors
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6.2.6 IFN-y/IL-2 Ratio (figure 6.2.6)
In the non-rejectors, there were no significant changes in IFN-y/IL-2 ratio when the
time points were compared sequentially with each other or with the pre-transplant
baseline.
In the rejectors, there were no significant changes in IFN-y/IL-2 ratio when the time
points were compared sequentially with each other either. Nevertheless, the ratios at
the pre-anti-rejection therapy and all 3 post-anti-rejection therapy time points were
significantly higher than the pre-transplant baseline (p=0.026, 0.009, 0.039 and 0.021
respectively), but there were no significant differences in the ratios when the
post-anti-rejection therapy time points were compared with the pre-anti-rejection
therapy time point.
6.3 Analysis of cytokine/CTL activation marker gene expression
profiles and cytokine ratios at all protocol sampling time points
prior to acute rejection
In this section, we looked at the data from all the protocol sampling time points prior
to commencing anti-rejection therapy for patients who had experienced early acute
rejection. We were interested to see if there were any significant differences in the
individual cytokine/CTL activation marker gene expression profile and the profile of
the cytokine ratios (as listed in the previous section) in the rejectors, at the time
points prior to the occurrence of the acute rejection episode, when compared with the
gene expression profile of the non-rejectors at the same time points.
As the number of protocol samples from 2 weeks post-transplant onwards in this
group of patients were small, meaningful analysis could only be made on the data
from the first 4 protocol sampling time points. Note that all pre-anti-rejection therapy
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Figure 6.2.6 - IFN-y/IL-2 ratios in non-rejectors and rejectors
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included in this analysis (thus accounting for the difference in the number of early
post-transplant samples shown in the rejector's graphs in the previous section
compared with that shown in this section).
The scale of the y-axis in each graph for the rejectors had been set to the same scale
as that for the non-rejectors in this section to facilitate the visual comparison between
the two groups over the same protocol sampling time points, and to further improve
the ease of comparison, the graphs for each cytokine/CTL activation marker in the
non-rejectors over the first 4 protocol sampling time points (graph "a" of all the
figures in sections 6.1 and 6.2) had been reproduced next to that for the rejectors.
The results of the analyses are set out in figures 6.3.1 to 6.3.14 (graph "a" and "b"
showing the profiles for rejectors and non-rejectors respectively). As in the previous
section, the 2-tailed p values quoted in all the figures in this section were obtained
using the Wilcoxon signed rank sum test for matched pairs comparing the data at one
time point with the one immediately preceding it. The p values comparing each post-
transplant time point with the pre-transplant baseline are quoted in the text. Only
p values of significant differences will be quoted in the text and in the figures,
otherwise the abbreviation "NS" will be used to denote all p values greater than 0.05.
6.3.1 IL-2 and IFN-y (figures 6.3.1 and 6.3.2)
In the rejectors, the pre-rejection gene expression profiles for IL-2 and IFN-y are
similar. There was a significant fall in the level of IL-2 and IFN-y gene expression at
the early post-transplant time point (p=0.011 and 0.017 respectively), and this
depressed level of both cytokines remained significantly below the pre-transplant
baseline at 1 week post-transplant (p=0.003 and 0.001 respectively). Although there
were no significant differences in the level of both cytokines between 1 week and 2
weeks post-transplant, both IL-2 and IFN-y levels at 2 weeks post-transplant were
nevertheless not significantly different from their respective pre-transplant baselines.
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Figure 6.3.1b - Non-rejectors
Figure 6.3.1 - Percentage change in IL-2 gene expression at pre-rejection time points
in rejectors compared with non-rejectors over the same time points
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Figure 6.3.2a - Rejectors
Figure 6.3.2b - Non-rejectors
Figure 6.3.2 - Percentage change in IFN-y gene expression at pre-rejection time
points in rejectors compared with non-rejectors over the same time points
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In contrast, both IL-2 and IFN-y gene expression profiles in the non-rejectors (figures
6.3.1b and 6.3.2b) were rather "flat" with no significant differences both sequentially
from one time point to the next and when all post-transplant time points were
compared with their respective pre-transplant baseline.
6.3.2 IL-4 (figure 6.3.3)
The pre-rejection trend of changes in IL-4 gene expression in the rejectors mirrors
quite closely to that seen in the non-rejectors over the same protocol time points.
There was a significant suppression of peripheral IL-4 gene expression from the
pre-transplant baseline at the early post-transplant time point in both rejectors and
non-rejectors (p=0.001 for both groups). This change was followed by a significant
rise in IL-4 gene expression at 1 week post-transplant (p=0.039 and 0.029
respectively), although this level of IL-4 was still significantly below the
pre-transplant baseline in both groups (p=0.009 and 0.006 respectively).
The only difference demonstrated in the two groups is in the sequential change in
IL-4 gene expression from 1 week post-transplant to 2 weeks post-transplant. While
there was a significant rise in IL-4 level in non-rejectors over this two time points
(p=0.003), no significant difference can be demonstrated in the rejectors over the
same time period. Nevertheless, at the 2 weeks post-transplant time point, the level
of IL-4 had returned to the pre-transplant baseline in both groups (p=NS when IL-4
levels at 2 weeks post-transplant time points in both groups were compared with their
respective pre-transplant baselines).
6.3.3 IL-10 (figure 6.3.4)
Like in IL-4, the pre-rejection trend of changes in IL-10 gene expression in the
rejectors also mirrors quite closely to that seen in the non-rejectors over the same
protocol time points. In both rejectors and non-rejectors, there was a significant rise
in peripheral IL-10 gene expression from the pre-transplant baseline at the early
post-transplant time point (p=0.004 and 0.002 respectively). Although this change
was followed by a significant fall at the 1 week post-transplant time point in the
- 181 -
Figure 6.3.3a - Rejectors
Figure 6.3.3b - Non-rejectors
Figure 6.3.3 - Percentage change in IL-4 gene expression at pre-rejection time points
in rejectors compared with non-rejectors over the same time points
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rejectors (p=0.009) but no significant change over the same period in the
non-rejectors (p=NS between early and 1 week post-transplant), the level of IL-10
gene expression at the 1 week post-transplant time point in both groups remained
significantly higher than the pre-transplant baselines in both groups (p=0.028 and
0.008 respectively).
The major difference in the post-transplant trends in IL-10 gene expression in
rejectors prior to the acute rejection episode and non-rejectors over the same time
points was the level of IL-10 at the 2 weeks post-transplant time point. Although no
significant change in IL-10 expression was seen between the 1 week and 2 weeks
post-transplant time points in both groups of patients, the level of IL-10 at 2 weeks
post-transplant was not significantly different from the pre-transplant baseline in the
rejectors but in the non-rejectors, IL-10 remained significantly above the
pre-transplant baseline at the 2 weeks post-transplant time point (p=0.041).
6.3.4 IL-5 (figure 6.3.5)
There are differences in the post-transplant level of IL-5 gene expression between
rejectors (pre-rejection time points) and non-rejectors despite the apparent
similarities between the two groups in their sequential pattern of changes in IL-5
expression. There was a significant fall in IL-5 at the early post-transplant time point
in both rejectors (p=0.041) and non-rejectors (p=0.012), but no further significant
sequential changes were seen in either group from early to 2 weeks post-transplant.
However, the level of IL-5 at the 1 and 2 weeks post-transplant time points were not
significantly different from the pre-transplant baseline in the rejectors, while in the
non-rejectors, IL-5 expression remained significantly below the pre-transplant
baseline at the 1 week (p=0.001) and 2 weeks (p=0.001) post-transplant time points.
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Figure 6.3.4 - Percentage change in IL-10 gene expression at pre-rejection time
points in rejectors compared with non-rejectors over the same time points
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Figure 6.3.5a - Rejectors
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Figure 6.3.5 - Percentage change in IL-5 gene expression at pre-rejection time points
in rejectors compared with non-rejectors over the same time points
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6.3.5 IL-13 (figure 6.3.6)
The IL-13 gene expression profile in the non-rejectors, like the profiles for IL-2 and
IFN-y, was rather "flat" with no significant differences either sequentially from one
time point to the next or when all post-transplant time points were compared with
their respective pre-transplant baseline.
In the rejectors, there was no significant change in IL-13 gene expression at the early
post-transplant time point either. Although there was a significant increase in IL-13
at 1 week post-transplant (p=0.011) from the early post-transplant time point, this
level was nevertheless not significantly different from the pre-transplant baseline.
Interestingly, the level of IL-13 at 2 weeks post-transplant was significantly higher
than the pre-transplant baseline (p=0.028) even though this level was not
significantly different from the previous time point at 1 week post-transplant.
6.3.6 GrB (figure 6.3.7)
There are interesting differences in GrB gene expression between rejectors
(pre-rejection profile) and non-rejectors. While there was a significant decrease in
GrB at the early post-transplant time point in the rejectors (p=0.001), no significant
change was demonstrated in the non-rejectors. There were no further significant
sequential changes in GrB expression at all the subsequent time points in either
groups, and the level of GrB at the 1 week post-transplant time point was
significantly below the pre-transplant baseline in both rejectors (p=0.006) and
non-rejectors (p=0.003).
However, by 2 weeks post-transplant, the level of GrB in the rejectors was no longer
significantly different from the pre-transplant baseline level, while in the
non-rejectors, GrB level remained significantly below the pre-transplant baseline at
the 2 weeks post-transplant time point (p=0.011).
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Figure 6.3.6 - Percentage change in IL-13 gene expression at pre-rejection time
points in rejectors compared with non-rejectors over the same time points
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Figure 6.3.7 - Percentage change in GrB gene expression at pre-rejection time points
in rejectors compared with non-rejectors over the same time points
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6.3.7 FasL (figure 6.3.8)
The post-transplant profiles of FasL in rejectors and non-rejectors are quite similar.
There were no significant sequential changes in FasL gene expression in the first 4
protocol time points in both groups of patients. The level of FasL at 1 week
post-transplant in both groups were significantly below their respective
pre-transplant baselines (p=0.019 in rejectors and p=0.032 in non-rejectors).
However, FasL level at 2 weeks post-transplant remained significantly below the
pre-transplant baseline in the rejectors (p=0.028), while no significant difference
between the level of FasL at 2 weeks post-transplant and the pre-transplant baseline
was demonstrated in the non-rejectors.
6.3.8 IL-10/IL-4 Ratio (figure 6.3.9)
The pre-rejection IL-10/IL-4 profile in rejectors over the first 4 protocol time points
is similar to the profile for non-rejectors over the same time points. In both rejectors
and non-rejectors, there was a significant rise in IL-10/IL-4 ratio at the early
post-transplant time point (p=0.001 and <0.001 respectively), followed by a
significant fall at 1 week post-transplant (p=0.006 and 0.003 respectively) to a level
that remained significantly above the pre-transplant baselines (p=0.005 and <0.001
respectively).
In the rejectors, although the IL-10/IL-4 ratio at 2 weeks post-transplant was not
significantly different from the ratio at 1 week post-transplant, this ratio had
nevertheless returned back to the pre-transplant baseline level (p=NS when the 2
weeks post-transplant ratio was compared with the pre-transplant baseline ratio). On
the other hand, despite a further significant sequential fall in IL-10/IL-4 ratio in the
non-rejectors at the 2 weeks post-transplant time point, this ratio remained
significantly above the pre-transplant baseline (p=0.038).
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Figure 6.3.8 - Percentage change in FasL gene expression at pre-rejection time
points in rejectors compared with non-rejectors over the same time points
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Figure 6.3.9a - Rejectors









N = 28 28 28 28 28
Pre-Tx Baseline 1 wk Post-Tx 4 wks Post-Tx
Early Post-Tx 2 wks Post-Tx
Figure 6.3.9 - IL-10/IL-4 ratios at pre-rejection time points in rejectors compared
with non-rejectors over the same time points
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6.3.9 IL-4/IL-2 Ratio (figure 6.3.10)
There was a significant fall in IL-4/IL-2 ratio at the early post-transplant time point
(p=0.011) in the non-rejectors which was not seen in the rejectors. In both groups of
patients, there was a significant subsequent rise in the ratio at 1 week post-transplant
(p=0.046 for rejectors and 0.036 for non-rejectors), but the ratios at this time point
were not significantly different from their respective pre-transplant baselines in the
two groups. IL-4/IL-2 ratio remained at the pre-transplant baseline level from 1 to 2
weeks post-transplant in both groups.
6.3.10 IL-4/IFN-v Ratio (figure 6.3.11)
The pre-rejection IL-4/IFN-y profile in rejectors is similar to the profile seen in
non-rejectors over the same protocol time points.
There was a significant fall in IL-4/IFN-y ratio at the early post-transplant time point
in both rejectors and non-rejectors (p=0.003 and 0.007 respectively), which was
followed by a significant rise in the ratio at 1 week post-transplant (p=0.002 and
0.003 respectively) back to the pre-transplant baseline level (p=NS when 1 week
post-transplant ratios were compared with the pre-transplant ratios).
The only difference between rejectors and non-rejectors is seen at 2 weeks
post-transplant. Although there were no significant changes in IL-4/IFN-y ratio from
1 to 2 weeks post-transplant in both groups, IL-4/IFN-y ratio at 2 weeks
post-transplant in rejectors was significantly higher than the pre-transplant baseline
(p=0.028), but no significant difference was demonstrated in the same comparison in
the non-rejectors.
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Figure 6.3.10 - IL-4/IL-2 ratios at pre-rejection time points in rejectors compared
with non-rejectors over the same time points
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Figure 6.3.1 la - Rejectors








N= 28 28 28 28 28
Pre-Tx Baseline 1 wk Post-Tx 4 wks Post-Tx
Early Post-Tx 2 wks Post-Tx
Figure 6.3.11 - IL-4/IFN-y ratios at pre-rejection time points in rejectors compared
with non-rejectors over the same time points
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6.3.11 IL-10/IL-2 and IL-10/IFN-y Ratios (figures 6.3.12 and 6.3.131
The post-transplant profiles of IL-10/IL-2 and IL-10/IFN-y ratios are similar in
rejectors (pre-rejection) and non-rejectors. In both groups, a highly significant
increase in the IL-10/IL-2 (p=0.001 in both groups) and IL-10/IFN-y (p=0.002 and
0.001 respectively) ratios were seen at the early post-transplant time point, followed
by no further significant sequential changes in the remaining protocol time points.
Both ratios at the 1 week post-transplant time point remained significantly above
their respective pre-transplant baselines in rejectors and non-rejectors (p=0.003 and
<0.001 respectively for IL-10/IL-2, p=0.004 and 0.006 respectively for IL-10/IFN-y).
At the 2 weeks post-transplant time point, only the IL-10/IL-2 ratio in the rejectors
remained significantly above its pre-transplant baseline (p=0.028). No significant
differences were demonstrated when IL-10/IL-2 ratio in non-rejectors and
IL-10/IFN-y ratio in both rejectors and non-rejectors at the 2 weeks post-transplant
time point were compared with their respective pre-transplant baselines.
6.3.12 IFN-y/IL-2 Ratio (figure 6.3.14)
IFN-y/IL-2 profiles for rejectors (pre-rejection time points) and non-rejectors are
very similar. In both groups of patients, no significant differences were demonstrated
when the IFN-y/IL-2 ratios at each time point were compared sequentially with each
other or when all post-transplant time points were compared with the pre-transplant
baseline.
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Figure 6.3.12 - IL-10/IL-2 ratios at pre-rejection time points in rejectors compared
with non-rejectors over the same time points
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Figure 6.3.13a - Rejectors
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Figure 6.3.13 - IL-10/IFN-y ratios at pre-rejection time points in rejectors compared
with non-rejectors over the same time points
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Figure 6.3.14 - IFN-y/IL-2 ratios at pre-rejection time points in rejectors compared
with non-rejectors over the same time points
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6.4 Comparison between rejectors and non-rejectors at each
protocol time point
This analysis of the data was undertaken to see if the differences in rejectors' and
non-rejectors' profiles shown by the sequential analyses in the previous sections are
also demonstrable when RT-PCR ELISA data of the two cohorts of patients at each
time point are compared, accepting the limitations of semi-quantitative data.
The non-parametric Mann-Whitney U test was applied to all the data from the first 4
protocol sampling time points in the rejectors (prior to the acute rejection episode)
and non-rejectors. This test was chosen to enable a statistical comparison of the
percentage changes in the level of cytokine/CTL activation marker gene expression
at each protocol sampling time point following renal transplantation between the
rejectors and the non-rejectors. In the same manner, the Mann-Whitney U test was
also applied to compare the ratios of the cytokine gene expression (IL-10/IL-4,
IL-4/IL-2, IL-4/IFN-y, IL-10/IL-2, IL-10/ IFN-y and IFN-y/IF-2) at each protocol
sampling time point between the rejectors and non-rejectors. The results of both
Mann-Whitney U tests are set out in tables 6.4.1 and 6.4.2 respectively. These
analyses are valid because only data from the same time point in the two groups were
compared.
In the table 6.4.1, indicates that the statistical comparison between the two groups
of patients was not performed at the pre-transplant time point. The reason for this is
that this time point was the baseline from which all the other sequential changes in
cytokines/CTL activation markers gene expression were compared with, and since it
had been arbitrarily set at 100%, statistical comparison between the groups at this
time point would therefore be meaningless. Comparisons at each time point between
the rejectors and non-rejectors which were not statistically significant (i.e. p value
greater than 0.05) is marked with "NS" and for comparisons which were statistically
significant, a 2-tailed p value is quoted.
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Table 6.4.1 - Mann-Whitney U test of percentage change in cytokine/CTL activation
marker gene expression between rejectors and non-rejectors.































IL-2 - <0.001 <0.001 0.013
IFN-y - NS NS NS
IL-4 - NS NS NS
g
1
IL-10 - NS NS NS !
IL-5 - NS NS NS
IL-13 - NS NS 0.009
GrB - NS NS NS
FasL - NS NS NS
Table 6.4.1 - Mann-Whitney U test of cytokine gene expression ratios between
rejectors and non-rejectors.








IL-10/IL-4 NS NS NS NS
IL-4/IL-2 NS NS NS NS
IL-4/IFN-y NS NS 0.047 0.034
IL-10/IL-2 NS NS NS NS
IL-10/IFN-y NS NS NS NS
IFN-y/IL-2 NS NS NS NS
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Chapter 7: DISCUSSION OF THE GENE EXPRESSION
PROFILES OF PERIPHERAL T CELLS
In this chapter, the significance and interpretation of the sequential profile of changes
in gene expression of the individual cytokines/CTL activation markers are discussed
in the first section while the relationships between the changes in the level of the
individual cytokine/CTL activation marker at each sampling time point is discussed
in the next section. The relevance of the changes seen in the profiles for the cytokine
ratios is discussed in the penultimate section, and the final section discusses the
statistical comparisons of the rejectors versus non-rejectors data at each protocol
sampling time points prior to acute rejection. All the relevant sub-sections referred to
from the previous chapters will be referenced by their sub-section numbers within
square brackets.
7.1 Sequential changes in cytokine/CTL activation marker gene
expression
In this section, the sequential pattern of changes in peripheral T cell gene expression
of the study cohort will be discussed individually for each cytokine/CTL activation
marker studied in the project. The cytokines and CTL activation markers will be
discussed in the same order as presented in the previous chapter.
7.1.1 IL-2 and IFN-y
The presence or an increase in proinflammatory cytokines like IL-2 and IFN-y at the
time of an acute allograft rejection process is theoretically sound and logical, and
indeed these two cytokines have been found to be associated with acute rejection in
several studies [Vie et al, 1985; Simpson et al, 1989; Colvin et al, 1989; Dallman et
al, 1991a; Dallman et al, 1991c; Papp et al, 1992; Takeuchi et al, 1992; Wu et al,
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1992; Papp et al, 1992; Takeuchi et al, 1992; Wu et al, 1992; O'Connell et al, 1993;
Kutukculer et al, 1995; Gaweco et al, 1995], however other studies have not been
able to confirm this association (as reviewed in sub-sections 1.5.1 and 1.5.2). Our
study also did not reveal an increase in IL-2 or IFN-y gene expression with acute
rejection, but instead found a surprising early reduction in the expression of
peripheral T cell IL-2 and IFN-y transcripts in patients who subsequently go on to
experience acute rejection. The return of IL-2 and IFN-y gene expression at 1 week
and 4 weeks following anti-rejection therapy back to the pre-transplant baseline as in
the non-rejectors' profiles, suggests that the early reduction in the expression of both
cytokines demonstrated by our study was a true reflection of the changes in
alloreactivity ofThl cells following their exposure to the renal allograft.
It may be that the reduction in the level of peripheral blood gene expression of both
Thl cytokines in the first week following renal transplantation is due to the
sequestration of this subset of T helper cells within the allograft or other lymphoid
compartments such as bone marrow or spleen in patients who then subsequently go
on to experience acute rejection. This sequestration of Thl producing cells within the
renal allograft early on following transplantation may be the source of the cytokine
trigger for the subsequent acute rejection process.
The reduction of both Thl cytokines at the time of rejection (marked by the
pre-anti-rejection therapy time point) or shortly following completion of
anti-rejection therapy (the early post-anti-rejection therapy time point) may again be a
reflection of further sequestration of Thl cytokine-producing cells in the allograft or
lymphoid compartments during the acute phase of the rejection process. Similar
findings of a decrease in induced IL-2 gene expression by peripheral mononuclear
cells below the pre-transplant level at the time of acute rejection in clinical renal
transplantation as well as in a canine model of renal transplantation have been
reported by one group of workers [Zucker et al, 1996],
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7.1.2 IL-4
Of all the cytokines and CTL activation markers studied in the project, peripheral
IL-4 gene expression profiles showed the most dramatic of changes in both rejectors
and non-rejectors by having statistically significant sequential changes at almost all
the time points [6.1.3 and 6.3.2], Overall, the profile of changes in peripheral IL-4
gene expression when correlated with the clinical course of our study cohort suggests
it to be a cytokine which is highly sensitive to the effect of immunosuppressive
drugs.
The highly significant fall in peripheral IL-4 gene expression in both groups of
patients following renal transplantation in the early post-transplant period prior to a
steady return back to the pre-transplant baseline expression level at 2 weeks
post-transplant [6.3.2] may be a reflection of the potent loading dose effect on the
level of peripheral IL-4 gene expression of the immunosuppressive drugs. Although
one could equally suggest that these early fall in the level of peripheral IL-4 gene
expression in both groups of patients may be the immunological consequence of the
"surgical insult" of the actual transplant operation itself, this possibility can be
reasonably discounted by the findings of a similar significant fall in peripheral IL-4
gene expression in the rejectors with the further administration of potent
immunosuppression at the time of acute rejection as discussed in the next paragraph.
At the time of acute rejection, the level of IL-4 gene expression remained the same as
the pre-transplant baseline, but immediately following the completion of
anti-rejection therapy (the early post-anti-rejection therapy time point), peripheral
IL-4 gene expression was again significantly reduced to a level below the
pre-transplant baseline, possibly reflecting the potent effect on IL-4 gene expression
of the additional immunosuppression received by the rejectors [6.1.3]. However, IL-4
gene expression returned more promptly back to the pre-transplant baseline by 1
week after anti-rejection therapy was completed, and remained at this baseline level
of gene expression at the 4 weeks post-anti-rejection therapy time point with the
recovery of the allograft from the acute rejection episode.
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Thus, we have not been able to demonstrate a difference in IL-4 gene expression at
the time of acute rejection in rejectors when compared with the non-rejectors.
However, the data suggests that peripheral monitoring of IL-4 gene expression may
be correlated with the responses to immunosuppressive therapy and it appears that
the changes in peripheral IL-4 gene expression do mirror the changes in the degree of
immunosuppression achieved rather than the changes in T cell alloreactivity.
Moreover, with the fall in peripheral IL-4 gene expression coinciding with the high
level of immunosuppression at the early post-transplant time point, it may be inferred
that IL-4 appears to behave more as a proinflammatory cytokine than an
immunosuppressive cytokine [Krams et al, 1992; Whitehead et al, 1993],
7.1.3 IL-10
As was demonstrated in the previous chapter, the trend of changes in peripheral T
cell IL-10 gene expression appeared to be opposite to that seen for IL-4. It is
interesting to note that while peripheral IL-4 gene expression fell significantly at the
early post-transplant time point and remained significantly below the pre-transplant
baseline level at the 1 week post-transplant time point for both non-rejectors and
rejectors, in contrast, peripheral IL-10 gene expression rose significantly above the
pre-transplant baseline at the early post-transplant time point and remained
significantly above that level at the 1 week post-transplant time point in both groups
of patients [6.3.3], If IL-4 appears to behave more as a proinflammatory cytokine,
then IL-10 would appear to behave more as an immunosuppressive cytokine since the
significant increase in IL-10 gene expression was in tandem with the high level of
immunosuppression present during the first week following renal transplantation.
This finding that IL-10 may be an immunosuppressive cytokine is in contrast to the
recent intragraft gene expression studies which associated IL-10 with acute renal
allograft rejection [Xu et al, 1995; Strehlau et al, 1997; Suthanthiran, 1997], The
different conclusion drawn on the role of IL-10 may be explained by the differences
between our study and those quoted previously, since our finding was based on a
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sequential, peripheral T cell gene expression study while those quoted previously
were single time-point intragraft gene expression studies.
The most important difference between the non-rejectors' and the rejectors'
peripheral T cell IL-10 gene expression profiles was that while the level of IL-10
gene expression remained consistently elevated above the pre-transplant baseline
level in the non-rejectors, and indeed increased further at 4 weeks post-transplant
[6.1.4], in the rejectors however, by 2 weeks post-transplant [6.3.3] and at the time of
acute rejection (the pre-anti-rejection therapy time point) [6.1.4], the level of IL-10
had returned to the level of the pre-transplant baseline. The consistently high level of
IL-10 expression seen in our non-rejecting cohort throughout the post-transplant
period is supported by the similar findings of high levels of endogenous IL-10
production seen in experimental models of tolerance [Roncarolo, 1995; Roncarolo et
al, 1996], One could surmise that there was a relative decrease in the efficiency of
immunosuppression at the cytokine level in the rejectors (even though both groups of
patients were equally immunosuppressed pharmacologically based on their
cyclosporin A profiles as shown in figures 5.5.9 and 5.5.10 in chapter 5) to account
for this difference in IL-10 gene expression profiles between the 2 groups of patients.
It is therefore not inconceivable that this relative decrease in peripheral IL-10 gene
expression may be the signal indicating the impending onset of an acute allograft
rejection process in the patients who subsequently go on to experience acute
rejection.
One weakness of the study was the limited number of data available for analysis at 2
weeks post-transplant in the rejectors, which may prompt critics to dismiss the return
to the pre-transplant baseline level of IL-10 gene expression seen at that time point.
However, a similar relative decrease in peripheral T cell IL-10 gene expression
(when compared with the non-rejectors' peripheral IL-10 gene expression profile) to
pre-transplant baseline level at the time of acute rejection seen in the rejectors (based
on 14 out of 15 rejectors' data at the pre-anti-rejection therapy time point available
for analysis) would support the contention that the relative decrease in peripheral
IL-10 gene expression at 2 weeks post-transplant was indeed a true reflection of the
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changes in T cell alloreactivity prior to, or during, an acute rejection process. The
subsequent significant increase in IL-10 gene expression above the pre-transplant
baseline at the completion of anti-rejection therapy (the early post-anti-rejection
therapy time point) points to the significant effect that the additional
immunosuppressive therapy had on IL-10 gene expression. Overall, these results
suggest that IL-10 may be another cytokine which is not only sensitive to changes in
the level of immunosuppression, albeit an opposite one to IL-4, but that it may be a
useful marker in distinguishing between the two groups of patients when the level of
expression of this cytokine is monitored sequentially. However, based on current
evidence, it cannot be said that the pattern of IL-10 gene expression could be a
predictive marker of acute rejection since the overall number of rejectors in our study
cohort was relatively small compared with the number of non-rejectors.
Finally, it is interesting to note that with the successful treatment of acute rejection,
the profile of IL-10 gene expression in the rejectors did not return to the profile seen
in the non-rejectors (i.e., a level of IL-10 consistently above the pre-transplant
baseline) as one would expect, but instead the level of IL-10 settled back to the
pre-transplant baseline level at 1 week and 4 weeks following completion of
anti-rejection therapy [6.1.4]. It may be that other factors influencing the cytokine
balance during the acute rejection episode, like the reciprocal negative feedback
mechanisms between the Thl and Th2 cytokines described in chapter 1, which may
continue to be dominant and therefore be influencing the IL-10 gene expression
profile, even though the renal allografts appear to be recovering both clinically and
biochemically from the acute rejection episode. As our study did not monitor the
peripheral T cell gene expression profiles beyond these time points, we do not know
whether IL-10 gene expression would ultimately return to the pattern seen in the
non-rejectors.
7.1.4 IL-5
The association of IL-5 with acute allograft rejection has been demonstrated by
intragraft gene expression studies in clinical liver [Martinez et al, 1992; Martinez et
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al, 1993a; Martinez et al, 1993b], renal [Krams et al, 1992] and lung transplantation
[Whitehead et al, 1993], and in murine cardiac transplantation [Chan et al, 1995],
IL-5 products in bile and serum were also found to be elevated in rejecting liver
allograft recipients [Lang et al, 1995],
We have found that IL-5 is another cytokine whose sequential gene expression
profiles in peripheral T cells have demonstrated substantive differences between
non-rejectors and rejectors. While the overall pattern in peripheral IL-5 gene
expression in non-rejectors remained significantly and consistently below the
pre-transplant baseline level at all post-transplant time points [6.1.5], this was not so
in the rejectors. Although the early post-transplant level of IL-5 gene expression of
peripheral T cells in the rejectors was below the pre-transplant baseline as in the
non-rejectors, the level of peripheral IL-5 gene expression had returned to the
pre-transplant baseline at the 1 week and 2 weeks post-transplant time points [6.3.4],
in contrast to the profile seen in the non-rejectors at these time points. This relative
rise in IL-5 gene expression in the rejectors may have provided the requisite trigger in
initiating or facilitating the occurrence of the subsequent acute rejection episodes
experienced by this group of patients, since IL-5 has been reported to be a
proinflammatory cytokine by its effects on eosinophil activation and function
[reviewed in 1.5.5],
Moreover, whilst the level of peripheral IL-5 gene expression in the rejectors was at
the pre-transplant baseline level at the time of rejection (the pre-anti-rejection therapy
time point), which was a relatively higher level of gene expression when compared
with the general post-transplant level of gene expression seen in the non-rejectors,
the beneficial effect of anti-rejection therapy was seen by the level of peripheral IL-5
gene expression falling significantly back below the pre-transplant baseline again at
all time points following the completion of anti-rejection therapy [6.1.5], a pattern
similar to that seen in the non-rejectors.
These differences in the profiles of peripheral IL-5 gene expression between the two
groups suggest that IL-5 may be important as a cytokine marker in differentiating
those patients who subsequently experience an acute allograft rejection episode.
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7.1.5 IL-13
Although IL-13 has a lot in common with IL-4 in terms of its spectrum of biological
activities and indeed may even share a common receptor or receptor component with
IL-4 [as reviewed in 1.5.6], the gene expression profiles for IL-13 in peripheral T
cells did not mirror the profiles seen for IL-4, and indeed showed fewer changes
between time points than for IL-4.
Like the other Th2 cytokines, IL-13 has both proinflammatory and
immunosuppressive properties [reviewed in 1.5.6]. However, the role of IL-13 in
transplantation immunology remains unknown and has not been systematically
investigated in any study published to date.
Unlike those patients who did not experience acute allograft rejection, a trend
towards increased peripheral IL-13 gene expression following renal transplantation
was seen in the rejectors, with the level at the 2 weeks post-transplant time point and
at the time of acute rejection (the pre-anti-rejection therapy time point) being
significantly higher than the pre-transplant baseline [6.1.6 and 6.3.5], This suggests
an upregulation in IL-13 gene expression with impending or during acute rejection,
since in contrast, the non-rejectors' gene expression profile for IL-13 was rather
"flat" with no significant changes at all time points following renal transplantation
[6.1.6],
The potent effect of anti-rejection therapy on peripheral IL-13 gene expression was
evidenced by the significant decrease in IL-13 gene expression back to the
pre-transplant baseline level at the completion of anti-rejection therapy (the early
post-anti-rejection therapy time point), and this level of IL-13 gene expression was
maintained at the pre-transplant baseline level at 1 week and 4 weeks following the
completion of anti-rejection therapy [6.1.6], Interestingly, unlike for IL-4, there was
no decrease in IL-13 gene expression at the early post-transplant time point in both
groups of patients with the loading dose of immunosuppressive drugs.
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Thus, IL-13 appears to be quite different in its sequential profile from IL-4, and like
IL-5, may be an important cytokine in distinguishing between the rejectors and the
non-rejectors.
7.1.6 GrB
The demonstration of functionally active CTLs accumulating within rejecting
allografts in clinical renal transplantation [Strom et al, 1975] and experimental
cardiac transplantation [Strom et al, 1977] in the early days, and the subsequent
findings of intragraft GrB gene transcripts, a marker of CTL activation, in acutely
rejecting allografts in clinical renal transplantation [Lipman et al, 1992; Lipman et al,
1994; Sharma et al, 1996; Strehlau et al, 1996; Strehlau et al, 1997; Suthanthiran,
1997] have raised hopes that GrB may be a marker of acute allograft rejection.
In our study, the only significant difference in the peripheral T cell GrB gene
expression profiles between non-rejectors and rejectors was the early fall in GrB
expression seen in the rejectors but not in the non-rejectors [6.1.7]. As a similar
parallel early fall in the two proinflammatory Thl cytokines studied in the project
(IL-2 and IFN-y) was also noted only in the rejectors as discussed in sub-section
7.1.1, one could speculate that GrB, being a marker of CTL activation, may be an
important marker suggesting an early sequestration of activated CTLs into the
allografts in patients who subsequently experience acute allograft rejection.
However, it is difficult to explain why the level of peripheral GrB gene expression
had decreased to a level significantly below the pre-transplant baseline in the
non-rejectors at the 1 week and 2 weeks post-transplant time points [6.1.7], since it is
not possible to use the same hypothesis of sequestration of activated CTLs into the
allografts in the rejectors at the early post-transplant and 1 week post-transplant time
points [6.3.6], These seemingly random changes in peripheral GrB gene expression
in both groups of patients demonstrated by our data suggest that GrB may not be a




Like GrB, FasL is another marker of CTL activation whose intragraft [Sharma et al,
1996; Strehlau et al, 1996; Strehlau et al, 1997] and peripheral blood leucocyte
[Vasconcellos et al, 1998] gene expression had been correlated with acute allograft
rejection in clinical renal transplantation. However, recent studies have produced
more conflicting findings, with gene expression studies in experimental renal [Wang
et al, 1997] and cardiac [Seino et al, 1996; Josien et al, 1998] transplantation
supporting a significant contribution of FasL to acute allograft rejection, while in a
murine non-vascularized heterotopic cardiac allograft model, Fas/FasL-mediated
cytotoxicity was shown not to be required for murine cardiac allograft rejection
[Djamali and Odorico, 1998], and in a murine skin allograft transplant model, it was
shown that while FasL gene expression correlated closely with rejection, FasL was
not required for allograft rejection [Borson et al, 1999]. A recent study in clinical
liver transplants [Tannapfel et al, 1999] had found that increased apoptosis, Fas, and
FasL expression were, taken by themselves, not useful as indicators of acute
rejection.
Overall, the peripheral FasL gene expression profile in the rejectors prior to the acute
rejection episodes was very similar to the FasL profile seen in the non-rejectors over
the same protocol sampling time points [6.3.7]. This similarity, coupled with the
surprisingly "flat" FasL gene expression profile in the rejectors at the time of acute
rejection and following the completion of anti-rejection therapy [6.1.8], suggests that
the only difference seen in FasL gene expression level between the 2 groups at the 2
weeks post-transplant time point may not be of any value in differentiating the
rejectors from the non-rejectors [6.3.7],
Based on the results of our study, we conclude that FasL, like GrB, may not be a
useful marker in the immunological monitoring of patients following renal
transplantation.
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7.2 Relationships between the changes in the level of the individual
cytokine/CTL activation marker gene expression at each
sampling time point
In the previous section, we discussed the sequential changes in peripheral T cell gene
expression and the differences in the individual cytokine/CTL activation marker gene
expression profiles between the non-rejectors and the rejectors following renal
transplantation. In this section, we summarise the individual changes in gene
expression of each cytokine/CTL activation marker at each sampling time point in
order to examine the relationships between individual cytokines/CTL activation
markers. For convenience, these relationships will be discussed in 3 separate
sub-sections, namely, those seen in the non-rejectors, those seen in the rejectors prior
to the acute rejection episodes, and finally, those seen at the time of acute rejection
and in the time period following completion of anti-rejection therapy.
7.2.1 Relationships between the cytokines/CTL activation markers in the non-
rejectors
In the absence of any additional immunological stimuli as in the processes leading up
to acute allograft rejection, the changes in the level of cytokines/CTL activation
markers gene expression at each sampling time seen in the non-rejectors should
reflect the outcome of the circulating T cells' exposure to the alloantigens of the
transplanted allograft and its modulation by the immunosuppression received.
The levels of IL-2, IFN-y and IL-13 expression remaining at their respective
pre-transplant baselines at all time points in the post-transplant period in the
non-rejectors suggest that the presence of the allograft and the immunosuppressive
agents did not influenced these 3 cytokines to any significant degree. It is unlikely
that the lack of changes in these cytokines were the result of a failure to detect the
changes since significant changes in all 3 cytokines were demonstrated in the
rejectors.
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IL-4 and IL-5 gene expression appeared to move in tandem initially with a significant
fall at the early post-transplant time point, while IL-10 expression was in the opposite
direction, increasing significantly from the pre-transplant baseline. The initial
parallelled decreased expression of IL-4 and IL-5 quickly diverged, with the level of
IL-4 expression reversing in trend from 1 week post-transplant onwards by gradually
and significantly increasing in expression back to the pre-transplant baseline level,
but the levels of IL-5 and IL-10 expression remained at their respective levels at 1
and 2 weeks post-transplant time points. While IL-5 expression remained
significantly below its pre-transplant baseline throughout the entire post-transplant
period, the level of IL-10 expression continued to be significantly above its
pre-transplant baseline throughout, and indeed increased significantly further at 4
weeks post-transplant.
The starkly different changes in the level of peripheral T cell IL-4, IL-5 and IL-10
gene expression in the non-rejectors demonstrate the varying effect of
immunosuppressive agents on gene expression levels of these cytokines. While the
"suppression" of IL-4 gene expression was transient, the same effect on IL-5 was
prolonged throughout the post-transplant period. In contrast, the effect on IL-10 gene
expression was the opposite, with ever increasing level of expression, possibly
reflecting the adequacy in the degree immunosuppression present in the non-rejectors
and the resulting absence of acute allograft rejection. Our results for IL-5 and IL-10
are in keeping with the known role of IL-10 in inhibiting IL-5 synthesis by T cells
[Pretolani and Goldman, 1997].
As for the 2 CTL activation markers, both their non-rejectors' profiles were very
similar by being relatively "flat" [6.1.7 and 6.1.8], with no significant sequential
changes from pre-transplant baseline to 2 weeks post-transplant followed by a
significant increase in expression at 4 weeks post-transplant from the previous time
point. However, while the level of GrB expression were significantly below its
pre-transplant level at 1 and 2 weeks post-transplant, for FasL, only the 1 week
post-transplant level was significantly below its pre-transplant level. Nevertheless,
both GrB and FasL expression at 4 weeks post-transplant were back at their
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respective pre-transplant baseline levels. It would appear from these findings that
neither the the allograft or the immunosuppressive agents had any significant impact
on the 2 CTL activation markers gene expression.
7.2.2 Relationships between the cytokines/CTL activation markers in the
rejectors prior to acute rejection
In this subgroup of results from the rejectors, the presence of the allograft coupled
with the ultimate failure of the immunosuppressive agents to prevent acute allograft
rejection clearly have significant and diverse impacts on the levels of gene expression
of the cytokines and CTL activation markers at the various sampling time points up
to 2 weeks post-transplant (prior to the acute rejection episode).
In the rejectors over this period, the levels of IL-2, IFN-y, IL-4 and IL-5 expression
all decreased significantly at the early post-transplant time point, while IL-10
increased significantly, but IL-13 remained at its pre-transplant baseline level. At the
1 week post-transplant time point, while IL-2, IFN-y and IL-5 remained unchanged at
below pre-transplant baseline levels, both IL-4 and IL-10 reversed their previous
trends by respectively increasing and decreasing significantly (IL-4 remaining
significantly below its pre-transplant baseline and IL-10 significantly above its
pre-transplant baseline). IL-13 also increased significantly, but it nevertheless
remained at its pre-transplant baseline level at the 1 week post-transplant time point.
By 2 weeks post-transplant, all cytokines had drifted back to their respective
pre-transplant baselines except for IL-13, which was significantly above its
pre-transplant baseline.
It is difficult to explain why the 2 proinflammatory Thl cytokines (IL-2 and IFN-y)
was "suppressed" below their respective pre-transplant baseline in the rejectors as
one would have expected the reverse. The possibility of sequestration of these Thl
cells into the allograft to account for these changes in IL-2 and IFN-y was discussed
section 7.1.1.
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With the exception of IL-4, the changes in the other cytokines could possibly be
explained by the effect of immunological processes leading up to the impending
acute rejection. By returning to their pre-transplant baselines, IL-5 expression was
relatively higher, while IL-10 expression was relatively lower than that seen at the
same time points in the non-rejectors. This reversal in the levels of IL-5 and IL-10
could be explained by a reduction in the inhibitory effect of IL-10 (with reduced
expression) resulting in an increase in IL-5 expression [Pretolani and Goldman,
1997], The level of IL-13 expression, on the other hand, had clearly increased
significantly above its pre-transplant baseline in contrast to that seen in non-rejectors
again. The combination of these increases in IL-5 and IL-13 gene expression may
therefore be significant markers heralding the imminent acute rejection process. The
common influence of both cytokines on eosinophil function [reviewed in sections
1.5.5 and 1.5.6] could suggest a role for allergic inflammation involving eosinophils
as part of the pathological process of acute allograft rejection, as was suggested by
Martinez and her co-workers [Martinez et al, 1993a] based on their work on
intragraft expression of IL-5 in liver transplantation.
IL-4 was the only cytokine in the rejectors to behave in the same manner as in the
non-rejectors at all time points from pre-transplant to 2 weeks post-transplant.
Therefore, it would appear that although peripheral T cell IL-4 gene expression do
vary significantly at different time points following transplantation, the impending
immunological processs leading to the acute rejection did not affect the level of IL-4
expression in any way. In the midst of conflicting findings on the role of IL-4 in acute
allograft rejection, our results for IL-4 have added further support to those studies
which did not find an association of IL-4 with acute allograft rejection.
For the CTL activation markers, GrB decreased significantly at the early
post-transplant time point while FasL remained at its pre-transplant baseline. At 1
week and 2 weeks post-transplant time points, although there were no further
significant sequential changes for both CTL activation markers, GrB initially
remained significantly below its pre-transplant baseline before drifting back to its
baseline, but FasL had drifted significantly below its pre-transplant baseline at both
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time points. The significance of the early fall in GrB but not in FasL is unclear. This,
coupled with the apparently reversed levels of expression of both CTL activation
markers for no clear reason would suggest that as in the non-rejectors, the changes in
the level of the CTL activation markers gene expression in the rejectors are not
helpful as markers of the impending acute rejection process.
7.2.3 Relationships between the cytokines/CTL activation markers in the
rejectors during acute rejection and following anti-rejection therapy
The gene expression levels of the cytokines or CTL activation markers at the time of
acute rejection (the pre-anti-rejection therapy time point in our study) can reveal
important relationships between the individual cytokines or CTL activation markers
and the acute rejection process, although we recognised that the timing of these
samples in relation to the timing and stage of the acute rejection process may be
variable between the patients. Nevertheless, the changes in the levels of
cytokines/CTL activation markers gene expression at the time of acute rejection, and
in addition, the changes seen in the time period following anti-rejection therapy has
the potential to provide important information about the role of the individual
cytokine/CTL activation marker in acute allograft rejection.
At the time of acute rejection, the levels of IFN-y, IL-4, IL-5 and IL-10 gene
expression were not significantly different from their respective pre-transplant
baselines. However, the levels of IL-2 and IL-13 were significantly below and above
their pre-transplant baselines respectively. Clearly the ongoing acute rejection
process had a significant impact on the level of peripheral T cell IL-5, IL-10 and
IL-13 gene expression, but did not affect IFN-y and IL-4 expression. The similar
increase in IL-5 and IL-13 expression (in relative or absolute terms respectively),
coupled with a reduced IL-10 expression, as seen in the time points preceding acute
rejection described previously [7.2.2], further reinforces the importance of IL-5 and
IL-13 as markers of the acute rejection process. However, it is difficult again to
explain the reduction in IL-2 expression at this time point, except for the possibility
of further sequestion of IL-2 producing Thl cells into the allograft to account for this.
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The additional immunosuppression given to the rejectors to treat the acute rejection
process clearly had a potent effect on cytokine gene expression, as seen by the
marked changes in the levels of most of the cytokines studied following the
completion of the anti-rejection therapy (the early post-anti-rejection therapy time
point). IFN-y, IL-4 and IL-5 decreased significantly below their pre-transplant
baselines, while IL-10 increased significantly above its pre-transplant baseline and
IL-13 decreased significantly back to its pre-transplant baseline. This downregulation
of IFN-y, IL-4, IL-5 and IL-13 gene expression with the additional
immunosuppression mirrors the downregulatory effect of corticosteroids on the gene
expression and protein secretion of these cytokines by peripheral blood mononuclear
cells [Braun et al, 1997], IL-2 was the only cytokine to remain unchanged by
persisting below its pre-transplant baseline. The reversal in the expression of IL-5,
IL-10 and IL-13 to that seen in the non-rejectors from their respective levels prior to
commencing anti-rejection therapy suggests that the expression of these 3
cytokines do mirror closely the changes in the immunological status within the
allograft and the dampening down of the acute rejection process. Moreover, the
changes in IL-5 and IL-13 expression before and after anti-rejection therapy mirror
the findings of blood eosinophilia following renal transplantation at the time of acute
cellular rejection episodes and its down-regulation following steroid pulse therapy by
Lautenschlager et al [1985], further supporting the role of eosinophils in acute
allograft rejection.
The decrease in IL-4 seen at this time point is reminiscent of the changes seen in both
groups of patients at the early post transplant time point, and further signify the
sensitivity of this cytokine to immunosuppressive agents. Although the additional
immunosuppression had affected IFN-y but not IL-2 expression, the overall variable
changes in both cytokines make it difficult to interprete the changes in these
cytokines at this particular time point.
However, the initial potent effect of the additional immunosuppression on the levels
of cytokine gene expression seen at the early post-anti-rejection therapy time point
had variable lasting effects on the different cytokines by 1 week and 4 weeks
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following completion of anti-rejection therapy. All the cytokines appeared to "drift"
back to their respective pre-transplant baseline level of expression, except for IL-5,
which persisted significantly below its pre-transplant baseline at both time points.
While the successful reversal of the acute rejection process clearly had return IL-5
and IL-13 gene expression to the levels seen in the non-rejectors, this was not so for
IL-10. Nevertheless, despite IL-10 expression not being elevated at these time points,
the level of IL-5 remained "suppressed", indicating that the relationship between the
expression of IL-10 and IL-5 may not be a direct one. As for IL-4 returning back to
its pre-transplant baseline again, this could be a marker that the level of
immunosuppression had returned to the "steady-state", as in the non-rejectors by 2
weeks post-transplant. There is nothing particularly noteworthy for the 2 Thl
cytokines.
As for GrB and FasL, neither the acute rejection process itself nor the anti-rejection
therapy had any effect on the level of gene expression of either CTL activation
markers with both GrB and FasL remaining at their respective pre-transplant baseline
levels at all time points before and after anti-rejection therapy.
7.3 Sequential changes in cytokine ratios
This section discusses the profiles of sequential changes in cytokine ratios as set out
in section 6.2 of the previous chapter. Overall, there were not as many, nor as
dramatic, changes seen in the profiles of cytokine ratios compared with the individual
cytokine profiles. The cytokine ratio that had the most interesting sequential profiles
for both rejectors and non-rejectors was the IL-10/IL-4 ratio, and this is discussed in
the first sub-section. Note that only the ratios of Th2 to Thl cytokines and between
the individual Th2 and Thl cytokines from the first phase of the study (i.e. IL-2,
IFN-y, IL-4 and IL-10) were analysed.
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7.3.1 IL-10/IL-4 Ratio
Several important differences in the pattern of changes in IL-10/IL-4 ratio were seen
between the non-rejectors and rejectors and these are highlighted in this sub-section.
Indeed the changes in IL-10/IL-4 ratio were more prominent in terms of the
magnitude of the changes than when either cytokine was considered separately, and
this was caused principally by the opposing pattern of changes between IL-10 and
IL-4 gene expression at each time point, thus producing the resulting IL-10/IL-4
profiles in rejectors and non-rejectors that were basically the accentuated profiles of
peripheral IL-10 gene expression alone.
The sharp rise in IL-10/IL-4 ratio in both groups of patients at the early
post-transplant time point [6.2.1], as for the parallel changes seen in both groups of
patients at this time point for the 2 cytokines alone, could again be interpreted as
reflecting the loading dose effect of the immunosuppressive drugs. It should be noted
that the levels of IL-10/IL-4 ratio in non-rejectors were consistently above the
pre-transplant baseline at all post-transplant time points [6.2.1], just as the
non-rejectors' profile for peripheral IL-10 gene expression alone had the same pattern
[6.1.4], In contrast, in the rejectors, the IL-10/IL-4 ratio returned to the pre-transplant
baseline level at 2 weeks post-transplant and at the time of acute rejection (the
pre-anti-rejection therapy time point) [6.3.8 and 6.2.1], mirroring the rejectors'
pattern of changes in peripheral IL-10 gene expression alone [6.3.3 and 6.1.4]. This
suggests a balance between these two Th2 cytokines such that the IL-10/IL-4 ratio
remaining elevated above the pre-transplant baseline level in the time period
following renal transplantation may be an important factor in preventing the
development of acute allograft rejection.
Moreover, the IL-10/IL-4 ratio rose significantly above the pre-transplant baseline
following the completion of anti-rejection therapy (the early post-anti-rejection
therapy time point), mirroring the significant rise in IL-10/IL-4 ratio seen at the early
post-transplant time point in both groups of patients [6.2.1], Therefore, this rise in
IL-10/IL-4 may be a reflection of the effect of additional immunosuppression in
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altering the cytokine balance in peripheral T cells back towards that seen in the
non-rejectors' profile. However, it was clear from the results set out in sub-section
6.2.1 that despite this initial rise in IL-10/IL-4 ratio following the completion of
anti-rejection therapy, the IL-10/IL-4 ratio in the rejectors did not return to a level
above the pre-transplant baseline (as seen in the non-rejectors' profile) even though
the acute rejection episode had been successfully treated. This pattern is again the
same as that seen for the rejectors' peripheral IL-10 gene expression profile [6.1.4].
The data from the IL-10/IL-4 ratio in our study suggest that the alteration in cytokine
balance caused by the acute rejection episode may persist for several weeks following
the cessation of the trigger that caused the initial alteration in cytokine balance in the
first place. Since no samples were taken beyond 4 weeks following the completion of
anti-rejection therapy, we do not know whether this level of IL-10/IL-4 ratio would
continue to be maintained at the pre-transplant baseline level in the long term, or that
the IL-10/IL-4 ratio will slowly return back to the non-rejectors' profile.
7.3.2 IL-4/IL-2 Ratio
There were only two main differences in the IL-4/IL-2 ratio profiles of rejectors and
non-rejectors. While there was a significant fall in IL-4/IL-2 ratio below the
pre-transplant baseline at the early post-transplant time point in the non-rejectors, the
IL-4/IL-2 ratio remained at the pre-transplant baseline level in the rejectors [6.2.2],
This difference is principally due to the significant fall in IL-2 gene expression seen
in the rejectors but not in the non-rejectors at the early post-transplant time point as
described previously [6.1.1].
The other finding of note was the increase in IL-4/IL-2 ratio at the time of acute
rejection (the pre-anti-rejection therapy time point) above the pre-transplant baseline,
and this rise in IL-4/IL-2 ratio appears to persist long after the completion of
successful anti-rejection therapy as seen by the IL-4/IL-2 ratio remaining significantly
above the pre-transplant baseline at the 1 week and 4 weeks post-anti-rejection
therapy time points [6.2.2], These changes were basically the same as that seen for
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peripheral IL-4 gene expression alone but with the changes "ironed out" and elevated
above the pre-transplant baseline due to the low level of peripheral IL-2 gene
expression. As a result, the acute rejection process appears to have elevated the
IL-4/IL-2 ratio but treatment of the acute rejection did not seem to reverse this trend.
Despite these clear differences seen between the two IL-4/IL-2 ratio profiles for each
patient group, it is difficult to explain the reasons for them since the changes do not
follow the clinical course as clearly as seen for the individual cytokines. It may be
that these changes in IL-4/IL-2 ratio were simply artefacts of this method of analysis,
or it implies that taking Th2 to Thl cytokine ratio as a means of elucidating the
Th2/Thl balance did not contribute in any way to the immunological monitoring of
our patients following renal transplantation.
7.3.3 IL-4/IFN-y Ratio
In contrast to IL-4/IL-2 ratio profiles, there did not seem to be any difference between
the rejectors and non-rejectors in their IL-4/IFN-y ratio profiles during the first week
following renal transplantation. However, at the 2 weeks post-transplant time point,
IL-4/IFN-y ratio was significantly higher than the pre-transplant baseline in the
rejectors but not in the non-rejectors [6.3.10]. As this was the only significant
difference between the 2 groups of patients, it should be interpreted cautiously,
especially since the number of samples available for analysis at this time point was
small in the rejectors. Moreover, our caution was perhaps justified seeing that the
IL-4/IFN-y ratio was not significantly different from the pre-transplant baseline at the
time of acute rejection and all the subsequent time points following completion of
anti-rejection therapy [6.2.3].
Therefore, as with the situation for IL-4/IL-2 ratio, the changes in IL-4/IFN-y do not
appear to follow the clinical course of our study cohort following renal
transplantation. These data enhanced our conclusion that taking Th2 to Thl cytokine
ratio as a means of elucidating the Th2/Thl balance may not be a useful method to
monitor our patients immunologically following renal transplantation.
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7.3.4 IL-10/IL-2 & IL-10/IFN-y Ratios
Overall, there were no major differences in the sequential profiles of both IL-10/IL-2
and IL-10/IFN-y ratios that would distinguish the rejectors (over the protocol time
points prior acute rejection) from the non-rejectors over the same time points
[6.3.11]. The 2 ratios were similarly unremarkable at the time of rejection (the
pre-anti-rejection therapy time point) and the time points following anti-rejection
therapy [6.2.4 and 6.2.5], and the changes do not appear to correlate well with the
clinical course of the patients in the light of the data obtained for peripheral IL-10
gene expression alone.
It is likely that these aberrations seen in the data for both IL-10/IL-2 and IL-10/IFN-y
ratios were artefactual, and as concluded in the discussions on the data for the other 2
Th2/Thl analyses [7.3.3 and 7.3.4], we believe that the determination of Th2/Thl
balance by taking Th2 to Thl cytokine ratio using these cytokines may not be of any
value as a means of immunological monitoring in patients renal transplantation. This
is in stark contrast to the determination of Th2 balance [7.3.1] which we have found
to be extremely useful, since the sequential changes noted for the individual Th2
cytokines were accentuated when their ratios were analysed.
7.3.5 IFN-y/IL-2 Ratio
This ratio was done mainly for completeness of the analysis to see if taking the ratio
of the two Thl cytokines would yield any interesting findings. Not surprisingly, there
were no major differences in the IFN-y/IL-2 ratio profiles between the two groups of
patients, especially prior to the acute rejection episode. There appeared to be a
persistent increase in IFN-y/IL-2 ratio with the during the acute rejection episode and
following its successful reversal, although the reasons for this are unclear. Overall,
the balance between these two Thl cytokines is probably not a useful marker to
distinguish between the two groups of patients.
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7.3.6 Concluding remarks about cytokine ratios
From the above discourse concerning the relevance or otherwise of cytokine ratios in
the immunological monitoring of patients following renal transplantation, it was clear
that the only cytokine ratio that reflects the progressive stages in the clinical course of
our study cohort most closely was the ratio between the 2 Th2 cytokines, IL-10 to
IL-4. The other cytokine ratios (i.e., the 4 ratios of Th2 to Thl cytokines and the ratio
between the 2 Thl cytokines) did not appear to correlate much with the clinical
course of the patients. The reason for this difference between IL-10/IL-4 ratio and the
other cytokine ratios may be that only IL-10 and IL-4 appeared to have clearly
opposite patterns of gene expression profiles when compared with each other, while
the other comparisons between the cytokines appeared to be more random.
7.4 Comparison between non-rejectors and rejectors at all protocol
time points prior to acute rejection
Overall, the statistical (Mann-Whitney U test) comparisons of the data at all protocol
time points for all cytokines/CTL activation markers or cytokine ratios between
non-rejectors and rejectors did not show any significant differences except for the
following: IL-2 at all 3 post-transplant time points, IL-13 at the 2 weeks
post-transplant time point and IL-4/IFN-y at 1 week and 2 weeks post-transplant time
points. This suggests that the general level of peripheral T cell gene expression in the
2 groups of patients were essentially similar at all time points prior to the acute
rejection episode and therefore the 2 groups of patients were comparable.
The difference in IL-2 gene expression at all 3 post-transplant time points between
the two groups is difficult to interprete clearly since the overall level of IL-2 gene
expression was generally low in comparison with the other cytokines studied.
Moreover, although the IFN-y gene expression profile showed similar changes to
IL-2 as discussed previously [7.1.1], no significant differences in IFN-y gene
expression profile between the two groups of patients can be demonstrated by the
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Mann-Whitney analysis. This suggests that the difference in IL-2 gene expression
between the 2 groups of patients was unique to this cytokine only, since the other
cytokines (except for IL-13 at one time point) and CTL activation markers studied in
the project did not show any significant differences. The reason why this should be
the case is unclear.
As for the significant difference detectable for IL-13 at the 2 weeks post-transplant
time point, it is difficult to explain why the level of peripheral IL-13 gene expression
in rejectors should be significantly higher than in the non-rejectors at this time point.
Although it is possible that of all the cytokines and CTL activation markers studied in
the project, the magnitude of change in the level of IL-13 gene expression as
compared with its pre-transplant baseline could potentially be an important factor in
identifying patients with impending acute rejection, we would be cautious in
interpreting the Mann-Whitney analysis in this way since the number of data
available for analysis at the 2 weeks post-transplant time point for the rejector group
was small as a sizeable number of patients in the rejectors' group had experienced
acute rejection by the 2 weeks post-transplant time point.
The two significant findings on Mann-Whitney analysis for IL-4/IFN-y ratio at the 1
week and 2 weeks post-transplant time points (with the IL-4/IFN-y ratio being higher
in the rejectors than in the non-rejectors) are also difficult to interprete. As the
sequential IL-4/IFN-y ratio profiles for both rejectors and non-rejectors over the same
protocol time points (except for the 2 weeks post-transplant time point discussed
previously in 7.3.3) were very similar, these findings are unlikely to have any clinical
relevance, particularly as the sequential profile for IL-4/IFN-y ratio at the time of
acute rejection and all the time points following completion of anti-rejection therapy
did not reveal any significant changes at all in this cytokine ratio.
7.4.1 Conclusions
The preceding discussion pointing out the general lack of statistical difference in the
Mann-Whitney analysis between the non-rejectors and rejectors at all protocol time
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points prior to acute rejection has served to highlight the importance of the sequential
analysis in demonstrating important differences in some of the cytokine gene
expression profiles between non-rejectors and rejectors reported in section 7.1 which
was clearly not possible to detect in the analysis directly comparing gene expression
levels of the two cohorts at the same sampling time point. This could perhaps also
explain the reason why conflicting findings about the significance of individual
cytokines in acute rejection is so common amongst the numerous single time point
cytokine gene expression studies.
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Chapter 8: GENERAL DISCUSSION AND
CONCLUSIONS
This project has achieved the objectives set out at its inception, namely, the
successful development of an efficient method of isolating peripheral blood T cells
for molecular analysis, the establishment of a RT-PCR ELISA methodology as a
semi-quantitative assay which is reliable, accurate and reproducible, and the
application of this methodology to study sequential cytokine and CTL activation
marker gene expression profiles of peripheral blood T cells. The results from this
study have revealed fresh insights into the patterns of peripheral T cell gene
expression in both patients who did not experience acute allograft rejection episodes
and those who did.
The preliminary cell separation experiments detailed in chapter 3 showed that T cells
can be easily and reliably obtained from peripheral blood using a combination of
well established cell separation techniques described in that chapter, and by
modifying these cell separation techniques, the cell separation component of the
overall project methodology has facilitated the isolation of peripheral blood T cells
from our study patients in the shortest time possible so that the risk of inadvertent
stimulation of the peripheral blood T cells thus isolated during the course of the cell
separation has been kept to a minimum. However, we did not examine the isolated T
cells for the expression of activation markers such as IL-2 receptor. The cell
separation methodology used in the project has also been successful even in patients
with low lymphocyte counts, as some of our patients were, especially following the
completion of biological agent anti-rejection therapy.
As may be surmised from the number of preliminary experiments performed on the
molecular aspects of the project as described in chapter 4, it was important to ensure
that this component of the project was thoroughly tested, fine-tuned and validated
prior to analysing the study samples using this methodology. The conditions for the
PCR component of the RT-PCR ELISA methodology were optimised and the overall
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RT-PCR ELISA methodology was checked for its reliability in providing an assay of
the sequential changes in the level of cytokines and CTL activation markers gene
expression from peripheral blood T cells that is truly semiquantitative. This was done
by demonstrating that an increasing amount of starting cDNA for the RT-PCR
ELISA assay corresponded closely with an increasing amount of PCR products
detected and vice versa. Confidence in the reliability of the RT-PCR ELISA
methodology was further strengthened by the demonstration that the results obtained
using this method were easily reproducible, in terms of obtaining the same pattern of
sequential changes when the RT-PCR ELISA methodology was applied on the same
set of samples at different times, and also when a set of samples were assayed at
different dilutions. These preliminary experiments also demonstrated that the
RT-PCR ELISA methodology is a very sensitive assay capable of detecting PCR
products from highly diluted cDNA samples. Ideally, we should have performed
studies to determine the half-life of the mRNA for all the cytokines and CTL
activation markers studied in the project.
All the preliminary molecular experiments convinced us that the RT-PCR ELISA
methodology developed during the early phase of the project was sufficiently reliable
to be used as a semiquantitative assay to enable us to study sequential changes in the
level of cytokines and CTL activation markers gene expression from peripheral blood
T cells of our study patients. Despite being a relatively complex and lengthy form of
assay for the analyses of a considerable number of samples for multiple markers, it
proved technically feasible both in terms of overall logistics and cost.
The statistical analyses applied on the data obtained from the project, both clinical
and molecular, had been simple and uncomplicated.
An overview of the analysis of the RT-PCR ELISA results from the study patients
has confirmed the importance of performing sequential sampling from the same
patient at different time points following transplantation, as opposed to the practice
of sampling at a single time point (usually at the time of suspected acute rejection)
which is so prevalent in the cytokine literature. Our results have demonstrated that an
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apparently insignificant level of cytokine or CTL activation marker gene expression
at any time point following renal transplantation on its own may actually be clearly
significant when analysed in the light of the level of gene expression at other
sampling time points in a sequential study. Moreover, it is clear from the analysis of
our results that comparing the level of gene expression of one cytokine or CTL
activation marker at all post-transplant time points with its corresponding
pre-transplant baseline level of gene expression generally yielded more useful
information than comparisons between sequential levels of gene expression. We
found that significant changes from the pre-transplant baselines may be present
without any significant changes between the sequential time points, although
sequential changes were important for some of the cytokines studied.
Overall, the profiles of changes obtained from the RT-PCR ELISA data have
demonstrated that peripheral monitoring of the changes in T cell gene expression can
provide useful information to distinguish the rejectors from the non-rejectors.
Of the cytokines and CTL activation markers studied in the project, the two Thl
cytokines, IL-2 and IFN-y, showed unexpected differences in their sequential profiles
between rejectors and non-rejectors. While an increase in the level of gene
expression following transplantation or with the onset of acute rejection would
theoretically be the expected behaviour of proinflammatory cytokines like IL-2 and
IFN-y, we found that the peripheral gene expression of both cytokines in our study
decreased significantly instead. Although we had speculated that these decreased
levels of IL-2 and IFN-y gene expression in the rejectors at the early post-transplant
time point and during the acute rejection period could be explained by a sequestration
of these Thl cells into the renal allografts or other immune compartments in the
patients, thus providing or facilitating the cytokine trigger for the subsequent acute
rejection episodes, as yet there are no published studies in the literature
demonstrating that this phenomenon occurs in clinical transplantation. Nevertheless,
this concept of the sequestration of Thl cells into the allograft and/or other sites of
immune activation like the spleen is plausible since the migration of lymphocytes in
rat cardiac transplant models has been shown to be influenced dramatically by the
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immunological status of the recipients of vascularized organ allografts [Kupiec-
Weglinski et al, 1982]. Moreover, the sequestration of activated CTLs into the
allografts has also been suggested as a possible explanation for the finding of a
considerably higher frequency of donor-specific CTLs in the graft cell population
when compared with the peripheral blood lymphocytes in clinical cardiac
transplantation [Suitters et al, 1990].
The only group of workers who have found a similar fall in peripheral IL-2 gene
expression (albeit induced expression) at the time of acute rejection episodes in both
human and canine renal transplantation [Zucker et al, 1996] also suggested the
possibility of sequestration of IL-2 producing cells into the allograft or other immune
organs like the spleen or bone marrow, quoting their previous work on mixed
lymphocyte culture-reactive cells in canine renal transplants [Miller et al, 1971;
Hattler et al, 1972], Another possible reason to account for the fall in the overall level
of peripheral IL-2 and IFN-y gene expression could be the localisation of IL-2 and
IFN-y producing Thl cells into lymphoid tissues where adhesion molecule
upregulation in these cells and/or high endothelial venules results in the
disappearance of these Thl cells from the peripheral blood [Brockmeyer et al, 1993;
Fuggle et al, 1993]. This sequestration hypothesis could be addressed by a study
looking at a sequential and simultaneous sampling of peripheral blood and fine
needle aspirations of the renal allografts so that the sequential cytokine gene
expression profiles in peripheral blood may be correlated with changes in intragraft
gene expression as well as with the clinical course of the patients following renal
transplantation.
Overall, all the so-called Th2 cytokines studied in the project, namely, IL-4, IL-5,
IL-10 and IL-13, showed more sequential changes following renal transplantation
than the Thl cytokines or CTL activation markers studied. A possible explanation for
this may be that Th2 cells were more readily recirculated back into the peripheral
blood following their "contact" with the allograft than the Thl cells or the CTLs
because they were not sequestered within the allograft or the other immune
compartments. Consequently, the molecular imprints of the Th2 cells' "contact" with
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the allograft were more prominently reflected by the sequential changes in the level
of their cytokine gene expression in the peripheral blood. Another possible
explanation for this observation is that Th2 cells may be more central in orchestrating
the immune response to the transplanted allograft than either Thl cells or CTLs and
therefore the changes in Th2 alloreactivity were more marked than the other two
groups of T cells.
Although peripheral IL-4 gene expression profiles showed the greatest number of
sequential changes compared with all the other cytokines and CTL activation markers
studied in the project (by having statistically significant sequential changes at almost
all the time points in both rejectors and non-rejectors), our results suggest that the
changes in the level of peripheral IL-4 gene expression can be explained more
convincingly by the changes in the degree of immunosuppression rather than any
clear differences between the rejectors and non-rejectors because of acute rejection.
This suggests that sequential monitoring of peripheral IL-4 gene expression could
potentially be useful as a method of assessing, at the molecular level, the degree of
immunosuppression at the different time points following renal transplantation.
However, monitoring of peripheral IL-4 gene expression was not able to distinguish
between the rejectors from the non-rejectors.
IL-10 was the first Th2 cytokine studied in the project to show promise as a cytokine
marker that could potentially distinguish the rejectors from the non-rejectors. Our
study has shown that the peripheral IL-10 gene expression profile in the rejectors was
distinctly different from that seen in the non-rejectors, although the profile in the
rejectors following completion of anti-rejection therapy did not return to a pattern
similar to that seen in the non-rejectors as one might have expected. Further
follow-up peripheral blood samplings over a longer time period following the
completion of anti-rejection therapy are required to determine whether the pattern of
peripheral IL-10 gene expression following the anti-rejection therapy would return to
the pattern seen in non-rejectors, i.e. at a level significantly above the pre-transplant
baseline. This is an important aspect to be incorporated into the protocols for future
studies as it would consolidate the evidence that IL-10 is indeed an important
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peripheral cytokine marker which could distinguish between rejectors and
non-rejectors.
IL-5 was the next Th2 cytokine that showed even more promise as a peripheral
cytokine marker in distinguishing between rejectors and non-rejectors. Like IL-10,
the post-transplant profile of IL-5 gene expression in the rejectors showed distinct
differences from that seen in the non-rejectors, but unlike IL-10, the IL-5 profile
returned to the pattern seen in non-rejectors following the successful completion of
anti-rejection therapy, suggesting that IL-5 is a cytokine that most closely reflects the
changes in T cell alloreactivity and thus most likely to be useful as a marker in the
immunological monitoring of patients following renal transplantation. This finding is
particularly exciting as it ties in with other intragraft studies [Martinez et al, 1992;
Krams et al, 1992; Martinez et al, 1993a; Martinez et al, 1993b; Whitehead et al,
1993; Lang et al, 1995] associating IL-5 with acute allograft rejection and the
non-classical pathway of acute allograft rejection involving eosinophils, the presence
of eosinophils being a well known but unexplained phenomenon in transplantation
immunology [reviewed in 1.5.5].
It has been discussed in the previous chapter that although IL-13 shares many
biological activities with IL-4 and indeed may even share a common receptor or
receptor component with IL-4 [as reviewed in 1.4.6], the peripheral T cell IL-13 gene
expression profiles were found to be quite different from those for IL-4 in both
non-rejectors and rejectors. Although the direction of the sequential changes seen for
IL-13 was similar to IL-4 in the rejectors, the profiles for the non-rejectors were
completely different for the two cytokines. It was this difference between the two
cytokines that separated them and resulted in a clear difference between the rejectors'
and non-rejectors' profiles for IL-13. Our study showed that the changes in the level
of IL-13 gene expression relative to its pre-transplant baseline yielded data
suggesting that peripheral IL-13 gene expression may be another promising marker in
distinguishing between rejectors and non-rejectors, since clear differences in the level
of IL-13 gene expression between the two groups of patients were seen at the time of
acute rejection. This was a novel finding since the role of IL-13 in allograft rejection
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has not been reported in the literature previously. Moreover, IL-13 is known to
induce IgE synthesis and eosinophil adhesion to endothelial cells [reviewed in 1.5.6]
and therefore its potential role in other T cell mediated processes like atopic diseases
has been postulated [de Vries and Zurawski, 1995]. The results of our study
demonstrating an increase in peripheral IL-13 gene expression at the time of acute
rejection above the pre-transplant baseline and the subsequent return to the
pre-transplant baseline following anti-rejection therapy, has tied in nicely with the
our results for peripheral IL-5 gene expression profiles described in the previous
paragraph.
Overall, both CTL activation markers, GrB and FasL, did not appear to have distinct
post-transplant changes in their profiles to distinguish the rejectors from the
non-rejectors.
The future
This project has demonstrated the experimental validity of sequential monitoring of
peripheral blood T cell gene expression of patients following renal transplantation. It
has also revealed a number of findings of potential immunological and clinical
relevance which would not be readily detectable from single time point studies. In
order that the technique may be applicable for possible clinical use in the future, it
would need to be simplified further and the turnaround time shortened. Moreover, to
allow the monitoring of gene expression of other immune cells in addition to the T
cells, the use of the entire mononuclear cell fraction from peripheral blood instead of
T cells alone would fulfil both objectives. The use of mononuclear cells instead of T
cells only would enable the study of other important non-T cell-derived T cell growth
factors like IL-12 and IL-15 which this project was not able to look into, and also
increase the reliability of results from studying cytokines produced by both T cells
and non-T cells like IL-10.
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An increase in the frequency of peripheral blood sampling in the first fortnight
following renal transplantation would undoubtedly improve the reliability in the use
of these cytokine profiles in distinguishing between the potential rejectors from those
unlikely to experience acute allograft rejection. A longer follow-up period than the
one chosen in this project would allow a more detailed assessment of the subsequent
profile of changes in cytokine gene expression following completion of anti-rejection
therapy in those patients who do experience acute allograft rejection.
A parallel study looking into the sequential changes in intragraft cytokine gene
expression at the same time as that occurring in the peripheral blood would allow the
two profiles of changes to be correlated and enable a better understanding of the
relationship between these immune cells sequestered into the renal allograft and
those circulating in the peripheral blood. It could end the conflicting findings so
prevalent in the literature by establishing the pattern of gene expression of the
different cytokines that are important in the process underlying acute allograft
rejection. However, the effectiveness of this study would inevitably be compromised
by the limitation in the frequency of intragraft sampling for cytokine gene expression
that would be acceptable to patients and clinicians alike since the sampling technique
is invasive with potential complications.
The recent application of real-time detection of PCR products using fluorogenic
probes (an oligonucleotide with both a reporter fluorescent dye and a quencher dye
attached) [Lee et al, 1993; Livak et al, 1995] incorporated into the PCR itself for the
quantification of cytokine gene expression in peripheral blood [Kruse et al, 1997]
could potentially make immunological monitoring based on peripheral blood
cytokine gene expression assay a clinical reality by considerably simplifying the
technical aspect of the assay while at the same time shortening the turnaround time
required for the assay to be performed. This so called 'TaqMan' assay is also
advantageous in that all measurements are based on the exponential phase of the
PCR, rather than its end-points. Theoretically, the amount of amplification required
to produce a threshold amount of PCR product is much more closely related to the
amount of starting material than it is to the final 'plateau' amount of end-point
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product. Secondly, this technique can be rendered truly quantitative by standardizing
against the total amount of mRNA starting material or the expression of a
housekeeping gene.
Finally, with the recent surge in interest in the relationship of cytokine promoter gene
polymorphisms - in particular, TNF-a and IL-10 - and acute allograft rejection
[Sankaran et al, 1999], it will be important to investigate whether these
polymorphisms do correlate with the cytokine gene expression profiles in renal
transplant patients examined in this study.
Some of these points are being addressed by my successor as part of a new research
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APPENDIX 1
PROFORMA FOR THE CYTOKINE PROJECT
a) surname and firstname:




f)CMV status: [ ] positive [ ] negative
g) cause of end-stage renal failure:
h) dialysis details: [ ] haemodialysis [ ] CAPD
2. Transplant details:
a) date of transplant (date of pre-transplant blood sampling): / /
b) sampling: [ ] pre-HD [ ] post-HD, hours post-HD
c) type - cadaveric / living related
d) side transplanted: R / L
e) primary / secondary transplant (state number of transplant):
f) donor blood group:
g) tissue type:
h) mismatch: : : [A : B : DR]
i) CMV status: [ ] positive [ ] negative
j ) % panel reactive antibodies:
3. Transplant function:
a) primary function? Y / N
1. Recipient details: Code:
b) biopsy? Y / N
c) histology result: [ ] cellular rejection
[ ] no rejection
[ ] others
[ ] vascular rejection
[ ] non-diagnostic
- 257-
4. Date second blood sampling (day 2-3 post-transplant): / /___
a) blood indices: urea creatinine CyA level
WCC Lymphocyte Neutrophils _
b) urine output: [ ] oliguric/anuric [ ] normal [ ] polyuric
c) any confirmed current/immediately recent infection:
[ ] UTI [ ] Chest infection
[ ] Fungal infection (oral/vaginal) [ ] CMV infection
d) pyrexia of unknown origin? Y / N
e) immunosuppression used: [ ] Cyclosporin [ ] Azathioprine
[ ] Prednisolone [ ] ATG
f) recent dialysis? Y / N If yes, days ago
5. Date second blood sampling (day 5-7 post-transplant): / /___
a) blood indices: urea creatinine CyA level
WCC Lymphocyte Neutrophils _
b) urine output: [ ] oliguric/anuric [ ] normal [ ] polyuric
c) any confirmed current/immediately recent infection:
[ ] UTI [ ] Chest infection
[ ] Fungal infection (oral/vaginal) [ ] CMV infection
d) pyrexia of unknown origin? Y / N
e) immunosuppression used: [ ] Cyclosporin [ ] Azathioprine
[ ] Prednisolone [ ] ATG
f) recent dialysis? Y / N If yes, days ago
6. Date third blood sampling (day 10-14 post-transplant): / /
a) blood indices: urea creatinine CyA level
WCC Lymphocyte Neutrophils _
b) urine output: [ ] oliguric/anuric [ ] normal [ ] polyuric
c) any confirmed current/immediately recent infection:
[ ] UTI [ ] Chest infection
[ ] Fungal infection (oral/vaginal) [ ] CMV infection
d) pyrexia of unknown origin? Y / N
e) immunosuppression used: [ ] Cyclosporin [ ] Azathioprine
[ ] Prednisolone [ ] ATG
f) recent dialysis? Y / N If yes, days ago
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7. Date of fourth blood sampling (about day 30 post-transplant): / /
a) blood indices: urea creatinine CyA level
WCC Lymphocyte Neutrophils _
b) urine output: [ ] oliguric/anuric [ ] normal [ ] polyuric
c) any confirmed current/immediately recent infection:
[ ] UTI [ ] Chest infection
[ ] Fungal infection (oral/vaginal) [ ] CMV infection
d) pyrexia of unknown origin? Y / N
e) immunosuppression used: [ ] Cyclosporin [ ] Azathioprine
[ ] Prednisolone [ ] ATG
f) recent dialysis? Y / N If yes, days ago
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Transplant flow chart
[ ] Good response [ ] Further antirejection Rx
Drug:
[ ] Good response
[ ] Partial/No response
1
[ 1 Rejection 2:
Pulsed methylprednisolone
[ ] No further rejection
[ ] Good response [ ] Further antirejection Rx
Drug:
[ ] Good response




[ 1 Rejection 3: [ ] No further rejection
Pulsed methylprednisolone
[ ] Good response [ ] Further antirejection Rx
Drug:
[ ] Good response
[ ] Partial/No response
1
f 1 Rejection 4:
Pulsed methylprednisolone
[ ] No further rejection
[ ] Good response
[ ] Further antirejection Rx
Drug:
[ ] Good response




1. a) date: / / days post-transplant:
b) blood indices: urea creatinine CyA level
WCC Lymphocyte Neutrophils
c) urine output: [ ] oliguric/anuric [ ] normal [ ] polyuric
d) any confirmed current/immediately recent infection:
[ ] UTI [ ] Chest infection
[ ] Fungal infection (oral/vaginal) [ ] CMV infection
e) pyrexia of unknown origin? Y / N
f) immunosuppression used: [ ] Cyclosporin [ ] Azathioprine
[ ] Prednisolone [ ] ATG
2. a) date: / / days post-transplant:
b) blood indices: urea creatinine CyA level
WCC Lymphocyte Neutrophils
c) urine output: [ ] oliguric/anuric [ ] normal [ ] polyuric
d) any confirmed current/immediately recent infection:
[ ] UTI [ ] Chest infection
[ ] Fungal infection (oral/vaginal) [ ] CMV infection
e) pyrexia of unknown origin? Y / N
f) immunosuppression used: [ ] Cyclosporin [ ] Azathioprine
[ ] Prednisolone [ ] ATG
3. a) date: / / days post-transplant:
b) blood indices: urea creatinine CyA level
WCC Lymphocyte Neutrophils
c) urine output: [ ] oliguric/anuric [ ] normal [ ] polyuric
d) any confirmed current/immediately recent infection:
[ ] UTI [ ] Chest infection
[ ] Fungal infection (oral/vaginal) [ ] CMV infection
e) pyrexia of unknown origin? Y / N
f) immunosuppression used: [ ] Cyclosporin [ ] Azathioprine





a) date blood sampled prior to anti-rejection therapy: / /_
b) blood indices: urea creatinine CyA level
c) recent haemodialysis dialysis? Y / N If yes, days ago
d) biopsy? Y / N
e) histology: [ ] cellular rejection [ ] vascular rejection
[ ] no rejection [ ] non-diagnostic
[ ] others
f) pulsed methylprednisolone? Y / N
date blood sampled following course of anti-rejection therapy: / /_
g) anti-thymocyte globulin therapy? Y / N
If yes, dosage: mg; total number of doses: over days
date blood sampled following course of anti-rejection therapy: / /_
h) response: [ ] complete success (full restoration of graft function)
[ ] partial success (partial restoration of graft function)
[ ] failure with loss of graft function
i) date blood sampled 7-10 days following end of anti-rejection therapy:
Rejection episode 2:
a) date blood sampled prior to anti-rejection therapy: / /_
b) blood indices: urea creatinine CyA level
c) recent haemodialysis dialysis? Y / N If yes, days ago
d) biopsy? Y / N
e) histology: [ ] cellular rejection [ ] vascular rejection
[ ] no rejection [ ] non-diagnostic
[ ] others
f) pulsed methylprednisolone? Y / N
date blood sampled following course of anti-rejection therapy: / /_
g) anti-thymocyte globulin therapy? Y / N
If yes, dosage: mg; total number of doses: over days
date blood sampled following course of anti-rejection therapy: / /_
h) response: [ ] complete success (full restoration of graft function)
[ ] partial success (partial restoration of graft function)
[ ] failure with loss of graft function
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i ) date blood sampled 7-10 days following end of anti-rejection therapy:
Rejection episode 3:
a) date blood sampled prior to anti-rejection therapy: / /
b) blood indices: urea creatinine CyA level
c) recent haemodialysis dialysis? Y / N If yes, days ago
d) biopsy? Y / N
e) histology: [ ] cellular rejection [ ] vascular rejection
[ ] no rejection [ ] non-diagnostic
[ ] others
f) pulsed methylprednisolone? Y / N
date blood sampled following course of anti-rejection therapy: / /_
g) anti-thymocyte globulin therapy? Y / N
If yes, dosage: mg; total number of doses: over days
date blood sampled following course of anti-rejection therapy: / /_
h) response: [ ] complete success (full restoration of graft function)
[ ] partial success (partial restoration of graft function)
[ ] failure with loss of graft function
i) date blood sampled 7-10 days following end of anti-rejection therapy:
Rejection episode 4:
a) date blood sampled prior to anti-rejection therapy: / /_
b) blood indices: urea creatinine CyA level
c) recent haemodialysis dialysis? Y / N If yes, days ago
d) biopsy? Y / N
e) histology: [ ] cellular rejection [ ] vascular rejection
[ ] no rejection [ ] non-diagnostic
[ ] others
f) pulsed methylprednisolone? Y / N
date blood sampled following course of anti-rejection therapy: / /_
g) anti-thymocyte globulin therapy? Y / N
If yes, dosage: mg; total number of doses: over days
date blood sampled following course of anti-rejection therapy: / /_
h) response: [ ] complete success (full restoration of graft function)
[ ] partial success (partial restoration of graft function)
[ ] failure with loss of graft function
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REC Prop No: 03/96/353 Cytokine Gene Expression in Renal Transplantation
This is to confirm that the Research Ethics Committee has approved the above study. Approval
for the study is only granted until the 1st October 1997, if your study continues after this date
further ethics committee approval will be required.
I remind you that you stated patients will not be participating in any other clinical trials. If there
is any change, you are obliged to draw this to the Committee's attention.
The Ethics Committee will require a copy of the completed study for its records, you are
therefore requested to submit a copy of the completed study to the address above. In addition
the Committee must be informed of any untoward or adverse events which occur during the
course of the study.
The ethics committee must also be informed of and approve, any proposed amendments to your
initial application.
If you have any further questions please do not hesitate to contact me.
Yours sincerely
Dr E Wozniak







e Tel 02392 286000 Ext 3120
Fax 02392 866108
Consent Form For Participation in Research Project
I, , having read the information leaflet about
the research project, hereby agrees to have bloods taken from me periodically for
analysis.
I understand that the research project will not have anything whatsover to do with my
care.
I also understand that I can withdraw my participation in the research project at any
time without my care being affected in any way.
Signed: Date:
Mr Saml Sadek, PhD. FRCS - Head
Mr Martin Wise. MD, FRCS
Miss Anne M Walters. MD. FRCS






Mr Saml Sadek, PhD, FRCS - Head
Mr Martin Wise, MD, FRCS
Miss Anne M Walters. MD, FRCS
St Mary's Hospital
Portsmouth P03 6AD




Transplant Surgery PORTSMOUTH HOSPITALS
NHS TRUST
Information Leaflet For The Research Project
The Wessex Regional Renal and Transplant Unit at St Mary's Hospital, Portsmouth
is currently researching into why the defence mechanism of your body (called the
immune system) may reject your kidney transplant despite being suppressed by
powerful drugs.
We hope we could enlist your help in our project. The research will not benefit your
care directly but it may help us to improve the care that we can give to patients
receiving a new kidney in the future by increasing our knowledge of the body's
defence mechanism.
It will involve us taking some blood specimens from you periodically from the time
you receive your new kidney transplant to 6 weeks following the operation.
We emphasize that you are under no obligation to participate in the research
project and your care will not be compromised in any way should you choose
not to participate in the research project. You are also at liberty to withdraw
your participation in the research project at any time.
We sincerely hope that you will help us in our efforts to improve the results of kidney
transplantation.
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APPENDIX 5 - Sampling Codes for Appendices 6 to 11
Protocol sampling time points
Codes Sampling Time Points
/PT Pre-transplant
12 Early post-transplant
13 1 week post-transplant
14 2 weeks post-transplant
15 4 weeks post-transplant
Additional Samples For Rejectors
For the rejectors, note the following:
a) the number pre-fixing the sampling codes refer to the rejection episode
number, i.e. 1 meaning first rejection episode, etc.
b) the letter "a" following the post-anti-rejection therapy sampling code
means that the sample was taken following antibody anti-rejection
therapy.
Codes Sampling Time Points
/PR Pre-anti-rejection therapy sample
/R1 Early post-anti-rejection therapy sample (usually post-steroid pulse)
/R2 1 week post-anti-rejection therapy sample
/R3 4 weeks post-anti-rejection therapy sample
Notes on calculation of percentage change in appendices 8 and 9:
PCR ELISA reading for each cytokine at pre-transplant time point (/PT) = Y
PCR ELISA reading for each cytokine at time point x = X
where /x=any post-Tx time point.
Percentage change at time point x = [Exponential (X) /Exponential (Y)] x 100
Note that the PCR ELISA readings are in natural logarithmic scale.
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APPENDIX 6 - Cell Separation Data
WHOLE BLOOD SEPARATED CELLS
Date Subject No. Sample LY MO Vol. No. % MO MNC Vol. No. % Loss
5/14/96 EP 001 /PT 1.6 0.4 13.5 27.0 20.0 0.6 15.0 9.0 66.7
5/16/96 EP 001 12 0.6 0.9 13.5 20.3 60.0 0.3 15.0 4.5 77.8
5/20/96 EP 001 /3 1.4 0.1 13.5 20.3 6.7 0.5 17.0 8.5 58.0
5/24/96 EP 001 /4 1.6 0.5 13.5 28.4 23.8 0.8 15.0 12.0 57.7
5/26/96 FO 003 /PT 0.9 0.6 13.5 20.3 40.0 0.3 15.0 4.5 77.8
5/27/96 PH 005 /PT 2.8 0.6 10.8 36.7 17.6 1.2 15.0 18.0 51.0
5/29/96 BR 006 /PT 2.0 0.6 13.5 35.1 23.1 1.0 15.0 15.0 57.3
5/29/96 FO 003 12 0.6 0.5 13.5 14.9 45.5 0.2 15.0 3.0 79.8
5/29/96 PG 007 /PT 0.9 0.7 13.5 21.6 43.8 0.4 15.0 6.0 72.2
5/29/96 PH 005 12 1.0 1.2 13.5 29.7 54.5 0.7 15.0 10.5 64.6
5/31/96 BR 006 12 0.7 0.1 9.0 7.2 12.5 0.3 15.0 4.5 37.5
5/31/96 FO 003 /3 0.6 1.1 9.0 15.3 64.7 0.2 15.0 3.0 80.4
5/31/96 PG 007 12 0.4 0.5 13.5 12.2 55.6 0.2 15.0 3.0 75.3
6/3/96 PH 005 /3 1.9 2.1 13.5 54.0 52.5 NR 15.0 NR NR
6/5/96 BR 006 /3 1.9 0.9 13.5 37.8 32.1 1.3 15.0 19.5 48.4
6/5/96 JM 008 /PT 1.6 0.5 13.5 28.4 23.8 1.0 15.0 15.0 47.1
6/5/96 PG 007 /3 0.7 0.6 13.5 17.6 46.2 0.3 15.0 4.5 74.4
6/7/96 FO 003 /4 1.0 0.6 13.5 21.6 37.5 0.4 15.0 6.0 72.2
6/7/96 JM 008 12 0.5 0.3 13.5 10.8 37.5 0.2 15.0 3.0 72.2
6/7/96 PH 005 /4 3.7 1.4 13.5 68.9 27.5 2.8 15.0 42.0 39.0
6/10/96 BR 006 /1R1 1.2 0.2 13.5 18.9 14.3 1.0 15.0 15.0 20.6
6/10/96 EP 001 /5 1.2 0.1 13.5 17.6 7.7 0.6 15.0 9.0 48.7
6/10/96 PG 007 /4 0.6 0.3 13.5 12.2 33.3 0.4 15.0 6.0 50.6
6/11/96 EJ 010 /PT 0.9 0.3 9.0 10.8 25.0 0.5 15.0 7.5 30.6
6/11/96 JM 008 /3 0.7 0.4 13.5 14.9 36.4 0.5 15.0 7.5 49.5
6/11/96 JW 009 /PT 0.9 0.4 13.5 17.6 30.8 0.6 15.0 9.0 48.7
6/14/96 EJ 010 12 0.7 0.6 13.5 17.6 46.2 0.3 15.0 4.5 74.4
6/14/96 JW 009 12 0.4 0.6 13.5 13.5 60.0 0.3 15.0 4.5 66.7
6/17/96 BR 006 /1R2 1.2 0.6 13.5 24.3 33.3 0.9 15.0 13.5 44.4
6/17/96 JM 008 /4 0.7 0.7 13.5 18.9 50.0 0.4 15.0 6.0 68.3
6/18/96 EJ 010 /3 1.5 0.6 13.3 27.9 28.6 0.9 15.0 13.5 51.7
6/18/96 JW 009 /3 1.4 0.6 13.3 26.6 30.0 0.9 15.0 13.5 49.2
6/18/96 SK 011 /PT 0.9 0.6 13.5 20.3 40.0 0.6 15.0 9.0 55.6
6/24/96 FO 003 /5 0.3 0.8 13.5 14.9 72.7 0.3 15.0 4.5 69.7
6/24/96 JW 009 /4 1.4 0.9 13.5 31.1 39.1 1.0 15.0 15.0 51.7
6/25/96 BR 006 /2R1 1.0 0.3 13.5 17.6 23.1 0.6 15.0 9.0 48.7
6/25/96 EJ 010 /4 1.3 0.8 13.5 28.4 38.1 0.8 15.0 12.0 57.7
6/25/96 JM 008 /1R1 0.3 0.2 13.5 6.8 40.0 0.1 15.0 1.5 77.8
6/25/96 PH 005 /I PR 1.2 1.0 13.5 29.7 45.5 0.9 15.0 13.5 54.5
6/28/96 PH 005 /1R1 NR NR 13.5 NR NR 0.3 15.0 4.5 NR
6/28/96 SK 011 12 2.0 0.7 13.5 36.5 25.9 1.3 15.0 19.5 46.5
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APPENDIX 6 - Cell Separation Data
WHOLE BLOOD SEPARATED CELLS
Date Subject No. Sample LY MO Vol. No. % MO MNC Vol. No. % Loss
7/1/96 SK Oil /3 4.4 0.9 13.5 71.6 17.0 3.0 15.0 45.0 37.1
7/1/96 BR 006 /2R2 1.1 0.1 13.5 16.2 8.3 0.7 15.0 10.5 35.2
7/1/96 JM 008 /1R2 0.3 0.3 13.5 8.1 50.0 0.3 15.0 4.5 44.4
7/2/96 EJ 010 /1PR 0.5 0.5 13.5 13.5 50.0 0.4 15.0 6.0 55.6
7/2/96 PG 007 /5 0.7 0.7 13.5 18.9 50.0 0.4 15.0 6.0 68.3
7/5/96 PH 005 /1R2 1.1 1.0 13.5 28.4 47.6 0.8 15.0 12.0 57.7
7/5/96 EJ 010 /1R1 0.3 0.2 13.5 6.8 40.0 0.2 15.0 3.0 55.6
7/8/96 SK Oil /4 3.6 1.3 13.3 65.2 26.5 3.0 15.0 45.0 30.9
7/8/96 DR 013 /PT 1.3 0.5 13.5 24.3 27.8 0.7 15.0 10.5 56.8
7/10/96 TG 014 /PT 2.8 0.8 13.5 48.6 22.2 1.8 15.0 27.0 44.4
7/10/96 MP 015 /PT 2.1 0.8 13.5 39.2 27.6 0.7 15.0 10.5 73.2
7/12/96 DR 013 /2 1.3 0.7 9.0 18.0 35.0 0.5 15.0 7.5 58.3
7/12/96 TG 014 12 1.2 1.0 8.1 17.8 45.5 0.4 15.0 6.0 66.3
7/12/96 MP 015 12 1.1 1.0 13.5 28.4 47.6 0.8 15.0 12.0 57.7
7/15/96 DR 013 /3 1.6 0.9 13.5 33.8 36.0 1.0 15.0 15.0 55.6
7/15/96 JW 009 /5 1.0 0.5 13.5 20.3 33.3 0.5 15.0 7.5 63.0
7/17/96 EJ 010 /1R2 0.3 0.5 13.5 10.8 62.5 0.2 15.0 3.0 72.2
7/17/96 TG 014 /3 1.3 1.6 13.5 39.2 55.2 0.9 15.0 13.5 65.5
7/17/96 MP 015 /3 1.9 1.2 13.5 41.9 38.7 1.2 15.0 18.0 57.0
7/22/96 TG 014 /1R1 1.6 0.8 13.3 31.9 33.3 1.0 15.0 15.0 53.0
7/22/96 MP 015 /4 2.5 1.4 13.5 52.7 35.9 1.9 15.0 28.5 45.9
7/22/96 SK Oil /5 2.9 1.0 13.4 52.3 25.6 2.3 15.0 34.5 34.0
7/23/96 DR 013 /4 1.0 1.4 13.5 32.4 58.3 0.6 16.0 9.6 70.4
7/29/96 TG 014 /1R2 1.0 0.5 13.4 20.1 33.3 0.6 15.0 9.0 55.2
8/5/96 DR 013 /5 1.1 0.7 13.5 24.3 38.9 0.7 16.0 11.2 53.9
8/5/96 MP 015 /1R1 1.7 0.3 13.5 27.0 15.0 1.1 17.0 18.7 30.7
8/16/96 MP 015 /1R2 0.2 0.2 19.0 7.6 50.0 0.2 15.0 3.0 60.5
10/2/96 BT 016 /PT 1.5 0.5 13.5 27.0 25.0 0.8 15.0 12.0 55.6
10/4/96 BT 016 12 0.5 1.2 18.0 30.6 70.6 NR 16.0 NR NR
10/7/96 BT 016 13 0.8 0.9 16.0 27.2 52.9 0.5 15.0 7.5 72.4
10/7/96 JS 017 /PT 1.9 0.7 16.0 41.6 26.9 1.3 15.0 19.5 53.1
10/11/96 JS 017 12 2.0 1.4 16.0 54.4 41.2 NR 15.0 NR NR
10/14/96 BT 016 /4 1.3 0.9 14.0 30.8 40.9 0.8 15.0 12.0 61.0
10/14/96 JS 017 /3 1.8 1.2 15.0 45.0 40.0 1.0 15.0 15.0 66.7
10/15/96 PC 018 /PT 1.2 0.3 17.0 25.5 20.0 1.0 15.0 15.0 41.2
10/18/96 PC 018 12 1.2 0.6 17.0 30.6 33.3 0.9 15.0 13.5 55.9
10/21/96 PC 018 13 1.6 0.2 16.0 28.8 11.1 0.9 15.0 13.5 53.1
10/21/96 JS 017 /4 NR NR 16.0 NR NR 2.9 15.0 43.5 NR
10/21/96 EC 019 /PT 1.3 0.4 16.0 27.2 23.5 1.5 15.0 22.5 17.3
10/25/96 EC 019 12 NR NR 16.0 NR NR 0.3 16.0 4.8 NR
10/28/96 PC 018 /4 1.6 0.7 17.0 39.1 30.4 1.5 15.0 22.5 42.5
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WHOLE BLOOD SEPARATED CELLS
Date Subject No. Sample LY MO Vol. No. % MO MNC Vol. No. % Loss
10/28/96 EC 019 /3 0.9 1.6 16.0 40.0 64.0 0.6 15.0 9.0 77.5
10/29/96 RE 020 /PT 0.9 0.6 17.0 25.5 40.0 0.6 15.0 9.0 64.7
10/29/96 AB 021 /PT 0.6 0.4 17.0 17.0 40.0 0.4 15.0 6.0 64.7
11/1/96 EC 019 /1R1 0.8 0.8 17.0 27.2 50.0 0.7 16.0 11.2 58.8
11/1/96 RF 020 12 NR NR 15.0 NR NR 0.8 16.0 12.8 NR
11/1/96 AB 021 12 0.5 0.5 15.0 15.0 50.0 0.3 15.0 4.5 70.0
11/4/96 RF 020 /3 1.9 0.9 14.0 39.2 32.1 1.1 15.0 16.5 57.9
11/4/96 AB 021 /3 0.5 0.6 16.0 17.6 54.5 0.4 15.0 6.0 65.9
11/6/96 RE 022 /PT 1.1 0.5 16.0 25.6 31.3 0.8 15.0 12.0 53.1
11/8/96 RE 022 12 1.6 0.9 14.5 36.3 36.0 0.8 15.0 12.0 66.9
11/8/96 EC 019 /1R2 1.8 1.3 16.0 49.6 41.9 1.1 15.0 16.5 66.7
11/11/96 BT 016 /5 0.8 1.0 14.0 25.2 55.6 0.9 15.0 13.5 46.4
11/11/96 JS 017 15 3.1 1.0 14.0 57.4 24.4 2.1 15.0 31.5 45.1
11/11/96 PC 018 15 1.2 0.5 15.0 25.5 29.4 0.8 15.0 12.0 52.9
11/11/96 RF 020 14 1.7 0.8 15.5 38.8 32.0 1.3 15.0 19.5 49.7
11/11/96 AB 021 14 0.8 0.6 15.0 21.0 42.9 0.1 15.0 1.5 92.9
11/12/96 RE 022 /3 2.5 0.6 16.0 49.6 19.4 1.8 15.0 27.0 45.6
11/12/96 NH 023 /PT 0.9 0.7 16.0 25.6 43.8 0.8 15.0 12.0 53.1
11/12/96 BM 024 /PT 2.1 1.0 16.0 49.6 32.3 1.5 15.0 22.5 54.6
11/14/96 VH 025 /PT 0.9 0.6 15.5 23.3 40.0 0.6 15.0 9.0 61.3
11/15/96 NH 023 12 0.8 0.5 16.0 20.8 38.5 0.7 15.0 10.5 49.5
11/15/96 BM 024 12 1.8 1.4 16.0 51.2 43.8 1.4 16.0 22.4 56.3
11/18/96 RE 022 14 1.7 0.3 17.0 34.0 15.0 1.2 16.0 19.2 43.5
11/18/96 NH 023 /3 1.1 0.6 16.0 27.2 35.3 0.9 15.0 13.5 50.4
11/18/96 BM 024 13 1.5 0.9 16.0 38.4 37.5 1.1 15.0 16.5 57.0
11/18/96 VH 025 12 0.6 0.9 14.0 21.0 60.0 0.5 16.0 8.0 61.9
11/19/96 EC 019 /2PR 2.1 0.8 15.5 45.0 27.6 1.0 15.0 15.0 66.6
11/19/96 AB 021 /1PR 0.6 1.0 16.0 25.6 62.5 0.4 15.0 6.0 76.6
11/20/96 VH 025 13 0.8 1.1 16.0 30.4 57.9 0.5 15.0 7.5 75.3
11/22/96 AB 021 /1R1 0.3 0.4 16.0 11.2 57.1 0.2 15.0 3.0 73.2
11/22/96 NH 023 /1PR 1.1 0.6 16.0 27.2 35.3 1.0 15.0 15.0 44.9
11/25/96 NH 023 /1R1 0.6 NR 15.5 NR NR 0.4 15.0 6.0 NR
11/25/96 BM 024 14 1.7 NR 16.0 NR NR 1.0 15.0 15.0 NR
11/25/96 VH 025 /1R1 0.8 NR 16.0 NR NR 0.7 15.0 10.5 NR
11/25/96 RF 020 15 3.0 0.4 16.5 56.1 11.8 2.2 15.0 33.0 41.2
12/2/96 NH 023 /2R1 0.6 NR 16.0 NR NR 0.4 15.0 6.0 NR
12/2/96 AB 021 /1R2 1.2 0.5 15.0 25.5 29.4 0.8 15.0 12.0 52.9
12/2/96 VH 025 /1R2 NR NR 16.5 NR NR 0.9 15.0 13.5 NR
12/9/96 BM 024 15 1.5 0.2 14.5 24.7 11.8 0.7 15.0 10.5 57.4
12/9/96 RE 022 15 0.8 0.2 12.0 12.0 20.0 0.3 15.0 4.5 62.5
12/9/96 NH 023 I2R2 0.3 0.1 15.5 6.2 25.0 0.2 15.0 3.0 51.6
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WHOLE BLOOD SEPARATED CELLS
Date Subject No. Sample LY MO Vol. No. % MO MNC Vol. No. % Loss
12/11/96 SM 026 /PT 1.5 0.6 15.5 32.6 28.6 0.8 15.0 12.0 63.1
12/13/96 SM 026 12 1.3 0.8 16.0 33.6 NR NR 16.0 NR NR
12/17/96 SM 026 /3 2.4 0.8 16.0 51.2 25.0 1.4 15.0 21.0 59.0
12/17/96 VH 025 /1R3 1.2 0.9 15.5 32.6 42.9 0.8 15.0 12.0 63.1
12/19/96 AB 021 /1R3 1.5 0.7 17.0 37.4 31.8 0.8 15.0 12.0 67.9
12/23/96 NH 023 /2R3 1.1 0.3 13.0 18.2 21.4 0.6 15.0 9.0 50.5
12/23/96 SM 026 /4 2.8 1.2 12.5 50.0 30.0 1.3 15.0 19.5 61.0
1/13/97 SM 026 /5 2.3 0.8 16.5 51.2 25.8 1.4 15.0 21.0 58.9
1/22/97 KB 027 /PT 2.3 0.6 15.5 45.0 20.7 1.5 15.0 22.5 49.9
1/24/97 KB 027 12 1.4 1.0 15.5 37.2 41.7 0.5 15.0 7.5 79.8
1/29/97 KB 027 /3 4.0 NR 13.0 NR NR 2.1 15.0 31.5 NR
2/3/97 KB 027 /4 2.6 1.4 14.0 56.0 35.0 1.5 15.0 22.5 59.8
2/3/97 JH 029 /PT 2.1 0.7 16.5 46.2 25.0 1.4 15.0 21.0 54.5
2/4/97 CA 030 /PT 1.8 0.8 16.0 41.6 30.8 1.4 15.0 21.0 49.5
2/4/97 RW 031 /PT 1.5 0.9 16.0 38.4 37.5 0.8 15.0 12.0 68.8
2/5/97 JH 029 12 1.0 1.0 16.0 32.0 50.0 0.6 15.0 9.0 71.9
2/5/97 GK 032 /PT 1.6 0.4 16.0 32.0 20.0 1.0 15.0 15.0 53.1
2/7/97 CA 030 12 1.9 1.1 15.0 45.0 36.7 0.9 15.0 13.5 70.0
2/7/97 RW 031 12 0.5 0.5 15.5 15.5 50.0 0.3 15.0 4.5 71.0
2/7/97 GK 032 12 2.1 0.9 16.0 48.0 30.0 1.4 15.0 21.0 56.3
2/10/97 JH 029 /3 1.7 1.2 15.5 45.0 41.4 1.3 15.0 19.5 56.6
2/10/97 AA 033 /PT 1.0 0.4 15.5 21.7 28.6 0.5 15.0 7.5 65.4
2/11/97 CA 030 /3 3.3 0.2 12.5 43.8 5.7 1.8 15.0 27.0 38.3
2/11/97 RW 031 /3 2.4 0.2 10.5 27.3 7.7 1.0 15.0 15.0 45.1
2/12/97 GK 032 /3 3.7 1.0 14.5 68.2 21.3 2.4 15.0 36.0 47.2
2/12/97 AA 033 12 0.6 0.2 16.0 12.8 25.0 0.4 15.0 6.0 53.1
2/14/97 JH 029 /4 1.7 1.1 14.5 40.6 39.3 1.3 15.0 19.5 52.0
2/17/97 CA 030 /4 3.0 1.0 16.5 66.0 25.0 2.1 15.0 31.5 52.3
2/17/97 RW 031 /4 1.1 0.5 16.5 26.4 31.3 0.6 15.0 9.0 65.9
2/17/97 GK 032 /4 3.5 0.9 15.5 68.2 20.5 2.4 15.0 36.0 47.2
2/17/97 AA 033 /3 1.6 0.6 14.5 31.9 27.3 0.9 15.0 13.5 57.7
2/19/97 JH 029 /4 1.7 0.4 16.5 34.7 19.0 0.8 15.0 12.0 65.4
2/19/97 NR 034 /PT 1.4 0.2 17.0 27.2 12.5 1.0 16.0 16.0 41.2
2/21/97 AA 033 /4 1.9 0.7 16.0 41.6 26.9 1.2 15.0 18.0 56.7
2/21/97 NR 034 12 1.5 0.4 16.0 30.4 21.1 0.8 15.0 12.0 60.5
2/21/97 LH 035 /PT o o k> 16.0 14.4 22.2 0.4 15.0 6.0 58.3
2/24/97 LH 035 12 0.3 0.1 16.0 6.4 25.0 0.3 15.0 4.5 29.7
2/24/97 DK 036 /PT 1.4 0.6 14.0 28.0 30.0 0.7 15.0 10.5 62.5
2/24/97 KB 037 /PT 1.1 0.5 16.0 25.6 31.3 0.7 15.0 10.5 59.0
2/27/97 LH 035 /3 0.4 NR 16.5 NR NR 0.2 15.0 3.0 NR
2/27/97 DK 036 12 1.5 0.8 16.5 38.0 34.8 1.0 15.0 15.0 60.5
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2/27/97 KB 037 12 1.0 1.0 15.5 31.0 50.0 0.6 15.0 9.0 71.0
3/3/97 DK 036 /3 1.9 1.2 16.0 49.6 38.7 1.2 15.0 18.0 63.7
3/3/97 KB 037 /3 1.7 1.0 14.5 39.2 37.0 1.2 15.0 18.0 54.0
3/3/97 RW 031 /5 0.6 0.5 13.5 14.9 45.5 0.3 15.0 4.5 69.7
3/3/97 CA 030 /5 1.6 0.6 10.0 22.0 27.3 0.6 15.0 9.0 59.1
3/5/97 JH 029 /lRla 0.1 0.0 16.0 1.6 0.0 0.1 15.0 1.5 6.3
3/5/97 IL 038 /PT 1.7 0.2 15.0 28.5 10.5 0.9 15.0 13.5 52.6
3/6/97 KB 027 /5 1.1 1.1 14.0 30.8 50.0 0.7 15.0 10.5 65.9
3/6/97 GK 032 /5 2.6 0.5 14.0 43.4 16.1 1.4 15.0 21.0 51.6
3/7/97 NR 034 /1R1 0.4 1.2 16.5 26.4 75.0 0.2 15.0 3.0 88.6
3/7/97 LH 035 /4 0.6 0.3 15.0 13.5 33.3 0.4 15.0 6.0 55.6
3/7/97 IL 038 12 0.4 0.2 16.0 9.6 33.3 0.2 15.0 3.0 68.8
3/10/97 AA 033 15 2.2 0.6 13.0 36.4 21.4 0.9 15.0 13.5 62.9
3/10/97 DK 036 /4 2.9 1.0 17.0 66.3 25.6 1.7 15.0 25.5 61.5
3/10/97 KB 037 /4 1.5 0.8 17.0 39.1 34.8 1.1 15.0 16.5 57.8
3/13/97 JH 029 /1R2 1.0 0.8 16.5 29.7 44.4 0.7 15.0 10.5 64.6
3/13/97 NR 034 /1R2 0.4 0.3 17.0 11.9 42.9 0.1 15.0 1.5 87.4 i
3/13/97 IL 038 /3 0.8 0.3 16.5 18.2 27.3 0.4 15.0 6.0 66.9
3/17/97 IL 038 /4 1.9 0.6 17.0 42.5 24.0 0.5 15.0 7.5 82.4
3/17/97 NR 034 /1R2 0.3 0.6 16.5 14.9 66.7 0.1 15.0 1.5 89.9
3/19/97 JR 039 /PT 1.7 0.4 14.0 29.4 19.0 1.0 15.0 15.0 49.0
3/21/97 MS 040 /PT 1.7 0.7 16.0 38.4 29.2 0.8 15.0 12.0 68.8
3/24/97 MS 040 12 1.5 0.8 16.0 36.8 34.8 0.7 15.0 10.5 71.5
3/24/97 DK 036 15 2.4 1.1 14.4 50.4 31.4 1.2 15.0 18.0 64.3
3/24/97 KB 037 15 1.1 0.9 16.0 32.0 45.0 0.6 15.0 9.0 71.9
3/24/97 LH 035 15 0.5 0.2 16.0 11.2 28.6 0.3 15.0 4.5 59.8
3/27/97 MS 040 /3 1.7 0.8 16.5 41.3 32.0 1.0 15.0 15.0 63.6
4/4/97 JR 039 12 1.1 0.5 17.5 28.0 31.3 0.8 15.0 12.0 57.1
4/4/97 MS 040 /4 1.3 0.6 16.0 30.4 31.6 0.7 15.0 10.5 65.5
4/7/97 JH 029 /1R3 1.4 0.3 16.0 27.2 17.6 0.5 15.0 7.5 72.4
4/7/97 IL 038 /5 1.8 0.6 16.0 38.4 25.0 1.4 15.0 21.0 45.3
4/7/97 NR 034 /1R3 0.2 0.4 15.5 9.3 66.7 0.1 15.0 1.5 83.9
4/9/97 JR 039 /3 2.9 0.7 16.5 59.4 19.4 2.1 15.0 31.5 47.0
4/14/97 JR 039 /4 2.9 0.8 17.5 64.8 21.6 1.8 15.0 27.0 58.3
4/21/97 MS 040 /5 0.6 0.6 16.0 19.2 50.0 0.3 15.0 4.5 76.6
4/24/97 IT 041 /PT 2.2 1.0 16.5 52.8 31.3 1.5 15.0 22.5 57.4
4/28/97 IT 041 12 0.9 0.9 17.0 30.6 50.0 0.5 15.0 7.5 75.5
4/30/97 IT 041 /3 1.4 1.1 16.5 41.3 44.0 0.8 15.0 12.0 70.9
4/30/97 CB 042 /PT 1.8 0.4 17.0 37.4 18.2 1.0 15.0 15.0 59.9
5/2/97 CB 042 12 1.4 0.3 14.5 24.7 17.6 0.7 15.0 10.5 57.4
5/5/97 EK 043 /PT 1.5 0.3 16.0 28.8 16.7 0.8 15.0 12.0 58.3
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5/5/97 DM 044 /PT 1.7 0.3 17.0 34.0 15.0 0.5 15.0 7.5 77.9
5/6/97 IT 041 /4 1.9 0.9 16.0 44.8 32.1 1.2 15.0 18.0 59.8
5/6/97 CB 042 /3 2.1 0.1 15.5 34.1 4.5 1.3 15.0 19.5 42.8
5/8/97 EK 043 12 0.6 0.4 16.0 16.0 40.0 0.2 15.0 3.0 81.3
5/8/97 DM 044 12 1.3 0.7 16.0 32.0 35.0 0.8 15.0 12.0 62.5
5/8/97 JR 039 /5 2.2 0.5 17.0 45.9 18.5 1.5 15.0 22.5 51.0
5/12/97 DM 044 /3 2.1 0.9 16.0 48.0 30.0 1.3 15.0 19.5 59.4
5/12/97 CB 042 /4 2.7 0.7 17.0 57.8 20.6 1.9 15.0 28.5 50.7
5/14/97 EK 043 /1R1 1.0 1.2 16.0 35.2 54.5 0.7 15.0 10.5 70.2
5/14/97 FB 045 /PT 1.2 0.3 16.0 24.0 20.0 0.9 15.0 13.5 43.8
5/16/97 FB 045 12 0.7 0.2 16.0 14.4 22.2 0.5 15.0 7.5 47.9
5/16/97 ER 046 /PT 1.4 0.3 16.0 27.2 17.6 0.9 15.0 13.5 50.4
5/19/97 DM 044 /4 3.3 0.5 16.0 60.8 13.2 1.6 16.0 25.6 57.9
5/19/97 ER 046 12 1.4 1.1 16.5 41.3 44.0 0.8 15.0 12.0 70.9
5/20/97 FB 045 /3 1.1 0.3 17.0 23.8 21.4 0.8 15.0 12.0 49.6
5/22/97 ER 046 /3 1.6 1.5 17.0 52.7 48.4 1.2 15.0 18.0 65.8
5/22/97 EK 043 /1R2 2.2 1.1 17.0 56.1 33.3 1.6 15.0 24.0 57.2
5/27/97 IT 041 /5 0.8 1.1 16.5 31.4 57.9 0.5 15.0 7.5 76.1
5/27/97 ER 046 /1R1 1.4 2.0 16.5 56.1 58.8 0.7 15.0 10.5 81.3
5/28/97 RM 047 /PT 2.3 0.7 17.0 51.0 23.3 1.7 15.0 25.5 50.0
5/30/97 RM 047 12 0.5 0.5 16.5 16.5 50.0 0.4 15.0 6.0 63.6
6/2/97 FB 045 /1R1 0.2 0.6 16.0 12.8 75.0 0.1 15.0 1.5 88.3
6/2/97 RM 047 /3 1.8 0.5 16.0 36.8 21.7 1.3 15.0 19.5 47.0
6/2/97 CB 042 /5 2.4 0.4 17.0 47.6 14.3 1.0 15.0 15.0 68.5
6/2/97 DM 044 /5 0.6 0.2 14.0 11.2 25.0 0.2 15.0 3.0 73.2
6/9/97 ER 046 /2R1 1.3 0.7 16.0 32.0 35.0 0.9 15.0 13.5 57.8
6/9/97 RM 047 /4 1.9 0.7 16.0 41.6 26.9 1.8 15.0 27.0 35.1
6/9/97 FB 045 /1R2 0.4 0.6 16.0 16.0 60.0 0.3 15.0 4.5 71.9
6/16/97 EK 043 /1R3 3.0 0.7 16.0 59.2 18.9 1.1 15.0 16.5 72.1
6/16/97 ER 046 /2R2 0.8 0.7 16.0 24.0 46.7 0.6 15.0 9.0 62.5
7/7/97 FB 045 /1R3 0.4 0.2 15.5 9.3 33.3 NR 15.0 NR NR
7/7/97 ER 046 /2R3 0.6 0.4 16.5 16.5 40.0 0.4 15.0 6.0 63.6
7/7/97 RM 047 /5 1.0 0.6 16.5 26.4 37.5 0.9 15.0 13.5 48.9
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LY MO Vol. No. % MO MNC Vol. No. % Loss
Average 1.4 0.7 15.0 31.2 34.2 0.9 15.1 13.1 58.9
Median 1.3 0.6 15.5 28.8 32.8 0.8 15.0 12.0 58.2
Maximum 4.4 2.1 19.0 71.6 75.0 3.0 17.0 45.0 92.9
Minimum 0.1 0.0 8.1 1.6 0.0 0.1 15.0 1.5 6.3
5th Percentile 0.3 0.2 13.0 10.8 12.5 0.2 15.0 3.0 37.5
95th Percentile 2.9 1.3 17.0 57.7 60.0 2.0 16.0 29.7 79.7
1st Quartile 0.8 0.4 13.5 20.2 23.9 0.5 15.0 7.5 50.6
3rd Quartile 1.8 0.9 16.0 40.3 43.8 1.1 15.0 16.5 67.7
Notes:
LY = Lymphocyte count (in millions per ml)
MO = Monocyte count (in millions per ml)
MNC = Mononuclear cell count (in millions per ml)
Vol. = Volume of blood or buffered saline resuspending the separated cells
No. = Number of mononuclear cells in whole blood or separated cells
% Loss = Percentage of mononuclear cells lost during cell separation
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APPENDIX 8
PCR ELISA Data (Non-Rejectors)
Patients SamDle IL-2 IL-2 %C IL-4 IL-4 %C IFN-G IFN-G %C IL-10 IL-10 %C
PC018 /PT 0.80 100.00 1.29 100.00 1.90 100.00 0.49 100.00
PC018 12 0.44 70.36 1.04 77.53 1.92 101.41 0.48 99.00
PC018 /3 0.25 57.81 0.97 72.54 1.53 68.73 0.68 120.50
PC018 /4 0.27 59.07 1.09 81.46 1.52 68.56 0.70 122.69
PC018 /5 0.57 79.57 0.44 42.66 1.16 47.64 0.02 62.69
JS017 /PT 2.06 100.00 2.20 100.00 2.37 100.00 1.71 100.00
JS017 12 0.74 26.63 1.37 43.87 2.39 101.46 1.70 98.56
JS017 13 0.64 24.20 1.78 65.51 2.08 74.90 1.59 88.25
JS017 14 0.28 16.86 1.69 59.96 1.29 33.74 1.11 54.88
JS017 15 0.24 16.17 1.19 36.31 1.81 57.04 1.02 50.21
CA030 /PT 0.07 100.00 1.61 100.00 1.47 100.00 0.07 100.00
CA030 12 0.18 112.02 1.62 101.06 1.86 147.18 0.27 122.63
CA030 13 0.47 148.51 1.77 118.29 2.16 199.77 0.93 236.32
CA030 14 0.08 101.21 1.77 118.29 2.10 187.95 1.24 321.23
CA030 15 0.08 100.90 1.42 82.86 1.92 156.36 0.44 144.27
KB027 /PT 0.09 100.00 1.38 100.00 2.10 100.00 0.08 100.00
KB027 12 0.10 101.26 0.68 49.93 2.17 107.09 0.96 239.05
KB027 13 0.13 104.50 0.87 59.99 1.72 68.59 0.16 108.06
KB027 14 0.12 102.84 0.93 63.83 1.35 47.35 0.08 100.00
KB027 15 0.25 118.12 1.76 146.52 1.58 59.51 0.10 101.51
SM026 /PT 0.62 100.00 1.34 100.00 2.22 100.00 0.07 100.00
SM026 12 0.43 82.86 0.17 31.08 2.09 87.94 0.72 190.50
SM026 13 0.78 117.53 0.92 65.54 1.97 77.84 0.36 132.84
SM026 14 0.41 81.38 1.44 110.79 2.31 109.91 0.03 96.08
SM026 15 0.17 64.34 1.16 82.99 1.74 61.88 0.18 111.74
RE022 /PT 0.05 100.00 0.77 100.00 1.93 100.00 0.09 100.00
RE022 12 1.54 446.60 0.00 46.46 1.74 82.20 0.88 221.22
RE022 13 0.10 105.28 0.18 55.49 2.17 127.12 0.29 122.14
RE022 14 0.13 109.14 0.15 53.71 1.35 56.16 1.04 258.18
RE022 15 0.57 168.96 1.39 185.99 1.56 68.90 1.83 566.89
BM024 /PT 0.16 100.00 0.88 100.00 2.12 100.00 0.44 100.00
BM024 12 0.80 190.60 0.28 55.02 2.16 103.30 0.38 94.46
BM024 13 0.23 107.73 1.29 150.53 1.67 63.41 1.20 214.04
BM024 14 0.42 129.95 1.73 235.26 2.11 98.86 0.14 74.01
BM024 15 1.29 311.58 1.69 226.03 2.30 119.48 1.61 324.79
RF020 /PT 0.95 100.00 2.15 100.00 1.89 100.00 1.90 100.00
RF020 12 0.44 59.96 1.16 36.97 1.72 85.00 1.90 99.60
RF020 13 0.48 62.88 1.94 80.90 1.34 57.75 1.57 71.89
RF020 14 0.25 49.68 1.24 40.31 1.24 52.23 0.90 36.66
RF020 15 0.13 43.96 0.90 28.64 0.43 23.34 0.14 17.08
BT016 /PT 1.23 100.00 1.74 100.00 2.31 100.00 0.87 100.00
BT016 12 0.28 38.79 0.10 19.48 2.06 78.31 1.79 250.68
BT016 13 0.31 39.83 0.86 41.60 1.93 68.35 1.63 214.58
BT016 14 0.52 48.94 1.92 120.26 1.97 71.68 1.82 258.31
BT016 15 0.41 44.13 1.80 106.61 2.10 80.98 1.73 237.26
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Patients Sample IL-2 IL-2 %C IL-4 IL-4 %C IFN-G IFN-G %C IL-10 IL-10 %C
EP001 /PT 0.60 100.00 1.95 100.00 2.05 100.00 1.33 100.00
EP001 12 0.27 71.78 1.51 63.92 1.67 67.98 1.14 82.82
EP001 /3 0.54 93.52 1.80 85.98 1.69 69.38 1.91 177.71
EP001 14 0.88 132.05 1.63 72.51 2.32 130.08 0.29 35.24
EPOOl 15 0.72 112.69 0.82 32.14 1.92 87.72 1.76 153.04
JW009 /PT 0.36 100.00 0.72 100.00 0.67 100.00 1.31 100.00
JW009 12 0.59 126.05 0.32 66.63 1.59 250.18 0.93 68.18
JW009 13 0.51 116.24 0.27 63.44 1.46 220.78 1.52 123.86
JW009 /4 0.45 109.64 0.83 111.57 1.19 168.54 1.61 135.19
JW009 /5 0.45 109.86 0.93 122.57 1.84 323.17 1.98 196.01
SK011 /PT 0.42 100.00 1.04 100.00 0.85 100.00 0.90 100.00
SK011 12 0.61 120.74 0.25 45.41 1.90 284.34 1.13 126.81
SK011 13 0.67 128.79 1.10 106.77 1.64 220.23 1.55 192.51
SK011 /4 0.45 102.84 1.18 115.66 1.29 154.81 1.41 166.28
SK011 /5 0.11 73.45 1.23 121.11 1.07 124.67 2.30 404.71
DR013 /PT 0.14 100.00 0.90 100.00 1.49 100.00 0.39 100.00
DR013 12 0.14 100.35 1.11 123.24 1.72 125.04 2.27 653.39
DR013 13 0.06 96.46 1.13 124.92 1.14 70.26 1.80 410.21
DR013 14 0.08 96.46 0.95 104.81 1.54 104.86 0.76 144.05
DR013 15 0.27 114.74 1.48 177.98 1.49 99.45 2.15 579.79
PG007 /PT 0.46 100.00 1.41 100.00 1.65 100.00 0.69 100.00
PG007 12 0.26 81.67 0.12 27.57 0.71 39.10 1.44 212.55
PG007 13 0.90 155.82 2.03 185.80 1.56 91.58 2.02 379.43
PG007 14 0.79 139.17 1.87 158.41 2.09 155.19 0.62 93.61
PG007 /5 0.94 161.69 2.15 209.17 2.02 144.41 2.04 387.68
F0003 /PT 0.13 100.00 1.17 100.00 0.88 100.00 1.56 100.00
F0003 12 0.09 96.95 0.01 31.40 0.39 61.11 1.57 101.66
F0003 13 0.15 101.46 0.01 31.44 0.56 72.61 2.00 156.05
F0003 14 0.16 103.30 0.39 45.96 0.84 96.13 1.58 102.63
F0003 15 0.19 106.08 0.88 75.01 0.70 83.40 1.76 123.18
RW031 /PT 0.17 100.00 1.03 100.00 1.95 100.00 0.16 100.00
RW031 12 0.21 103.51 0.23 44.80 2.01 106.66 1.15 268.99
RW031 13 0.04 93.19 0.19 43.13 1.05 40.45 0.09 93.15
RW031 14 0.27 110.08 0.70 71.43 1.98 102.94 1.09 254.21
RW031 15 0.12 95.46 1.62 179.41 2.05 110.52 1.13 264.59
GK032 /PT 0.39 100.00 1.85 100.00 2.23 100.00 0.15 100.00
GK032 12 0.32 93.38 1.06 45.50 1.69 58.33 0.70 173.33
GK032 13 0.25 87.50 1.76 91.81 2.39 118.41 1.01 237.26 ;
GK032 14 0.03 75.20 1.57 76.00 1.89 71.57 1.31 319.31
GK032 15 1.11 205.96 1.58 76.76 2.07 85.34 0.66 167.36
KB037 /PT 0.09 100.00 1.99 100.00 1.81 100.00 0.87 100.00
KB037 12 0.05 100.00 1.07 39.83 1.24 56.98 0.68 82.70
KB037 13 0.04 100.00 1.01 37.53 0.38 24.06 0.21 51.38
KB037 14 0.50 149.18 2.00 101.51 2.32 166.70 0.83 95.93
KB037 15 0.32 124.79 1.62 69.07 2.32 167.62 1.21 140.49
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Patients SamDle IL-2 IL-2 %C IL-4 IL-4 %C IFN-G IFN-G %C IL-10 IL-10 %C
AA033 /PT 0.14 100.00 1.45 100.00 1.66 100.00 0.10 100.00
AA033 12 0.17 103.25 0.58 41.67 1.74 108.60 0.62 167.95
AA033 /3 0.04 95.89 0.73 48.46 2.00 141.48 0.78 196.70
AA033 /4 1.60 429.95 1.76 136.55 2.28 186.92 0.57 160.08
AA033 /5 0.20 106.18 1.01 64.56 1.87 123.61 0.20 109.64
DK036 /PT 0.41 100.00 1.78 100.00 2.08 100.00 0.37 100.00
DK036 12 0.05 73.27 0.86 39.99 0.91 31.08 0.26 89.14
DK036 /3 0.01 73.27 0.14 19.43 0.31 17.15 0.02 70.47
DK036 /4 0.34 93.10 1.10 50.48 2.27 121.84 0.34 96.42
DK036 15 0.09 73.27 0.50 27.72 1.85 79.89 0.30 92.96
LH035 /PT 0.01 100.00 0.58 100.00 0.33 100.00 0.02 100.00
LH035 12 0.02 100.00 1.32 209.38 2.00 530.69 2.06 766.76
LH035 /3 0.03 100.00 0.99 149.71 2.21 658.96 0.82 222.44
LH035 14 0.03 100.00 1.86 359.66 1.79 431.89 1.43 408.57
LH035 15 0.13 102.84 1.62 283.20 2.00 533.35 1.57 473.51
IL038 /PT 0.23 100.00 0.28 100.00 2.46 100.00 0.28 100.00
IL038 12 0.01 88.12 0.02 76.76 2.26 81.55 1.23 257.54
IL038 /3 0.00 88.12 0.00 75.43 1.36 33.25 0.03 77.65
IL038 14 0.01 88.12 0.54 128.79 2.10 69.70 0.07 80.98
IL038 15 0.02 88.12 1.56 358.59 1.32 31.85 0.27 98.41
JR039 /PT 0.11 100.00 1.25 100.00 1.93 100.00 0.16 100.00
JR039 12 0.94 229.10 0.57 50.69 2.02 109.58 0.86 199.57
JR039 /3 0.06 99.35 0.73 59.87 1.24 50.13 0.09 92.68
JR039 14 0.01 99.35 0.83 66.10 1.29 52.73 0.25 108.98
JR039 15 0.07 99.35 0.96 75.31 1.11 44.13 0.21 104.86
MS040 /PT 1.28 100.00 1.86 100.00 2.17 100.00 0.23 100.00
MS040 12 0.32 38.29 1.00 42.34 0.72 23.49 0.63 148.96
MS040 /3 0.39 41.02 1.23 53.47 1.76 66.23 0.58 141.55
MS040 14 0.56 48.55 1.71 86.37 0.97 30.21 0.99 213.93
MS040 15 0.31 37.66 1.71 86.55 0.75 24.29 1.55 372.48
IT041 /PT 0.32 100.00 1.15 100.00 2.06 100.00 0.11 100.00
IT041 12 0.15 84.70 1.79 190.79 2.12 106.45 1.53 415.99
IT041 /3 0.04 80.37 0.50 52.07 1.46 55.05 0.04 93.99
IT041 14 0.10 80.73 1.03 89.05 1.12 39.16 0.18 107.47
IT041 15 0.10 80.57 1.51 143.40 1.87 82.61 1.12 276.21
CB042 /PT 0.02 100.00 0.53 100.00 1.02 100.00 0.15 100.00
CB042 12 0.13 102.69 0.36 84.20 1.34 137.92 0.15 100.15
CB042 /3 0.03 100.00 0.44 91.12 0.36 51.94 0.28 114.34
CB042 14 0.19 109.91 0.56 103.61 1.13 111.52 0.41 130.08
CB042 15 0.03 100.00 0.39 86.94 0.62 67.13 0.16 101.51
DM044 /PT 1.09 100.00 1.15 100.00 1.95 100.00 1.39 100.00
DM044 12 0.42 51.35 1.13 98.22 1.27 50.48 1.08 73.16
DM044 13 0.54 57.67 1.08 92.96 1.39 56.84 0.55 43.11
DM044 14 0.22 42.02 1.26 111.35 0.59 25.46 0.14 28.69
DM044 15 0.23 42.61 1.13 97.78 2.02 107.14 0.56 43.87
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PCR ELISA Data (Non-Rejectors)
Patients Sample IL-2 IL-2 %C IL-4 IL-4 %C IFN-G IFN-G %C IL-10 IL-10 %C
RM047 /PT 0.08 100.00 1.01 100.00 1.50 100.00 0.22 100.00
RM047 12 0.08 100.00 0.01 36.71 1.78 132.11 1.44 338.55
RM047 /3 0.01 100.00 0.00 36.53 0.22 27.83 0.03 82.78
RM047 /4 0.39 133.44 0.61 67.20 1.66 117.53 0.28 106.61
RM047 15 0.05 100.00 1.05 104.39 2.11 183.40 0.65 154.34
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PCR ELISA Data (Non-Rejectors)
Patients Sample IL-5 IL-5 %C IL-13 IL-13 %C GrB GrB %C FasL FasL %C
AA033 /PT 0.60 100.00 0.38 100.00 1.66 100.00 0.22 100.00
AA033 12 0.75 116.47 0.28 90.12 1.70 104.55 0.31 110.41
AA033 /3 0.27 72.36 0.16 80.05 1.49 84.32 0.38 118.29
AA033 /4 1.30 202.59 0.24 86.81 1.78 112.86 0.34 113.48
AA033 ts 0.32 76.11 0.36 98.22 1.69 103.87 0.40 119.66
LH035 /PT 0.01 100.00 0.00 100.00 0.93 100.00 0.04 100.00
LH035 12 0.04 103.46 0.06 105.92 1.62 200.27 0.32 133.11
LH035 /3 0.14 113.83 0.02 101.41 1.72 221.67 0.23 121.17
LH035 /4 0.03 101.87 0.76 212.55 1.19 130.73 0.30 129.43
LH035 /5 0.03 102.28 0.40 149.26 1.41 162.42 0.34 135.59
DK036 /PT 1.99 100.00 0.18 100.00 2.06 100.00 0.51 100.00
DK036 12 0.18 16.36 0.09 91.67 1.10 38.29 0.29 79.97
DK036 /3 0.04 14.28 0.00 0.00 0.10 14.13 0.03 61.72
DK036 /4 0.76 29.13 0.16 98.22 2.04 98.12 0.49 97.43
DK036 15 0.26 17.68 0.07 89.09 1.48 56.21 0.32 82.49
MS040 /PT 0.22 100.00 0.58 100.00 1.58 100.00 0.47 100.00
MS040 12 0.10 88.74 0.26 72.69 1.46 88.69 0.44 96.85
MS040 /3 0.06 85.73 0.58 99.85 1.63 105.23 0.33 86.33
MS040 /4 0.12 90.98 0.63 104.92 1.79 123.55 0.50 102.48
MS040 15 0.05 84.62 0.33 77.96 1.90 137.37 0.55 108.27
EP001 /PT 0.11 100.00 0.16 100.00 2.10 100.00 0.48 100.00
EP001 12 0.04 92.68 0.28 112.58 1.32 45.82 0.27 81.10
EP001 /3 0.04 92.77 0.22 106.72 1.79 73.49 0.45 97.68
EP001 /4 0.05 93.71 0.04 88.51 1.69 66.53 0.31 84.70
EP001 15 0.05 93.94 0.01 85.81 1.91 83.03 0.37 90.03
JW009 /PT 0.04 100.00 0.08 100.00 1.84 100.00 0.40 100.00
JW009 12 0.02 97.73 0.01 92.87 1.35 61.14 0.17 79.61
JW009 /3 0.02 98.31 0.01 93.24 1.40 64.53 0.27 87.59
JW009 /4 0.02 98.12 0.06 97.34 1.83 98.46 0.47 107.36
JW009 /5 0.02 98.27 0.06 97.43 2.06 124.30 0.70 135.66
KB037 /PT 0.12 100.00 0.02 100.00 1.78 100.00 0.20 100.00
KB037 12 0.04 92.45 0.19 118.65 0.96 43.91 0.23 103.25
KB037 13 0.01 89.72 0.05 103.82 0.56 29.38 0.08 88.38
KB037 14 0.09 97.14 0.36 140.99 1.30 61.66 0.30 110.52
KB037 15 0.08 96.18 0.09 108.06 1.14 52.81 0.34 114.51
IT041 /PT 0.04 100.00 0.35 100.00 2.08 100.00 0.41 100.00
IT041 12 0.02 98.46 0.94 180.04 2.07 99.25 0.50 109.97
IT041 /3 0.02 97.87 0.13 80.53 1.40 50.94 0.18 79.57
IT041 14 0.02 98.27 0.16 82.57 1.13 38.58 0.31 90.76
IT041 15 0.13 109.75 1.01 193.29 1.70 68.15 0.51 110.13
SK011 /PT 0.04 100.00 0.45 100.00 2.34 100.00 0.34 100.00
SK011 12 0.05 101.61 0.03 65.31 1.94 67.57 0.40 106.88
SK011 13 0.07 102.74 0.34 89.00 1.85 61.39 0.36 101.77
SK011 14 0.01 97.09 0.27 83.03 2.10 78.94 0.23 89.99
SKOll 15 0.01 97.24 0.47 101.87 2.18 85.86 0.28 94.46
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PCR ELISA Data (Non-Rejectors)
Patients Sample IL-5 IL-5 %C IL-13 IL-13 %C GrB GrB %C FasL FasL %C
DR013 /PT 0.07 100.00 0.02 100.00 2.08 100.00 0.26 100.00
DR013 12 0.05 98.31 0.37 142.26 1.94 87.42 0.33 106.82
DR013 /3 0.02 95.50 0.65 188.99 2.12 104.71 0.36 111.13
DR013 /4 0.01 94.55 0.03 101.46 1.94 86.94 0.21 95.65
DR013 /5 0.01 94.46 0.59 176.65 1.78 74.56 0.34 107.90
BT016 /PT 0.06 100.00 0.06 100.00 1.32 100.00 0.28 100.00
BT016 12 0.01 95.74 0.01 94.93 1.28 96.18 0.26 97.82
BT016 /3 0.01 95.46 0.03 97.00 1.61 134.18 0.19 91.21
BT016 /4 0.02 96.46 0.58 168.96 1.48 117.82 0.25 97.68
BT016 15 0.00 94.79 0.07 101.11 1.87 174.28 0.27 99.05
JS017 /PT 0.50 100.00 0.33 100.00 2.27 100.00 0.54 100.00
JS017 12 0.15 70.19 0.27 94.65 1.90 68.87 0.38 85.68
JS017 /3 0.10 66.83 0.25 92.82 1.22 34.99 0.41 88.07
JS017 /4 0.03 62.10 0.26 93.15 2.06 80.86 0.31 79.57
JS017 /5 0.02 61.45 0.25 92.13 0.93 26.28 0.19 70.65
RE022 /PT 0.04 100.00 0.00 100.00 1.05 100.00 0.18 100.00
RE022 12 0.12 108.49 0.02 102.22 1.90 232.80 0.37 120.50
RE022 13 0.07 102.43 0.01 100.45 0.09 38.17 0.11 93.38
RE022 /4 0.02 97.68 0.00 0.00 1.37 137.23 0.15 97.14
RE022 15 0.06 101.46 0.22 124.86 2.22 320.91 0.72 171.77
SM026 /PT 0.04 100.00 0.13 100.00 1.99 100.00 0.37 100.00
SM026 12 0.03 98.96 0.01 88.87 1.34 52.10 0.34 97.82
SM026 13 0.04 99.60 0.05 92.77 0.51 22.82 0.33 96.75
SM026 14 0.01 96.85 0.00 0.00 0.56 23.98 0.02 70.54
SM026 15 0.01 96.66 0.01 89.40 1.22 46.49 0.25 88.78
PG007 /PT 0.10 100.00 0.12 100.00 2.15 100.00 0.48 100.00
PG007 12 0.01 91.99 0.01 89.00 1.14 36.51 0.20 75.16
PG007 13 0.10 100.35 0.57 156.83 1.69 63.07 0.55 106.88
PG007 14 0.03 93.57 0.54 151.66 1.60 57.90 0.37 89.45
PG007 15 0.16 106.88 0.65 169.81 1.76 67.91 0.60 111.91
RF020 /PT 0.04 100.00 0.36 100.00 2.39 100.00 0.54 100.00
RF020 12 0.04 100.50 0.14 80.41 2.27 88.16 0.48 93.85
RF020 13 0.01 97.87 0.54 119.60 2.17 79.77 0.43 89.67
RF020 14 0.01 97.58 0.02 71.32 0.21 11.26 0.10 64.60
RF020 15 0.01 97.43 0.05 73.79 2.29 89.72 0.16 68.45
FO003 /PT 0.06 100.00 0.71 100.00 0.40 100.00 0.26 100.00
FO003 12 0.00 0.00 0.03 50.54 0.02 68.76 0.10 85.86
FO003 13 0.02 96.37 0.06 52.13 0.05 70.79 0.16 90.71
FO003 14 0.01 95.12 0.12 55.46 0.03 68.94 0.21 95.12
FO003 15 0.00 94.46 0.41 73.68 1.87 436.01 0.55 134.72
BM024 /PT 0.07 100.00 0.05 100.00 2.24 100.00 0.21 100.00
BM024 12 0.02 95.65 0.00 95.65 1.27 37.81 0.15 94.08
BM024 13 0.03 96.51 0.02 96.95 1.95 74.34 0.14 93.75
BM024 14 0.03 96.90 0.26 123.24 1.63 54.04 0.32 111.96
BM024 15 0.03 96.66 0.20 116.18 2.11 87.77 0.49 133.31
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PCR ELISA Data (Non-Rejectors)
Patients Sample IL-5 IL-5 %C IL-13 IL-13 %C GrB GrB %C FasL FasL %C
KB027 /PT 0.08 100.00 0.28 100.00 1.36 100.00 0.18 100.00
KB027 12 0.02 94.65 0.07 81.14 2.36 271.83 0.50 136.96
KB027 13 0.04 95.93 0.25 97.09 0.31 34.92 0.08 90.26
KB027 /4 0.04 96.03 0.40 113.15 0.49 42.17 0.06 88.87
KB027 15 0.02 93.89 0.96 196.50 0.23 32.43 0.24 105.71
CA030 /PT 0.16 100.00 0.20 100.00 1.39 100.00 0.07 100.00
CA030 12 0.05 89.05 0.46 130.28 1.64 128.85 0.13 106.18
CA030 /3 0.11 94.60 0.60 149.56 1.76 144.77 0.27 121.41
CA030 /4 0.05 89.27 0.63 154.88 1.92 170.92 0.47 149.33
CA030 /5 0.01 85.56 0.19 99.55 2.18 221.11 0.36 133.24
PC018 /PT 0.03 100.00 0.13 100.00 2.28 100.00 0.64 100.00
PC018 12 0.01 98.02 0.06 92.59 1.68 55.27 0.33 72.98
PC018 13 0.02 99.00 0.11 97.68 2.29 101.92 0.42 79.81
PC018 /4 0.04 100.30 0.23 109.58 2.23 95.12 0.40 78.19
PC018 /5 0.01 97.82 0.00 0.00 0.48 16.68 0.11 58.63
RW031 /PT 0.02 100.00 0.25 100.00 1.71 100.00 0.15 100.00
RW031 12 0.01 98.66 0.04 80.98 1.87 117.41 0.22 106.72
RW031 13 0.02 99.25 0.00 0.00 0.90 44.18 0.03 89.00
RW031 14 0.03 100.80 0.18 93.19 1.58 87.46 0.28 113.54
RW031 IS 0.16 115.08 0.43 119.96 1.79 108.38 0.32 118.47
GK032 /PT 0.09 100.00 0.34 100.00 2.20 100.00 0.29 100.00
GK032 12 0.04 95.08 0.12 80.57 0.68 21.90 0.20 91.67
GK032 13 0.10 101.01 0.52 120.50 2.23 103.05 0.38 109.97
GK032 14 0.09 99.30 0.25 91.53 1.54 51.79 0.44 116.82
GK032 15 0.05 95.89 0.68 141.48 1.72 61.75 0.53 127.44
JR039 /PT 0.03 100.00 0.29 100.00 1.32 100.00 0.45 100.00
JR039 12 0.04 101.16 0.06 79.25 2.21 243.63 0.41 95.74
JR039 13 0.03 99.90 0.06 79.37 0.54 46.07 0.14 73.34
JR039 14 0.05 102.28 0.16 87.90 0.34 37.68 0.21 78.94
JR039 IS 0.02 99.25 0.19 90.03 1.89 177.54 0.48 102.84
CB042 /PT 0.05 100.00 0.23 100.00 1.09 100.00 0.23 100.00
CB042 12 0.05 100.75 0.17 93.94 2.14 284.91 0.36 113.37
CB042 13 0.04 99.75 0.21 97.73 0.87 80.09 0.18 95.22
CB042 14 0.04 99.00 0.21 98.12 0.99 90.17 0.31 107.84
CB042 IS 0.01 96.80 0.04 83.15 0.87 79.97 0.04 82.53
DM044 /PT 0.50 100.00 0.47 100.00 2.22 100.00 0.56 100.00
DM044 12 0.37 87.68 0.21 77.22 2.17 95.22 0.51 94.98
DM044 13 0.28 80.61 0.19 75.20 1.73 61.63 0.37 82.37
DM044 14 0.04 62.94 0.19 75.65 1.62 55.13 0.21 70.15
DM044 15 0.05 64.02 0.58 112.02 2.11 89.40 0.46 90.21
RM047 /PT 0.09 100.00 0.27 100.00 2.39 100.00 0.75 100.00
RM047 12 0.15 105.81 0.10 84.32 2.25 87.42 1.00 127.19
RM047 13 0.02 93.33 0.00 0.00 0.09 10.11 0.07 50.33
RM047 14 0.08 99.20 0.04 79.14 2.40 101.41 0.55 81.26
RM047 IS 0.13 104.29 0.18 91.16 2.02 69.56 0.95 122.02
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PCR ELISA Data (Rejectors)
Patients Sample IL-2 IL-2 %C IL-4 IL-4 %C IFN-G IFN-G %C IL-10 IL-10 %C
NR034 /PT 0.06 100.00 1.73 100.00 1.09 100.00 0.03 100.00
NR034 12 0.05 99.25 1.73 100.15 1.85 214.04 0.25 125.73
NR034 /1R1 0.01 94.93 2.24 165.78 0.72 69.11 0.49 158.49
NR034 /1R2 0.01 95.74 2.34 184.41 1.81 204.62 0.33 136.00
NR034 /1R3 0.03 97.29 2.11 146.52 1.25 117.47 0.12 109.58
EK043 /PT 1.37 100.00 2.27 100.00 2.21 100.00 1.78 100.00
EK043 12 0.16 29.57 1.26 36.48 1.82 67.30 1.50 75.73
EK043 /1R1 0.16 29.78 0.35 14.73 2.12 91.35 2.07 133.24
EK043 /1R2 0.04 26.34 0.55 17.85 0.18 13.12 0.09 18.48
EK043 /1R3 0.05 26.49 1.26 36.39 0.37 15.79 0.05 17.76
JH029 /PT 0.08 100.00 1.36 100.00 1.89 100.00 0.21 100.00
JH029 12 0.01 93.89 0.55 44.42 1.33 56.78 0.60 147.62
JH029 /3 0.07 99.35 1.13 79.49 1.17 48.41 0.48 130.93
JH029 /4 0.59 167.03 1.71 141.62 2.04 115.95 1.62 413.09
JH029 /1R1 0.03 95.79 1.24 88.51 1.34 57.55 1.50 363.28
JH029 /lRla 0.01 93.75 1.06 74.56 0.63 28.29 0.19 98.81
JH029 /1R2 0.04 96.03 1.41 105.50 2.00 111.85 1.39 327.23
JH029 /1R3 0.05 97.09 1.53 119.07 2.10 122.88 1.04 231.06
JM008 /PT 0.02 100.00 1.31 100.00 1.62 100.00 0.03 100.00
JM008 12 0.03 100.55 0.00 27.21 1.28 71.46 0.63 182.67
JM008 /3 0.02 99.60 0.02 27.76 1.62 99.80 0.15 112.75
JM008 /4 0.01 98.17 1.76 157.78 2.00 146.96 0.21 119.18
JM008 /1R1 0.10 108.11 0.06 28.77 1.78 117.64 0.73 200.77
JM008 /1R2 0.00 97.78 1.83 169.55 2.22 182.76 1.25 340.25
VH025 /PT 1.58 100.00 1.69 100.00 2.32 100.00 1.01 100.00
VH025 12 0.53 35.03 1.02 51.15 1.97 70.75 1.89 241.33
VH025 /3 0.63 38.56 0.94 47.57 2.24 93.05 0.96 95.17
VH025 /1R1 0.73 42.66 0.09 20.26 1.89 65.51 1.84 227.73
VH025 /1R2 1.35 79.41 1.80 111.74 2.32 100.65 2.01 271.69
VH025 /1R3 1.21 68.76 1.27 66.10 2.15 85.04 1.76 210.33
AB021 /PT 1.17 100.00 1.85 100.00 2.21 100.00 1.70 100.00
AB021 12 0.61 56.78 1.71 86.85 2.23 102.38 1.23 62.31
AB021 13 0.54 53.34 1.89 103.72 2.08 87.99 1.93 126.24
AB021 /4 0.41 46.84 1.61 78.35 1.86 71.14 0.79 40.27
AB021 /1PR 0.37 44.78 2.08 126.36 1.96 78.15 0.44 28.42
AB021 /1R1 0.17 36.73 1.11 47.50 2.25 104.08 1.39 73.71
AB021 /1R2 1.03 87.02 2.31 158.41 2.25 104.86 1.36 71.39
AB021 /1R3 1.02 86.11 1.86 101.16 2.21 100.30 0.93 46.56
MP015 /PT 0.47 100.00 1.85 100.00 2.09 100.00 1.50 100.00
MP015 12 0.47 99.60 1.21 52.65 1.68 66.46 2.22 206.27
MP015 13 0.18 74.30 1.26 55.63 1.28 44.53 1.77 130.67
MP015 /4 0.26 80.29 1.50 70.79 1.29 45.00 1.90 149.48
MP015 /1R1 0.24 78.70 0.20 19.21 1.34 47.21 1.86 144.20
MP015 /lRla 0.03 63.95 1.66 82.78 0.42 18.85 2.23 207.82
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PCR ELISA Data (Rejectors)
Patients Sanrnle IL-2 IL-2 % C IL-4 IL-4 % C IFN-G IFN-G % C IL-10 IL-10 % C
NH023 /PT 0.53 100.00 0.95 100.00 2.05 100.00 1.02 100.00
NH023 12 0.07 63.48 0.18 46.16 1.85 81.79 0.94 91.71
NH023 /3 0.55 102.48 0.72 79.77 1.77 75.88 0.69 71.39
NH023 /1PR 0.22 73.68 0.86 91.44 1.66 67.67 0.63 67.54
NH023 /1R1 0.21 73.12 0.09 42.17 1.84 81.06 1.22 122.26
NH023 /2R1 0.36 84.20 0.09 42.21 1.86 82.74 1.26 126.68
NH023 /2R2 0.13 67.17 1.18 125.29 1.95 90.71 1.41 147.77
NH023 /2R3 0.07 63.29 0.86 91.30 2.06 101.21 0.30 48.48
BR006 /PT 0.61 100.00 1.05 100.00 1.99 100.00 0.65 100.00
BR006 12 0.66 105.65 0.10 38.67 1.27 48.65 1.75 300.12
BR006 13 0.46 86.37 0.86 82.53 1.70 74.56 0.80 116.59
BR006 /1R1 0.12 61.45 0.13 39.87 1.30 50.18 1.63 265.91
BR006 /1R2 1.12 166.53 2.11 289.50 2.34 142.19 1.99 383.44
BR006 /2R1 0.52 91.85 0.95 90.21 2.26 130.80 1.83 327.23
BR006 /2R2 0.83 124.92 1.47 152.50 2.09 109.91 1.70 286.91
PH005 /PT 0.82 100.00 1.09 100.00 1.56 100.00 1.18 100.00
PH005 12 0.45 69.49 0.39 49.34 0.73 43.47 2.12 256.38
PH005 13 0.48 71.61 1.05 95.70 1.19 69.25 1.70 167.87
PH005 14 0.27 57.78 0.78 73.09 0.64 39.93 1.09 91.76
PH005 15 0.66 85.30 1.32 125.48 1.46 90.94 1.84 192.42
PH005 /1R1 0.37 63.67 0.02 34.23 1.58 102.33 2.04 235.26
PH005 /1R2 0.87 105.18 0.74 70.26 1.27 74.64 0.95 79.06
EJ010 /PT 1.00 100.00 2.11 100.00 1.09 100.00 0.61 100.00
EJ010 12 1.05 104.66 0.65 23.28 1.13 104.55 0.94 139.17
EJ010 13 0.74 76.57 1.32 45.32 0.20 41.02 0.67 106.45
EJ010 14 1.54 170.83 2.02 91.35 0.95 87.33 2.10 442.38
EJ010 /I PR 1.20 122.14 2.36 128.40 1.55 159.04 1.45 230.48
EJ010 /lRla 0.48 59.34 1.61 61.12 1.01 92.26 1.89 360.33
TG014 /PT 0.77 100.00 1.01 100.00 1.05 100.00 1.37 100.00
TG014 12 0.48 74.49 0.80 81.42 0.92 87.94 2.01 189.93
TG014 13 0.18 55.71 0.79 80.29 0.13 39.83 1.74 145.21
TG014 /1R1 0.13 52.97 0.62 67.88 0.82 79.25 2.09 205.65
TG014 /1R2 0.32 63.83 1.70 199.57 1.48 154.50 1.73 143.05
FB045 /PT 1.03 100.00 1.84 100.00 1.39 100.00 0.30 100.00
FB045 12 1.01 98.17 1.21 53.21 1.17 80.01 0.49 120.80
FB045 13 0.07 38.14 1.99 116.77 0.48 40.27 0.21 91.03
FB045 /1R1 0.05 37.44 2.14 135.12 0.49 40.68 1.74 421.65
FB045 /1R2 0.01 35.93 1.17 51.20 0.03 25.54 0.02 75.09
FB045 /1R3 0.44 55.32 2.07 126.30 2.29 245.71 0.50 122.32
ECO 19 /PT 0.26 100.00 0.95 100.00 1.36 100.00 1.51 100.00
ECO 19 12 0.24 98.46 1.06 110.96 1.09 75.96 1.99 162.26
ECO 19 13 0.07 82.49 1.03 108.17 0.90 63.29 1.95 155.35
ECO 19 /1R1 0.19 92.91 0.01 39.14 1.06 73.90 2.28 215.65
ECO 19 /1R2 1.00 210.22 0.61 71.28 1.39 102.79 0.85 51.61
ECO 19 /1R3 0.98 205.44 0.89 93.61 1.70 139.79 0.89 53.50
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PCR ELISA Data (Rejectors)
Patients Sample IL-2 IL-2 % C IL-4 IL-4 % C IFN-G IFN-G % C IL-10 IL-10 % C
ER046 /PT 1.05 100.00 1.87 100.00 2.08 100.00 0.80 100.00
ER046 12 0.56 61.51 1.64 79.25 2.03 94.84 1.18 146.30
ER046 13 0.31 47.85 1.52 70.08 1.12 38.35 0.82 101.51
ER046 /1R1 0.55 60.47 1.85 97.68 1.27 44.64 1.99 326.91
ER046 /2R1 0.76 74.83 1.73 86.94 2.11 103.10 1.47 195.62
ER046 /2R2 0.58 62.53 1.39 61.91 1.69 67.54 0.82 101.56
ER046 /2R3 0.23 44.00 1.51 69.98 1.77 73.16 0.98 119.30
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Patients Sample IL-5 IL-5 %C IL-13 IL-13 %C GrB GrB %C FasL FasL %C
AB021 /PT 0.04 100.00 0.43 100.00 2.20 100.00 0.28 100.00
AB021 12 0.03 98.81 0.76 139.79 1.69 59.84 0.36 108.33
AB021 /3 0.04 100.60 0.58 116.42 1.83 69.28 0.11 83.69
AB021 /4 0.01 96.80 0.99 175.15 1.44 46.91 0.04 78.51
AB021 /1PR 0.02 97.97 1.14 204.42 1.56 52.83 0.09 81.95
AB021 /1R1 0.01 97.63 0.16 76.84 1.17 35.90 0.24 95.89
AB021 /1R2 0.02 98.71 1.29 238.10 2.08 89.09 0.31 103.05
AB021 /1R3 0.01 97.58 0.74 136.34 1.53 51.35 0.32 103.20
EK043 /PT 0.17 100.00 0.93 100.00 2.29 100.00 0.34 100.00
EK043 12 0.04 87.77 0.54 67.33 1.67 53.55 0.25 91.76
EK043 /1R1 0.03 87.02 0.02 40.13 1.41 41.46 0.23 89.76
EK043 /1R2 0.03 86.59 0.04 41.09 0.02 10.24 0.04 74.56
EK043 /1R3 0.02 85.98 0.04 41.05 0.13 11.51 0.06 76.11
JM008 /PT 0.03 100.00 0.72 100.00 2.09 100.00 0.75 100.00
JM008 12 0.05 101.66 -0.01 0.00 0.72 25.45 0.41 71.28
JM008 13 0.13 110.24 0.04 50.81 2.23 115.08 0.70 95.60
JM008 /4 0.27 127.00 1.29 177.71 2.17 108.17 0.64 89.49
JM008 /1R1 0.02 98.76 0.04 50.61 2.28 120.68 0.76 100.80
JM008 /1R2 0.12 109.47 1.10 145.64 2.27 120.32 0.64 90.21
MP015 /PT 0.04 100.00 0.33 100.00 2.08 100.00 0.71 100.00
MP015 12 0.00 0.00 0.32 98.86 0.46 19.74 0.75 103.98
MP015 13 0.00 96.46 0.75 152.27 0.52 21.07 0.78 106.66
MP015 /4 -0.01 0.00 0.77 155.50 1.10 37.64 0.40 72.72
MP015 /1R1 0.02 97.92 0.19 86.68 1.46 53.74 0.85 114.40
MP015 /1R2 0.01 96.90 0.44 111.68 0.11 13.99 0.16 57.55
TG014 /PT 0.06 100.00 0.12 100.00 1.95 100.00 0.44 100.00
TG014 12 0.05 99.30 0.07 95.36 1.69 77.61 0.24 82.28
TG014 13 0.01 95.17 0.07 94.70 1.41 58.57 0.09 70.86
TG014 /1R1 0.02 96.46 0.14 101.66 1.17 45.98 0.17 76.80
TG014 /1R2 0.01 94.65 0.54 151.66 1.95 100.20 0.35 91.53
PH005 /PT 0.02 100.00 0.06 100.00 1.29 100.00 0.22 100.00
PH005 12 0.02 99.80 0.01 95.17 0.90 67.74 0.26 104.13
PH005 13 0.02 100.00 0.13 107.09 0.93 69.77 0.16 94.46
PH005 /4 0.03 100.50 0.08 102.07 0.39 40.66 0.06 85.38
PH005 15 0.03 100.55 0.45 148.36 1.88 180.13 0.39 118.71
PH005 /1R1 0.01 99.05 0.00 94.70 1.34 105.02 0.20 98.31
PH005 /1R2 0.01 98.86 0.08 102.38 1.72 154.03 0.12 90.44
BR006 /PT 0.19 100.00 0.08 100.00 1.45 100.00 0.29 100.00
BR006 12 0.01 83.53 0.01 93.47 0.87 56.10 0.14 86.07
BR006 13 0.02 84.16 0.08 99.95 1.49 104.24 0.18 89.54
BR006 /1R1 0.02 83.90 0.01 92.77 1.06 68.32 0.04 78.08
BR006 /1R2 0.03 84.92 0.52 155.35 0.90 58.22 0.22 93.71
BR006 /2R1 0.04 85.68 0.18 110.30 1.02 65.41 0.25 96.51
BR006 /2R2 0.02 83.78 0.42 140.07 0.83 54.12 0.16 87.90
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APPENDIX 9
PCR ELISA Data (Rejectors)
Patients Sample IL-5 IL-5 %C IL-13 IL-13 %C GrB GrB %C FasL FasL %C
ECO 19 /PT 0.05 100.00 0.22 100.00 2.32 100.00 0.40 100.00
ECO 19 12 0.02 100.00 0.24 100.00 1.80 100.00 0.12 100.00
ECO 19 /3 0.03 100.45 0.76 167.36 1.86 106.40 0.21 109.91
ECO 19 /1R1 0.06 103.72 0.00 0.00 1.47 72.47 0.19 107.09
ECO 19 /1R2 0.03 100.20 0.43 120.68 0.88 40.15 0.40 131.92
ECO 19 /1R3 0.07 104.39 0.39 116.42 1.00 44.91 0.16 103.98
VH025 /PT 0.06 100.00 0.26 100.00 1.96 100.00 0.37 100.00
VH025 /2 0.02 96.27 0.12 87.50 1.59 68.66 0.26 89.58
VH025 /3 0.04 97.34 0.24 98.02 1.52 64.27 0.20 83.78
VH025 /1R1 0.02 96.32 0.03 79.61 1.70 76.87 0.32 94.51
VH025 /1R2 0.10 103.46 0.90 190.12 2.00 103.87 0.60 125.48
VH025 /1R3 0.02 95.93 0.53 131.65 1.68 75.50 0.46 109.58
EJ010 /PT 0.05 100.00 0.87 100.00 2.27 100.00 0.46 100.00
EJ010 12 0.03 97.87 0.08 45.36 1.90 68.80 0.29 85.00
EJ010 /3 0.01 95.93 0.20 51.22 1.59 50.94 0.07 68.15
EJOIO /4 0.10 104.66 0.88 101.01 1.98 74.60 0.40 94.41
EJ010 /1PR 0.84 218.80 1.26 147.92 2.24 97.34 0.45 99.25
EJ010 /lRla 0.02 96.61 0.31 57.15 2.34 107.04 0.34 89.14
FB045 /PT 0.08 100.00 0.68 100.00 0.61 100.00 0.24 100.00
FB045 12 0.10 101.82 0.37 73.42 0.05 57.04 0.11 87.42
FB045 /3 0.04 96.08 0.90 123.99 0.05 57.21 0.19 94.70
FB045 /1R1 0.05 96.56 1.41 206.89 0.51 90.57 0.10 86.76
FB045 /1R2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
FB045 /1R3 0.00 0.00 0.67 98.56 2.23 503.80 0.66 152.20
NR034 /PT 0.01 100.00 0.19 100.00 0.38 100.00 0.06 100.00
NR034 12 0.07 106.40 0.33 114.57 0.18 82.08 0.18 112.47
NR034 /1R1 0.00 0.00 0.94 210.75 0.07 73.86 0.12 106.08
NR034 /1R2 0.00 99.05 0.66 158.96 1.76 397.49 0.24 119.42
NR034 /1R3 0.00 0.00 0.68 163.39 0.94 174.80 0.16 111.02
ER046 /PT 0.27 100.00 0.65 100.00 2.19 100.00 0.48 100.00
ER046 12 0.14 87.77 0.98 138.40 2.12 93.05 0.49 100.80
ER046 /3 0.08 82.32 1.02 144.92 1.67 59.48 0.19 74.83
ER046 /1R1 0.13 86.94 1.35 200.17 2.10 91.53 0.36 88.60
ER046 /2R1 0.03 78.58 0.70 104.97 2.25 106.29 0.24 78.35
ER046 /2R2 0.05 79.57 0.47 83.40 2.06 87.63 0.30 83.53
ER046 /2R3 0.06 81.14 0.68 102.43 2.16 97.09 0.33 86.07
JH029 /PT 0.15 100.00 0.62 100.00 0.62 100.00 0.36 100.00
JH029 12 0.01 87.24 0.05 56.72 0.16 63.32 0.28 92.54
JH029 /3 0.05 90.48 0.56 94.08 0.09 58.92 0.21 85.98
JH029 /4 0.26 111.46 1.06 155.89 2.16 465.53 0.28 92.68
JH029 /1R1 0.26 111.74 0.95 139.79 2.22 493.82 0.29 93.43
JH029 /lRla 0.01 87.55 0.06 57.15 1.74 305.72 0.08 75.77
JH029 /1R2 0.00 86.50 0.58 96.27 2.32 549.04 0.65 134.11
JH029 /1R3 0.11 96.18 0.80 120.38 2.31 541.41 0.72 142.69
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APPENDIX 9
PCR ELISA Data (Rejectors)
Patients Sample IL-5 IL-5 %C IL-13 IL-13 %C GrB GrB %C FasL FasL %C
NH023 /PT 0.02 88.16 0.20 65.67 2.08 428.45 0.25 89.76
NH023 12 0.02 88.03 0.01 54.47 1.60 266.58 0.30 93.99
NH023 /3 0.02 88.25 0.19 65.02 1.26 189.74 0.28 92.64
NH023 /1PR 0.09 94.60 0.41 81.06 1.57 259.09 0.37 100.50
NH023 /1R1 0.02 88.43 0.02 55.02 1.88 351.31 0.48 113.03
NH023 /2R1 0.04 89.45 0.02 54.91 1.94 375.47 0.52 117.70
NH023 /2R2 0.03 88.56 0.86 127.12 2.26 517.07 0.65 134.18




Patients SamDle IL-4/IL-2 IL-10/IL-2 IFN-G/IL-2 IL-4/IFN-G IL-10/IFN-G IL-10/IL-4
PC018 /PT 1.62 0.62 2.39 0.68 0.26 0.38
PC018 12 2.34 1.08 4.31 0.54 0.25 0.46
PC018 /3 3.92 2.73 6.15 0.64 0.44 0.70
PC018 /4 4.04 2.58 5.65 0.71 0.46 0.64
PC018 15 0.78 0.04 2.04 0.38 0.02 0.05
JS017 /PT 1.07 0.83 1.15 0.93 0.72 0.78
JS017 /2 1.86 2.30 3.24 0.58 0.71 1.23
JS017 13 2.77 2.47 3.25 0.85 0.76 0.89
JS017 14 6.03 3.97 4.59 1.31 0.86 0.66
JS017 15 4.98 4.29 7.61 0.65 0.56 0.86
CA030 /PT 22.94 0.99 21.03 1.09 0.05 0.04
CA030 12 8.81 1.49 10.13 0.87 0.15 0.17
CA030 12 3.81 2.00 4.65 0.82 0.43 0.52
CA030 14 21.63 15.07 25.65 0.84 0.59 0.70
CA030 15 17.94 5.51 24.29 0.74 0.23 0.31
KB027 /PT 15.66 0.96 23.82 0.66 0.04 0.06
KB027 12 6.81 9.51 21.54 0.32 0.44 1.40
KB027 13 6.57 1.23 13.03 0.50 0.09 0.19
KB027 14 8.01 0.73 11.63 0.69 0.06 0.09
KB027 15 6.92 0.39 6.20 1.12 0.06 0.06
SM026 /PT 2.18 0.12 3.60 0.60 0.03 0.05
SM026 12 0.40 1.68 4.89 0.08 0.34 4.14
SM026 13 1.18 0.46 2.53 0.47 0.18 0.39
SM026 14 3.53 0.08 5.65 0.62 0.01 0.02
SM026 15 6.62 1.05 9.96 0.66 0.11 0.16
RE022 /PT 16.92 1.98 42.45 0.40 0.05 0.12
RE022 12 0.00 0.57 1.13 0.00 0.51 252.57
RE022 13 1.87 2.99 22.39 0.08 0.13 1.60
RE022 14 1.12 7.81 10.18 0.11 0.77 6.99
RE022 15 2.44 3.20 2.74 0.89 1.17 1.31
BM024 /PT 5.59 2.78 13.52 0.41 0.21 0.50
BM024 12 0.35 0.47 2.69 0.13 0.18 1.36
BM024 13 5.56 5.17 7.20 0.77 0.72 0.93
BM024 14 4.13 0.32 5.04 0.82 0.06 0.08
BM024 15 1.31 1.25 1.78 0.74 0.70 0.95
RF020 /PT 2.27 2.01 1.99 1.14 1.01 0.88
RF020 12 2.65 4.36 3.95 0.67 1.10 1.64
RF020 12 4.01 3.25 2.76 1.45 1.18 0.81
RF020 14 5.01 3.63 4.98 1.01 0.73 0.72
RF020 15 7.18 1.09 3.43 2.10 0.32 0.15
BT016 /PT 1.41 0.70 1.87 0.75 0.38 0.50
BT016 12 0.35 6.29 7.26 0.05 0.87 17.76
BT016 13 2.77 5.25 6.20 0.45 0.85 1.90
BT016 14 3.72 3.51 3.82 0.97 0.92 0.94




Patients Sample IL-4/IL-2 IL-10/IL-2 IFN-G/IL-2 IL-4/IFN-G IL-10/IFN-G IL-10/IL-4
EP001 /PT 3.24 2.21 3.40 0.95 0.65 0.68
EP001 n 5.54 4.21 6.13 0.90 0.69 0.76
EP001 /3 3.36 3.56 3.15 1.07 1.13 1.06
EP001 /4 1.85 0.33 2.63 0.70 0.13 0.18
EP001 IS 1.13 2.43 2.66 0.43 0.91 2.15
JW009 /PT 2.01 3.65 1.86 1.08 1.96 1.81
JW009 /2 0.54 1.57 2.68 0.20 0.58 2.93
JW009 /3 0.52 2.99 2.87 0.18 1.04 5.70
JW009 /4 1.84 3.57 2.64 0.70 1.35 1.94
JW009 15 2.04 4.37 4.06 0.50 1.08 2.14
SK011 /PT 2.47 2.13 2.02 1.22 1.05 0.86
SK011 12 0.41 1.86 3.11 0.13 0.60 4.57
SK011 13 1.64 2.30 2.43 0.67 0.95 1.41
SK011 14 2.64 3.13 2.87 0.92 1.09 1.19
SK011 IS 10.93 20.40 9.52 1,15 2.14 1.87
DR013 /PT 6.64 2.88 10.97 0.61 0.26 0.43
DR013 12 7.97 16.26 12.30 0.65 1.32 2.04
DR013 13 17.87 28.61 18.08 0.99 1.58 1.60
DR013 14 12.26 9.75 19.86 0.62 0.49 0.80
DR013 15 5.41 7.86 5.44 1.00 1.45 1.45
PG007 /PT 3.05 1.49 3.58 0.85 0.42 0.49
PG007 12 0.46 5.57 2.75 0.17 2.03 12.11
PG007 13 2.24 2.23 1.73 1.30 1.29 1.00
PG007 14 2.36 0.78 2.64 0.89 0.30 0.33
PG007 IS 2.28 2.17 2.14 1.06 1.01 0.95
F0003 /PT 8.94 11.87 6.74 1.32 1.76 1.33
F0003 12 0.14 18.17 4.52 0.03 4.02 131.00
F0003 13 0.09 13.75 3.87 0.02 3.55 148.19
F0003 14 2.40 9.67 5.16 0.47 1.87 4.02
F0003 15 4.65 9.28 3.69 1.26 2.51 2.00
RW031 /PT 6.07 0.92 11.44 0.53 0.08 0.15
RW031 12 1.13 5.59 9.83 0.11 0.57 4.95
RW031 13 4.66 2.06 25.18 0.19 0.08 0.44
RW031 14 2.62 4.09 7.43 0.35 0.55 1.56
RW031 15 13.06 9.11 16.53 0.79 0.55 0.70
GK032 /PT 4.79 0.39 5.78 0.83 0.07 0.08
GK032 12 3.34 2.21 5.33 0.63 0.41 0.66
GK032 13 7.00 4.03 9.52 0.73 0.42 0.58
GK032 14 61.59 51.37 74.14 0.83 0.69 0.83
GK032 15 1.43 0.60 1.87 0.76 0.32 0.42
KB037 /PT 23.25 10.21 21.13 1.10 0.48 0.44
KB037 12 20.93 13.39 24.39 0.86 0.55 0.64
KB037 13 24.89 5.11 9.43 2.64 0.54 0.21
KB037 14 4.01 1.66 4.64 0.86 0.36 0.42




Patients Sample IL-4/IL-2 IL-10/IL-2 IFN-G/IL-2 IL-4/IFN-G IL-10/IFN-G IL-10/IL-4
AA033 /PT 10.23 0.73 11.67 0.88 0.06 0.07
AA033 12 3.31 3.58 10.00 0.33 0.36 1.08
AA033 13 16.53 17.74 45.55 0.36 0.39 1.07
AA033 /4 1.10 0.36 1.43 0.77 0.25 0.33
AA033 15 5.02 0.97 9.25 0.54 0.10 0.19
DK036 /PT 4.33 0.91 5.05 0.86 0.18 0.21
DK036 12 15.83 4.75 16.64 0.95 0.29 0.30
DK036 13 11.75 2.00 26.04 0.45 0.08 0.17
DK036 /4 3.23 0.99 6.70 0.48 0.15 0.31
DK036 15 5.43 3.29 20.23 0.27 0.16 0.61
LH035 /PT 64.67 2.11 36.33 1.78 0.06 0.03
LH035 12 55.04 85.67 83.17 0.66 1.03 1.56
LH035 13 37.90 31.48 85.10 0.45 0.37 0.83
LH035 /4 74.48 57.06 71.60 1.04 0.80 0.77
LH035 15 12.68 12.30 15.63 0.81 0.79 0.97
IL038 /PT 1.25 1.24 10.88 0.12 0.11 0.99
IL038 12 2.17 136.39 251.17 0.01 0.54 62.95
IL038 13 2.00 28.50 1363.50 0.00 0.02 14.25
IL038 /4 42.96 5.64 168.28 0.26 0.03 0.13
IL038 15 78.05 13.28 66.03 1.18 0.20 0.17
JR039 /PT 11.69 1.54 18.14 0.64 0.09 0.13
JR039 12 0.60 0.91 2.16 0.28 0.42 1.51
JR039 13 11.62 1.40 19.71 0.59 0.07 0.12
JR039 /4 63.92 19.27 99.38 0.64 0.19 0.30
JR039 15 13.17 2.90 15.26 0.86 0.19 0.22
MS040 /PT 1.45 0.18 1.69 0.86 0.11 0.12
MS040 12 3.09 1.95 2.23 1.38 0.87 0.63
MS040 13 3.14 1.48 4.49 0.70 0.33 0.47
MS040 /4 3.05 1.77 1.74 1.76 1.02 0.58
MS040 15 5.60 5.05 2.46 2.27 2.05 0.90
IT041 /PT 3.61 0.33 6.46 0.56 0.05 0.09
IT041 12 11.77 10.05 13.91 0.85 0.72 0.85
IT041 13 12.25 1.10 36.10 0.34 0.03 0.09
IT041 /4 9.88 1.71 10.73 0.92 0.16 0.17
IT041 15 14.72 10.95 18.22 0.81 0.60 0.74
CB042 /PT 27.13 7.49 52.28 0.52 0.14 0.28
CB042 12 2.82 1.17 10.60 0.27 0.11 0.41
CB042 13 17.44 11.20 14.58 1.20 0.77 0.64
CB042 /4 2.90 2.10 5.80 0.50 0.36 0.72
CB042 15 11.28 4.67 18.00 0.63 0.26 0.41
DM044 /PT 1.06 1.28 1.80 0.59 0.71 1.21
DM044 12 2.68 2.55 3.02 0.89 0.85 0.95
DM044 13 2.00 1.02 2.59 0.77 0.39 0.51
DM044 /4 5.69 0.63 2.66 2.14 0.24 0.11




Patients Sample IL-4/IL-2 IL-10/IL-2 IFN-G/IL-2 IL-4/IFN-G IL-10/IFN-G IL-10/IL-4
RM047 /PT 12.60 2.73 18.76 0.67 0.15 0.22
RM047 12 0.08 18.44 22.81 0.00 0.81 239.67
RM047 /3 0.08 2.46 18.46 0.00 0.13 29.50
RM047 /4 1.57 0.73 4.28 0.37 0.17 0.46




Patients Sample IL-4/IL-2 IL-10/IL-2 IFN-G/IL-2 IL-4/IFN-G IL-10/IFN-G IL-10/IL-4
NR034 /PT 30.12 0.44 18.94 1.59 0.02 0.01
NR034 12 34.67 5.09 37.00 0.94 0.14 0.15
NR034 /1R1 406.82 88.36 130.82 3.11 0.68 0.22
NR034 /1R2 167.43 23.79 128.93 1.30 0.18 0.14
NR034 /1R3 70.47 3.90 41.67 1.69 0.09 0.06
EK043 /PT 1.65 1.29 1.61 1.03 0.80 0.78
EK043 12 8.10 9.65 11.67 0.69 0.83 1.19
EK043 /1R1 2.18 12.71 13.05 0.17 0.97 5.84
EK043 /1R2 13.64 2.24 4.50 3.03 0.50 0.16
EK043 /1R3 27.64 1.10 8.03 3.44 0.14 0.04
JH029 /PT 17.86 2.71 24.89 0.72 0.11 0.15
JH029 12 41.96 45.81 101.96 0.41 0.45 1.09
JH029 /3 16.22 6.84 16.78 0.97 0.41 0.42
JH029 /4 2.89 2.76 3.46 0.84 0.80 0.95
JH029 /1R1 37.42 45.33 40.58 0.92 1.12 1.21
JH029 /lRla 92.48 16.87 54.70 1.69 0.31 0.18
JH029 /1R2 39.73 39.20 56.44 0.70 0.69 0.99
JH029 /1R3 32.94 22.44 45.11 0.73 0.50 0.68
JM008 /PT 55.53 1.28 68.81 0.81 0.02 0.02
JM008 12 0.12 21.81 44.17 0.00 0.49 180.71
JM008 /3 1.21 7.69 82.82 0.01 0.09 6.38
JM008 /4 352.20 41.10 400.40 0.88 0.10 0.12
JM008 /1R1 0.58 7.16 17.53 0.03 0.41 12.32
JM008 /1R2 1833.00 1254.50 2220.00 0.83 0.57 0.68
VH025 /PT 1.07 0.64 1.46 0.73 0.44 0.60
VH025 12 1.90 3.55 3.69 0.52 0.96 1.87
VH025 13 1.50 1.53 3.56 0.42 0.43 1.02
VH025 /1R1 0.12 2.51 2.59 0.05 0.97 20.52
VH025 /1R2 1.33 1.49 1.72 0.77 0.87 1.12
VH025 /1R3 1.05 1.45 1.78 0.59 0.82 1.38
AB021 /PT 1.58 1.45 1.88 0.84 0.77 0.92
AB021 12 2.83 2.03 3.68 0.77 0.55 0.72
AB021 13 3.48 3.56 3.83 0.91 0.93 1.02
AB021 /4 3.89 1.91 4.52 0.86 0.42 0.49
AB021 /1PR 5.67 1.20 5.33 1.06 0.22 0.21
AB021 /1R1 6.53 8.22 13.24 0.49 0.62 1.26
AB021 /1R2 2.24 1.32 2.18 1.03 0.60 0.59
AB021 /1R3 1.82 0.91 2.16 0.84 0.42 0.50
MP015 /PT 3.89 3.16 4.40 0.88 0.72 0.81
MP015 12 2.56 4.72 3.57 0.72 1.32 1.84
MP015 13 7.11 9.94 7.21 0.99 1.38 1.40
MP015 /4 5.89 7.45 5.06 1.16 1.47 1.26
MP015 /1R1 0.84 7.93 5.70 0.15 1.39 9.39




Patients Sample IL-4/IL-2 IL-10/IL-2 IFN-G/IL-2 IL4IFN IL-10/IFN-G IL-10/IL-4
NH023 /PT 1.80 1.94 3.88 0.46 0.50 1.08
NH023 12 2.43 12.82 25.29 0.10 0.51 5.27
NH023 /3 1.31 1.24 3.21 0.41 0.39 0.95
NH023 /1PR 3.88 2.84 7.46 0.52 0.38 0.73
NH023 /1R1 0.41 5.70 8.57 0.05 0.67 14.06
NH023 /2R1 0.25 3.54 5.23 0.05 0.68 14.31
NH023 /2R2 9.08 10.91 15.06 0.60 0.72 1.20
NH023 /2R3 12.28 4.26 29.42 0.42 0.14 0.35
BR006 /PT 1.73 1.07 3.28 0.53 0.32 0.62
BR006 12 0.15 2.64 1.92 0.08 1.37 17.64
BR006 /3 1.86 1.74 3.68 0.50 0.47 0.93
BR006 /1R1 1.07 13.49 10.80 0.10 1.25 12.55
BR006 /1R2 1.89 1.78 2.10 0.90 0.85 0.94
BR006 /2R1 1.81 3.51 4.32 0.42 0.81 1.94
BR006 /2R2 1.77 2.05 2.51 0.71 0.82 1.16
PH005 /PT 1.34 1.44 1.91 0.70 0.76 1.08
PH005 12 0.85 4.67 1.60 0.53 2.92 5.47
PH005 /3 2.17 3.51 2.46 0.88 1.43 1.62
PH005 /4 2.90 4.06 2.38 1.22 1.71 1.40
PH005 /5 2.01 2.78 2.22 0.90 1.25 1.39
PH005 /1R1 0.06 5.56 4.32 0.01 1.29 90.49
PH005 /1R2 0.85 1.09 1.46 0.59 0.75 1.28
EJ010 /PT 2.10 0.61 1.09 1.93 0.56 0.29
EJ010 12 0.62 0.90 1.08 0.57 0.83 1.45
EJ010 13 1.79 0.92 0.27 6.63 3.40 0.51
EJ010 14 1.31 1.36 0.62 2.11 2.20 1.04
EJ010 /1PR 1.96 1.20 1.29 1.52 0.93 0.61
EJ010 /lRla 3.36 3.93 2.09 1.60 1.88 1.17
TG014 /PT 1.31 1.78 1.36 0.96 1.30 1.36
TG014 12 1.69 4.23 1.94 0.87 2.18 2.50
TG014 12 4.28 9.44 0.70 6.15 13.55 2.20
TG014 /1R1 4.64 15.59 6.09 0.76 2.56 3.36
TG014 /1R2 5.31 5.39 4.63 1.15 1.16 1.02
FB045 /PT 1.79 0.29 1.35 1.32 0.22 0.16
FB045 12 1.19 0.49 1.15 1.03 0.42 0.41
FB045 12 30.44 3.18 7.34 4.14 0.43 0.10
FB045 /1R1 45.52 37.05 10.45 4.36 3.55 0.81
FB045 /1R2 194.83 2.67 4.25 45.84 0.63 0.01
FB045 /1R3 4.74 1.15 5.23 0.91 0.22 0.24
ECO 19 /PT 3.68 5.84 5.27 0.70 1.11 1.59
ECO 19 12 4.35 8.21 4.47 0.97 1.83 1.89
ECO 19 13 15.62 29.56 13.70 1.14 2.16 1.89
ECO 19 /1R1 0.08 12.32 5.73 0.01 2.15 157.17
ECO 19 /1R2 0.61 0.85 1.39 0.44 0.61 1.38




Patients Sanrnle IL-4/IL-2 IL-10/IL-2 IFN-G/IL-2 IL4IFN IL-10/IFN-G IL-10/IL-4
ER046 /PT 1.79 0.77 1.98 0.90 0.39 0.43
ER046 12 2.92 2.11 3.61 0.81 0.58 0.72
ER046 /3 4.87 2.63 3.60 1.35 0.73 0.54
ER046 /1R1 3.39 3.65 2.34 1.45 1.56 1.08
ER046 /2R1 2.28 1.94 2.78 0.82 0.70 0.85
ER046 /2R2 2.41 1.41 2.92 0.83 0.49 0.59
ER046 /2R3 6.67 4.31 7.78 0.86 0.55 0.65
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